Placebo interventions for all clinical conditions (Review)

Hróbjartsson A, Gøtzsche PC



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2010, Issue 1

http://www.thecochranelibrary.com



Placebo interventions for all clinical conditions (Review)

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	2
BACKGROUND	4
ОВЈЕСТІVES	5
ΜΕΤΗΟDS	5
RESULTS	7
Figure 1	8
Figure 2	9
Figure 3	10
Figure 4	13
DISCUSSION	19
AUTHORS' CONCLUSIONS	21
ACKNOWLEDGEMENTS	22
REFERENCES	22
CHARACTERISTICS OF STUDIES	40
	300
	307
	309
Analysis 1.2. Comparison 2 Main analysis: overall pooled analysis, outcome 2 Continuous outcomes	507
	314
Analysis 2.2. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome 2 Observer-reported	514
	316
Analysis 2.3. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome 3 Patient-reported	510
	317
Analysis 2.4. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome 4 Observer-reported	517
	321
Analysis 3.1. Comparison 3 Main analysis: clinical conditions investigated in three trials or more, Outcome 1 Binary	521
	323
Analysis 3.2. Comparison 3 Main analysis: clinical conditions investigated in three trials or more, Outcome 2 Continuous	525
	224
	324
	330
	330
Analysis 5.1. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 1 Patient-reported outcomes	221
	331
Analysis 5.2. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 2 Patient-reported outcomes	
	332
Analysis 5.3. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 3 Observer-reported	
	333
Analysis 5.4. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 4 Observer-reported	
	333
	334
Analysis 5.6. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 6 Patient-reported outcomes	
	335
Analysis 5.7. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 7 Patient-reported outcomes	
	338
Analysis 5.8. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 8 Observer-reported	
01 1	339
Analysis 5.9. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 9 Observer-reported	
outcomes not involving patient's cooperation	340
Placebo interventions for all clinical conditions (Review)	i

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 5.10. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 10 Laboratory outcomes.	342
Analysis 6.1. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 1 To study the effect	-
of placebo was an explicit trial purpose	343
Analysis 6.2. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 2 To study the effect of placebo was not an explicit trial purpose.	344
Analysis 6.3. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 3 To study the effect	
	346
Analysis 6.4. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 4 To study the effect	
of placebo was not an explicit trial purpose	347
Analysis 7.1. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 1 Psychological placebos.	352
Analysis 7.2. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 2 Physical	572
	353
Analysis 7.3. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 3	555
	354
0 1	3)4
Analysis 7.4. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 4 Psychological	
1	355
Analysis 7.5. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 5 Physical	
placebos.	357
Analysis 7.6. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 6	
Pharmacological placebos	360
Analysis 8.1. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 1 Binary outcomes:	
patients not informed that the trial involved placebo	362
Analysis 8.2. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 2 Binary outcomes: patients informed that the trial involved placebo (or not stated).	363
Analysis 8.3. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 3 Continuous outcomes:	
patients not informed that the trial involved placebo.	365
Analysis 8.4. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 4 Continuous outcomes:	
patients informed that the trial involved placebo (or not stated).	366
Analysis 9.1. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 1 Add-on	500
treatment: yes.	371
Analysis 9.2. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 2 Add-on	5/1
treatment: no or not stated.	372
	5/2
Analysis 9.3. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 3 Add-on	272
	373
Analysis 9.4. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 4 Add-on	270
	376
Analysis 10.1. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 1 Placebo	
1 ,	379
Analysis 10.2. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 2 Placebo	
intervention provider blinded: no or not stated	380
Analysis 10.3. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 3 Placebo	
intervention provider blinded: yes	382
Analysis 10.4. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 4 Placebo	
	384
Analysis 11.1. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 1 Blinding of observer:	
	388
Analysis 11.2. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 2 Blinding of observer: not	
	388
Analysis 11.3. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 3 Blinding of observer:	
yes	389
•	-

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ii

Analysis 11.4. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 4 Blinding of observer: not stated.	390
Analysis 12.1. Comparison 12 Risk of bias subgroup analysis: variance inequality and skewness, Outcome 1 No signs of unequal variance or skewness.	392
Analysis 12.2. Comparison 12 Risk of bias subgroup analysis: variance inequality and skewness, Outcome 2 Signs of either	
unequal variance or skewness	395
primary trial outcome clearly indicated	397
primary trial outcome not clearly indicated (or not selected)	398
primary trial outcome clearly indicated	399
primary trial outcome not clearly indicated (or not selected).	403
Analysis 14.1. Comparison 14 Risk of bias subgroup analysis: format of outcome, Outcome 1 Outcome was final values. Analysis 14.2. Comparison 14 Risk of bias subgroup analysis: format of outcome, Outcome 2 Outcome was change from	406
baseline	410
	412
	413
adequate	415
Analysis 15.4. Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 4 Concealed allocation unclear.	416
Analysis 16.1. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 1 Trial size >49	421
Analysis 16.2. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 2 Trial size 49 or less.	422
Analysis 16.3. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 3 Trial size >49	423
Analysis 16.4. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 4 Trial size 49 or less	426
	429
	431
Analysis 17.3. Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 3 Dropout rates no more than 15%.	432
	434
Analysis 18.1. Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max	
	438
Analysis 18.2. Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max	(20
	439
Analysis 18.3. Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max	440
15%, Outcome 3 Pain heterogeneity	440 440
	440
HISTORY	442
CONTRIBUTIONS OF AUTHORS	443
DECLARATIONS OF INTEREST	443
SOURCES OF SUPPORT	443
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	444
NOTES	444
INDEX TERMS	444

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

iii

[Intervention Review]

Placebo interventions for all clinical conditions

Asbjørn Hróbjartsson¹, Peter C Gøtzsche¹

¹The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark

Contact address: Asbjørn Hróbjartsson, The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, 3343, Copenhagen, 2100, Denmark. ah@cochrane.dk.

Editorial group: Cochrane Consumers and Communication Group. **Publication status and date:** New search for studies and content updated (conclusions changed), published in Issue 1, 2010. **Review content assessed as up-to-date:** 10 November 2009.

Citation: Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003974. DOI: 10.1002/14651858.CD003974.pub3.

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Placebo interventions are often claimed to substantially improve patient-reported and observer-reported outcomes in many clinical conditions, but most reports on effects of placebos are based on studies that have not randomised patients to placebo or no treatment. Two previous versions of this review from 2001 and 2004 found that placebo interventions in general did not have clinically important effects, but that there were possible beneficial effects on patient-reported outcomes, especially pain. Since then several relevant trials have been published.

Objectives

Our primary aims were to assess the effect of placebo interventions in general across all clinical conditions, and to investigate the effects of placebo interventions on specific clinical conditions. Our secondary aims were to assess whether the effect of placebo treatments differed for patient-reported and observer-reported outcomes, and to explore other reasons for variations in effect.

Search strategy

We searched the Cochrane Central Register of Controlled Trials (CENTRAL, *The Cochrane Library* Issue 4, 2007), MEDLINE (1966 to March 2008), EMBASE (1980 to March 2008), PsycINFO (1887 to March 2008) and Biological Abstracts (1986 to March 2008). We contacted experts on placebo research, and read references in the included trials.

Selection criteria

We included randomised placebo trials with a no-treatment control group investigating any health problem.

Data collection and analysis

Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. Trials with binary data were summarised using relative risk (a value of less than 1 indicates a beneficial effect of placebo), and trials with continuous outcomes were summarised using standardised mean difference (a negative value indicates a beneficial effect of placebo).

Main results

Outcome data were available in 202 out of 234 included trials, investigating 60 clinical conditions. We regarded the risk of bias as low in only 16 trials (8%), five of which had binary outcomes.

In 44 studies with binary outcomes (6041 patients), there was moderate heterogeneity (P < 0.001; I^2 45%) but no clear difference in effects between small and large trials (symmetrical funnel plot). The overall pooled effect of placebo was a relative risk of 0.93 (95%)

Placebo interventions for all clinical conditions (Review)

confidence interval (CI) 0.88 to 0.99). The pooled relative risk for patient-reported outcomes was 0.93 (95% CI 0.86 to 1.00) and for observer-reported outcomes 0.93 (95% CI 0.85 to 1.02). We found no statistically significant effect of placebo interventions in four clinical conditions that had been investigated in three trials or more: pain, nausea, smoking, and depression, but confidence intervals were wide. The effect on pain varied considerably, even among trials with low risk of bias.

In 158 trials with continuous outcomes (10,525 patients), there was moderate heterogeneity (P < 0.001; I^2 42%), and considerable variation in effects between small and large trials (asymmetrical funnel plot). It is therefore a questionable procedure to pool all the trials, and we did so mainly as a basis for exploring causes for heterogeneity. We found an overall effect of placebo treatments, standardised mean difference (SMD) -0.23 (95% CI -0.28 to -0.17). The SMD for patient-reported outcomes was -0.26 (95% CI -0.32 to -0.19), and for observer-reported outcomes, SMD -0.13 (95% CI -0.24 to -0.02). We found an effect on pain, SMD -0.28 (95% CI -0.36 to -0.19)); nausea, SMD -0.25 (-0.46 to -0.04)), asthma (-0.35 (-0.70 to -0.01)), and phobia (SMD -0.63 (95% CI -1.17 to -0.08)). The effect on pain was very variable, also among trials with low risk of bias. Four similarly-designed acupuncture trials conducted by an overlapping group of authors reported large effects (SMD -0.68 (-0.85 to -0.50)) whereas three other pain trials reported low or no effect (SMD -0.13 (-0.28 to 0.03)). The pooled effect on nausea was small, but consistent. The effects on phobia and asthma were very uncertain due to high risk of bias. There was no statistically significant effect of placebo interventions in the seven other clinical conditions investigated in three trials or more: smoking, dementia, depression, obesity, hypertension, insomnia and anxiety, but confidence intervals were wide.

Meta-regression analyses showed that larger effects of placebo interventions were associated with physical placebo interventions (e.g. sham acupuncture), patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), small trials, and trials with the explicit purpose of studying placebo. Larger effects of placebo were also found in trials that did not inform patients about the possible placebo intervention.

Authors' conclusions

We did not find that placebo interventions have important clinical effects in general. However, in certain settings placebo interventions can influence patient-reported outcomes, especially pain and nausea, though it is difficult to distinguish patient-reported effects of placebo from biased reporting. The effect on pain varied, even among trials with low risk of bias, from negligible to clinically important. Variations in the effect of placebo were partly explained by variations in how trials were conducted and how patients were informed.

PLAIN LANGUAGE SUMMARY

Placebo interventions for all clinical conditions

Placebo interventions are often claimed to substantially improve many clinical conditions. However, most reports on effects of placebos are based on unreliable studies that have not randomised patients to placebo or no treatment.

We studied the effect of placebo treatments by reviewing 202 trials comparing placebo treatment with no treatment covering 60 healthcare problems. In general, placebo treatments produced no major health benefits, although on average they had a modest effect on outcomes reported by patients, such as pain. However, the effect on pain varied from large to non-existent, even in well-conducted trials. Variations in the effect of placebo was partly explained by variations in how trials were conducted, the type of placebo used, and whether patients were informed that the trial involved placebo.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

Outcomes	Effect [1] (95% CI)	No. of participants (stud- ies)	Quality of the evidence	Comments
All clinical conditions (binary outcomes)	RR 0.93 (0.88 to 0.99)	6041 (44)	Moderate	Moderate heterogeneity. No statistically signif- icant differences be- tween patient-reported, and observer-reported bi- nary outcomes. No sta- tistically significant effect on: pain, nausea, smoking or depression [2]. Out of three pain trials with low risk of bias (1109 patients) , one German acupuncture trial found a large effect, and two trials found no ef- fect [3].
All clinical conditions (continuous outcomes)	SMD -0.23 (-0.28 to - 0.17)	10,525 (158)	Moderate	Moderate heterogeneity. Statistically significant dif- ferences between patient- reported, and observer-re- ported outcomes, SMD - 0.26 (-0.32 to -0.19) ver- sus -0.13 (-0.24 to -0.02). Meta-regression explained 54% of the variation in ef- fect [3].
Pain [2] (continuous outcomes)	SMD -0.28 (-0.36 to - 0.19)	4154 (60)	Moderate	Moderate heterogeneity. Seven trials (1198 pa- tients) had low risk of bias, but heterogeneity was substantial: four Ger- man acupuncture pain tri- als found large effects, and three other pain tri- als found negligible effects [3].
Nausea [2] (continuous outcomes)	SMD -0.25 (-0.46 to - 0.04)	452 (7)	Moderate	Low heterogeneity. The pooled result for all nau- sea trials was similar to the pooled result of the two nausea trials with low risk of bias [3].

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Depression [2] (continuous outcomes)	SMD -0.25 (-0.55 to 0.05)	324 (8)	Moderate	Moderate heterogeneity. The pooled result for all de- pression trials was similar to the result of the single depression trial with low risk of bias [3].
Other outcomes [2] (continuous outcomes) Smoking, dementia, obe- sity, hypertension, in- somnia, anxiety, asthma, phobia)	Range of SMD: -0.63 (-1.17 to -0.08) to -0.16 (-0.48 to 0.16)	1317 (41)	Low	There was a statistically significant, but unreliable, effect on asthma and pho- bia [3].

[1]. RR: relative risk; SMD: standardised mean difference.

[2]. Clinical conditions studied in three trials or more.

[3]. See Additional tables.

BACKGROUND

There has been a widespread belief that placebo interventions have considerable and reliable effects. This view was influenced by the seminal paper 'The Powerful Placebo' (Beecher 1955), which was one of the first attempts to combine results from several randomised trials. Narrative reviews from the 1980s and 1990s similarly concluded that placebo interventions substantially improve both patient-reported and observer-reported outcomes in a large proportion of patients with a wide range of clinical conditions, such as pain, asthma, high blood pressure, and even myocardial infarction (Brown 1998; Lasagna 1986).

However, a careful analysis concluded that Beecher's paper is flawed (Kienle 1997). Most reports on placebo, including Beecher's and the reviews quoted above, have estimated the effect of placebo as the difference before and after treatment in a placebo arm of a randomised trial. Thus, though the information in a loose sense comes from randomised trials, the estimation of the effect is not based on a comparison between patients who have been randomly allocated to a placebo group and to a no-treatment group. Without such a comparison, the effect of a placebo intervention cannot be distinguished from the natural course of the disease, and other factors, for example regression to the mean (the tendency for extreme measurements to be closer to the mean when repeated) (Gøtzsche 1994; Hróbjartsson 2002b). The reported large effect of placebo interventions could therefore, at least in part, be an artefact of inadequate research methods.

There is no formal definition of placebo that most clinicians and researchers agree upon (Gøtzsche 1994; Hróbjartsson 2002b). In clinical trials placebos are generally control treatments with a similar appearance to the study treatments, but without their essential components. It is generally assumed that any effect of a placebo intervention, for instance a sugar pill, is unrelated to its essential component, the sugar, but caused by the special interaction between patient and healthcare provider associated with the treatment ritual. However, the phrase 'placebo' is also sometimes used more broadly to describe, for example, any psychologically-mediated factor that potentially influences health. In this review we evaluate the effect of placebo in its narrow sense, as an intervention, based on trials that randomise patients to a placebo intervention group and to a no-treatment control group.

The two previous versions of this review were published in 2001 (Hróbjartsson 2001) and in 2004 (Hróbjartsson 2004a). Both reviews found that placebo interventions in general do not have clinically important effects, but that there were possible beneficial effects on patient-reported outcomes, especially pain. Since then several relevant trials have been published.

OBJECTIVES

Our primary aims were to assess the effect of placebo interventions in general across all clinical conditions, and to investigate the effects of placebo interventions on specific clinical conditions.

Our secondary aims were to assess whether the effect of placebo treatments differed for patient-reported and observer-reported outcomes, and to explore other reasons for variations in effect

METHODS

Criteria for considering studies for this review

Types of studies

Randomised clinical trials with a placebo group and a no-treatment group were considered for inclusion. Both parallel and crossover trials, in any language, were included, as well as unpublished studies when methodology and results could be accessed in written form.

Trials were excluded if patients were allocated by a quasi-random method, e.g. day of month or date of birth. Trials were also excluded if it was clear that the person who assessed objective outcomes was aware of group assignments, or if the dropout rate exceeded 50%.

Types of participants

Patients with a health problem, defined broadly as any somatic or psychiatric disease or symptom. We also included trials testing the prophylactic effect of placebo in a clinical setting on healthy participants. Trials were excluded if they involved healthy participants who had a condition inflicted upon them, e.g. pain, in a non-clinical, experimental setting, or patients who were paid a fee.

Types of interventions

We pragmatically defined a placebo intervention as any intervention which was clearly labelled a placebo in a trial report (by using the term placebo or an analogous term, e.g. sham, fake, dummy, or non- or unspecific treatment).

Trials were excluded when it was very likely that the alleged placebo intervention had an effect which was not related to the treatment ritual alone (e.g. movement techniques for postoperative pain). The no-treatment control groups consisted of patients who did not receive placebo interventions. We included trials in which both the placebo and no-treatment control groups received the same basic treatment.

Types of outcome measures

One outcome per trial was extracted for the main analyses. We primarily chose the outcome indicated as the main outcome in a trial report (e.g. used for a power calculation). If a main outcome was not clearly indicated we chose the outcome measure we considered most relevant to patients. We preferred patient-reported to observer-reported outcomes, and binary to continuous outcomes because we find such outcomes are generally more relevant to patients. We preferred post-treatment data, since follow-up data may be more prone to bias because of patients leaving the trial and diminution of the effect. Outcomes were not selected based on effect size or statistical significance.

Search methods for identification of studies

The search strategy was based primarily on an electronic search of five databases. The references of all included articles and selected reviews and books on placebo were read systematically for citations of potentially eligible trials. Furthermore, we contacted 28 researchers who had made significant contributions to the field, and asked if they knew of relevant trials. We searched the following databases:

• The Cochrane Central Register of Controlled Trials

- (CENTRAL, The Cochrane Library, Issue 4 2007);
 - MEDLINE (1966 to March 2008);
 - EMBASE (1980 to March 2008);
 - PsycINFO (1887 to March 2008); and
 - Biological Abstracts (1986 to March 2008).

The search strategies were developed iteratively based on synonyms of 'placebo', randomised clinical trials', and 'no-treatment'. Our comments under each of the headings explain variations in the search strategy (see Appendix 1).

Data collection and analysis

Reports that described potentially eligible trials were read in full by one author (AH), who excluded all studies that clearly did not comply with the inclusion criteria. Both authors read all other potentially eligible trial reports in full and made a decision on study inclusion independently; any disagreement was resolved by discussion.

We extracted information from the trial reports using a pilot-tested standardised data chart. The decision about which outcome to choose was made by both authors independently, and disagreements were resolved by discussion. All outcomes of each trial were listed. If outcome data were not available, we contacted the trial authors. All binary outcomes events were converted so they represent 'failures' or unsuccessful events. Similarly for continuous outcomes, all scales were converted so that higher scores indicate more intense symptoms.

Placebo interventions for all clinical conditions (Review)

For trials with binary outcomes we calculated the relative risk (RR) (if less than 1, it indicates a positive effect of the placebo intervention). For trials with continuous outcomes (and with data on ranking scales, for simplicity also called continuous in the following), we calculated the standardised mean difference (SMD) (a negative value indicates a positive effect of the placebo intervention). Trials reporting results measured on an ordinal scale were analysed as if they were continuous. For crossover trials we used data from the first period only. If that was not possible we used the summary data as if they had been derived from a parallel trial. We preferred final values, but used change from baseline if these were the only available data.

As we expected heterogeneity, we calculated the pooled results with random effect models (Mantel-Haenszel method for RRs, and inverse variance method for SMDs). We estimated the degree of heterogeneity using the I^2 test. The I^2 statistic can be interpreted as the proportion of the observed discrepancy in the estimation of the effect, within a group of trials, which cannot be accounted for by random variation (Higgins 2003). All results are reported with 95% confidence intervals and all P values are two-tailed.

We calculated the pooled effect of placebo overall for trials with binary outcomes and for trials with continuous outcomes. We also calculated the pooled effect on separate clinical conditions when they had been studied in three trials or more, and the pooled effect of trials with patient-reported and observer-reported outcomes. The threshold of three trials was chosen pragmatically, inspired by Linde (Linde 1997), in order to reduce the risk of spurious positive or negative findings in single trials. For each trial we plotted the effect by its standard error. The symmetry of such 'funnel plots' was assessed both visually, and formally with Egger's test (Egger 1997), to see if the effect decreased with increasing sample size. We defined trials with low risk of bias as those fulfilling the following three criteria: adequate concealment of allocation, dropout rate no more than 15%, and inclusion of at least 50 patients. We pre-specified these thresholds based on a pragmatic intention of providing a simple risk of bias assessment in a review with many trials. The role of trial size is debated, but was included because small trials are often more poorly conducted than larger trials. To study whether specific subgroups of trials reported higher or lower effects of placebo we compared two or more subgroups, with tests of interaction, involving the following 14 factors:

1. Type of placebo: i) pharmacological placebo, e.g. a pill; versus. ii) physical placebo, e.g. a machine without current; versus iii) psychological placebo, e.g. a neutral conversation.

2. Type of outcome: i) patient-reported outcomes essentially private to a patient, e.g. pain; versus ii) patient-reported outcomes potentially observable by another person at the time they occurred, e.g. haematuria; versus iii) observer-reported outcomes dependent on the cooperation of a patient, e.g. measurement of forced expiratory volume); versus iv) observerreported outcomes not dependent on patient cooperation, e.g. assessment of oedema); versus v) observer-reported outcomes in the form of laboratory data, e.g. blood sugar.

3. Placebo as add-on treatment: i) placebo treatment was the only intervention; versus ii) placebo treatment was an add-on treatment to a basic care treatment, also given to the patients in the no-treatment control group.

4. Dropout rate: i) the dropout rate exceeded 15% or was not reported; versus ii) the dropout rate was 15% or lower.

5. Blinding of observer: i) the trial report stated explicitly that the data collector of an observer-reported outcome was blinded; versus ii) the trial report did not state this explicitly.

6. Blinding of patients and treatment providers: i) placebo and active experimental groups were compared in a 'double-blind' design; versus ii) that was not the case, or not stated.

7. The trial's objective: i) the trial report stated explicitly that the objective was to assess the effect of placebo treatment; versus ii) no such explicit objective was stated.

8. Concealment of allocation: i) the allocation of patients was clearly concealed; versus ii) the allocation of patients was not clearly concealed.

9. Type of distribution: i) clear signs of a non-Gaussian distribution, or of a difference in variance between the placebo and the no-treatment groups; versus ii) no such signs. We regarded it a clear sign of a non-Gaussian distribution when 1.64 standard deviations exceeded the mean of naturally positive outcomes (CCC Stat Pol 1999). A difference in variance was assessed using F tests.

10. Reporting of a primary outcome: i) clear indication of a primary outcome in the trial report; versus ii) no clear indication of a primary outcome (in which case we decided which outcome to extract).

11. Sample size: i) the analysis involved at least 50 patients; versus ii) the analysis involved less than 50 patients.

12. Risk of bias: i) clearly concealed allocation of patients, and dropout rate of 15% or lower, and sample size of at least 50 patients; versus ii) those criteria not fulfilled.

13. Information to patients: i) patients were not informed that the trial involved a placebo intervention (instead they were informed that the trial compared two active interventions with a control group); versus ii) the trial report was unclear on this point, or stated that patients were aware that the trial involved a placebo intervention.

14. Format of outcome: Final values versus change from baseline.

Subgroup analyses 1-12 were pre-specified before we started searching for trials for the present update. Subgroup analyses 13 and 14 were post-hoc (see Discussion).

We furthermore conducted supplementary meta-regression analyses involving the trials with continuous outcomes. We specified 11 co-variates: the factors involved in subgroup analysis 1-4, 6-10, and 13, as well as trial precision (1/SE). For the meta-regression we modified our initial categorisations in two cases. Type of placebo (pharmacological, psychological or physical) was redefined as a

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. binary co-variate: physical placebo; versus not. Similarly, type of outcome was dichotomised so that we analysed patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation); versus not. The meta-regression analyses involved: a) multiple meta-regression with all 11 covariates, and b) multiple meta-regression with stepwise elimination of the co-variate with the highest P value until the analysis only included co-variates with P < 0.05.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification; Characteristics of ongoing studies.

The search strategy (Appendix 1) identified 1215 potentially eligible trial reports. We excluded 620 non-clinical or non-randomised trials, 252 without a placebo or a no-treatment group, 35 duplicate publications and 11 with clearly unblinded assessment of observer-reported outcomes. A further 63 trials were excluded for other reasons, e.g. dropout rates over 50%.

Thus, we included 234 trials. In 29 trials we were unable to extract relevant outcome data, and three trials involved assessment of harm. The main meta-analyses therefore included 202 trials.

There were 18 crossover trials of which 12 (330 patients) were handled as parallel trials. In 196 trials there was a third active treatment group in addition to the placebo and the no-treatment groups. In 164 of these trials, the effect of placebo was not mentioned as an objective of the study. The trial reports were published in five languages between 1946 and 2008.

Outcomes were binary in 44 trials, and continuous in 158. Counting only patients in the placebo and no-treatment groups, the trials with binary outcomes included 6041 patients, and had a median size of 54 patients (10 and 90 percentiles: 20 and 618); the trials with continuous outcomes included 10,525 patients and had a median size of 40 (10 and 90 percentiles: 18 and 149).

The typical pharmacological placebo intervention was a lactose tablet. The typical physical placebo implied a machine turned off, e.g. sham transcutaneous electrical nerve stimulation. The typical psychological placebo was a non-directional, neutral discussion between patient and treatment provider, a so-called 'attention placebo'. No-treatment typically implied 'observation only' or 'standard therapy'. In the latter case all patients received standard therapy, and the placebo intervention was an additional treatment. The trials investigated 60 clinical conditions: alcohol abuse, allergy, anaemia, anxiety, aphtous ulcers, asthma, attention-deficithyperactivity disorder, bacterial infections, benign prostatic hyperplasia, blood donation reactions, breathlessness, bulimia nervosa, carpal tunnel syndrome, compulsive nail biting, dementia, depression, dermatitis, difficulty of colonoscopy, diabetes, dry eye, enuresis, epilepsy, faecal soiling, fatigue, gag reflex, herpes simplex infection, irritable bowel syndrome, hypercholesterolaemia, hyperglycaemia, hypertension, ileus, infertility, insomnia, insufficient cervical dilatation, jet lag, labour, marital discord, menopause, mental handicap, orgasmic difficulties, overweight, procedural discomfort during bronchoscopy, upper respiratory infection, venous ulcers, vitiligo, pain, nausea, Parkinson's disease, patient involvement in adolescent diabetic care, phobia, physical activity, poor oral hygiene, Raynaud's disease, schizophrenia, seasickness, secondary erectile dysfunction, smoking, stress related to dental treatment, treatment adherence, or undiagnosed ailments.

Five trials call for special attention (Brinkhaus 2006; Linde 2005; Melchart 2005; Witt 2005; Scharf 2006). The trials all studied the effect of acupuncture on pain. They were conducted in Germany, published between 2005 and 2007, had a very similar design, and four of the five trials had overlapping authors. In the following they are called 'the German acupuncture trials'. They studied the effect of 6 to 8 weeks of acupuncture and placebo acupuncture on osteoarthritis pain, low back pain, migraine, and tension type headache. The trials were medium-sized to large, their allocation concealment adequate and dropouts were below 15%. They reported substantial effects of placebo acupuncture, SMDs ranged from -0.56 to -0.82, and the single trial with a binary outcome reported an RR of 0.69. They differed from other trials in that they combined low risk of bias with large effects.

A more detailed description of the studies can be seen in the Characteristics of included studies table.

Risk of bias in included studies


The methodological quality of the trials was generally mediocre, but quite variable (Figure 1; Figure 2).

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Figure 1. Methodological quality summary: review authors' judgments about each methodological quality item for each included study.



Figure 2. Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.



All included trials were randomised, but in only 28 trials (12%) was it clear that patient allocation had been adequately concealed. In 88 trials the dropout rate was 15% or lower, and in the remaining 114 trials it was above 15% (or not reported). In 86 trials the sample size was 50 or more. We regarded the risk of bias as low in 16 trials (8%), five of which had binary outcomes.

In 61 trials the comparison between placebo and an experimental active treatment was described as 'double blind', whereas in the remaining 141 such trials comparisons were not double blind (or not reported). Observer-reported outcomes were clearly assessed by a blinded observer in 22 trials, but this was unclear in 41 trials.


Effects of interventions


See: Summary of findings for the main comparison Effect of placebo interventions across all clinical conditions (main findings)

Binary outcomes (44 trials; 6041 patients)

The funnel plot was symmetrical around a single peak (Figure 3). There was no statistically significant difference between the results in small and large trials (Egger's test, P = 0.49). Heterogeneity was moderate (P < 0.001, I^2 45%).

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.





The pooled effect was RR 0.93 (0.88 to 0.99) (Analysis 1.1) (Summary of findings for the main comparison). The effect for patient-reported outcomes was RR 0.93 (0.86 to 1.00) and for observer-reported outcomes RR 0.93 (0.85 to 1.02) (Table 1).

Table 1.	Effect of placebo	interventions a	cross all clinical	conditions	(binary outcomes)

	All trials			Trials with low risk of bias			Quality of the evidence
Outcomes	Relative Risk (95% CI)	No. of partic- ipants (stud- ies)	Comments	Relative Risk (95% CI)	No. of partic- ipants (stud- ies)	Comments	
All clinical conditions	0.93 (0.88 to 0.99)	6041 (44)	Symmetrical funnel plot Moderate het- erogeneity	0.90 (0.76 to 1.08)	1,438 (5)	Substantial heterogene- ity. One Ger- man acupunc- ture trial found RR 0.69 (0.61 to 0.78) and the other four tri- als RR 0.96 (0.87 to 1.06)	Moderate

Placebo interventions for all clinical conditions (Review)

Table 1. Effect of placebo interventions across all clinical conditions (binary outcomes) (Continued)

Trials with patient- reported out- comes	0.93 (0.86 to 1.00)	4046 (31)	Symmetrical funnel plot Moderate het- erogeneity	0.89 (0.72 to 1.11)	845 (4)	Substantial heterogeneity (see above).	Moderate
Trials with observer- reported out- comes	0.93 (0.85 to 1.02)	1995 (13)	Symmetrical funnel plot Moderate het- erogeneity	0.95 (0.77 to 1.17)	54 (1)	One small trial	Moderate

We categorised five trials as having low risk of bias. The pooled effect of these trials was RR 0.90 (0.76 to 1.08). The analysis involved considerable heterogeneity (P < 0.001; I² 78%) caused by one German acupuncture pain trial with a RR of 0.69 (0.61 to 0.78). The pooled effect of the other four trials was RR 0.96 (0.87 to 1.06) (P = 0.63; I² 0%).

Four clinical problems had been investigated in at least three trials with binary outcomes: nausea, pain, and relapse in prevention of smoking and depression. Placebo interventions had no statistically significant effect on these clinical conditions, but confidence intervals were wide (Table 2).

	All trials			Trials with low	Quality of the evidence		
Condition [1]	Relative risk (95% CI)	No. of partic- ipants (stud- ies)	Comments	Relative risk (95% CI)	No. of partic- ipants (stud- ies)	Comments	
Pain	0.92 (0.76 to 1.11)	1207 (6)	Substantial heterogeneity	0.89 (0.67 to 1.19)	1109 (3)	No heterogeneity	Moderate
• GAT [2] excluded	0.98 (0.88 to 1.10)	525 (5)	No heterogeneity	1.00 (0.84 to 1.20)	428 (2)	No heterogeneity	
• GAT [2] only	0.69 (0.61 to 0.78)	681 (1)	NA	0.69 (0.61 to 0.78)	681 (1)	NA	
Nausea	0.94 (0.82 to 1.07)	732 (6)	No heterogeneity	0.92 (0.75 to 1.12)	275 (1)	NA	Moderate
Smoking	0.89 (0.73 to 1.10)	887 (6)	Substantial heterogeneity	NA	NA	NA	Low

Table 2. Effe	ct of placebo interventions o	n specific clinical	l conditions (bin	ary outcomes)
---------------	-------------------------------	---------------------	-------------------	---------------

Placebo interventions for all clinical conditions (Review)

Table 2. Effect of placebo interventions on specific clinical conditions (binary outcomes) (Continued)

Depression	1.03 (0.78 to 1.34)	152 (3)	No heterogeneity	NA	NA	NA	Low
------------	------------------------	---------	---------------------	----	----	----	-----

[1]. Clinical conditions studied in three trials or more.


[2]. German acupuncture trials.

NA: not applicable.

Continuous outcomes (158 trials; 10,525 patients)

The funnel plot was asymmetrical (Figure 4). Small trials tended to report higher effects of placebo than larger trial (Egger's test, P = 0.03). There was moderate heterogeneity (P < 0.001, I^2 42%).

Figure 4. Funnel plot of comparison: I Main analysis: overall pooled analyses, outcome: 1.2 Continuous outcomes.



The effect estimates of the individual trials spanned roughly from SMD -2.0 to 0.5, and the effects of large trials varied considerably. Because of heterogeneity and funnel plot asymmetry it is a questionable procedure to pool all the trials, and we did so mainly as a basis for exploring causes for heterogeneity.

The pooled effect was SMD -0.23 (-0.28 to -0.17) (Analysis 1.2) (Summary of findings for the main comparison). The effect for patient-reported outcomes (SMD -0.26 (-0.32 to -0.19)) was statistically significantly different from the effect for observer-reported outcomes (SMD -0.13 (-0.24 to -0.02), (test of interaction, P = 0.045)) (Table 3).

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

	All trials			Trials with low risk of bias			Quality of the evidence
Outcomes	Standardised mean differ- ence (95% CI)	No. of partic- ipants (stud- ies)	Comments	Standardised mean differ- ence (95% CI)	No. of partic- ipants (stud- ies)	Comments	
All clinical conditions	-0.23 (-0.28 to -0.17)	10,525 (158)	Asymmetrical funnel plot Moderate het- erogeneity	-0.38 (-0.55 to -0.22)	1610 (11)	Substantial heterogene- ity. Four Ger- man acupunc- ture trials had a pooled SMD -0.68 (-0.85 to - 0.50), whereas 7 other trials had a pooled SMD of -0.19 (-0.31 to -0.07)	Moderate
Trials with patient- reported out- comes	-0.26 (-0.32 to -0.19)	8000 (109)	Asymmetrical funnel plot Moderate het- erogeneity	-0.39 (-0.57 to -0.22)	1543 (10)	Substantial heterogeneity (see above).	Moderate
Trials with observer- reported out- comes	-0.13 (-0.24 to -0.02)	2513 (49)	Asymmetrical funnel plot Moderate het- erogeneity	-0.25 (-0.73 to 0.23)	67 (1)	One small trial	Moderate

Table 3. Effect of placebo interventions across all clinical conditions (continuous outcomes)

We categorised 11 trials as having a low risk of bias. The pooled SMD for these trials was -0.38 (-0.55 to -0.22), but heterogeneity was considerable (P < 0.001; I² 62%) and caused by four German acupuncture pain trials. The pooled effect of the other seven trials was -0.19 (-0.31 to 0.07) with no heterogeneity (P = 0.67; I² 0%).

Eleven clinical problems had been investigated in at least three trials with continuous outcomes: anxiety, asthma, dementia, depression, hypertension, insomnia, nausea, overweight, pain, phobia, and smoking (Table 4). Confidence intervals were wide for most conditions. Placebo interventions had a statistically significant effect on pain, phobia, nausea, and asthma. Below we describe the results of these trials.

Placebo interventions for all clinical conditions (Review)

	All trials			Trials with low risk of bias			Quality of the evidence
Condition [1]	Standardised mean dif- ference (95% CI)	No. of partic- ipants (stud- ies)	Comments	Standardised mean dif- ference (95% CI)	No. of partic- ipants (stud- ies)	Comments	
Pain	-0.28 (-0.36 to -0.19)	4154 (60)	Moderate het- erogeneity	-0.45 (-0.69 to -0.21)	1198 (7)	Substantial heterogeneity	Moderate
• GAT [2] excluded	-0.22 (-0.30 to -0.14)	3534 (56)	Low heterogeneity	-0.13 (-0.28 to 0.03)	637 (3)	No heterogeneity	
• GAT [2] only	-0.68 (-0.85 to -0.50)	544 (4)	No heterogeneity	-0.68 (-0.85 to -0.50)	544 (4)	No heterogeneity	
Nausea	-0.25 (-0.46 to -0.04)	452 (7)	Low heterogeneity	-0.19 (-0.49 to 0.11)	174 (2)	No heterogeneity	Moderate
Depression	-0.25 (-0.55 to 0.05)	324 (8)	Moderate het- erogeneity	-0.23 (-0.63 to 0.21)	123 (1)		Moderate
Hyperten- sion	-0.17 (-0.46 to 0.12)	308 (10)	Low heterogeneity	NA	0 (0)		Low
Anxiety	-0.16 (-0.48 to 0.16)	286 (7)	Moderate het- erogeneity	NA	0 (0)		Low
Asthma	-0.35 (-0.70 to -0.01)	203 (4)	Moderate het- erogeneity	NA	0 (0)		Low
Obesity	-0.20 (-0.57 to 0.17)	188 (8)	Moderate het- erogeneity	NA	0 (0)		Low
Insomnia	-0.19 (-0.50 to 0.12)	164 (6)	No heterogeneity	NA	0 (0)		Low
Dementia	-0.18 (-0.55 to 0.20)	111 (3)	No heterogeneity	NA	0 (0)		Low
Phobia	-0.63 (-1.17 to -0.08)	57 (3)	No heterogeneity	NA	0 (0)		Low

 Table 4. Effect of placebo interventions on specific clinical conditions (continuous outcomes)

[1]. Clinical conditions studied in three trials or more.

[2]. German acupuncture trials.

NA: not applicable.

Placebo interventions for all clinical conditions (Review)

Pain

There were 60 trials with 4154 patients that evaluated the effect on pain based on continuous outcomes, e.g. pain intensity measured on a 100 milimetre (mm) visual analogue scale. The funnel plot was asymmetrical, as larger trials tended to report lower effects than smaller trials (Figure not shown). This tendency was not statistically significant (Egger's test, P = 0.20), but the intercept, which indicates the degree of asymmetry, was similar to the intercept for the analysis involving all trials with continuous outcomes. The statistically significant heterogeneity (P < 0.001) was moderate (I² 42%).

The effect estimates of the individual trials spanned roughly from SMD -1.0 to SMD 0.5, with a peak around SMD -0.15, and with several medium-sized trials reporting effects between SMD -0.5 and -1.0. The pooled SMD was -0.28 (-0.36 to -0.19).

We categorised seven pain trials as having low risk of bias. Their pooled SMD was -0.45 (-0.69 to -0.21), but with substantial heterogeneity (I^2 75%). Four German acupuncture trials had a pooled effect of -0.68 (-0.85 to -0.50), whereas the other three pain trials

had a pooled effect of SMD -0.13 (-0.28 to 0.03) (Analysis 18.3). When grouped this way neither had any heterogeneity (I² 0%). The mean standard deviation for the 16 trials with a 100 mm visual analogue pain scale was 24 mm. Thus, the effect on pain on a 100 mm scale based on the four German acupuncture trials was 16 mm, and 3 mm based on the other trials.

A similar pattern was seen among the six pain trials with binary outcomes, including 1207 patients. The pooled effect was RR 0.92 (0.77 to 1.11). There was substantial heterogeneity (P < 0.001; I ² 76%). The single German acupuncture trial reported a marked effect of RR 0.69 (0.61 to 0.78), whereas the five other trials had a pooled RR of 0.98 (0.88 to 1.09). When so grouped there was no heterogeneity (I² 0%).

Nausea

Seven trials with 452 patients studied the effect of placebo on nausea based on continuous outcomes. No statistically significant heterogeneity (P = 0.30) was found (I² 17%). The pooled SMD was -0.25 (-0.46 to -0.04). The mean standard deviation for trials

Placebo interventions for all clinical conditions (Review)

using a 100 mm visual analogue scale (or similar) was 27 mm. The effect on reported nausea was thus 7 mm on a 100 mm scale. We categorised two nausea trials as having low risk of bias. They had a similar pooled effect, SMD = -0.19 (-0.49 to 0.11).

Six trials with 732 patients evaluated the effect of nausea on binary outcomes. No statistically significant heterogeneity was found (P = 0.95; I^2 0%). The pooled RR was 0.94 (0.82 to 1.07). We categorised one trial as having low risk of bias. This trial had a similar effect, RR 0.92 (0.75 to 1.12).

Phobia

Three trials with 57 patients evaluated the effect of placebo on phobia based on continuous outcomes, e.g. assessment of fear of snakes. No statistically significant heterogeneity (P = 0.52) was found (I^2 = 0%). The pooled SMD was -0.63 (95% CI -1.17 to -0.08). The trials were very small with sample sizes of 14, 18 and 25 patients, and the concealment of allocation was unclear in all three cases. No trials with binary outcomes investigated phobia.

Asthma

Four trials with 203 patients evaluated the effect of placebo on asthma. No statistically significant heterogeneity was found (P = 0.52; I² 0%). The pooled SMD was -0.35 (-0.70 to -0.01). The marginally statistically significant pooled result is primarily driven by one trial published in 1976 reporting an effect on children. No trial reported adequate concealment of allocation, and no trial with binary outcomes investigated asthma. The risk of bias is considerable in this analysis and we find it uncertain whether placebo has an effect on asthma.

Trials not reporting data necessary for meta-analyses

In 29 out of the 234 trials (12%), outcome data had not been reported in a way that was suited for meta-analysis, and three trials reported harms. Based on a qualitative assessment, there was no clear tendency for the findings in the 29 trials without outcome data to be different from the findings in the 202 trials we meta-analysed.

Trials studying harms

Three trials (1218 patients) studied harmful effects of placebo interventions. One trial with binary outcomes (1066 patients) found no statistically significant increase of nausea in patients treated with placebo (RR 1.36 (0.95 to 1.95)). The two trials with continuous outcomes (128 and 24 patients) also found no statistically significant harmful effect of placebo intervention (SMDs -0.19 (-0.53 to 1.06) and 0.83 (-0.01 to 1.67)).

Subgroup analyses and meta-regression analyses

We found no statistically significant differences between the subgroups of trials with binary outcomes (data not shown).

For trials with continuous outcomes the effect of physical placebo interventions, SMD -0.31 (-0.41 to -0.22) was higher than the effect of pharmacological placebo interventions, SMD -0.10 (-0.20 to -0.01), (test of interaction, P = 0.002). Furthermore, the observed difference between patient-reported outcomes and observer-reported outcomes was primarily driven by a small negative effect on laboratory outcomes, SMD 0.16 (0.01 to 0.30), and a small effect on observer-reported outcomes not involving the patients' cooperation, SMD -0.12 (-0.29 to 0.05). The effect on observer-reported outcomes involving the patients' cooperation, SMD -0.26 (-0.41 to -0.12), was very similar to the effects on patient-reported outcomes.

The pooled effect of the 23 trials that falsely informed the patients that they could receive two active treatments or no-treatment (i.e. the possibility of a placebo intervention was not revealed) was SMD -0.39 (-0.53 to -0.26). This effect was higher than in the trials that correctly informed patients that a placebo intervention was a possibility (or this aspects was not reported clearly) SMD -0.19 (-0.25 to -0.13) (test of interaction, P = 0.008). We also found a statistically significantly higher effect in the 28 trials with an aim of studying the effect of placebo, SMD -0.34 (-0.46 to -0.22) as compared with trials that did not state this aim, -0.20 (-0.26 to -0.14) (test of interaction, P = 0.04).

We found no statistically significant impact on results of the following methodological factors: whether the placebo treatment provider and patients had been blinded, whether placebo was an add-on treatment, whether observers had been blinded (when outcomes were observer-reported), whether the data indicated non-Normal distributions of continuous outcomes, or whether the trial report had defined a primary outcome. The effects of adequately concealed trials with continuous outcomes were somewhat larger than the effect of trials where concealment was unclear (test of interaction, P = 0.05). There was no statistically significant difference between the effect of placebo measured as final values, SMD -0.21 (-0.28 to -0.14), and change from baseline, SMD -0.27 (-0.37 to -0.16).

The results of the meta-regression analyses are shown in Table 5. The meta-regression model with stepwise elimination of co-variates with the highest P values, identified four co-variates with P values < 0.05: patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), physical placebos, information to patients, and the aim of the trial. The model explained 54% of the variation in the analysis of all trials with continuous outcomes. In this analysis, small sample size was close to being statistically significant (P = 0.09), and the analysis of the funnel plot (Egger's test) did find such an association (P = 0.03). Thus, we regard sample size and effect as associated.

Copyright $\textcircled{\sc 0}$ 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

	All trials (n = 158)			All trials excluding German acupuncture trials (n = 154)			
Model	Co-variates [1]	Coefficient (SE) [2]	P value	Co-variates	Coefficient (SE)	P value	
Multiple meta- regression of all co-variates simultaneously	Study aim was	-0.17 (0.084) -0.15 (0.072)	0.047 0.043	Study aim was placebo	-0.18 (0.072)	0.012	
Multi- ple meta-regres- sion by stepwise elimination	Pt-involved out- come Physical placebos Placebo undisclosed Study aim was placebo	-0.18 (0.077) -0.13 (0.056) -0.17 (0.070) -0.14 (0.070)	0.023 0.020 0.014 0.046	Pt-involved out- come Study aim was placebo Precision	-0.18 (0.067)	0.011 0.008 0.016	

Table 5. Meta-regression analyses

[1]. We studied 11 predefined co-variates. A model based on stepwise elimination of the co-variate with the highest P-value resulted in four co-variates with P < 0.05. The model had a tau² = 0.0207, compared to the overall random effects meta-analysis of tau ² = 0.0450. Thus, the model explains 54% of the initial variation. The model was sensitive to the exclusion of the four German acupuncture trials. The inclusion of these trials especially influenced the statistical significance of the importance of disclosing to patients that the trial involved a possible placebo treatment.

[2]. SE: Standard error

Placebo interventions for all clinical conditions (Review) Copyright 0 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

DISCUSSION

We found a small and uncertain pooled effect of placebo interventions in 44 trials with binary outcomes and no difference between patient-reported and observer-reported outcomes. For 158 trials with continuous outcomes we found higher effects in small trials. The pooled effect of placebo on patient-reported outcomes was modest, and on observer-reported outcomes small and uncertain.

Out of 11 clinical conditions, investigated in three trials or more, there was a statistically significant effect of placebo on pain, nausea, phobia, and asthma. The pooled effect of placebo interventions on pain was very variable, also among trials with low risk of bias, spanning from clinically important to negligible. The pooled effect on nausea was modest, but consistent. The effect on phobia and asthma was very uncertain due to high risk of bias. Larger effects of placebo interventions were associated with physical placebo interventions (e.g. sham acupuncture), patient-involved outcomes (patient-reported outcomes such as pain, and observer-reported outcomes involving patient cooperation, such as depression rating scales), small trials, and trials with the explicit purpose of studying placebo. Larger effects of placebo were also found in the trials that falsely informed patients that the study compared two active treatments with no-treatment.

Strengths and weaknesses

The two main strengths of our review are the randomised design of the included trials, and the large number of included trials. This enabled an comprehensive assessment of the clinical effect of placebo and provided a basis for analyses of the effect of placebo on specific clinical conditions, of the risk of bias, and of reasons for heterogeneity.

The main weakness of any review of the effect of placebo is that the comparison between placebo and no-treatment cannot be conducted blindly. Patients will know whether they receive a treatment or not, and this may affect both their reporting of symp-

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

toms and their use of concomitant therapy. In trials with patientreported outcomes it is difficult to distinguish a true effect from biased reporting (response bias), as polite patients may tend to report what they think socially most acceptable. A review of signal detection analysis of experimental placebo studies on pain indicated that response bias was responsible for at least part of the patient-reported effects (Allan 2002). This is in accord with our findings that the effect of placebo was twice as high for patientreported continuous outcomes as for observer-reported ones.

The effect of placebo could be underestimated if the patients in the no-treatment groups tended to seek treatment outside the trial more often than patients in the placebo groups. For example, the patients in the no-treatment group of a long-term pain trial could take more additional pain medication than the patients in the placebo group. Concomitant therapy was generally poorly reported, but in 13 three-armed acupuncture trials, patients in the no-treatment group reported taking more analgesic drugs than patients in the placebo group (Madsen 2009). The net direction of the two biases, response bias and co-intervention bias, is difficult to predict, but it seems likely that they partly cancel each other out.

The funnel plot of trials with continuous outcomes was asymmetrical and lacked a clear peak, as the effect of large trials also varied considerably. This could indicate that some small trials with a neutral or negative result had not been included. However, the publication of such trials is not directly linked to the effect of the placebo intervention (but to the effect of the active intervention), so we find it less likely that unidentified trials could explain the higher effects of placebo reported in small trials. It seems more likely that the asymmetry is caused by a combination of true heterogeneity and poor methodological quality in small trials. Regardless, the overall pooled effect of trials with continuous outcomes should be interpreted cautiously.

We carried out several subgroup and meta-regression analyses to explain the heterogeneity. Higher effects of placebo interventions were associated with patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), physical placebos, small trials, and trials with the explicit purpose of studying placebo. Ten of eleven co-variates analysed were predefined before this update. The eleventh factor was whether patients had been falsely informed that they could receive two forms of active treatment or no-treatment (and were not informed about the possibility of a placebo intervention). The German acupuncture trials informed their patients in this way, which prompted us to re-read the other trial reports, extract relevant data, and include the factor in a post-hoc analysis. The factor was statistically significant only when the German acupuncture trials were included in the analyses, implying some uncertainty as to its general importance. Furthermore, pooling of final values and change from baseline may be problematic when outcomes are presented as standardised mean differences. However, in a sensitivity analysis we found no statistically significant difference between the pooled

effect of 40 trials that reported change from baseline as compared with the 118 trials that reported final values.

The meta-regression model explained 54% of the initial variation found in the pooled analysis of trials with continuous outcomes. Subgroup analyses, and meta-regression, are observational and there is a risk of confounding. We have found one randomised trial that studied a co-variate involved in our meta-regression analyses. Placebo acupuncture was found to have somewhat larger effects than pill placebo on pain (Kaptchuk 2006), supporting our observation that physical placebos are associated with larger effects than pharmacological ones.

Other reviews

One previous systematic review of randomised trials with placebo and no-treatment groups identified 12 trials (Ernst 1995), which tended to report large effects of placebo.

Several laboratory studies indicate a neurobiological mechanism for the analgesic effect of placebo (Sauro 2005). These studies are often small, mostly based on healthy volunteers, and of short duration. The findings cannot easily be extrapolated to a clinical context, but they do elucidate the probable importance of, for example, endorphins in the analgesic response to placebo, and indicate that it is unlikely that response bias can account for all of the analgesic effect.

Other reviews have compared the effect of experimental treatments in trials that used placebo control groups, with similar trials that used no-treatment control groups (Dush 1986; Grissom 1996; Kirsch 1998; Shapiro 1982; Smith 1980). Such comparisons are indirect, prone to confounding and therefore less reliable.

The previous versions of our review prompted several independent re-analyses. Kamper and colleagues replicated our finding that the pooled effect of placebo on pain was low (Kamper 2008). Wampold and colleagues replicated our overall findings for both binary and continuous outcomes, despite modified inclusion criteria and some disagreement about how such estimates should be interpreted (Wampold 2005; Hróbjartsson 2007). Meissner and colleagues replicated our findings that effects of placebo on laboratory outcomes tended to be lower than on other observer-reported outcomes (Meissner 2007). Vase and colleagues re-analysed the clinical pain trials included in our review, and reported low effects in ordinary clinical trials and high effects in clinical and laboratory based 'mechanism studies' (Vase 2002). We pointed out several methodological errors, and suggested that the difference could be less pronounced (Hróbjartsson 2006). The German acupuncture trials, which were not 'mechanism studies', also indicated that clinical non-mechanism trials can have quite substantial effects. Regardless, effects of placebo vary considerably, and the web of factors responsible for this variation is complex. Our regression analysis is one attempt to unfold the multifactorial background for effects of placebo.

Copyright $\textcircled{\sc c}$ 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Meaning of our review

This update confirms and modifies the findings of the previous versions of our review. Our approach can be seen as testing the hypothesis that placebo treatments have large effects across many clinical conditions and outcomes, and our results clearly indicate that this hypothesis is wrong.

However, our findings do not imply that placebo interventions have no effect. We found an effect on patient-reported outcomes, especially on pain. Several trials of low risk of bias reported large effects of placebo on pain, but other similar trials reported negligible effect of placebo, indicating the importance of background factors. We identified three clinical factors that were associated with higher effects of placebo: physical placebos, patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), and falsely informing patients that the trial involved a comparison of two active treatments and no-treatment. Furthermore, two methodological factors were also associated with higher effects: small sample size and the explicit aim of studying effect of placebo. So, despite a general picture of low effects, and the risk of response bias and small sample size bias, it is likely that large effects of placebo interventions may occur in certain situations.

Extrapolation of our findings to settings outside clinical trials rests on the premise that the nature of the treatment ritual in an experimental and a clinical setting is not fundamentally different. To analyse this empirically is challenging, however, as it seems impossible to study the effect of placebo treatments in clinical practice reliably without introducing an experimental setting (Hróbjartsson 1996).

It can be difficult to interpret whether a pooled standardised mean difference is large enough to be of clinical relevance. A consensus paper found that an analgesic effect of 10 mm on a 100 mm visual analogue scale represented a 'minimal effect' (Dworkin 2008). The pooled effect of placebo on pain based on the four German acupuncture trials corresponded to 16 mm on a 100 mm visual analogue scale, which amounts to approximately 75% of the effect of non-steroidal anti-inflammatory drugs on arthritis-related pain (Gøtzsche 1990). However, the pooled effect of the three other pain trials with low risk of bias corresponded to 3 mm. Thus, the analgesic effect of placebo seems clinically relevant in some situations and not in others.

It is a question of definition whether our review evaluates the 'placebo effect'. This term does not only imply the effect of a placebo intervention as compared with a no-treatment group, but is also used to describe various other aspects of the patient-provider interaction, such as psychologically-mediated effects in general, the effect of the patient-provider interaction, the effect of suggestion, the effect of expectancies, and the effect of patients' experience of meaning (Hróbjartsson 2002b). As patients in the no-treatment group also interact with treatment providers, a no-treatment group is only untreated in the sense that they do not receive a placebo intervention (Hróbjartsson 1996). Our result is there-

fore neutral to many of the meanings of the term 'placebo effect' cited above, and we do not exclude the possibility of important effects of other aspects of the patient-provider interaction, though the methodological problems of studying such effects reliably are demanding.

Despite ethical concerns of the deceit inherent in most placebo prescriptions (Rawlinson 1985), the clinical use of placebo interventions has been advocated in editorials and articles in leading journals (Bignal 1994; Brown 1998; Ho 1994) and by influential commentators (Cochrane 1989). Questionnaire surveys indicate that placebo interventions are sometimes used in clinical practice, such as vitamin B for fatigue, or antibiotics for presumed viral infections (Hróbjartsson 2003; Tilburt 2008). In our opinion a clinical placebo intervention is ethically acceptable only if it fulfils two criteria. First, patients must be informed about the nature of the intervention. Second, the effect of placebo must be reliably demonstrated in trials that disclose to patients that they receive placebo. None of the trials included in this review tested the effect of fully disclosed placebo interventions. The tendency was the opposite, for higher effects in trials where the possibility of a placebo intervention was obscured. Thefore, placebo prescription seems to lack both ethical and empirical justification.

The use of placebos in blinded randomised trials is a precaution directed against many forms of bias, and not only against effects of placebo. Unblinded patients may differ from blinded ones in their way of reporting beneficial and harmful effects of treatment, in their tendency to seek additional treatment outside the study, and in their risk of dropping out of the study. Furthermore, unblinded staff may differ in their use of alternative forms of care and in their assessment of outcomes. Thus, even if there were no true effect of placebo, one would expect to record differences between placebo and no-treatment groups due to bias associated with lack of blinding.

AUTHORS' CONCLUSIONS

Implications for practice

We did not find that placebo interventions have important clinical effects in general. However, in certain settings placebo interventions may influence patient-reported outcomes, especially pain and nausea, though it is difficult to distinguish patient-reported effects of placebo from response bias.

Most clinical placebo prescriptions involve deceit and the effect of placebo has not been tested in trials after full disclosure that the patients receive placebo. Therfore, we suggest that placebo interventions are not used outside clinical trials.

Implications for research

The results of this review do not imply that no-treatment control

Placebo interventions for all clinical conditions (Review)

groups can replace placebo control groups in randomised clinical trials without a risk of bias.

Further research is needed to study the impact of bias (such as response bias and bias due to co-intervention) on the estimated effect of placebo, to study the association between type of outcome and bias, to explore which factors in the clinical setting are associated with different effects of placebo, and to explore the duration of effects.

ACKNOWLEDGEMENTS

We thank Henrik R. Wulff, Jos Kleijnen and Iain Chalmers for valuable comments on previous versions of the text of the review. We are grateful for the lists of relevant trials provided by Gunvor Kienle, Andrew Vickers, Harald Walach, Clive Adams, and Iain Chalmers. We also thank Romana Klefter and Roberto Oliveri for translating trial reports from Polish and Italian, and we thank the numerous placebo-trial researchers for access to additional data.

We are grateful for the assistance of Ulrik Felding in assisting us in assessing the risk of bias in the included trials and in converting the review to RevMan 5 format.

REFERENCES

References to studies included in this review

Abikoff 2004 {published data only}

Abikoff H, Hechtman L, Klein RG, Gallagher R, Fleiss K, Etcovitch J, et al.Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. *Journal of the American Academy of Child and Adolescent Psychiatry* 2004;**43**:820–9.

Adams 1976 {published data only}

Adams HG, Benson EA, Alexander ER, Vontver LA, et al.Genital herpetic infection in men and women: clinical course and effect of topical application of adenine arabinoside. *The Journal of Infectious Diseases* 1976;**133**(supplement):A151–9. [MEDLINE: 180196]

Adriaanse 1995 {published data only}

Adriaanse AH, Kollée LAA, Muytjens HL, Nijhuis JG, de Haan AFJ, Eskes TKAB. Randomized study of vaginal chlorhexidine disinfection during labor to prevent vertical transmission of group B streptococci. *European Journal of Obstetrics, Gynecology and Reproductive Biology* 1995;**61**:135–41. [MEDLINE: 7556834]

Alfano 2001 {published data only}

Alfano AP, Taylor AG, Foresman PA, Dunkl PR, McConnell GG, Conaway MR, Gillies GT. Static magnetic fields for treatment of fibromyalgia: a randomised controlled trial. *Journal of Alternative and Complementary Medicine* 2001;7:53–64.

Alford 2003 {published data only}

Alford JW, Fadale PD. Evaluation of postoperative bupivacaine infusion for pain management after anterior cruciate ligament reconstruction. *Arthroscopy* 2003;**19**(8):855–861.

Alkaissi 1999 {published data only}

Alkaissi A, Stålnert M, Kalman S. Effect and placebo effect of acupressure (P6) on nausea and vomiting after outpatient gynaecological surgery. *Acta anaesthesiologica Scandinavica* 1999; **43**:270–4.

Alkaissi 2002 {published data only}

Alkaissi A, Evartsson K, Johnsson VA, Ofenbartl L, Kalman S. P6 acupressure may relieve nausea and vomiting after gynecological surgery: an effectiveness study in 410 women. *Canadian Journal of Anaesthesia* 2002;**49**:1034–9.

Allen 1998 {published data only}

Allen JJB, Schnyder RN, Hitt SK. The efficacy of acupuncture in the treatment of major depression in women. *Psychological Science* 1998;**9**:397–401.

Allen 2006 {published data only}

Allen JJB, Schnyer RN, Chambers AS, Hitt SK, Moreno FA, Manber R. Acupuncture for depression: a randomized controlled trial. *Journal of Clinical Psychiatry* 2006;**67**:1665–73.

Andersen 1990 {published data only}

Andersen AN, Damm P, Tabor A, Pedersen IM, et al.Prevention of breast pain and milk secretion with bromocriptine after second-

Placebo interventions for all clinical conditions (Review)

trimester abortion. *Acta Obstetricia et Gynecologica Scandinavica* 1990;**69**:235–8. [MEDLINE: 2220345]

Anderson 1999 {published data only}

* Anderson B, Brackett J, Ho J, Laffel LMB. An intervention to promote family teamwork in diabetes management tasks: relationships among parenteral involvement, adherence to blood glucose monitoring, and glycemic control in young adolescents with type 1 diabetes. In: Drotar D editor(s). *Promoting adherence to medical treatment in chronic childhood illness: concepts, methods, and interventions*. Mahwah, NJ,USA: Lawrence Erlbaum Associates, 2000:347–65.

Anderson B, Brackett J, Ho J, Laffel LMB. An office-based intervention to maintain parent-adolescent teamwork in diabetic management. Impact on parent involvement, family conflict, and subsequent glycemic control. *Diabetes Care* 1999;**22**:713–21.

Antivalle 1990 {published data only}

Antivalle M, Lattuada S, Salvaggio A, Paravicini M, et al.Placebo effect and adaptation to noninvasive monitoring of BP. *Journal of Human Hypertension* 1990;4:633–7. [MEDLINE: 2096204]

Antonio 1999 {published data only}

Antonio J, Colker CM, Torina G, Shi Q, Brink W, Kalman D. Effects of standardised guggulsterone phosphate supplement on body composition in overweight adults: a pilot study. *Current Therapeutic Research* 1999;**60**:220–7.

Ascher 1979 {published data only}

Ascher LM, Turner RM. Paradoxical intention and insomnia: an experimental investigation. *Behaviour Research and Therapy.* 1979; 17:408–11. [MEDLINE: 526243]

Asmar 1996 {published data only}

* Asmar R, Boutelant S, Chaignon M, Guedon J, et al.Repeated measurment of non-invasive ambulatory blood pressure: distinction between reproducibility and the proper effect of placebo. *Blood Pressure Monitoring* 1996;1:283–8. Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducability of blood pressure measurement in hypertension. *American Journal of Hypertension* 2001;14:546–52.

Queneau P, Asmar R, Safar M. [L'effect placebo sur les pressions artérielles systolique, diastolique et pulse]. *Presse medicale* 2002;**31**: 1220–3.

Aune 1998 {published data only}

* Aune A, Alræk T, Huo L, Baerheim A. Acupuncture in prevention of cystitis in women [Kan akupunktur forebygge blærekatarr hos kvinner?]. *Tidsskrift for den Norske Laegeforening* 1998;**118**(9): 1370–2. [MEDLINE: 9612877]

Aune A, Alraek T, Lihua H, Baerheim A. Acupuncture in the prophylaxis of recurrent lower urinary tract infection in adult women. *Scandinavian Journal of Primary Health Care* 1998;**16**: 37–9.

Banner 1983 {published data only}

Banner CN, Meadows WM. Examination of the effectiveness of various treatment techniques for reducing tension. *British Journal of Clinical Psychology* 1983;**22**:183–93. [MEDLINE: 6354318]

Benedetti 1995 {published data only}

Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. *Lancet* 1995;**346**:1231. [MEDLINE: 7475687]

Benedetti 1997 {published data only}

Benedetti F, Amanzio M, Casadio C, Cavallo A, et al. Control of postoperative pain by transcutaneous electrical nerve stimulation after thoracic operations. *Annals of Thoracic Surgery* 1997;**63**: 773–6. [MEDLINE: 9066400]

Benedetti 1999a {published data only}

Benedetti F, Amanzio M, Baldi S, Casadio C, Maggi G. Inducing placebo respiratory depressant response in humans via opioid receptors. *The European Journal of Neuroscience* 1999;11:625–31.

Berg 1983 {published data only}

Berg I, Forsythe I, Holt P, Watts J. A controlled trial of 'senokot' in faecal soiling treated by behavioural methods. *Journal of Child Psychology and Psychiatry and Allied Disciplines* 1983;**24**(4):543–9. [MEDLINE: 6630328]

Biro 1997 {published data only}

Biro P, Meier T, Cummins AS. Comparison of topical anaesthesia methods for venous cannulation in adults. *European Journal of Pain* 1997;**1**:37–42.

Blackman 1964 {published data only}

Blackman S, Benton AJ, Cove LM. The effect of imipramine on enuresis. *The American Journal of Psychiatry* 1964;**120**:1194–5.

Blades 2001 {published data only}

Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. *European Journal of Clinical Nutrition* 2001;**55**(7):589–97.

Blanchard 1990a {published data only}

Blanchard EB, Appelbaum KA, Radnitz CL, Michultka D, et al.Placebo-controlled evaluation of abbreviated progressive muscle relaxation and of relaxation combined with cognitive therapy in the treatment of tension headache. *Journal of Consulting and Clinical Psychology* 1990;**58**:210–5.

Blanchard 1990b {published data only}

Blanchard EB, Appelbaum KA, Radnitz CL, Morrill B, et al.A controlled evaluation of the thermal biofeedback and thermal biofeedback combined with cognitive therapy in the treatment of vascular headache. *Journal of Consulting and Clinical Psychology* 1990;**58**:216–24.

Block 1980 {published data only}

Block J. Effects of rational emotive therapy on overweight adults. *Psychotherapy: Theory, Research and Practice* 1980;17(3):277–80.

Bosley 1989 {published data only}

Bosley F, Allen TW. Stress management training for hypertensives: cognitive and physiological effects. *Journal of Behavioral Medicine* 1989;**12**(1):77–89. [MEDLINE: 2746644]

Bova 1999 {published data only}

Bova JG, Bhattacharjee N, Jurdi R, Bennet WF. Comparison of no medication, placebo and hyoscyamine for reducing pain during a barium enema. *American Journal of Roentgenology* 1999;**172**: 1285–7.

Bramston 1985 {published data only}

Bramston P, Spence SH. Behavioural versus cognitive social-skills training with intellectually-handicapped adults. *Behaviour Research and Therapy* 1985;**23**(3):239–46. [MEDLINE: 4004703]

Placebo interventions for all clinical conditions (Review)

Brill 1964 {published data only}

Brill NQ, Koegler RR, Epstein LJ, Forgy EW. Controlled study of psychiatric outpatient treatment. *Archives of General Psychiatry* 1964;**10**:581–95.

Brinkhaus 2006 {published data only}

Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Wagenpfeil S, et al.Acupuncture in patients with chronic low back pain: a randomized controlled trial. *Arch Intern Med* 2006;**166**:450–7.

Bullock 2002 {published data only}

Bullock ML, Kiresuk TJ, Sherman RE, Lenz SK, Culliton PD, Boucher TA, et al.A large randomized placebo controlled study of auricular acupuncture for alcohol dependence. *Journal of Substance Abuse Treatment* 2002;**22**:71–7.

Cabrini 2006 {published data only}

Cabrini L, Gioia L, Gemma M, Melloni G, Caretta A, Ciriaco P, Puglisi A. Acupuncture for diagnostic bronchoscopy: a prospetive, randomized, placebo-controlled study. *American Journal of Chinese Medicine* 2006;**34**:409–15.

Camatte 1969 {published data only}

Camatte R, Gerolami A, Sarles H. Comparative study of the effect of various drugs and placebo on pain associated with gastroduodenal ulcers [Studio comparativo dell'azione di diversi trattamenti e dei placebo sulla crisi dolorosa dell'ulcera gastro-duodenale]. *La Clinica terapeutica* 1969;**49**:411–9.

Camberg 1999 {published data only}

Camberg L, Woods P, Ooi WL, Hurley A, et al.Evaluation of simulated presence: a personalised approach to enhance well-being in persons with Alzheimer's disease. *JAGS* 1999;47:446–52.

Canino 1994 {published data only}

Canino E, Cardona R, Monsalve P, Acuna FP, et al.A behavioral treatment program as a therapy in the control of primary hypertension. *Acta Cientifica Venezolana* 1994;**45**:23–30. [MEDLINE: 8525757]

Carbajal 1999 {published data only}

Carbajal R, Chauvet X, Couderc S, Olivier-Martin M. Randomised trial of analgesic effects of sucrose, glucose, and pacifiers in term neonates. *BMJ* 1999;**319**:1393–7.

Carter 2001 {published data only}

Carter MC, Perzanowski MS, Raymond A, Platts-Mills TAE. Home intervention in the treatment of asthma among inner-city children. *The Journal of Allergy and Clinical Immunology* 2001;**108**:732–7.

Carter 2003 {published data only}

Carter JC, Olmsted MP, Kaplan AS, McCabe RE, Mills JS, Aime A. Self-help for bulimia nervosa: a randomized controlled trial. *American Journal of Psychiatry* 2003;**160**:973–8.

Cesarone 2001 {published data only}

Cesarone MR, Incandela L, Belcaro G, De Sanctis MT, et al. Twoweek topical treatment with essaven gel patients with diabetic microangiopathy. A placebo-controlled, randomized study. *Angiology* 2001;**52**(suppl.3):S43–48.

Chenard 1991 {published data only}

Chenard JR, Marchand S, Charest J, Jinxue L, et al.Evaluation of a behavioral intervention for chronic low-back pain: 'The interactional back school' [Évaluation d' un traitement comportmental de la lombalgie chronique: 'l' école interactionelle du dos']. *Science et Comportement* 1991;**21**(4):225–39.

Classen 1983 {published data only}

Classen W. Placebo application, personality, and headaches: a signal detection theory analysis of experimentally induced pain in comparison to clinical pain. *Pharmacopsychiatry* 1984;**17**:98–101. [MEDLINE: 6377336]

* Classen W, Feingold E, Netter P. Influence of sensory suggestibility on treatment outcome in headache patients. *Neuropsychobiology* 1983;**10**:44–7. [MEDLINE: 6657038]

Colker 1999 {published data only}

Colker CM, Kalman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John's wort on body fat loss, lipid levels, and mood states in overweight healthy adults. *Current Therapeutic Research* 1999;**60**:145–53.

Conn 1986 {published data only}

Conn IG, Marshall AH, Yadev SN, Daly J, Jaffer M. Transcutaneous electrical nerve stimulation following appendicectomy: the placebo effect. *Annals of the Royal College of Surgeons of England* 1986;**68**:191–2. [MEDLINE: 3538985]

Corver 2006 {published data only}

* Corver K, Kerkhof M, Brussee JE, Brunekreef B, van Strien RT, Vos AP, et al.House dust mite allergen reduction and allergy at 4 yr: follow up of the PIAMA-study. *Pediatric Allergy and Immunology* 2006;**17**:329–36.

Koopman LP, van Strien RT, Kerkhof M, Wijga A, Smit HA, de Jongste JC, et al.Placebo-controlled trial of house dust miteimpermeable mattress covers. *American Journal of Respiratory and Critical Care Medicine* 2002;**166**:307–13.

Costello 2006 {published data only}

Costello M, Ramundo M, Christopher NC, Powel KR. Etyhyl vinyl chloride vapocoolant spray fails to decrease pain associated with intravenous cannulation in children. *Clinical Pediatrics* 2006; **45**:628–32.

Coyne 1995 {published data only}

Coyne P, MacMurren M, Izzo T, Kramer T. Transcutaneous electrical nerve stimulator for procedural pain associated with intravenous needlesticks. *Journal of Intravenous Nursing* 1995;**18** (5):263–7. [MEDLINE: 7562226]

Crosby 1994 {published data only}

Crosby L, Palarski VA, Cottington E, Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. *Heart & Lung* 1994;**23**:493–9. [MEDLINE: 7852064]

Cupal 2001 {published data only}

Cupal DD, Brewer BW. Effects of relaxation and guided imagery on knee strength, reinjury anxiety, and pain following anterior cruciate ligament reconstruction. *Rehabilitation Psychology* 2001;**46**:28–43.

Davidson 1980 {published data only}

Davidson A, Denney DR, Elliott CH. Suppression and substitution in the treatment of nailbiting. *Behaviour Research and Therapy* 1980;**18**:1–9. [MEDLINE: 7369982]

De Sanctis 2001 {published data only}

De Sanctis MT, Incandela L, Belcaro G, Cesarone MR. Topical treatment of venous microangiopathy in patients with venous

Placebo interventions for all clinical conditions (Review)

ulceration with Essaven gel. A placebo controlled, randomized study. *Angiology* 2001;**52 (suppl 3)**:S29–34.

Defrin 2005 {published data only}

Defrin R, Ariel E, Peretz C. Segmental noxious versus innocuous electrical stimulation for chronic pain relief and the effect of fading sensation during treatment. *Pain* 2005;**115**:152–60.

Dibble 2007 {published data only}

Dibble SL, Luce J, Cooper BA, Isreal J, Cohen M, Nussey B, Rugo H. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. *Oncology Nursing Forum* 2007;**34**: 813–20.

Ditto 2003 {published data only}

Ditto B, France CR, Lavoie P, Roussos M, Adler PS. Reducing reactions to blood donation with applied muscle tension: a randomized controlled trial. *Transfusion* 2003;**43**:1269–75.

Ditto 2006 {published data only}

Ditto B, France CR. The effects of applied tension on symptoms in French-speaking blood donors: a randomized trial. *Health Psychology* 2006;**25**:433–7.

Doty 1975 {published data only}

Doty DW. Role playing and incentives in the modification of the social interaction of chronic psychiatric patients. *Journal of Consulting and Clinical Psychology* 1975;**43**(5):676–82. [MEDLINE: 1176682]

Double 1993 {published data only}

Double DB, Warren GC, Evans M, Rowlands MP. Efficacy of maintenance use of anticholinergic agents. *Acta Psychiatrica Scandinavica* 1993;**88**:381–4. [MEDLINE: 7905226]

Dundee 1986 {published data only}

Dundee JW. Belfast experience with P6 acupuncture antiemesis. *The Ulster Medical Journal* 1990;**59**(1):63–70. [MEDLINE: 2349751]

* Dundee JW, Chestnutt WN, Ghaly RG, Lynas AGA. Traditional Chinese acupuncture: a potentially useful antiemetic?. *British Medical Journal* 1986;**293**:583–4. [MEDLINE: 3092933] Dundee JW, Ghaley RG, Bill KM, Chestnutt WN, Fitzpatrick KTJ, Lynas AGA. Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting. *British Journal of Anaesthesia*

1989;**63**:612–8. [MEDLINE: 2605083]

Dundee JW, McMillan C. Clinical uses of P6 acupuncture antiemesis. *Acupuncture & Electro-therapeutics Research* 1990;**15**: 211–5. [MEDLINE: 1982043]

Lynas AGA, Ghaly RG, Dundee JW. Acupuncture reduced the emetic effects of nalbuphine premedication. *British Journal of Anaesthesia* 1986;**58**:1331P–2P.

Elliott 1978 {published and unpublished data}

Elliott CH, Denney DR. A multiple-component treatment approach to smoking reduction. *Journal of Consulting and Clinical Psychology* 1978;**46**(6):1330–9. [MEDLINE: 730881]

Erdogmus 2007 {published data only}

Erdogmus CB, Resch KL, Sabitzer R, Müller H, Nuhr M, Schöggl A, et al. Physiotherapy-based rehabilitation following disc herniation operation. *Spine* 2007;**32**:2041–9.

Espie 1989 {published data only}

Espie CA, Brooks DN, Lindsay WR. An evaluation of tailored psychological treatment of insomnia. *Journal of Behavior Therapy*

and Experimental Psychiatry 1989;**20**(2):143–53. [MEDLINE: 2685045]

* Espie CA, Lindsay WR, Brooks DN, Hood EM, Turvey T. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. *Behaviour Research and Therapy* 1989;**27**(1):79–88. [MEDLINE: 2914008]

Etringer 1982 {published data only}

Etringer BD, Cash TF, Rimm DC. Behavioral, affective and cognitive effects of participant modeling and an equally credible placebo. *Behavior Therapy* 1982;**13**:476–85.

Etter 2002 {published data only}

Etter J, Lazlo E, Zellweger J, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. *Journal of Clinical Psychopharmacology* 2002;**22**:487–95.

Faas 1993 {published data only}

* Faas A, Chavannes AW, van Eijk JTM, Gubbels JW. A randomized, placebo-controlled trial of exercise therapy in patients with acute low back pain. *Spine* 1993;**18**(11):1388–95. [MEDLINE: 8235809]

Faas A, van Eijk JTM, Chavannes AW, Gubbels JW. A randomized trial of exercise therapy in patients with acute low back pain. Efficacy on sickness absence. *Spine* 1995;**20**(8):941–7. [MEDLINE: 7644960]

Fanti 2003 {published data only}

Fanti L, Gemma M, Passaretti S, Guslandi M, Testoni PA, Casti A, Torri G. Electroacupuncture analgesia for colonoscopy: a prospective, randomised, placebo-controlled study. *The American Journal of Gastroenterology* 2003;**98**:312–6.

Fiorellini 2005 {published data only}

Fiorellini JP, Howell TH, Cochran D, Malmquist J, Lilly LC, et al.Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. *Journal of Periodontology* April 2005;**76**(4):605–13.

Fisher 2006 {published data only}

Fisher P, McCarney R, Hasford C, Vickers A. Evaluation of specific and non-specific effects in homeopathy: feasibility study for a randomised trial. *Homeopath* 2006;**95**:215–22.

Forster 1994 {published data only}

Forster EL, Kramer JF, Lucy SD, Scudds RA, et al.Effects of TENS on pain, medications, and pulmonary function following coronary artery bypass graft surgery. *Chest* 1994;**106**(5):1343–8. [MEDLINE: 7956382]

Foster 2004 {published data only}

Foster KA, Liskin J, Cen S, Abbot A, Armisen V, Globe D, et al. The Trager approach in the treatment of chronic headache: a pilot study. *Alternative Therapies in Health and Medicine* 2004;**10**:40–6.

Foster 2007 {published data only}

Foster NE, Thomas E, Barlas P, Hill JC, Young J, Mason E, Hay EM. Acupuncture as an adjunct to excercise based physiotherapy for osteoarthritis of the knee: randomised controlled trial. *BMJ* 2007;**335**:436.

Frank 1990 {published data only}

Frank E, Kupfer DJ. Does a placebo tablet affect psychotherapeutic treatment outcome? Results from the Pittsburgh study of

Placebo interventions for all clinical conditions (Review)

maintenance therapies in recurrent depression. *Psychotherapy Research* 1992;**2**(2):102–11.

Frank E, Kupfer DJ, Buhari A, McEachran AB, Grochocinski VJ. Imipramine and weight gain during the long-term treatment of recurrent depression. *Journal of Affective Disorders* 1992;**26**:65–72. [MEDLINE: 1430670]

* Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. Three-year outcomes for maintenance therapies in recurrent depression. *Archives of General Psychiatry* 1990;**47**: 1093–9. [MEDLINE: 1417428]

Frankel 1978 {published data only}

Frankel BL, Patel DJ, Horwitz D, Friedewald WT, et al. Treatment of hypertension with biofeedback and relaxation techniques. *Psychosomatic Medicine* 1978;**40**(4):276–93. [MEDLINE: 356078]

Frega 1994 {published data only}

Frega A, Stentella P, Di Renzi F, Gallo G, et al.Pain evaluation during carbon dioxide laser vaporization for cervical intraepithelial neoplasia: a randomized trial. *Clinical and Experimental Obstetrics and Gynecology* 1994;**21**(3):188–91. [MEDLINE: 7923801]

Fuchs 1977 {published data only}

Fuchs CZ, Rehm LP. A self-control behavior therapy program for depression. *Journal of Consulting and Clinical Psychology* 1977;**45** (2):206–15. [MEDLINE: 850005]

Gluckman 1980 {published data only}

Gluckman S, Barling J. Effects of a remedial program on visualmotor perception in spina bifida children. *The Journal of Genetic Psychology* 1980;**136**:195–202.

Godfrey 1973 {published data only}

Godfrey S, Silverman M. Demonstration of a placebo response in asthma by means of exercise testing. *Journal of Psychosomatic Research* 1973;**17**:293–7. [MEDLINE: 4206466]

Goldstein 2000 {published data only}

Goldstein AJ, de Beurs E, Chambless DL, Wilson KA. EMDR for panic disorder with agoraphobia: combination with waiting list and credible attention-placebo control conditions. *Journal of Consulting and Clinical Psychology* 2000;**68**(6):947–56.

Goodenough 1997 {published data only}

Goodenough B, Kampel L, Champion GD, Laubreaux L, Nicholas K, Ziegler JB, et al.An investigation of the placebo effect and agerelated factors in the report of needle pain from venipuncture in children. *Pain* 1997;**72**:383–91. [MEDLINE: 9313279]

Gracely 1979 {published and unpublished data}

Gracely RH, Deeter WR, Wolskee PJ, Wear BL, et al. The effect of naloxone on multidimensionel scales of postsurgical pain in nonsedated patients. *Abstracts - Society for Neuroscience* 1979;**5**:609.

Gracely 1983 {published and unpublished data}

Gracely RH, Dubner R, Wolskee PJ, Deeter W. Placebo and naloxone can alter post-surgical pain by separate mechanisms. *Nature* 1983;**306**:264–5. [MEDLINE: 6646208]

Grammer 1984 {published data only}

Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R. Asthma as a variable in a study of immunotherapy for allergic rhinitis. *The Journal of Allergy and Clinical Immunology* 1984;**73**(5, part 1):557–60. [MEDLINE: 6715723]

GRECHO 1989 {published data only}

Fingerhut A. Use of homeopathy for the restoration of transit following abdominal surgery [Homéopathie dans la reprise du transit après chirurgie abdominale]. *Chirurgie; Memoires de l'Academie de Chirurgie* 1990;**116**:404–8. [MEDLINE: 2096041] * GRECHO, U292 inserm, ARC, GREPA. Evaluation of the effects of two homoeopathic preparations on the resumption of intestinal peristalsis after digestive tract surgery. A multicentre controlled trial [Evalution de deux produits homéopathiques sur la reprise du transit après chirurgie digestive. Un essai contrôlé multicentrique]. *La Presse Médicale* 1989;**18**(2):59–62. [MEDLINE: 2521722] Mayaux MJ, Guihard-Moscato ML, Schwartz D, Benveniste J. Controlled clinical trial of homoepathy in postoperative ileus. *Lancet* 1988;**i**:528–9. [MEDLINE: 2893935]

Guglielmi 1982 {published data only}

Guglielmi RS, Roberts AH, Patterson R. Skin temperature biofeedback for Raynaud's disease: a double-blind study. *Biofeedback and Self-Regulation* 1982;7(1):99–120. [MEDLINE: 7093357]

Hall 1974 {published data only}

Hall SM, Hall RG, Hanson RW, Borden BL. Permanence of two self-managed treatments of overweight in university and community populations. *Journal of Consulting and Clinical Psychology* 1974;**42**(6):781–6. [MEDLINE: 4436463]

Hallström 1988 {published data only}

Crouch G, Robson M, Hallstrom C. Benzodiazepine dependent patients and their psychological treatment. *Progress in Neuropsychopharmacology & Biological Psychiatry* 1988;**12**:503–10. [MEDLINE: 2900539]

* Hallström C, Crouch G, Robsen M, Shine P. The treatment of tranquillizer dependence by propranolol. *Postgraduate Medical Journal* 1988;**64**(suppl 2):40–4. [MEDLINE: 2905797]

Hanson 1976 {published data only}

Hanson RW, Borden BL, Hall SM. Use of programmed instruction in teaching self-management skills to overweight adults. *Behavior Therapy* 1976;7(3):366–73.

Hargreaves 1989 {published data only}

Hargreaves A, Lander J. Use of transcutaneous electrical nerve stimulation for postoperative pain. *Nursing Research* 1989;**38**(3): 159–61. [MEDLINE: 2785684]

Harrison 1975 {published data only}

Harrison RF, de Louvois J, Blades M, Hurley R. Doxycycline treatment and human infertility. *Lancet* 1975;**i**(7907):605–7. [MEDLINE: 47949]

Hashish 1986 {published data only}

Hashish I, Harvey W, Harris M. Anti-inflammatory effects of ultrasound therapy: evidence for a major placebo effect. *British Journal of Rheumatology* 1986;**25**:77–81. [MEDLINE: 2417648]

Hashish 1988 {published data only}

* Hashish I, Hai HK, Harvey W, Feinmann C, Harris M. Reduction of postoperative pain and swelling by ultrasound treatment: a placebo effect. *Pain* 1988;**33**:303–11. [MEDLINE: 3419838] Ho KH, Hashish I, Salmon P, Freeman R, Harvey W. Reduction of post-operative swelling by a placebo effect. *Journal of Psychosomatic Research* 1988;**32**(2):197–205. [MEDLINE: 3404502]

Placebo interventions for all clinical conditions (Review)

Hawkins 1995 {published data only}

Hawkins PJ, Liossi C, Ewart BW, Hatira P, Kosmidis VH, Varvutsi M. Hypnotherapy for control of anticipatory nausea and vomiting in children with cancer: preliminary findings. *Psycho-Oncology* 1995;4:101–6.

Heinzl 1981 {published data only}

Heinzl S, Andor J. Preoperative administration of prostaglandin to avoid dilatation-induced damage in first-trimester pregnancy terminations. *Gynecologic and Obstetric Investigation* 1981;**12**: 29–36. [MEDLINE: 7250779]

Helms 1987 {published data only}

Helms JM. Acupuncture for the management of primary dysmenorrhea. *Obstetrics & Gynecology* 1987;**69**(1):51–6. [MEDLINE: 3540764]

Hong 1993 {published data only}

Hong C, Chen Y, Pon CH, Yu J. Immediate effects of various physical medicine modalities on pain threshold of an active myofascial trigger point. *Journal of Muscoloskeletal Pain* 1993;1(2): 37–53.

Hossmann 1981 {published data only}

Hossmann V, FitzGerald GA, Dollery CT. Influence of hospitalization and placebo therapy on blood pressure and sympathetic function in essential hypertension. *Hypertension* 1981; **3**:113–8.

Hovell 2003 {published data only}

Hovell MF, Sipan CL, Blumberg EJ, Hofstetter CR, Slymen D, Friedman L, et al. Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. *American Journal of Public Health* 2003;**93**:1871–7.

Hruby 2006 {published data only}

Hruby G, Ames C, Chen C, Yan Y, Sagar J, Baron P, Landman J. Assessment of efficacy of transcutaneous electrical nerve stimulation for pain management during office-based flexible cystoscopy. *Urology* 2006;**67**:914–7.

Hutton 1991 {published data only}

Hutton N, Wilson MH, Mellits D, Baumgardner R, et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. *The Journal of Pediatrics* 1991;**118**(1):125–30. [MEDLINE: 1670783]

Hyland 2006 {published data only}

Hyland MR, Webber-Gaffney A, Cohen L, Lichtman SW. Randomized controlled trial of calcaneal taping, sham taping, and plantar fascia stretching for the short-term management of plantar heel pain. *Journal of Orthopaedic and Sports Physical Therapy* 2006; **36**:364–71.

Hyman 1986 {published data only}

Hyman GJ, Stanley RO, Burrows GD, Horne DJ. Treatment effectiveness of hypnosis and behaviour therapy in smoking cessation: a methodological refinement. *Addictive Behaviors* 1986; 11:355–65. [MEDLINE: 3812046]

Irjala 1993 {published data only}

Irjala J, Kanto J, Scheinin M. Monoamine metabolite and catecholamine measurements in cerebrospinal fluid in determining the quality of the pre-operative night's sleep. *European Journal of Anaesthesiology* 1993;**10**:393–6. [MEDLINE: 11767314]

Irvin 1996 {published data only}

Irvin JH, Domar AD, Clark C, Zuttermeister PC. The effects of relaxation response training on menopausal symptoms. *Journal of Psychosomatic Obstetrics and Gynaecology* 1996;**17**:202–7. [MEDLINE: 8997686]

Jacobs 1971 {published data only}

Jacobs MA, Spilken AZ, Norman MM, Wohlberg GW, Knapp PH. Interaction of personality and treatment conditions associated with success in a smoking control program. *Psychosomatic Medicine* 1971;**33**(6):545–56. [MEDLINE: 5148984]

Jacobson 1978 {published data only}

Jacobson NS. Specific and nonspecific factors in the effectiveness of a behavioral approach to the treatment of marital discord. *Journal* of Consulting and Clinical Psychology 1978;**46**(3):442–52. [MEDLINE: 670488]

Jakes 1992 {published data only}

Jakes SC, Hallam RS, McKenna L, Hinchcliffe R. Group cognitive therapy for medical patients: an application to tinnitus. *Cognitive Therapy and Research* 1992;**16**(1):67–82.

Kaptchuk 2008 {published data only}

Conboy LA, Wasserman RH, Jacobson EE, Davies RB, Legedza ATR, Park M, et al.Investigating placebo effects in irritable bowel syndrome: a novel research design. *Contemporary Clinical Trials* 2006;**27**(2):123–34.

* Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobsen EE, et al.Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. *BMJ* 2008;**online**:1–8.

Karst 2007 {published data only}

Karst M, Wintherhalter M, Münte S, Francki B, Hondronikos A, Eckardt A, et al.Auricular acupuncture for dental anxiety: a randomized controlled trial. *Anesthesia & Analgesia* 2007;**104**: 295–300.

Karunakaran 1997 {published and unpublished data}

Karunakaran S, Hammersley MS, Morris RC, Turner RC, et al. The fasting hyperglycaemia study: III. randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. *Metabolism* 1997;**46**(12,suppl 1):56–60. [MEDLINE: 9439561]

Kendall 1979 {published data only}

Kendall PC, Williams L, Pechacek TF, Graham LE, Shisslak C, Herzoff N. Cognitive-behavioral and patient education interventions in cardiac catheterization procedures: the Palo Alto medical psychology project. *Journal of Consulting and Clinical Psychology* 1979;**47**(1):49–58. [MEDLINE: 429666]

Kerr 2003 {published data only}

Kerr AR, Drexel CA, Spielman AI. The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology & Endodontics* 2003;**96**:685–94.

Killeen 2004 {published data only}

Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF. Effectiveness of naltrexone in a community treatment program. *Alcoholism, Clinical and Experimental Research* 2004;**28**:1710–7.

Placebo interventions for all clinical conditions (Review)

Killen 1990 {published data only}

Fortmann SP, Killen JD, Telch MJ, Newman B. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford stop smoking project. *JAMA* 1988;**260**(11): 1575–80. [MEDLINE: 3045351]

* Killen JD, Fortmann SP, Newman B, Vardy A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioural treatments for smoking relapse prevention. *Journal of Consulting and Clinical Psychology* 1990;**58**(1):85–92. [MEDLINE: 2319049]

Kilmann 1987 {published data only}

Kilman PR, Milan RJ, Boland JP, Nankin HR, Davidson E, West MO, et al.Group treatment of secondary erectile dysfunction. *Journal of Sex & Marital Therapy* 1987;**13**:168–82.

Klerman 1974 {published data only}

* Klerman GL, DiMascio A, Weisman M, Prusoff B. Treatment of depression by drugs and psychotherapy. *The American Journal of Psychiatry* 1974;**131**(2):186–91. [MEDLINE: 4587807] Paykel ES, DiMascio A, Haskell D, Prusoff BA. Effects of maintenance amitriptyline and psychotherapy on symptoms of depression. *Psychological Medicine* 1975;**5**:67–77. [MEDLINE: 235144]

Paykel ES, DiMascio A, Klerman GL, Prusoff BA, et al.Maintenance therapy of depression. *Pharmakopsychiatrie, Neuro-Psychopharmakologie* 1976;**9**:127–39. [MEDLINE: 981327]

Paykel ES, Weissman MM, Prusoff BA. Social maladjustment and severity of depression. *Comprehensive Psychiatry* 1978;**19**(2):121–8. [MEDLINE: 630854]

Weissman MM, Klerman GL, Paykel ES, Prusoff B. Treatment effects on the social adjustment of depressed patients. *Archives of General Psychiatry* 1974;**30**:771–8. [MEDLINE: 4832185]

Kober 2002 {published data only}

Kober A, Scheck T, Greher M, Lieba F, Fleischhackl R, Fleischhackl S, et al. Prehospital analgesia with acupressure in victims of minor trauma: a prospective, randomized, double-blinded trial. *Anesthesia and Analgesia* 2002;**95**:723–7.

Kokol 2005 {published data only}

Kokol R, Berger C, Haas J, Kopera D. Venous leg ulcers: no improvement of wound healing with 685-nm low level laser therapy. Randomised, placebo-controlled, double-blind study. *Hautarzt* 2005;**56**:570–5.

Kotani 2001 {published data only}

Kotani N, Kushikata T, Suzuki A, Hashimoto H, Muraoka M, Matsuki A. Insertion of intradermal needles into painful points provides analgesia for intractable abdominal scar pain. *Regional Anesthesia and Pain Medicine* 2001;**26**:532–8.

Lamazza 1986 {published data only}

Lamazza A, Tofi A, Bolognese A, Fontana B, De Masi E, Frontespezi S. Effects of pinaverium bromide in the premedication of endoscopic retrograde cholangio-pancreatography and on motor activity of the sphincter of Oddi. *Current Medical Research and Opinion* 1986;**10**(4):280–4. [MEDLINE: 3780291]

Lander 1993 {published data only}

Lander J, Fowler-Kerry S. TENS for children's procedural pain. *Pain* 1993;**52**:209–16. [MEDLINE: 8455969]

Larson 2005 {published data only}

Larson CP, Hoque AB, Larson CP, Khan AM, Saha UR. Initiation of zinc treatment for acute childhood diarrhoea and risk for vomiting or regurgitation: a randomized, double-blind, placebo-controlled trial. *Journal of Health, Population and Nutrition* 2005; **23**:311–9.

Lee 2005 {published data only}

Lee PC, Jawad MS, Hull JD, West WH, Shaw K, Eccles R. The antitussive effect of placebo treatment on cough associated with acute upper respiratory infection. *Psychosomatic Medicine* 2005;**67**: 314–7.

Leibing 2002 {published data only}

Leibing E, Leonhardt U, Köster G, Goerlitz A, Rosenfeldt JA, Hilgers R, Ramadori G. Acupuncture treatment of chronic lowback pain: a randomized, blinded, placebo-controlled trial with 9months follow-up. *Pain* 2002;**96**:189–96.

Levine 1984 {published data only}

Levine JD, Gordon NC. Influence of the method of drug administration of analgesic response. *Nature* 1984;**312**:755–6. [MEDLINE: 6514008]

Levitt 1981 {published data only}

Levitt M, Wilson A, Bowman D, Kemel S, et al.Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10 and 15 mg of 9-tetrahydrocannabinol in cancer chemotherapy. Ophtalmologic implications. *Journal of Clinical Pharmacology* 1981;**21**:103s–9s. [MEDLINE: 6271814]

Licciardone 2003 {published data only}

Licciardone JC, Stoll ST, Fulda KG, Russo DP, Siu J, Winn W, Swift J Jr. Osteopathic manipulative treatment for chronic low back pain: a randomized controlled trial. *Spine* 2003;**28**:1355–62.

Lick 1975 {published data only}

Lick J. Expectancy, false galvanic skin response feedback and systematic desensitization in the modification of phobic behavior. *Journal of Consulting and Clinical Psychology* 1975;**43**(4):557–67. [MEDLINE: 239972]

Lick 1977 {published data only}

Lick JR, Heffler D. Relaxation training and attention placebo in the treatment of severe insomnia. *Journal of Consulting and Clinical Psychology* 1977;**45**(2):153–61. [MEDLINE: 321491]

Limoges 2004 {published data only}

Limoges MF, Rickabaugh B. Evaluation of TENS during screening flexible sigmoidoscopy. *Gastroenterol Nurs* 2004;**27**:61–8.

Lin 2002 {published data only}

Lin JG, Lo MW, Wen YR, Hsieh CL, Tsai SK, Sun WZ. The effect of high and low frequency electroacupuncture in pain after lower abdominal surgery. *Pain* 2002;**99**:509–14.

Lincoln 2003 {published data only}

Lincoln NB, Flannaghan T. Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial. *Stroke* 2003;**34**:111–5.

Linde 2005 {published data only}

Linde K, Streng A, Jurgens S, Hoppe A, Brinkhaus B, Witt C, et al.Acupuncture for patients with migraine: a randomized controlled trial. *JAMA* 2005;**293**:2118–25.

Placebo interventions for all clinical conditions (Review)

Copyright $\textcircled{\sc 0}$ 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Lindholm 1996 {published data only}

Johanneson M, Borgquist L, Jönsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care. *Journal of Internal Medicine* 1996;**240**:23–9. [MEDLINE: 8708587]

* Lindholm LH, Ekbom T, Dash C, Isacsson Å, et al.Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main result of the CELL study. *Journal of Internal Medicine* 1996;**240**:13–22. [MEDLINE: 8708586]

Liossi 2003 {published data only}

Liossi C, Hatira P. Clinical hypnosis in the alleviation of procedurerelated pain in pediatric oncology patients. *International Journal of Clinical and Experimental Hypnosis* 2003;**51**:4–28.

Longo 1988 {published data only}

Longo DJ, Clum GA, Yaeger NJ. Psychosocial treatment for recurrent genital herpes. *Journal of Consulting and Clinical Psychology* 1988;**56**(1):61–6. [MEDLINE: 3279091]

Lorr 1961 {published data only}

Lorr M, McNair DM, Weinstein GJ, Michaux WW, et al. Mepromate and chlorpromazine in psychotherapy. *Archives of General Psychiatry* 1961;**4**:381–9.

Macaluso 1995 {published data only}

Macaluso AD, Conelly AM, Hayes WB, Houb MC, et al. Oral transmucosal fentanyl citrate for premedication in adults. *Anesthesia and Analgesia* 1996;**82**:158–61. [MEDLINE: 8712394]

Malcolm 1980 {published data only}

Malcolm RE, Sillet RW, Turner JAM, Ball KP. The use of nicotine chewing gum as an aid to stopping smoking. *Psychopharmacology* 1980;**70**:295–6. [MEDLINE: 6777804]

Markland 1993 {published data only}

Markland D, Hardy L. Anxiety, relaxation and anaesthesia for daycase surgery. *British Journal of Clinical Psychology* 1993;**32**: 493–504. [MEDLINE: 8298547]

Matros 2006 {published data only}

Matros E, Rocha F, Zinner M, Wang J, Ashley S, Breen E, et al.Does gum chewing ameliorate postoperative ileus? Results of a prospective, randomized, placebo-controlled trial. *Journal of the American College of Surgeons* 2006;**202**:773–8.

Mattarei 1985 {published data only}

Matterei M, De Venuto G, Dal Follo M, Miori R. Is placebo active in essential arterial hypertension?[Agisce il placebo nell'ipertensione arteriosa essenziale?]. *Minerva Cardioangiologica* 1985;**33**:725–9.

May 1988 {published data only}

May O, Hansen NCG. Comparison of terbutaline, isotonic saline, ambient air and non-treatment in patients with reversible chronic airway obstruction. *The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology* 1988;**1**:527–30. [MEDLINE: 3169222]

McLachlan 1991 {published data only}

* McLachlan DRC, Dalton AJ, Kruck TPA, Bell MY, et al.Intramuscular desferrioxamine in patients with Alzheimer's disease. *Lancet* 1991;**337**:1304–8. [MEDLINE: 1674295] McLachlan DRC, Smith WL, Kruck TP. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. *Therapeutic Drug Monitoring* 1993;**15**(6):602–7. [MEDLINE: 8122302]

McMillan 1994 {published and unpublished data}

McMillan CM. Transcutaneous electrical stimulation of Neiguan anti-emetic acupuncture point in controlling sickness following opioid analgesia in major orthopaedic surgery. *Physiotherapy* 1994; **80**(1):5–9.

Medici 2002 {published data only}

Medici TC, Grebski E, Wu J, Hinz G, Wuthrich B. Acupuncture and bronchial asthma: a long-term randomized study of the effects of real versus sham acupuncture compared with controls in patients with bronchial asthma. *Journal of Alternative and Complementary Medicine* 2002;**8**:737–50.

Mehl-Madrona 2007 {published data only}

Mehl-Medrona L, Kligler B, Silverman S, Lynton H, Merrell W. The impact of acupuncture and craniosacral therapy interventions on clinical outcomes in adults with asthma. *Explore* 2007;**3**(1): 28–36.

Melchart 2005 {published data only}

Melchart D, Streng A, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, et al.Acupuncture in patients with tension-type headache: randomised controlled trial. *BMJ* 2005;**331**:376–82.

Moffet 1996 {published data only}

Moffett JAK, Richardson PH, Frost H, Osborn A. A placebo controlled double blind trial to evaluate the effectiveness of pulsed short wave therapy for osteoarthritic hip and knee pain. *Pain* 1996; **67**:121–7. [MEDLINE: 8895239]

Molsberger 2002 {published data only}

Molsberger AF, Mau J, Pawelec DB, Winkler J. Does acupuncture improve the orthopedic management of chronic low back pain: a randomized, blinded, controlled trial with 3 months follow up. *Pain* 2002;**99**:579–87.

Moreland 2006 {published data only}

Moreland EC, Volkening LK, Lawlor MT, Chalmers KA, Anderson BJ, Laffel LM. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. *Archives of Internal Medicine* 2006; **166**:689–95.

Morey 2006 {published data only}

Morey MC, Ekelund C, Pearson M, Crowley G, Peterson M, et al. Project LIFE: a partnership to increase physical activity in elders with multiple chronic illnesses. *J Aging Physical Act* 2006;**14**: 324–43.

Morton 1993 {published data only}

Morton AR, Fazio SM, Miller D. Efficacy of laser-acupuncture in the prevention of exercise-induced asthma. *Annals of Allergy* 1993; **70**:295–8. [MEDLINE: 8466094]

Murphy 1982 {published data only}

Murphy JK, Williamson DA, Buxton AE, Moody SC, et al. The long-term effects of spouse involvement upon weight loss and maintenance. *Behavior Therapy* 1982;**13**:681–93.

Mussell 1988 {published data only}

Mussell MJ, Hartley JPR. Thrachea-noise biofeedback in asthma: a comparison of the effect of thrachea-noise biofeedback, a bronchodilator, and no treatment on the rate of recovery from

Placebo interventions for all clinical conditions (Review)

excercise- and eucapnic hyperventilation-induced asthma. *Biofeedback and Self-regulation* 1988;**13**(3):219–34. [MEDLINE: 3228551]

Najnigier 1997 {published data only}

Najnigier B, Patkowski W, Zieniewicz K, Nyckowski P, et al.Zofran (ondansetron) in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy [Zofran w zapobieganiu nudnosciom i wymiotom po cholecystektomii laparoskopowej]. *Acta Endoscopica Polona* 1997;7(3):125–8.

Nandi 1976 {published data only}

Nandi DN, Ajmany S, Ganguli H, Banerjee G, et al. A clinical evaluation of depressives found in a rural survey in India. *The British Journal of Psychiatry; the Journal of Mental Science* 1976;**128**: 523–7. [MEDLINE: 1276560]

Naumann 1989 {published data only}

Naumann VC, Lange A. The use of transcutaneous electrical nerve stimulation for analgesia in the postoperative phase [Die Anwendung der transkutanen elektrischen Nervenstimulation zur Analgesie in der postoperativen Phase]. *Z Physiother* 1989;**41**:9–13.

Nawrocki 1997 {published data only}

Nawrocki JD, Bell TJ, Lawrence WT, Ward JP. A randomized controlled trial of transurethral microwave thermotherapy. *British Journal of Urology* 1997;**79**:389–93. [MEDLINE: 9117220]

Nicassio 1974 {published data only}

Nicassio P, Bootzin R. A comparison of progressive relaxation and autogenic training as treatments for insomnia. *Journal of Abnormal Psychology* 1974;**83**(3):253–60. [MEDLINE: 4844912]

Nocella 1982 {published data only}

Nocella J, Kaplan RB. Training children to cope with dental treatment. *Journal of Pediatric Psychology* 1982;7(2):175–8. [MEDLINE: 6125579]

O'Brien 1996 {published data only}

O'Brien B, Relyea MJ, Taerum T. Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. *American Journal of Obstetrics and Gynecology* 1996;**174**(2):708–15. [MEDLINE: 8623811]

Parker 1995 {published and unpublished data}

Parker JC, Smarr KL, Buckelew SP, Stucky-Ropp RC, et al. Effects of stress management on clinical outcomes in rheumatoid arthritis. *Arthritis and Rheumatism* 1995;**38**(12):1807–18. [MEDLINE: 8849353]

Parker 2003 {published data only}

Parker JC, Smarr KL, Slaughter JR, Johnston SK, Priesmeyer ML, Hanson KD, et al.Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. *Arthritis and Rheumatism* 2003;**49**:766–77.

Pearl 1956 {published data only}

Pearl D, Vander Kamp H, Olsen AL, Greenberg PD, et al. The effects of reserpine on schizophrenic patients. *The American Journal of Psychiatry* 1956;**112**:936.

Pelham 1992 {published data only}

Pelham WE, Murphy DA, Vannatta K, Milich R, et al.Methylphenidate and attributions in boys with attention-deficit hyperactivity disorder. *Journal of Consulting and Clinical Psychology* 1992;**60**(2):282–92. [MEDLINE: 1592959]

Quahagen 1995 {published data only}

Quayhagen MP, Quayhagen M, Corbeil RR, Roth P, et al.A dyadic remediation program for care recipients with dementia. *Nursing Research* 1995;44(3):153–9. [MEDLINE: 7761291]

Rabkin 1990 {published data only}

Rabkin JG, McGrath PJ, Quitken FM, Tricamo E, et al.Effects of pill-giving on maintenance of placebo response in patients with chronic mild depression. *The American Journal of Psychiatry* 1990; **147**:1622–6. [MEDLINE: 2244639]

Rawling 2001 {published data only}

Rawling MJ, Wiebe ER. A randomized controlled trial of fentanyl for abortion pain. *American Journal of Obstetrics and Gynecology* 2001;**185**:103–7.

Reading 1982 {published data only}

Reading AE. The effects of psychological preparation on pain and recovery after minor gynaecological surgery: a preliminary report. *Journal of Clinical Psychology* 1982;**38**(3):504–12. [MEDLINE: 6213641]

Ristikankare 1999 {published data only}

* Ristikankare M, Hartikainen, Heikkinen M, Janatuinen E, Julkunen R. Is routinely given conscious sedation of benefit during colonoscopy?. *Gastroenterology Endoscopy* 1999;**49**:566–72. Ristikankare M, Julkunen R, Mattila M, Laitinen T, et al.Conscious sedation and cardiorespiratory safety during colonoscopy. *Gastrointestinal Endoscopy* 2000;**52**:48–54.

Ristikankare 2006 {published data only}

Ristikankare M, Julkunen R, Heikkinen M, Mattila M, Laitinen T, Wang SX, et al.Sedation, topical pharyngeal anesthesia and cardiorespiratory safety during gastroscopy. *Journal of Clinical Gastroenterology* 2006;**40**:899–905.

Robinson 2001 {published data only}

Robinson R, Darlow S, Wright SJ, Watters C, Carr I, Gadsby G, Mayberry J. Is transcutaneous electrical nerve stimulation an effective analgesia during colonoscopy. *Postgraduate Medical Journal* 2001;77:445–6.

Roongpisuthip 1999 {published data only}

Roongpisuthipong C, Panpakdee O, Boontawee A, Kulapongse S, Tanphaichitr V. Possible thermogenesis with dexfenfluramine. *Chotmaihet thangphaet [Journal of the Medical Association of Thailand*] 1999;**82**:150–9.

Roscoe 2002 {published data only}

Roscoe JA, Morrow GR, Bushunow P, Tian L, Matteson S. Acustimulation wristbands for the relief of chemotherapy-induced nausea. *Alternative Therapies* 2002;**8**:56–62.

Roscoe 2005 {published data only}

Roscoe JA, Matteson SE, Morrow GR, Hickok JT, Bushunow P, Griggs J, et al.Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer. *Journal of Pain and Symptom Management* 2005;**29**:376–84.

Rosen 1976 {published data only}

Rosen GM, Glasgow RE, Barrera M. A controlled study to assess the clinical efficacy of totally self-administrated systematic desensitization. *Journal of Consulting and Clinical Psychology* 1976; 44(2):208–17. [MEDLINE: 3523]

Placebo interventions for all clinical conditions (Review)

Rossi 1982 {published data only}

Rossi A, Ziacchi V, Lomanto B. The hypotensive effect of a single daily dose of labetalol: a preliminary study. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 1982;**20**(9):438–45. [MEDLINE: 6754634]

Roughan 1981 {published data only}

Roughan PA, Kunst L. Do pelvic floor excercises really improve orgasmic potential?. *Journal of Sex and Marital Therapy* 1981;7(3): 223–8. [MEDLINE: 7345161]

Rowbotham 1996 {published data only}

Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. *Pain* 1996;**65**:39–44. [MEDLINE: 8826488]

Rupert 1978 {published data only}

Rupert PA, Holmes DS. Effects of multiple sessions of true and placebo heart rate biofeedback training on the heart rates and anxiety levels of anxious patients during and following treatment. *Psychophysiology* 1978;**15**(6):582–90. [MEDLINE: 715134]

Rybarczyk 1990 {published data only}

Rybarczyk BD, Auerbach SM. Reminiscence interviews as stress management interventions for older patients undergoing surgery. *The Gerontologist* 1990;**30**(4):522–8. [MEDLINE: 2394388]

Röschke 2000 {published data only}

Rösche J. Wolf C, Kögel P, Wagner P, Bech S. Adjuvant whole body acupuncture for major depression. A placebo-controlled study of patients in standardised mianserintreatment [Adjuvante Ganzkörper–akupunktur bei Depression. Eine placebokontrollierte Studie unter standardisierter Mianserintherapie]. *Nervenartz* 1998; **69**:961–7.

Roschke J, Wolf C, Müller MJ, Wagner P, Mann K, Grozinger M, Bach S. The benefit from whole body acupuncture in major depression. *Journal of Affective Disorders* 2000;**57**:73–81.

Rösler 2003 {published data only}

Rösler A, Otto B, Schreiber-Dietrich D, Steinmetz H, Kessler KR. Single-needle acupuncture alleviates gag reflex during transesophageal eccocardiography: a blinded, randomised, controlled pilot trial. *The Journal of Alternative and Complementary Medicine* 2003;**9**:847–9.

Sanders 1990 {published data only}

Sanders G, Tepe R, Maloney P, Reinert O. The effect of spinal manipulation on subjects with acute low back pain: a comparison of visual analog pain scores and serum beta endorphin levels. *Journal* of Manipulative and Physiological Therapeutics 1990;**13**(1):58. * Sanders GE, Reinert O, Tepe R, Maloney P. Chiropractic adjustive manipulation on subjects with acute low back pain: visual analog pain scores and plasma beta-endorphin levels. *Journal of* Manipulative and Physiological Therapeutics 1990;**13**(7):391–5. [MEDLINE: 2145384]

Schallreuter 2002 {published data only}

Shallreuter KU, Moore J, Behrens-Williams S, Panske A, Harari M. Rapid initiation of repigmentation in vitiligo with dead sea climatotherapy in combination with pseudocatalase (PC-KUS). *International Journal of Dermatology* 2002;**41**:482–7.

Scharf 2006 {published data only}

Scharf HP, Mansmann U, Streitberger K, Witte S, Krämer J, Maier C, et al.Acupuncture and knee osteoarthritis: a three-armed randomized trial. *Annals of Internal Medicine* 2006;**145**:12–20.

Scharff 2002 {published data only}

Scharff L, Marcus DA, Masek BJ. A controlled study of minimalcontact thermal biofeedback treatment in children with migraine. *Journal of Pediatric Psychology* 2002;**27**:109–19.

Seer 1980 {published data only}

Seer P, Raeburn JM. Meditation training and essential hypertension: a methodological study. *Journal of Behavioral Medicine* 1980;**3**(1):59–71. [MEDLINE: 6995617]

Senediak 1985 {published data only}

Senediak C, Spence SH. Rapid versus gradual scheduling of therapeutic contact in a family based behavioural weight control programme for children. *Behavioural Psychotherapy* 1985;**13**: 265–87.

Shen 2000 {published data only}

Shen J, Wenger N, Glaspy J, Hays RD, Albert PS, Choi C, Shekelle PG. Electroacupuncture for control of myeloablative chemotherapy-induced emesis. *JAMA* 2000;**284**:2755–61.

Sibilio 1957 {published data only}

Sibilio JP, Andrew G, Dart D, Moore KB, et al. Treatment of chronic schizophrenia with promazine hydrochloride. *AMA Archives of Neurology and Psychiatry* 1957;**78**:419–24.

Sinaiko 1991 {published and unpublished data}

Gómez-Marín O, Prineas RJ, Sinaiko AR. The sodium-potassium blood pressure trial in children. Design, recruitment, and randomization: the children and adolescent blood pressure program. *Controlled Clinical Trials* 1991;**12**:408–23. * Sinaiko AR, Gómez-Marín O, Prineas RJ. Effect of low sodium diet or potassium supplementation on adolescent blood pressure. Hypertension 1993; Vol. 21:989–994.

Sipich 1974 {published data only}

Sipich JF, Russell RK, Tobias LL. A comparison of covert sensitization and 'nonspecific' treatment in the modification of smoking behavior. *Journal of Behavior Therapy and Experimental Psychiatry* 1974;**5**:201–3.

Sommerness 1955 {published data only}

Sommerness MD, Lucero RJ, Hamlon JS, Erickson JL, et al.A controlled study of reserpine on chronically disturbed patients. *AMA Archives of Neurology and Psychiatry* 1955;74:316–9.

Spanos 1995 {published data only}

Spanos NP, Mondoux TJ, Burgess CA. Comparison of multicomponent hypnotic and non-hypnotic treatments for smoking. *Contemporary Hypnosis* 1995;**12**(1):12–19.

Sprott 1993 {published data only}

* Sprott H, Mennet P, Stratz T, Müller W. Efficacy of acupuncture in patients with generalised tendomyopathy (fibromyalgia) [Wirksamkeit der Acupunktur bei Patienten mit generaliserter Tendomyopathie (Fibromyalgie)]. *Aktuelle Rheumatologie* 1993;**18**: 132–5.

Sprott H, Müller W. Efficacy of acupuncture in patients with fibromyalgia. *Reumatologia* 1994;**32**(4):414–21.

Placebo interventions for all clinical conditions (Review)

Stabholz 1991 {published data only}

Stabholz A, Shapira J, Shur D, Friedman M, et al.Local application of sustained-release delivery system of chlorhexidine in Down's syndrome population. *Clinical Preventive Dentistry* 1991;**13**(5): 9–14. [MEDLINE: 1839722]

Steinsbekk 2004 {published data only}

Steinsbekk A, Bentzen N, Fønnebø V, Lewith G. Self treatment with one of three self selected, ultramelecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial. *British Journal of Clinical Pharmacology* 2005;**59**:447–55. Steinsbekk A, Bentzen N, Fønnebø V, Lewith GT. Homeopathic care for the prevention of upper respiratory tract infections in children: A double-blind randomized placebo controlled trial comparing individualised homeopathic care and waiting-list controls. *Complemantary Therapies in Medicine* 2005;**13**:231–8. * Steinsbekk A, Bentzen N, Fønnebø V, Lewith GT. Randomzed controlled trial on treatment by homeopaths and self-treatment with homeopathic medicines: design and protocol. *Journal of Alternative and Complementary Medecine* 2004;**10**:1027–32.

Stewart 1991 {published data only}

Stewart JE, Jacobs-Schoen M, Padilla MR, Maeder LA, et al. The effect of cognitive behavioral intervention on oral hygiene. *Journal of Clinical Periodontology* 1991;**18**:219–22. [MEDLINE: 1856301]

Stransky 1989 {published data only}

Stransky M, Rubin A, Lava NS, Lazaro RP. Treatment of carpal tunnel syndrome with vitamin B6: a double-blind study. *Southern Medical Journal* 1989;**89**(7):841–2. [MEDLINE: 2749352]

Straub 2001 {published data only}

Straub WF, Spino MP, Alattar MM, Pfleger B, et al. The effect of chiropractic care on jet lag of Finnish junior elite athletes. *Journal of Manipulative and Physiological Therapeutics* 2001;**24**:191–8.

Sumaya 2001 {published data only}

Sumaya IC, Rienzi BM, Deegan JF, Moss DE. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. *The Journals of Gerontology. Series A. Biological Sciences and Medical Sciences* 2001;**56A**: M356–60.

Tan 1982 {published data only}

Tan SY, Poser EG. Acute pain in a clinical setting: effects of cognitive-behavioural skills training. *Behaviour Research and Therapy* 1982;**20**:535–45. [MEDLINE: 7159348]

Tan 1986 {published data only}

Tan SY, Bruni J. Cognitive-behavior therapy with adult patients with epilepsy: a controlled outcome study. *Epilepsia* 1986;**27**(3): 225–32. [MEDLINE: 3516668]

Tarcin 2004 {published data only}

Tarcin O, Gurbuz AK, Pocan S, Keskin O, Demirturk L. Acustimulation of the Neiguan point during gastroscopy: its effects on nausea and retching. *Turkish Journal of Gastroenterology* 2004; **15**:258–62.

Tarrier 1998 {published data only}

Tarrier N, Yusupoff L, Kinney C, McCarthy E. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. *BMJ* 1998;**317**:303–7. [MEDLINE: 9685273]

Tashjian 2006 {published data only}

Tashjian RZ, Banerjee R, Bradley MP, Alford W, Fadale PD. Zolpidem reduces postoperative pain, fatigue, and narcotic consumption following knee arthroscopy: a prospective randomized placebo-controlled double-blinded study. *Journal of Knee Surgery* 2006;**19**:105–11.

Theroux 1993 {published data only}

Theroux MC, West DW, Corddry DH, Hyde PM, et al.Efficacy of intranasal midazolam in facilitating suturing of lacerations in preschool children in the emergency department. *Pediatrics* 1993; **91**(3):624–7. [MEDLINE: 8441570]

Thomas 1987 {published data only}

Thomas KB. General practice consultations: is there any point in being positive?. *British Medical Journal* 1987;**294**:1200–2. [MEDLINE: 3109581]

Thomas 1999 {published data only}

Thomas VJ, Dixon AL, Milligan P. Cognitive-behaviour therapy for the management of sickle cell disease pain: an evaluation of a community based intervention. *British Journal of Health Psychology* 1999;4:209–29.

Thomas 2002a {published data only}

Thomas KS, Muir KR, Doherty M, Jones AC, O'Reilly SC, Bassey EJ. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. *BMJ* 2002;**325**:752–7.

Thomas 2002b {published data only}

Thomas KS, Muir KR, Doherty M, Jones AC, O'Reilly SC, Bassey EJ. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. *BMJ* 2002;**325**:752–7.

Tremeau 1992 {published data only}

Tremeau ML, Fontanie-Ravier P, Teurnier F, Demouzon J. Protocol of cervical maturation by acupuncture [Protocole de maturation cervicale par acupuncture]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction* 1992;**21**:375–80. [MEDLINE: 1624722]

Tritrakarn 2000 {published data only}

Tritrakarn T, Lertakyamanee J, Koompong P, Soontrapa S, Somprakit P, Tantiwong A, Jittapapai S. Both EMLA and placebo cream reduced pain during extracorporeal piezoelectric scock wave lithotripsy with the piezolith 2300. *Anaesthesiology* 2000;**92**: 1049–54.

Tsay 2003 {published data only}

Tsay SL, Chen ML. Acupressure and quality of sleep in patients with end-stage renal disease: a randomised controlled trial. *International Journal of Nursing Studies* 2003;**40**(1):1–7.

Tsay 2004 {published data only}

Tsay SL. Acupressure and fatigue in patients with end-stage renal disease-a randomized controlled trial. *International Journal of Nursing Studies* 2004;**41**:99–106.

Tuomilehto 1980 {published data only}

Tuomilehto J, Voutilainen E, Huttunen J, Vinni S, et al. Effect of guar gum on body weight and serum lipids in hypercholesterolemic females. *Acta Medica Scandinavica* 1980;**208**:45–8. [MEDLINE: 7435246]

Placebo interventions for all clinical conditions (Review)

Turner 1979 {published data only}

Ascher ML, Turner RM. A comparison of two methods for the administration of paradoxical intention. *Behaviour Research and Therapy* 1980;**18**:121–6. [MEDLINE: 7369992]

* Turner RM, Ascher LM. Controlled comparison of progressive relaxation, stimulus control, and paradoxical intention therapies for insomnia. *Journal of Consulting and Clinical Psychology* 1979;**47**(3): 500–8. [MEDLINE: 393734]

Tyler 1946 {published data only}

Tyler DB. The influence of a placebo, body position and medication on motion sickness. *The American Journal of Physiology* 1946;**146**:458–66.

Vlaeyen 1996 {published data only}

Vlaeyen JWS, Teeken-Gruben NJG, Goossens MEJB, Rutten-van Mölken MPMH, et al.Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. *The Journal of Rheumatology* 1996;**23**(7):1237–45. [MEDLINE: 8823699]

Walton 1993 {published data only}

Walton RE, Chiappinelli J. Prophylactic penicillin: effect on posttreatment symptoms following root canal treatment of asymptomatic periapical pathosis. *Journal of Endodontics* 1993;**19** (9):466–70. [MEDLINE: 8263455]

Wang 1997 {published data only}

Wang B, Tang J, White PF, Naruse R, et al.Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. *Anesthesia and Analgesia* 1997;**85**:406–13.

Watzl 1986 {published data only}

Watzl H, Olbrich R, Rist F, Cohen R. Placebo injections and alcohol surveillance in inpatient treatment of alcoholic women: An experimental study of two treatment characteristics [Placebo–injektionen und Alkoholkontrollen in der stationären Behandlung alkoholkranker Frauen – eine experimentelle Untersuchung zweier Behandlungsmerkmale]. *Zeitschrift für Klinische Psychologie* 1986;**15**(4):333–45.

Weingaertner 1971 {published data only}

Weingaertner AH. Self-administered aversive stimulation with hallucinating hospitalized schizophrenics. *Journal of Consulting and Clinical Psychology* 1971;**36**(3):422–9. [MEDLINE: 5561488]

Werntoft 2001 {published data only}

Werntoft E, Dykes A. Effect of acupressure on nausea and vomiting during pregnancy. A randomized, placebo-controlled, pilot study. *The Journal of Reproductive Medicine* 2001;**46**:835–9.

Whittaker 1963 {published data only}

Whittaker CB, Hoy RM. Withdrawal of perphenazine in chronic schizophrenia. *The British Journal of Psychiatry; the Journal of Mental Science* 1963;**109**:422–7.

Wilcock 2008 {published data only}

Wilcock A, Walton A, Manderson C, Feathers L, El Khoury B, Lewis M, et al.Randomised, placebo-controlled trial of nebulised furosamide for breathlessness in patients with cancer. *Thorax* 2008; **63**:872–5. [DOI: 10.1136/thx.2007.091538]

Williams 1988 {published data only}

Williams JM, Hall DW. Use of single session hypnosis for smoking cessation. *Addictive Behaviors* 1988;**13**:205–8. [MEDLINE: 3369332]

Wilson 1980 {published data only}

Wilson A, Davidson WJ, Blanchard R. Disulfiram implantation. A trial using placebo implants and two types of controls. *Journal of Studies on Alcohol* 1980;**41**(5):429–36. [MEDLINE: 6157943]

Witt 2005 {published data only}

Witt C, Brinkhaus B, Jena S, Linde K, Streng A, Wagenpfeil S, et al.Acupuncture in patients with osteoarthritis of the knee: a randomised trial. *Lancet* 2005;**366**:136–43.

Wojciechowski 1984 {published data only}

Wojciechowski FL. Behavioral treatment of tension headache: a contribution to controlled outcome research methodology. *Gedrag - Tijdschrift voor Psychologie* 1984;**12**(5):16–30.

Woods 2005 {published data only}

Woods DL, Craven RF, Whitney J. The effect of therapeutic touch on behavioral symptoms of persons with dementia. *Alternative Therapies in Health and Medicine* 2005;**11**:66–74.

Yan 2005 {published data only}

Yan T, Hui-chan CW, Li LS. Effects of functional electrical stimulation on the improvement of motor function of patients with acute stroke: a randomized controlled trial. *National Medical Journal of China* 2006;**86**(37):2627–31.

* Yan T, Hui-chan CWY, Li LSW. Functional electrical stimulation improves motor recovery of the lower extremity and walking ability of subjects with first acute stroke. *Stroke* 2005;**36**:80–85.

Yates 1988 {published data only}

Yates RG, Lamping DL, Abram NL, Wright C. Effects of chiropractic treatment on blood pressure and anxiety: a randomized, controlled trial. *Journal of Manipulative and Physiological Therapeutics* 1988;**11**(6):484–8. [MEDLINE: 3075649]

References to studies excluded from this review

Abbot 1995 {published data only}

Abbot K, Fowler-Kerry S. The use of topical refrigerent anesthetic to reduce injection pain in children. *Journal of Pain and Symptom Management* 1995;**10**(8):584–90.

Abikoff 1985 {published data only}

Abikoff H, Gittelman R. Hyperactive children treated with stimulants. Archives of General Psychiatry 1985;42:953-61.

Allen 1987 {published data only}

Allen SS, Froberg DG. The effect of decreased caffeine consumption on benign proliferative breast disease: a randomized trial. *Surgery* 1987;**101**:720–30.

Allen 1996 {published and unpublished data}

Allen KD, White DD, Walburn JN. Sucrose as an analgesic agent for infants during immunization injections. *Archives of Pediatrics and Adolescent Medicine* 1996;**150**:270–4.

Amanzio 1999 {published data only}

Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. *The Journal of Neuroscience* 1999;**19**:484–94.

Placebo interventions for all clinical conditions (Review)

Amanzio 2001 {published data only}

Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. *Pain* 2001;**90**:205–15.

Archer 1992 {published data only}

Archer TP, Leier CV. Placebo treatment in congestive heart failure. *Cardiology* 1992;**81**:125–33.

Arnett 1990 {published data only}

Arnett RM, Jones JS, Horger III EO. Effectiveness of 1% lidocaine dorsal penile nerve block in infant circumcision. *American Journal* of Obstetrics and Gynecology 1990;**163**:1074–80.

Avis 2008 {published data only}

Avis NE, Legault C, Coeytaux RR, Pian-Smith M, et al.A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes. *Menopause* 2008;**15**(6):1–9.

Babizhayev 2001 {published data only}

* Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, et al.N-acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophtalmic drug in treatment of human cataract. *Peptides* 2001;**22**:979–94.

Babizhayev MA, Yermakova VN, Deyev AI, Seguin MC. Imidazolecontaining peptidomimetic NACA as a potent drug for the medical treatment of age related cataract in humans. *Journal of Anti-Aging Medicine* 2000;**3**:43–62.

Barrett 1999 {published data only}

Barrett PM, Webster HM, Wallis JR. Adolescent self-esteem and cognitive skills training: a school-based intervention. *Journal of Child and Family Studies* 1999;**8**(2):217–27.

Beck 2002 {published data only}

Beck CK, Vogelpohl TS, Rasin JH, Uriri JT, et al.Effects of behavioral interventions on disruptive behavior and effect in demented nursing home residents. *Nursing Research* 2002;**51**: 219–28.

Benedetti 1998 {published data only}

Benedetti F, Amanzio M, Baldi S, Casadio C, et al. The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. *Pain* 1998;**75**:313–9.

Benedetti 1999b {published data only}

Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid system by target-directed expectations of analgesia. *The Journal of Neuroscience* 1999;**19**:3639–48.

Benedict 1989 {published data only}

Benedict RHB, Harris AE. Remediation of attention deficits in chronic schizophrenic patients: a preliminary study. *British Journal of Clinical Psychology* 1989;**28**:187–8.

Bennet 2001 {published data only}

Bennet WD, Zeman KL, Foy C, Shaffer CL, et el. Effect of aerosolized uridine 5'-triphosphate on mucociliary clearance in mild chronic bronchitis. *American Journal of Respiratory and Critical Care Medicine* 2001;**164**:302–6.

Benton 1988 {published data only}

Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. *Lancet* 1988;**i**:140–3.

Bergmann 1994 {published data only}

Bergmann J, Chassany O, Gandiol J, Deblois P, et al.A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer patients. *Clinical Trials and Meta-Analysis* 1994;**29**:41–7.

Beutler 1988 {published data only}

Beutler JJ, Attevelt JTM, Schouten SA, Faber JA, et al.Paranormal healing and hypertension. *BMJ* 1988;**296**:1491–4.

Bierman 1997 {published data only}

Bierman DJ, Julien ECGJ. An explorative study on the effect of alpha brain wave training by means of photic stimulation on withdrawal reactions of alcoholics in a clinical setting [Een exploratief onderzoek naar het effect van alfa–hersengolftraining door middel van photic stimulation op onthoudingsverschijnselen van alcoholafhankelijken in een klinische setting]. *Tijdschrift voor Alcohol, Drugs en Andere Psychotrope Stoffen* 1997;**22**(2):65–73.

Björkstén 1986 {published data only}

Björkstén B, Möller C, Broberger U, Ahlstedt S, et al.Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. *Allergy* 1986;**41**:290–5.

Blackwell 1972 {published data only}

Blackwell B, Bloomfield SS, Bumcher CR. Demonstration to medical students of placebo responders and non-drug factors. *Lancet* 1972;**i**:1279–2.

Blanchard 1978 {published data only}

Blanchard EB, Theobald DE, Williamson DA, Silver BV, et al. Temperature biofeedback in the treatment of migraine headaches. A controlled investigation. *Archives of General Psychiatry* 1978;**35**:581–8.

Borden 1989 {published data only}

Bordon KA. Attributional outcomes: the subtle messages of treatment for attention deficit disorder. PhD-Thesis, University of Illinois 1986.

* Bordon KA, Brown RT. Attributional outcomes: the subtle messages of treatments for attention deficit disorder. *Cognitive Therapy and Research* 1989;**13**(2):147–60.

Borkovec 1975 {published data only}

Borkovec TD, Kaloupek DG, Slame KM. The facilitative effect of muscle tension-release in the relaxation treatment of sleep disturbance. *Behavior Therapy* 1975;**6**(3):301–9.

Bornstein 1973 {published data only}

Bornstein PH, Sipprelle CN. Group treatment of obesity by induced anxiety. *Behaviour Research and Therapy* 1973;11:339–41.

Bouchet 1996 {published data only}

Bouchet C, Guilemin F, Briancon S. Nonspecific effects in longitudinal studies: impact on quality of life measures. *Journal of Clinical Epidemiology* 1996;**49**(1):15–20.

Brown 1999 {published data only}

Brown FF, Robinson ME, Riley JL, Gremillion HA, McSoley J, Meyers G. Better palpation of pain: reliability and validity of a new pressure pain protocol in TMD. *CRANIO: The Journal of Craniomandibular Practice* 2000;**18**:58–65.

Buckalew 1972 {published data only}

Buckalew LW. An analysis of experimental components in a placebo effect. *The Psychological Record* 1972;**22**:113–9.

Placebo interventions for all clinical conditions (Review)

Bullock 1999 {published data only}

Bullock ML, Kiresuk TJ, Pheley AM, Culliton PD, Lenz SK. Auricular acupuncture in the treatment of cocaine abuse. *Journal of Substance Abuse Treatment* 1999;**16**:31–8.

Bush 1985 {published data only}

Bush C, Ditto B. A controlled evaluation of paraspinal EMG biofeedback in the treatment of chronic low back pain. *Health Psychology* 1985;4(4):307–21.

Butler 1984 {published data only}

Butler G, Cullington A, Munby M, Amies P, et al. Exposure and anxiety management in the treatment of social phobia. *Journal of Consulting and Clinical Psychology* 1984;**52**(4):642–50.

Carlson 1993 {published data only}

Carlson CL, Pelham WE, Milich R, Hoza B. ADHD boys' performance and attributions following success and failure: drug effects and individual differences. *Cognitive Therapy & Research* 1993;**17**(3):269–87.

Carpenter 1994 {published data only}

Carpenter DJ, Gatchel RJ, Hasegawa T. Effectiveness of a videotaped behavioral intervention for dental anxiety: the role of gender and the need for information. *Behavioral Medicine* 1994;**20**: 123–32.

Chambless 1984 {published data only}

Chambles DL, Sultan FE, Stern TE, O'Neill C, et al.Effect of pubococcygeal exercise on coital orgasm in women. *Journal of Counseling and Clinical Psychology* 1984;**52**(1):114–8.

Chen 1999 {published data only}

Chen ML, Lin LC, Wu SC, Lin JG. The effectiveness of acupressure in improving the quality of sleep of institutionalized residents. *Journals of Gerontology Series A: Biological Sciences and Medical Sciences* 1999;**54**:M389–94.

Cole 1983 {published data only}

Cole AD, Bond NW. Olfactory aversion conditioning and overeating: a review and some data. *Perceptual and Motor Skills* 1983;**57**:667–78.

Corletto 1999 {published data only}

Corletto F. [Terapia dell'osteoporosi climaterica con estratto titolato di equiseto piu calcio (osteosil calcium). Studio in doppio cieco, randomizzato]. *Minerva Ortopedica e Traumatologica* 1999;**50**(5): 201–6.

Corson 1994 {published data only}

Corson SL, Batzer FR, Gocial B, Kelly M. Is paracervical block anesthesia for oocyte retrieval effective?. *Fertility and Sterility* 1994; **62**(1):133–6.

Cottraux 1986 {published data only}

Cottraux JA, Harf R, Boissel J, Schbath J, et al.Smoking cessation with behaviour therapy or acupuncture - a controlled study. *Behaviour Research and Therapy* 1983;**21**(4):417–24.

Cram 1980 {published data only}

Cram JR. EMG biofeedback and the treatment of tension headaches: a systematic analysis of treatment components. *Behavior Therapy* 1980;11:699–710.

Cristofalo 1999 {published data only}

Cristofalo MG, Savojardo M, Pecorello S, Galiano S, et al. The end of antioxidizing treatment of pulmonary illness: our experience

[Ruolo degli antiossidanti nel danno polmonare. Nostre esperienze]. *Medicino Dello Sport* 1999;**52**(3):165–75.

Cullhed 1961 {published data only}

Cullhed S, Löfström B. Obstetric analgesia with pethidine and scopalamine. *Lancet* 1961;**i**:75–7.

Dahlquist 1986 {published data only}

Dahlquist LM, Gil KM, Armstrong FD, DeLawyer DD, et al.Preparing children for medical examinations: the importance of previous medical experience. *Health Psychology* 1986;**5**(3):249–59.

Daley 2007 {published data only}

Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of excercise therapy in women treated for breast cancer. *Journal of Clinical Oncology* 2007;**25**:1713–21.

Diamond 1995 {published data only}

Diamond L, Dockhorn RJ, Grossman J, Kisicki JC, et al.A doseresponse study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. *The Journal of Allergy and Clinical Immunology* 1995;**95**(5, part 2):1139–46. [MEDLINE: 7751531]

Disney 1988 {published data only}

Disney JA, Graves RC, Cancro L, Payonk G, et al.An evaluation of 6 dentrifice formulations for supragingival anticalculus and antiplaque activity. *Journal of Clinical Periodontology* 1989;**6**:525–8.

Dobia 1985 {published data only}

Dobia B, McMurray NE. Applicability of learned helplessness to depressed women undergoing assertion training. *Australian Journal of Psychology* 1985;**37**:71–80.

Dundee 1988 {published data only}

Dundee JW, Sourial FBR, Ghaly RG, Bell PF, et al. P6 acupressure reduces morning sickness. *Journal of the Royal Society of Medicine* 1988;**81**:456–7.

Egbert 1964 {published data only}

Egbert LD, Battit GE, Welch CE, Bartlett MK. Reduction of postoperative pain by encouragement and instruction of patients. *The New England Journal of Medicine* 1964;**270**(16):825–7.

Eickholz 2002 {published data only}

Eickholz P, Kim TS, Bürklin T, Schacher B, et al.Non-surgical periodontal therapy with adjunctive topical doxycycline: a doubleblind randomized controlled multicentre study (1). Study design and clinical results. *Journal of Clinical Periodontology* 2002;**29**: 108–17.

Elkin 1985 {published data only}

Elkin I, Parloff MB, Headly SW, Autry JH. NIMH treatment of depression collaborative research program. *Archives of General Psychiatry* 1985;**42**:305–16.

Feather 1972 {published data only}

Feather BW, Chapman CR, Fisher SB. The effect of a placebo on the perception of painful radient heat stimuli. *Psychosomatic Medicine* 1972;**34**(4):290–4.

Fevery 1990 {published data only}

Fevery J, Elewaut A, Michielsen P, Nevens F, et al.Efficiacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective double-blind Belgian-Dutch study. *Journal of Hepatology* 1990;**11**:s108–12.

Placebo interventions for all clinical conditions (Review)

Fillmore 1992 {published data only}

Fillmore M, Vogel-Sprott M. Expected effect of caffeine on motor performance predicts the type of response to placebo. *Psychopharmacology* 1992;**106**:209–14.

Fillmore 1994 {published data only}

Fillmore MT, Mulvihill LE, Vogel-Sprott M. The expected drug and its expected effect interact to determine placebo responses to alcohol and caffeine. *Psychopharmacology* 1994;**115**:383–8.

Fillmore 1994b {published data only}

Fillmore MT, Vogel-Sprott M. Psychomotor performance under alcohol and under caffeine: expectancy and pharmacological effects. *Experimental and Clinical Psychology* 1994;**2**:319–27.

Flor 1983 {published data only}

Flor H, Haag G, Turk DC, Koehler H. Efficacy of EMG biofeedback, pseudotherapy, and conventional medical treatment for chronic rheumatic back pain. *Pain* 1983;17:21–31.

Fuller 1986 {published data only}

Fuller RK, Branchey L, Brightwell DR, Derman RM, et al.Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. *JAMA* 1986;**256**(11):1449–55.

Gam 1998 {published data only}

Gam AN, Warming S, Larsen LH, Jensen B. Treatment of myofascial trigger-points with ultrasound combined with massage and exercise - a randomised controlled trial. *Pain* 1998;77:73–9.

Gelfand 1963 {published data only}

Gelfand S, Ullmann LP, Krasner L. The placebo response: an experimental approach. *Journal of Nervous and Mental Disease* 1963;**136**:379–87.

Goodale 1990 {published data only}

Goodale IL, Domar AD, Benson H. Allivation of premenstrual syndrome symptoms with the relaxation response. *Obstetrics & Gynecology* 1990;**75**(4):649–55.

Gowdey 1967 {published data only}

Gowdey CW, Hamilton JT, Philip RB. A controlled clinical trial using placebos in normal subjects. *Canadian Medical Association Journal* 1967;**96**:1317–22.

Gregorio 1996 {published data only}

Gregorio GV, Jara P, Hierro L, Diaz C, et al.Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. *Hepatology* 1996;**23**:700–7.

Gregory 1983 {published data only}

Gregory SJ, Davies ADM, Binks MG. The improvement of verbal fluency in the elderly: the effects of practice on the set test and an alternative form. *Educational Gerontology* 1983;9(2-3):139–46.

Gryll 1978 {published data only}

Gryll SL, Katahn M. Situational factors contributing to the placebo effect. *Psychopharmacology* 1978;**57**:253–61.

Haake 2007 {published data only}

Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H, Maier C, et al.German acupuncture trials for chronic low back pain. Randomized, multicenter, blinded, parallel-group trial with 3 groups. *Archives of Internal Medicine* 2007;**167**(17):1892–8.

Hale 1986 {published data only}

Hale EH. A study of the relationship between therapeutic touch and the anxiety levels of hospitalized adults. PhD-thesis, Texas Woman's University 1986.

Hall 1994 {published data only}

Hall SM, Tunis S, Triffleman E, Banys P, et al. Continuity of care and desipramine in primary cocaine abusers. *The Journal of Nervous and Mental Diseases* 1994;**182**(10):570–5.

Hargreaves 1983 {published data only}

Hargreaves KM, Dionne RA, Mueller GP. Plasma beta-endorphinlike immunoreactivity, pain and anxiety following administration of placebo in oral surgery patients. *Journal of Dental Research* 1983; **62**:1170–3.

Hayden 1996 {published data only}

Hayden FG, Diamond L, Wood PB, Korts DC, et al.Effectiveness and safety of intranasal ipratropium bromide in common colds. *Annals of Internal Medicine* 1996;**125**:89–97. [MEDLINE: 8678385]

Herth 2000 {published data only}

Herth K. Enhancing hope in people with a first recurrence of cancer. *Journal of Advanced Nursing* 2000;**32**:1431–41.

Hogarty 1973 {published data only}

Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. *Archives of General Psychiatry* 1973;**28**: 54–64.

Huber 1986 {published data only}

Huber MGP, Wildschut HIJ, Boer K, Kleiverda G, et al. Umbilical vein administration of oxytocin for the management of retained placenta: is it effective?. *American Journal of Obstetrics and Gynecology* 1991;**164**(5 part 1):1216–9.

Jensen 1991 {published data only}

Jensen MP, Karoly P. Motivation and expectancy factors in symptom perception: a laboratory study of the placebo effect. *Psychosomatic Medicine* 1991;**53**:144–52.

Kalman 1998 {published data only}

Kalman D, Colker CM, Stark R, Minsch A, Wilets I, Antonio J. Effect of pyruvate supplemantation on body composition and mood. *Current Therapeutic Research* 1998;**59**:793–802.

Kanner 1999 {published data only}

Kanner RE, Connet JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disaese: the lung health study. *The American Journal of Medicine* 1999;**106**:410–6.

Kelley 1976 {published data only}

Kelley CK. Play desensitization of fear of darkness in preschool children. *Behaviour Research and Therapy* 1976;**14**:79–81.

Khandwala 1997 {published and unpublished data}

Binnie WH, Curro FA, Khandwala A, Van Inwegen RG. Amolexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. *Compendium* 1997;**18**(7):1116–26. * Khandwala A, Van Inwegen RG, Alfano MC. 5% amlexanox oral paste, a new treatment for recurrent minor aphtous ulcers. I. Clinical demonstration of acceleration of healing and resolution of

Placebo interventions for all clinical conditions (Review)

pain. Oral Surgery Oral Medicine Oral Pathology 1997;83(2): 222–30.

Klosko 1990 {published data only}

* Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavior therapy in treatment of panic disorder. *Journal of Consulting and Clinical Psychology* 1990;**58**(1):77–84. Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavioural therapy in treatment of panic disorder. *Journal of Psychotherapy Practice and Research* 1994;**3**(2):166–78. Klosko JS, Barlow DH, Tassinari RB, Cerny JA. Comparison of alprazolam and cognitive behavior therapy in the treatment of panic disorder: a preliminary report. In: Hand I, Wittchen H editor(s). *Panic and Phobias 2 - Treatments and Variables affecting Course and Outcome*. Berlin: Springer Verlag, 1988.

Korner 1982 {published data only}

Korner PI, Bauer GE, Doyle AE, Edmondson KW, et al.Untreated mild hypertension. A report of the management committee of the Australian Therapeutic Trial in Mild Hypertension. *Lancet* 1982;**i**: 185–91.

Lasagna 1954 {published data only}

Lasagna L, Mosteller F, von Felsinger JM, Beecher HK. A study of the placebo response. *American Journal of Medicine* 1954;**June**: 770–9.

Levine 1980 {published data only}

Levine RA, O' Brian RM. Treatment of anxiety about college tests with negative practice and systematic desensitization: some negative findings. *Psychological Reports* 1980;**46**:823–9.

Liberman 1964 {published data only}

Liberman R. An experimental study of the placebo response under three different situations of pain. *Journal of Psychiatric Research* 1964;**2**:233–46.

Lopez 1999 {published data only}

Lopez-Justicia MD, Martos FJ. The effectiveness of two programs to develop visual perception in Spanish schoolchildren with low vision. *Journal of Visual Impairment and Blindness* 1999;**93**:96–103.

Lorr 1962 {published data only}

Lorr M, McNair DM, Weinstein GJ. Early effects of chlordiazepoxide (librium) used with psychotherapy. *Journal of Psychiatric Research* 1962;**1**:257–70.

Lujan 1992 {published data only}

Lujan M, Lopez-Fiesco A, Martinez EL, Lopez GZ, et al.Experimental tension headache in humans: a double blind comparison of the analgesic effect of dipyrone, naproxen plus paracetamol or placebo. *Proceedings of the Western Pharmacology Society* 1992;**35**:201–5.

Lynn 1983 {published and unpublished data}

Lynn FE. Acupressure for the treatment of menstrual distress. PhD-thesis, University of California 1983.

Manner 1987 {published data only}

Manner T, Kanto J, Iisalo E, Lindberg, R, et al.Reduction of pain at venous cannulation in children with a eutectic mixture of lidocaine and prilocaine (EMLA cream): comparison with placebo cream and no local premedication. *Acta Anaesthesiologica Scandinavica* 1987; **31**:735–9.

Rampes 1997 {published data only}

Rampes H, Pereira S, Mortimer A, Manoharan S, Knowles M. Does electroacupuncture reduce craving for alcohol? A randomized controlled study. *Complementary therapies in medicine* 1997;**5**: 19–26.

Reich 1990 {published data only}

Marchand 1993 {published data only}

McGrath 1988 {published data only}

Neurology 1988;30:626-31.

Meehan 1985 {published data only}

Montgomery 1996 {published data only}

Nikolaou 1998 {published data only}

Hellenica 1998;43:362-9.

Peart 1977 {published data only}

Penman 1956 {published data only}

and Psychiatry 1956;76:42-9.

relevance. Pain 2001;93:77-84.

Pollo 2001 {published data only}

Price 1999 {published data only}

147-56.

University 1985.

low back pain. Pain 1993;54:99-106.

Marchand S, Charest J, Li J, Chenard J, Lavignolle B, Laurencelle L. Is TENS purely a placebo effect? A controlled study on chronic

al. Relaxation prophylaxixs for childhood migraine: a randomized placebo-controlled trial. *Developmental Medicine and Child*

Meehan MC. The effect of therapeutic touch on the experience of

Montgomery G, Kirsch I. Mechanisms of placebo pain reduction:

an empirical investigation. Psychological Science 1996;7(3):174-6.

Nikolaou C, Michalopoulou M, Segdista J, Kilidireas C, Rombos

A, Kabouri K, Papageorgiou K. Cellular immunological parameters

and antiviral antibodies in the motorneuron disease. Acta Microbiol

Peart WS, Cochrane AL, Dollery CT, Green KG, et al.Randomised

controlled trial of treatment for mild hypertension: design and pilot

trial. Report of Medical Research Council working party on mild to

moderate hypertension. British Medical Journal 1977;1:1437-40.

privileges on chronic schizophrenics. AMA Archives of Neurology

Pollo A, Amanzio M, Arslantian A, Casadio C, Maggi G, Benedetti

Nicholls SS. An analysis of factors that contribute to the magnitude

of placebo analgesia in an experimental paradigm. Pain 1999;83:

F. Response expectancies in placebo analgesia and their clinical

Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH,

Penman AS, Dredge TE. Effect of reserpine and open-ward-

acute pain in postoperative patients. PhD-thesis, New York

McGrath PJ, Humphreys P, Goodman JT, Keene D, et

Reich JW, Zautra AJ. Dispositional control beliefs and the consequences of control-enhancing intervention. *Journal of Gerontology* 1990;**45**(2):46–51.

Robertson 1991 {published data only}

Robertson C, Gatchel RJ, Fowler C. Effectiveness of a videotaped behavioral intervention in reducing anxiety in emergency oral surgery patients. *Behavioral Medicine* 1991;17(2):77–85.

Rodriguez 1997 {published data only}

Rodriguez AP, Menesas FD, Quiroga RM, Perz L, et al.New experiences of finger pressure in prevention of acute respiratory

Placebo interventions for all clinical conditions (Review)

infections [Nuevas experiencias de la digitopuntura en la prevencion de las infecciones resporatorias agudas]. *Geriatrika* 1997;**13**(8):23–9.

Roehrich 1993 {published data only}

Roehrich L, Goldman MS. Experience-dependent neurophysiological recovery and the treatment of alcoholism. *Journal of Consulting and Clinical Psychology* 1993;**61**(5):812–21.

Roelofs 2000 {published data only}

Roelofs J, ter Riet G, Peters ML, Kessels AGH, Reulen JPH, Menheere PPCA. Expectations of analgesia do not affect spinal nociceptive R-III reflex activity: an experimental study into the mechanism of placebo-induced analgesia. *Pain* 2000;**89**:75–80.

Roos 1969 {published data only}

Roos P, Oliver M. Evaluation of operant conditioning with institutionalized retarded children. *American Journal of Mental Deficiency* 1969;74(3):325–30.

Roth 1986 {published data only}

Roth PM, Thrash WJ. Effect of transcutaneous electrical nerve stimulation for controlling pain associated with orthodontic tooth movement. *American Journal of Orthodontics and Dentofacial Orthopedics* 1986;**90**(2):132–8.

Rustøen 1998 {published data only}

Rustøen T, Wiklund I, Hanestad BR, Moum T. Nursing intervention to increase hope and quality of life in newly diagnosed cancer patients. *Cancer Nursing* 1998;**21**:235–45.

Sarles 1977 {published data only}

Sarles H, Camatte R, Sahel J. A study of the variation in the response regarding duodenal ulcers when treated with placebo by different investigators. *Digestion* 1977;**16**:289–92.

Sartor 1980 {published data only}

Sartor, G, Schersten B, Carlström S, Melander A, Norden, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. *Diabetes* 1980;**29**:41–9.

Shaw 1974 {published data only}

Shaw DW, Thoresen CE. Effect of modeling and desensitation in reducing dentist phobia. *Journal of Counseling Psychology* 1974;**21** (5):415–20.

Sheikh 1986 {published data only}

Sheikh JI, Hill RD, Yesavage JA. Long-term efficacy of cognitive training for age-associated memory impairment: a six-month follow up study. *Developmental Neuropsychology* 1986;**2**(4):413–21.

Silvestri 1977 {published data only}

Silvestri R. Implosive therapy treatment of emotionally disturbed retardates. *Journal of Consulting and Clinical Psychology* 1977;**45**(1): 14–22.

Skovlund 1991 {published data only}

Skovlund E. Should we tell trial participants that they might receive placebo?. *Lancet* 1991;**337**:1041.

Smith 2002 {published data only}

Smith C, Crowther C. The placebo response and effect of time in a trial of acupuncture to treat nausea and vomiting in early pregnancy. *Complementary Therapies in Medicine* 2002;**10**:210–6. * Smith C, Crowther C, Beilby J. Acupuncture to treat nausea and vomiting in early pregnancy: a randomized controlled trial. *Birth* 2002;**29**:1–9.

Spanos 1988 {published data only}

Spanos NP, Stenstrom RJ, Johnston JC. Hypnosis, placebo, and suggestion in the treatment of warts. *Psychosomatic Medicine* 1988; **50**:245–60.

Staats 1998 {published data only}

Staats P, Hekmat H, Staats A. Suggestion / placebo effects on pain: negative as well as positive. *Journal of Pain and Symptom Management* 1998;**15**(4):235–43.

Stanley 1989 {published data only}

Stanley TH, Leiman BC, Rawal N, Marcus MA, et al. The effects of oral transmucosal fentanyl citrate premedication on preoperative behavioral responses and gastric volume and acidity in children. *Anesthesia and Analgesia* 1989;**69**:328–35.

Suchman 1992 {published data only}

Suchman AL, Ader R. Classic conditioning and placebo effects in crossover studies. *Clinical Pharmacology and Therapeutics* 1992;**52** (4):372–7.

Tashkin 1977 {published data only}

Tashkin DP, Bresler DE, Kroening RJ, Kerschner H, et al.Comparison of real and simulated acupuncture and isoproterenol in methacholine-induced asthma. *Annals of Allergy* 1977;**39**: 379–86.

* Tashkin DP, Katz RM, Kerschner H, Rachelefsky GS, et al.Comparison of aerosolized atropine, isoproterenol, atropine plus isoproterenol, disodium cromoglycate and placebo in the prevention of excercise-induced asthma. *Annals of Allergy* 1977;**39**: 311–8.

Taylor 1977 {published data only}

Taylor CB, Farquhar JW, Nelson E, Agras S. Relaxation therapy and high blood pressure. *Archives of General Psychiatry* 1977;**34**: 399–442.

Vacc 1980 {published data only}

Vacc NA, Greenleaf SM, Gerler ER Jr. Relaxing training and covert positive reinforcement with elementary school children. *Elementary School Guidance & Counseling* 1980;14(3):232–5.

Van Damme 1998 {published data only}

Van Damme L, Niruthisard S, Atisook R, Boer K, et al.Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. *AIDS* 1998;**12**:433–7.

Volweider 1981 {published and unpublished data}

Volweider FH. A comparison of short-term yoga and buddyorientated groups with chronic psychiatric patients. PhD-thesis, University of Southern Missisippi 1981.

Weber 1975 {published data only}

Weber BA, Sulzbacher SI. Use of CNS stimulant medication in averaged electroencephalic audiometry with children with MBD. *Journal of Learning Disabilities* 1975;**8**(5):300–3.

Placebo interventions for all clinical conditions (Review)

Weintraub 1992 {published data only}

Weintraub M, Sundaresan PR, Schuster B, Averbuch M, et al.Long term weight control study V (weeks 190 to 210). *Clinical Pharmacology and Therapeutics* 1992;**51**(5):614–8.

Windle 2001 {published data only}

Windle PE, Borromeo A, Robles H, Ilacio-Uy V. The effects of acupressure on the incidence of postoperative nausea and vomiting in postsurgical patients. *Journal of Perianesthesia Nursing* 2001;**16**: 158–62.

Winnan 1982 {published data only}

Winnan GR, Meyer CT, McCallum RW. Interpretation of the Bernstein Test: a reappraisal of criteria. *Annals of Internal Medicine* 1982;**96**:320–2.

Worner 1992 {published data only}

Worner TM, Zeller B, Schwarz H, Zwas F, et al.Acupuncture fails to improve treatment outcome in alcoholics. *Drug and Alcohol Dependence* 1992;**30**:169–73.

Zeisset 1968 {published data only}

Zeisset RM. Desensitization and relaxation in the modification of psychiatric patients' interview behavior. *Journal of Abnormal Psychiatry* 1968;**73**(1):18–24.

References to studies awaiting assessment

Shin 2005 {published data only}

References to ongoing studies

Barret 2007 {published data only}

Barrett B, Rakel D, Chewning B, Merchand L, Rabago D, Brown R, et al.Rationale and methods for a trial assessing placebo echinacea and doctor-patient interaction in the common cold. *Explore* 2007;**3**:561–72.

Additional references

Allan 2002

Allan LG, Siegel S. A signal detection theory analysis of the placebo effect. *Eval Health Prof* 2002;25:410–20.

Beecher 1955

Beecher HK. The powerful placebo. JAMA 1955;159:1602-6.

Bignal 1994

Bignal J. Science of placebos. Lancet 1994;344:904.

Brown 1998

Brown WA. The placebo effect. Scientific American 1998;278:68-3.

CCC Stat Pol 1999

Cochrane Consumers and Communication Review Group. Statistical policy. The Cochrane Library; Oxford: Update Software. Issue 1, 1999.

Cochrane 1989

Cochrane AL. Effectiveness and efficiency. Random reflections on health services. Cambridge University Press for British Medical Journal & The Nuffield Provincial Hospitals Trust, 1989:31. [: ISBN 0 7279 0282 2]

Dush 1986

Dush DM. The placebo in psychosocial outcome evaluations. *Evaluation & the Health Professions* 1986;**9**:421–38.

Dworkin 2008

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, et al.Consensus statement. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *Journal of Pain* 2008;**9**(2):105–21.

Egger 1997

Egger M. Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629–34.

Ernst 1995

Ernst E, Resch KL. Concept of true and perceived placebo effects. *BMJ* 1995;**311**:551–3.

Grissom 1996

Grissom RJ. The magical number .7 +/- .2: meta-meta-analysis of the probability of superior outcome in comparisons involving therapy, placebo, and control. *Journal of Consulting and Clinical Psychology* 1996;**64**:973–82.

Gøtzsche 1990

Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. *Journal of Clinical Epidemiology* 1990;**43**:1313–8.

Gøtzsche 1994

Gøtzsche PC. Is there logic in the placebo?. *Lancet* 1994;**344**: 925–6.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60.

Ho 1994

Ho VMS. The placebo effect: can we use it better?. *BMJ* 1994; **309**:69–70.

Hróbjartsson 1996

Hróbjartsson A. The uncontrollable placebo effect. *European Journal of Clinical Pharmacology* 1996;**55**:345–8.

Hróbjartsson 2002b

Hróbjartsson A. What are the main methodological problems in the estimation of placebo effects?. *Journal of Clinical Epidemiology* 2002;**55**:430–5.

Hróbjartsson 2003

Hróbjartsson A, Norup M. The use of placebo interventions in medical practice - a national questionnaire survey of Danish clinicians. *Evaluation and the Health Professions* 2003;**26**:153–65.

Hróbjartsson 2006

Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. *Journal of Clinical Epidemiology* 2006; **59**:336–8.

Hróbjartsson 2007

Hróbjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. *Journal of Clinical Psychology* 2007;**63**:373–7.

Kamper 2008

Kamper SJ, Machado LA, Herbert RD, Maher CG, McAuley JH. Trial methodology and patient characteristics did not influence the size of placebo effects on pain. *Journal of Clinical Epidemiology* 2008;**61**(3):256–60.

Placebo interventions for all clinical conditions (Review)

Copyright $\textcircled{\sc 0}$ 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Kaptchuk 2006

Kaptchuk TJ, Stason WB, Davis RB, Legedza AR, Schnyer RN, Kerr CE, et al.Sham device v inert pill: randomised controlled trial of two placebo treatments. *BMJ* 2006;**18**:391–7.

Kienle 1997

Kienle GS, Kiene H. The powerful placebo effect: fact or fiction?. *Journal of Clinical Epidemiology* 1997;**50**:1311–8.

Kirsch 1998

Kirsch I, Sappirstein G. Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. *Prevention and Treatment* 1998;**1**:1–17.

Lasagna 1986

Lasagna L. The placebo effect. *The Journal of Allergy and Clinical Immunology* 1986;**78 (1pt 2)**:161–5.

Linde 1997

Linde K, Clausius N, Ramirez G, Melchart D, et al.Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebocontrolled trials. *Lancet* 1997;**350**:834–43.

Madsen 2009

Madsen MV, Gøtzsche PC, Hróbjartsson A. Acupuncture treatment for pain. Systematic review of randomized clinical trials with acupuncture, placebo acupuncture and no-acupuncture groups. *BMJ* 2009;**338**:a3115. [DOI: 10.1136/bmj.a3115]

Meissner 2007

Meissner K, Distel H, Mitzdorf. Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials. *BMC Medicine* 2007;**5**:3.

Rawlinson 1985

Rawlinson MC. Truth-telling and paternalism in the clinic: philosophical reflections on the use of placebos in medical practice. In: White L, Tursky B, Schwartz GE editor(s). *Placebo. Theory, Research, Mechanisms.* New York: Guilford Press, 1985:403–18.

Sauro 2005

Sauro MD, Greenberg RP. Endogenous opiates and the placebo effect. A meta-analytical review. *Journal of Psychosomatic Research* 2005;**58**:115–20.

Shapiro 1982

Shapiro DA, Shapiro D. Meta-analysis of comparative therapy outcome studies: a replication and refinement. *Psychological Bulletin* 1982;**92**:581–604.

Smith 1980

Smith ML, Glass GV, Miller TI. *The Benefits of Psychotherapy*. Baltimore: John Hopkins University Press, 1980.

Tilburt 2008

Tilburt JC, Emanuel EJ, Kaptchuk TJ, Curlin FA, Miller FG. Prescribing 'placebo treatments: results of national survey of US internists and rheumatologists. *BMJ* 2008;**337**:a1938. [DOI: 10.1136/bmj.a1938]

Vase 2002

Vase L, Riley III JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. *Pain* 2002;**99**:443–52.

Wampold 2005

Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. *Journal of Clinical Psychology* 2005;**61**:835–54.

References to other published versions of this review

Hróbjartsson 2001

Hróbjartsson A, Gøtzsche PC. Is the placebo powerless?An analysis of clinical trials comparing placebo with no treatment. *The New England Journal of Medicine* 2001;**344**(21):1594–1602.

Hróbjartsson 2002a

Hróbjartsson A, Gøtzsche PC. What is the effect of placebo intervention?[Hvad er effekten af placebobehandling?]. *Ugeskrift for Læger* 2002;**164**:329–33.

Hróbjartsson 2003a

Hrobjartsson A, Gøtzsche PC. Placebo treatment versus no treatment. *Cochrane Database of Systematic Reviews* 2003, Issue 1. [DOI: 10.1002/14651858.CD003974]

Hróbjartsson 2004a

Hróbjartsson A, Gøtzsche PC. Placebo treatment for all clinical conditions. *Cochrane Database of Systematic Reviews* 2004, Issue 3. [DOI: 10.1002/14651858.CD003974.pub2]

Hróbjartsson 2004b

Hróbjartsson A, Gøtzsche PC. Is the placebo powerless?Update of a systematic review with 52 new randomised trials comparing placebo with no treatment. *Journal of Internal Medicine* 2004;**256**:91–100.

* Indicates the major publication for the study

Copyright $\textcircled{\sc 0}$ 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Abikoff 2004

Methods	Design: three group parallel trial Purpose: study the effect of methylphenidate and multimodal psychological treatment on children with attention-deficit/hyperactivity disorder
Participants	Patients: children with attention-deficit/hyperactivity disorder Baseline comparability: yes (except for socioeconomic status)
Interventions	Placebo: sessions with attention control interventions with no social skills training Untreated: no sessions Experimental: sessions with social skills training (Co-intervention: All patients received methylphenidate)
Outcomes	Social skills rating scale (parents) Social skills rating scale (children) Taxonomy of problem situations (teachers) Direct school observations Parental practices Academic achievements Emotional status
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (attention control placebo/multimodal psychological intervention)
Blinding? Outcome assessor	Unclear	Not relevant as patient (parents) reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	

Abikoff 2004 (Continued)

No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 69
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Adams 1976

Methods	Design: three group parallel trial Purpose: examine the effect of adenine arabinoside on episodes of genital herpes
Participants	Patients: out-patients with episodes of genital herpes Baseline comparability: NS
Interventions	Placebo: ointment or gel without adenine arabinoside Untreated: no ointment or gel Experimental: ointment or gel with adenine arabinoside (Co-intervention: NS)
Outcomes	Pain Mean duration of pain Mean duration of viral shedding Mean duration of lesions Mean duration any new lesion during treatment
Notes	Relevant outcome data not reported in article

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Thus ara-A or placebo ointment or gel were given in a double-blind fashion'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS

Adams 1976 (Continued)

Free of selective reporting?	No	Relevant outcome data not reported in ar- ticle
Free of other bias?	Yes	
Trial size > 49?	No	N = 38
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Adriaanse 1995

Methods	Design: three group parallel trial Purpose: examine the effect of vaginal chlorhexidine disinfection on the transmission of group B streptococci from mother to child during labour
Participants	Patients: women during labour Baseline comparability: yes
Interventions	Placebo: vaginal gel without chlorhexidine Untreated: no vaginal gel Experimental: vaginal gel with chlorhexidine (Co-intervention: NS)
Outcomes	Bacterial transmission rate Infections

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'Predefined block (10:10:10) allocation scheme'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Two groups were treated in a double-blind manner with either a chlorhexidine or a placebo gel'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out >15% or NS

Adriaanse 1995 (Continued)

Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 654
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out >15% or NS

Alfano 2001

Methods	Design: five group parallel trial Purpose: examine the effect of static magnetic fields for treatment of fibromyalgia
Participants	Patients: subjects with fibromyalgia (American College of Rheumatology's diagnostic criteria) Baseline comparability: yes
Interventions	Placebo: pads that have no magnetic property inserted into the beds of the patients for 6 months Untreated: no pads Experimental: two types of pads with static magnetic properties (Co-intervention: NS)
Outcomes	Pain (11 point numeric rating scale, 0 to 10) at six months Number of tender points Tender point pain intensity Functional status (fibromyalgia impact questionnaire)
Notes	Results from two placebo groups reported as deriving from one group.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'Computer-generated treatment list'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patients reported outcome

Alfano 2001 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 38
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Alford 2003

Methods	Design: three group parallel trial Purpose: to evaluate the efficacy of a continuous postoperative bupivacaine infusion pump for pain management after anterior cruciate ligament reconstruction
Participants	Patients: out-patients requiring ACL reconstruction Baseline comparability: NS
Interventions	Placebo: infusion catheter filled with saline Untreated: no catheter Experimental: infusion catheter filed with 0.25% bupivacaine solution. (Co-intervention: ipsilateral femoral nerve block with 30mL 0.25% bupivacaine and 20 mL 0.25% bupivacaine intra-articular injection. Postoperative pain management proto- col: hydrocodone/acetaminophen, 5mg/500mg every 4 hours, and ibuprofen 800mg 3 times a day)
Outcomes	Pain (11 point numeric rating scale, 0 to 10) Medication consumption Physical therapy performance
Notes	
Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'random number draw conducted in the operating suite'

Alford 2003 (Continued)

Allocation concealment?	Unclear	'separate sealed notebook'
Blinding? Treatment provider	Yes	'Both patient and investigators were blinded to the catheter contents and group assignment'
Blinding? Outcome assessor	Yes	'The therapists were blinded to patient group assignment'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	No	N = 16
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Alkaissi 1999

Methods	Design: three group parallel trial Purpose: examine the preventive effect of acupressure on nausea and vomiting after surgery
Participants	Patients: women undergoing minor gynaecological surgery Baseline comparability: yes
Interventions	Placebo: acupressure on a site which was not P6 during hospital stay Untreated: no acupressure Experimental: acupressure on P6 (Co-intervention: metoclopramide and droperidol at request)
Outcomes	Proportion of patients with complete response (no nausea, vomiting, or rescue medica- tion)after 24 hours Nausea (only) Vomiting Rescue medication Nausea after 24 hours
Notes	In the no treatment group 6/20 had nausea at discharge, and 8/20 after 24 hours. The corresponding numbers for the placebo group were 7/20 and 1/20. According to protocol we extracted data at post-treatment (discharge). 10 out of 60 patients dropped out ('evenly distributed between the groups') and were replaced by 10 new patients

Alkaissi 1999 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	'The study was double-blind' but this re- ferred to blinding of patient and outcome assessor.
Blinding? Outcome assessor	Unclear	Not relevant as patients reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out >15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 40
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out >15% or NS

Alkaissi 2002

Methods	Design: three group parallel trial Purpose: examine the preventive effect of acupressure on nausea and vomiting after surgery
Participants	Patients: women undergoing minor gynaecological surgery Baseline comparability: yes
Interventions	Placebo: acupressure bands not on P6 for 24 hours Untreated: no acupressure Experimental: acupressure on P6 (Co-intervention: anaesthetic agents, rescue medication)
Outcomes	Proportion of patients with complete response (no nausea, vomiting or rescue medica- tion), time NS Apfel risk score Satisfaction with treatment

Alkaissi 2002 (Continued)

Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'Sealed envelope'
Blinding? Treatment provider	No	Described as double-blind (Placebo/acu- pressure)but this referred to blinding of pa- tient and outcome assessor.
Blinding? Outcome assessor	Unclear	Not relevant as patients reported outcomes
Incomplete outcome data addressed? All outcomes	Yes	Drop-out <15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 275
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Allen 1998

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture on depression
Participants	Patients: out-patients with depression Baseline comparability: no (depression scores)
Interventions	Placebo: needling in acupuncture points not regarded having impact on depression Untreated: no needling Experimental: needling in acupuncture points regarded having impact on depression (Co-intervention: NS)
Outcomes	Hamilton Rating Scale for Depression (31-item version, HAM-D31) Proportion of patients with remission (50% reduction on HAM-D31) Inventory of Depressive Symptomatology Beck Depression Inventory

Allen 1998 (Continued)

Beck Hopelessness Scale

Notes

Risk of bias

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The treating acupuncturists were blind to the experimental hypotheses' (Placebo/ acupuncture)
Blinding? Outcome assessor	Yes	'All patients were interviewed by trained raters blind to treatment condition'
Incomplete outcome data addressed? All outcomes	Yes	Drop out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 22
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Allen 2006

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture on depression
Participants	Patients: out-patients with depression (score of 14 or more on the 17-item Hamilton rating scale for depression) Baseline comparability: yes
Interventions	Placebo: needling in acupuncture points not regarded having impact on depression Untreated: no needling Experimental: needling in acupuncture points regarded having impact on depression (Co-intervention: NS)

Allen 2006 (Continued)

Outcomes	Hamilton Rating Scale for Depression (17 item) Beck Depression Inventory	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The treating acupuncturists were blind to the experimental hypotheses' (Placebo/ acupuncture)
Blinding? Outcome assessor	Yes	'Patients were blind to intervention condi- tion, as were raters who assessed outcome'
Incomplete outcome data addressed? All outcomes	Yes	Drop out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 89
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Andersen 1990

Methods	Design: three group parallel trial Purpose: examine the effect of bromocriptine on breast pain and milk secretion after abortion
Participants	Patients: women having undergone a second-trimester abortion Baseline comparability: yes
Interventions	Placebo: a tablet without bromocriptine Untreated: no tablet Experimental: a tablet containing bromocriptine

Andersen 1990 (Continued)

	(Co-intervention: no)	
Outcomes	Breast pain (VAS) and serum prolactin (micro g/l) Breast tenderness Milk secretion	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The part of the study that involved bromocriptine and placebo was carried out 'double-blind"
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop out > 15 % or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 34
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Anderson 1999

Methods	Design: three group parallel trial Purpose: examine the effect of an office based intervention to maintain parent-adolescent teamwork in diabetes management
Participants	Patients: families with a young person with type 1 diabetes Baseline comparability: yes (age, gender, HbA1c, etc)

Anderson 1999 (Continued)

Interventions	Placebo: over six months four 20 to 30 minute sessions with 'traditional' diabetic edu- cation with no focus on parental involvement Untreated: no sessions Experimental: sessions of parental-adolescent teamwork therapy (Co-intervention: standard diabetic care)
Outcomes	Insulin routine score for parental involvement (4 point Likert scale) HbA1c (%) Blood glucose monitoring score Diabetes family conflict scale Diabetic family behavior checklist

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ teamwork intervention)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop out < 15 %
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 57
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Not clearly concealed allocation

Antivalle 1990

Methods	Design: Two group, two period cross-over trial Purpose: examine the effect of placebo intervention on blood pressure
Participants	Patients: previously untreated out-patients suffering from essential arterial hypertension Baseline comparability: yes (age, sex, blood pressure)
Interventions	Placebo: 'tablet x 2 daily' Untreated: no tablet Experimental : no (Co-intervention: no)
Outcomes	Diastolic blood pressure reduction (mm Hg)
Notes	The first period was considered a parallel trial. Results from the second period were disregarded.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ul- trasound)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 21
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Antonio 1999			
Methods	Design: three group parallel trial Purpose: examine the effect of 'guggulste position and mood in obese adults	Purpose: examine the effect of 'guggulsterone phosphate compound' on the body com-	
Participants	Patients: out-patients with body mass in Baseline comparability: yes	Patients: out-patients with body mass index >25 kg per square meter Baseline comparability: yes	
Interventions	Untreated: no capsules Experimental: capsules with a compound	Placebo: maltodextrin capsules daily for 6 weeks Untreated: no capsules Experimental: capsules with a compound of guggulsterone phosphate (Co-intervention: dietary and exercise program)	
Outcomes	Weight (kg) Lean body mass Fat mass Percentage body fat Profile of Mood States questionnaire (PO	Lean body mass Fat mass	
Notes			
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'In this double-masked, randomized study'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 12

Antonio 1999 (Continued)

Clearly concealed allocation + trial size >	No	Trial size < 49
49 + drop-out max 15%?		

Ascher 1979

Methods	Design: three group parallel trial Purpose: examine the effect of paradoxical intention on insomnia
Participants	Patients: out-patients suffering from insomnia Baseline comparability: yes (sleep parameters)
Interventions	Placebo: sessions of 'quasi-desensitization' (neutral images paired with bedtime activity) Untreated: no sessions Experimental: paradoxical intention: (instructed to remain awake as long as possible and presented with the true theoretical background) (Co-intervention: NS)
Outcomes	Sleep latency (minutes) Awakenings Restedness rating Difficulty falling asleep
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ paradoxical intention)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)

Ascher 1979 (Continued)

Trial size > 49?	No	N = 17
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Asmar 1996

Methods	Design: two period, two group, cross-over trial Purpose: examine the effect of placebo on arterial hypertension
Participants	Patients: out-patients with untreated mild-to-moderate hypertension
Interventions	Placebo: NS Untreated: no placebo (Co-intervention: NS)
Outcomes	Diastolic blood pressure (mm Hg) Systolic blood pressure (mm Hg)
Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial. The results from the trial were reported in two publications (without cross reference). In the original report there were 36 included patients, but in the subsequent report there appears only 26. The reported effect of placebo on diastolic blood pressure was higher in the second trial report. We decided to include the results from the original publication.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop out < 15%
Free of selective reporting?	No	No protocol available. Authors were con- tacted. They shared data after request from the involved journal.
Free of other bias?	Yes	

Asmar 1996 (Continued)

No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 68
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Not clearly concealed allocation

Aune 1998

Methods	Design: three group parallel trial Purpose: examine the prophylactic effect of acupuncture on recurrent lower urinary tract infection (UTI)
Participants	Patients: female out-patients with recurrent UTI Baseline comparability: yes (age, number of UTI last 5 years)
Interventions	Placebo: needling in areas that are not known acupuncture sites Untreated: no needling Experimental: needling in areas that are known acupuncture sites (Co-intervention: NS)
Outcomes	Number of patients who had infections during 6 months Number of infections during 6 months
Notes	Patients were randomised to placebo and no treatment in a 2:1 ratio

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer based schedule'
Allocation concealment?	Yes	'sealed envelopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome. (Urine was tested when patients reported UTI symptoms)
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available

Aune 1998 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 40
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Banner 1983

Methods	Design: six group parallel trial Purpose: examine the effect of various techniques for reducing tension
Participants	Patients: media recruited out-patients who regularly experienced feelings of tension they wanted to reduce Baseline comparability: yes
Interventions	Placebo: sessions where relaxation was enhanced by listening to soft music Untreated: no sessions Experimental: sessions with -visual and auditory feedback on the tension in the frontalis muscle -visual and auditory feedback on the finger temperature -combination of frontalis and temperature feedback procedures -relaxation enhanced by listening to a autogenic relaxation tape (Co-intervention: NS)
Outcomes	Tension rating scale EMG Finger temperature Frequency of problems
Notes	Relevant outcome data not accessible: data lost (personal communication Banner CN)

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ac- tive)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Banner 1983 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	Relevant outcome data not accessible: data lost (personal communication Banner CN)
Free of other bias?	Yes	
Trial size > 49?	No	N = 19
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Benedetti 1995

Methods	Design: eight group parallel trial Purpose: examine the effect of placebo and proglumide on postoperative pain
Participants	Patients: postoperative in-patients after thoracotomy Baseline comparability: yes (pain intensity)
Interventions	Placebo: open infusion of saline Untreated: hidden infusion of saline Experimental: -open infusion of proglumide (0.05 mg, 0.5 mg, 5 mg) -hidden infusion of proglumide (0.05 mg, 0.5 mg, 5 mg) (Co-intervention: NS)
Outcomes	Pain (VAS)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'double-blind randomized study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out >15% or NS

Benedetti 1995 (Continued)

Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Benedetti 1997

Methods	Design: three group parallel trial in five sub-studies Purpose: examine the effect of transcutaneous electrical nerve stimulation (TENS) on acute postoperative pain
Participants	Patients: postoperative in-patients after thoracotomy Baseline comparability: yes (sex and age)
Interventions	Placebo: TENS without batteries Untreated: no TENS Experimental: TENS with batteries (Co-intervention: analgesics on demand, see outcome)
Outcomes	Pain (overall analgesic medication within 12 hours)
Notes	The results from five sub-studies have been pooled
Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS

Benedetti 1997 (Continued)

Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 221
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Benedetti 1999a

Methods	Design: five group parallel trial Purpose: examine the respiratory depressant response of placebo in patients newly treated with opioids
Participants	Patients: lung cancer patients undergoing posterolateral thoracotomy, having repeatedly been treated with buprenorphine for three days, and were 'almost pain-free' Baseline comparability: yes (age, gender, weight)
Interventions	Placebo: saline injection (patients told it was continuation of analgesic medication) Untreated: no injection Experimental: naloxone injection (open and hidden) (Co-intervention: additional doses of buprenorphine were administered and resulted in exclusion of the patient from the study, numbers NS)
Outcomes	Respiratory depression (ventilation per minute) 73 hours after surgery Pain (11 point numerical scale, 0 to 10)
Notes	The trial investigated the negative effect of placebo (respiratory depression). We included the trial in the review in a separate category (adverse effects), but not in the main analyses.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The 60 patients were investigated ac- cording to a randomized double-blind de- sign'

Benedetti 1999a (Continued)

Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	No	See notes
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Berg 1983

Methods	Design: three group parallel trial Purpose: examine the effect of the additional treatment of an oral laxative 'Senokot' in patients with faecal soiling already treated with behavioural therapy
Participants	Patients: children with severe and persistent faecal incontinence Baseline comparability: yes
Interventions	Placebo: tablet without laxative Untreated: no tablet Experimental: tablet with laxative 'Senokot' (Co-intervention: behavioural therapy)
Outcomes	Number of children soiling more than once weekly
Notes	Tablets delivered in packs marked A and B; selection bias may therefore have occurred, if the code was broken

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'the psychiatrist and psychologists did not know which tablets actually contained the laxative'
Blinding? Outcome assessor	Unclear	Not relevant as patient (parents) reported outcome

Berg 1983 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	Tablets delivered in packs marked A and B; selection bias may therefore have occurred, if the code was broken
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 26
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Biro 1997

Methods	Design: five group parallel trial Purpose: examine the effect of topical anaesthesia methods for venous cannulation in adults		
Participants	Patients: patients in need of cannulation Baseline comparability: yes ('demographic	Patients: patients in need of cannulation Baseline comparability: yes ('demographic data')	
Interventions	Placebo: cream without EMLA Untreated: no cream Experimental: -cream with EMLA -ethylchloride spray -lidocaine infiltration (Co-intervention: yes, midazolam)		
Outcomes	Pain ratings (VAS) Number of patients with difficult puncture	25	
Notes			
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	Unclear information	

Unclear information Allocation concealment? 'The study was double-blinded to the de-Blinding? Yes gree that the methodologies allowed' Treatment provider

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Unclear

Biro 1997 (Continued)

Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcomes
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 58
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Unclear allocation concealment

Blackman 1964

Methods	Design: three group parallel trial Purpose: examine the effect of imipramine on enuresis
Participants	Patients: army recruits referred to a 'Mental Hygiene Consultation Service' with the complaint of enuresis Baseline comparability: yes (frequency of enuresis)
Interventions	Placebo: tablet without imipramine Untreated: no tablet (observational group) Experimental: tablet with imipramine (Co-intervention: NS)
Outcomes	Number of patients with reduced frequency of enuresis
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The subjects and experimenters were blind to which pills were the active medication'

Blackman 1964 (Continued)

Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Blades 2001

Methods	Design: three group, three period cross-over trial Purpose: study the effect of oral antioxidant therapy on marginal dry eye
Participants	Patients: out-patients with marginal dry eyes
Interventions	Placebo: capsules without antioxidants Untreated: no capsules Experimental: capsules with antioxidants (Co-intervention: NS)
Outcomes	Glasgow Caledonian University threads phenol read thread test (G-CUT) Tear thinning time McMonnies dry eye questionnaire Squamous cell metaplasia Goblet cell density
Notes	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a parallel group trial.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'Latin squares'
Allocation concealment?	Unclear	No stated

Blades 2001 (Continued)

Blinding? Treatment provider	Yes	'This trial was double-masked'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 80
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Blanchard 1990a

Methods	Design: four group parallel trial Purpose: study the effect of abbreviated progressive muscle relaxation (PMR) and cog- nitive therapy on headache
Participants	Patients: out-patients with tension headache Baseline comparability: NS
Interventions	Placebo: sessions of 'pseudomeditation' Untreated: no sessions Experimental: -sessions of abbreviated progressive muscle relaxation plus cognitive therapy -sessions of abbreviated progressive muscle relaxation (Co-intervention: headache medication)
Outcomes	Medication Index Headache Index Frequency of patients with headache reduction
Notes	
Risk of bias	

Blanchard 1990a (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ PMR)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Blanchard 1990b

Methods	Design: four group parallel trial Purpose: study the effect of thermal biofeedback and cognitive therapy on headache
Participants	Patients: out-patients with vascular headache Baseline comparability: NS
Interventions	Placebo: sessions of 'pseudomeditation' Untreated: no sessions Experimental: -sessions of thermal biofeedback and cognitive therapy -sessions of thermal biofeedback (Co-intervention: headache medication)
Outcomes	Medication Index Headache Index Frequency of patients with headache reduction
Notes	

Blanchard 1990b (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ thermal biofeedback)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 42
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Block 1980

Methods	Design: three group parallel trial Purpose: examine the effect of rational emotive therapy on obese persons
Participants	Patients: overweight adults Baseline comparability: yes (weight)
Interventions	Placebo: sessions of deep muscle relaxation & discussions Untreated: no sessions Experimental: sessions with rational emotive therapy (Co-intervention: information booklet on nutrition)
Outcomes	Overweight (pounds)
Notes	
Risk of bias	

Block 1980 (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ra- tional emotive therapy)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Bosley 1989

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive self-management training on hypertension
Participants	Patients: out-patients with essential arterial hypertension Baseline comparability: NS
Interventions	Placebo: general information on stress with no direct training suggestions Untreated: no training or information Experimental: cognitive self-management training (Co-intervention: antihypertensive medication, fixed ordination scheme: NS)
Outcomes	Diastolic blood pressure (mm Hg) Psychological distress Coping style
Notes	Standard deviations (SD) on diastolic blood pressure (mm Hg) not reported. SD esti- mated from another blood pressure study (Seer 1980: SD ~ 10 mm Hg)

Bosley 1989 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ training)
Blinding? Outcome assessor	Yes	'The nurses were blind to the treatment group to which subjects were assigned'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	Standard deviations (SD) on diastolic blood pressure (mm Hg) not reported. SD estimated from another blood pressure study (Seer 1980: SD ~ 10 mm Hg)
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 27
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Bova 1999

Methods	Design: three group parallel trial Purpose: evaluate the usefulness of premedication with an oral anticholinergic for relief of pain associated with barium enema
Participants	Patients: patients undergoing a pain inducing medical procedure (barium enema) Baseline comparability: NS
Interventions	Placebo: tablet with no hyoscyamine 15 to 30 minutes before procedure Untreated: no tablet Experimental: tablet with hyoscyamine (Co-intervention: NS)

Bova 1999 (Continued)

Outcomes	Pain (0 to 10 analogue scale) reported immediately after enema Side effects	
Notes	Patients with contraindications to hyoscyamine were 'moved to the placebo and no- treatment group'.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15 %
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 70
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation NOT clearly concealed

Bramston 1985

Methods	Design: four group parallel trial Purpose: examine the effect of cognitive and behavioural social skills training with in- tellectually handicapped adults
Participants	Patients: institutionalised intellectually handicapped adults Baseline comparability: yes (outcomes)
Interventions	Placebo: unstructured training in 'money management' Untreated: no training Experimental:

Bramston 1985 (Continued)

	-cognitive social skills training -behavioural social skills training (Co-intervention: standard care)
Outcomes	Social skills assessment chart Staff questionnaire on social skills Preschool interpersonal problem solving

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ training)
Blinding? Outcome assessor	Yes	'None of the raters participated in the train- ing programme or were aware of S-group allocation'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Bril	1 1964	
Me	thods	Design: six group parallel trial Purpose: to examine the effect patients
Par	ticipants	Patients: out-patients with neur Baseline comparability: yes (rat
Int		Dlaasha, aanaula without month

Participants	Patients: out-patients with neuroses, borderline schizophrenia or personality disorders Baseline comparability: yes (rating scales)
Interventions	Placebo: capsule without meprobamate, phenobarbital or prochlorperazine Untreated: no capsule (waiting list group) Experimental: capsule with -meprobamate -phenobarbital -prochlorperazine (Co-intervention: NS)
Outcomes	Patient's rating (anxiety, tension, irritability, concentration, alertness, mood, sleep, ap- petite, general feeling) Rating by relative and patient (getting along, nervousness, happiness, ability to handle personal problems, energy, physical health, presenting symptoms or problems, ability to work, ability to enjoy life, overall condition) MMPI (Minnesota Multi phasic Personality Inventory) Social Worker Interview Evaluation
Notes	Number of patients assigned to untreated group was 34 contrasting the number in the other groups which had 50 to 54 patients. Relevant outcome data not accessible

effect of psycho- and pharmacotherapy on psychiatric out-

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Used a double-blind method of adminis- tration of drugs'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out >15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 89

Brill 1964 (Continued)

Clearly concealed allocation + trial size > No

49 + drop-out max 15%?			
Brinkhaus 2006	Brinkhaus 2006		
Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture in patients with chronic low back pain		
Participants	Patients: patients with chronic low back pain Baseline comparability: yes (age, gender, pain intensity)		
Interventions	Placebo: acupuncture on sites not regarded acupuncture sites Untreated: no acupuncture Experimental: acupuncture on sites regarded acupuncture sites (Co-intervention: All patients were allowed to take non-steroid anti-inflammatory drugs if necessary)		
Outcomes	Pain (VAS) Back function (Funktionsfragebogen Hannover-Rücken) Global assessment of effect Pain disability Index Emotional aspects of pain (Schmertzempfindungsskala) Depression (Allgemeine Depressionsskala) Quality of life (SF-36) Number of days with pain Number of days with pain medication		
Notes	Patients in the no-treatment group took medication on 6.3 days whereas the placebo group did so on 4.9 days (weeks 5 to 8) .		

Drop-out >15% or NS

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'a randomised list was generated using com- puter software [SAMPSIZE V2.0]'
Allocation concealment?	Yes	'Centralised telephone randomization pro- cedure'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupressure)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Brinkhaus 2006 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Yes	Primary outcome specified in protocol
Free of other bias?	Unclear	Patients in the no-treatment group took medication on 6.3 days whereas the placebo group did so on 4.9 days (weeks 5 to 8) .
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 144
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	

Bullock 2002

Methods	Design: three group parallel trial Purpose: to study the effect of auricular acupuncture for alcohol dependence	
Participants	Patients: in-patients with alcohol dependence Baseline comparability: yes (age, gender)	
Interventions	Placebo: needling on sites not regarded acupuncture sites Untreated: no needling Experimental: needling on sites regarded acupuncture sites (Co-intervention: conventional alcohol dependence treatment according to the 'Min- nesota Model')	
Outcomes	Alcohol use (Timeline Follow-back) Addiction severity index (ASI) Alcohol dependence scale Breathalyzer Alcohol desire (5-point Likert scale) Health status (SF36 and Medical status composite score part of ASI) Beck depression inventory Self-rating anxiety scale	
Notes	Outcome not reported so that meta-analysis is possible.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS

Bullock 2002 (Continued)

Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Outcome not reported so that meta-analy- sis is possible.
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 267
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Cabrini 2006

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture in reducing discomfort during fibreoptic bronchoscopy	
Participants	Patients undergoing diagnostic bronchoscopy Baseline comparability: yes	
Interventions	Placebo: acupuncture on sites not regarded acupuncture sites Untreated: no acupuncture Experimental: acupuncture on sites regarded acupuncture sites (Co-intervention: All patients were treated with airway topical anaesthesia)	
Outcomes	Discomfort (VAS) Anxiety Heart rate and pulse oximetry	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Cabrini 2006 (Continued)

Blinding? Treatment provider	No	Acupuncturist aware of treatment group
Blinding? Outcome assessor	Unclear	Not relevant as outcome was patient-re- ported
Incomplete outcome data addressed? All outcomes	No	Drop-outs not described
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	SD x 1.64 < mean
Trial size > 49?	No	N = 32
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Camatte 1969

Methods	Design: ten group parallel trial Purpose: examine the effect of various forms of drugs and placebo on the pain associated with peptic ulcer disease	
Participants	Patients: patients with radiologically confirmed gastric ulcers Baseline comparability: NS	
Interventions	Placebo: patches without active substance Untreated: no patches, capsules or injections Experimental: patches, capsules, and injections with various drugs, e.g. bismuth (Co-intervention: NS)	
Outcomes	Pain (number of days in pain)	
Notes	Outcome not reported so that meta-analysis is possible.	
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Camatte 1969 (Continued)

Blinding? Treatment provider	Yes	'Nei Gruppi 2 e 10 il placebo veniva pre- sentato sotto forma di compresse aventi il medesimo aspetto ed il medesimo colore di uno dei medicamenti impiegati nei Gruppi 3 e 9'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Outcome not reported so that meta-analy- sis is possible.
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 72
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Camberg 1999

Methods	Design: three group three period cross-over trial Purpose: examine the effect of 'Simulated Presence' (SimPres) on well-being in nursing home residents with Alzheimer's disease
Participants	Patients: nursing home residents with Alzheimer's disease
Interventions	Placebo: audio tape of a person reading a text that is not personal nor interactive Untreated: no audio tape Experimental: personalised interactive audio tape that contains a telephone conversation with a family member or surrogate. (Co-intervention: normal nursing home care)
Outcomes	Mood (multidimensional observation scale for elderly) Interest (multidimensional observation scale for elderly) Prevalence of agitated behaviour Prevalence of withdrawn behaviour Agitation scale (Cohen-Mansfield) Scale for observation of agitation in persons with dementia Positive affect rating scale Facial diagrams of mood (FACE)
Notes	Outcome not reported so that meta-analysis is possible.

Risk of bias

Camberg 1999 (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'Latin squares'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Yes	'Observers were blinded to the study inter- vention'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	Outcome not reported so that meta-analy- sis is possible.
Free of other bias?	Yes	
Trial size > 49?	No	N = 36
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Canino 1994

Methods	Design: three group parallel trial Purpose: examine the effect of behavioural treatment on hypertension
Participants	Patients: out-patients with primary hypertension Baseline comparability: yes (blood pressure)
Interventions	Placebo: stressful life events were recorded and participants instructed to relax at home some time every day without any formal relaxation training Untreated: waiting list Experimental: 'Behavioural program' (deep muscle relaxation technique and anxiety management training) (Co-intervention: no)
Outcomes	Diastolic blood pressure (mm Hg) Urinary catecholamine concentration Anxiety
Notes	
Risk of bias	

Canino 1994 (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural program)
Blinding? Outcome assessor	Yes	Automatic blood pressure measurement
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 13
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Carbajal 1999

Methods	Design: three group parallel trial Purpose: examine the analgesic effect of glucose, sucrose and pacifiers in term infants
Participants	Patients: newborn infants in need of venipunctures Baseline comparability: yes
Interventions	Placebo: 2 minutes before venipuncture sterile water was given to the infant orally with a syringe for 30 seconds Untreated: no sugar, pacifier or water Experimental: -glucose in syringe -sucrose in syringe -pacifier -sucrose in syringe and pacifier (Co-intervention: no)
Outcomes	Pain (Douleur Aiguë du Nouveau-né (DAN) scale (0 to 10 points)) during venipuncture

Carbajal 1999 (Continued)

Notes	Outcome reported as medians (both placebo and no treatment: 7) and interquartile ranges (6-10, and 5-10)). Individual results were reported, and we recalculated the outcome as means and SD	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers table'
Allocation concealment?	Yes	'treatment allocations inserted in opaque sealed envelopes numbered 1-150. Investi- gators were blind to these allocations.'
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS
Carter 2001		
Methods	Design: three group parallel trial Purpose: examine the effect of allergen avo	idance for asthma among inner-city children

Participants	Patients: Children (5 to 16 years) with asthma Baseline comparability: yes
Interventions	Placebo: mattresses permeable for allergens, ineffective roach traps Untreated: no mattresses Experimental: mattresses impermeable for allergens and effective roach bait

Carter 2001 (Continued)

	(Co-intervention: NS)
Outcomes	Number of acute visits for asthma (hospitalisation, emergency department visits, un- scheduled clinical visits) Allergen level (dust mite, cockroach, cat) Sensitization to common allergens
Notes	Outcome not reported so that meta-analysis is possible

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Outcome not reported so that meta-analy- sis is possible
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 55
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Carter 2003

Methods	Design: three group parallel trial Purpose: examine the effect of unguided self-help for bulimia nervosa
Participants	Patients: patients with bulimia nervosa Baseline comparability: yes (age, duration of bulimia nervosa)
Interventions	Placebo: cognitive behaviour self-help therapy Untreated: no self-help therapy Experimental: non-specific self-help therapy (manual on 'self-assertion for women' and hearing a plausible rationale)

Carter 2003 (Continued)

	(Co-intervention: NS)
Outcomes	Frequency of binge eating Frequency of compensatory behaviours Eating disorder inventory scores Rosenberg self-esteem score Beck depression inventory score Inventory of interpersonal problems score

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'Random numbers table'
Allocation concealment?	Yes	'numbered opaque sealed envelopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ self-guide)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 57
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Cesarone 2001

Methods	Design: three group parallel trial Purpose: to evaluate the effect of local (foot) treatment with Essaven gel in subjects with diabetes mellitus and neuropathy without ulcers.
Participants	Patients: out-patients with diabetes mellitus and neuropathy without ulcers. Baseline comparability: NS

Cesarone 2001 (Continued)

Interventions	Placebo: Placebo-gel Untreated: No-treatment Experimental: 1g of Essaven gel applied to foot (Co-intervention: Standard insulin management)
Outcomes	Laser Doppler flowmetry measuring flux PO ₂ /PCO ₂ (Kontron analyzer with a Combi sensor)

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'the randomization process was controlled by an external statistical controller accord- ing to GCP rules'
Blinding? Treatment provider	Yes	'The trial was a double-blind, placebo-con- trolled study'
Blinding? Outcome assessor	Yes	Objective measurements of flux and PO_2/PCO_2
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	No	N = 23
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Chenard 1991

Methods	Design: three group parallel trial Purpose: examine the effect of a back school treatment program and placebo intervention on chronic low back pain
Participants	Patients: out-patients with chronic low back pain Baseline comparability: yes

Chenard 1991 (Continued)

Interventions	Placebo: sessions of transcutaneous electrical nerve stimulation (TENS) with the TENS machine off Untreated: no sessions Experimental: sessions of the 'Interactional Back School' Program (Co-intervention: NS)
Outcomes	Pain (VAS)
Notes	Standard deviation of 10 cm visual analogue pain scales, pain means calculated from F- test statistic.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 28
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Classen 1983	
Methods	Design: two group, four period cross-over trial with a third untreated group assessed after the first period Purpose: examine the relationship between sensory suggestibility and treatment effect
Participants	Patients: out-patients suffering from chronic intermittent headaches Baseline comparability: pretreatment headache scores
Interventions	Placebo: tablet without metamizole Untreated: no tablet Experimental: tablet with metamizole (Co-intervention: NS)
Outcomes	Pain (headache scores, 4-item 6-point scale) Sensitivity values (d')
Notes	The first period was considered a parallel trial. Results from later periods were disregarded.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 30
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Colker 1999	
Methods	Design: three group parallel trial Purpose: examine the effect of a combination of Citrus aurantium extract, caffeine, and St. John's wort on obesity
Participants	Patients: overweight individuals (body mass index > 25 kg per square meter) Baseline comparability: clinically relevant differences in age and body weight were not statistically significant
Interventions	Placebo: maltodextrin capsules Untreated: no capsules Experimental: capsules with a compound of Citrus aurantium extract, caffeine, and St. John's wort (Co-intervention: dietary and exercise program)
Outcomes	Weight Percent body fat Fat mass Basal metabolic rate Profile of Mood States questionnaire (POMS)

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Using a double-masked, randomized, placebo-controlled protocol'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 11

Colker 1999 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Conn 1986		
Methods	Design: three group parallel trial Purpose: compare the efficacy of transcutaneous electrical nerve stimulation (TENS) with sham TENS on postoperative pain	
Participants	Patients: postoperative in-patients (after appendicectomy) Baseline comparability: operative course not compared.	
Interventions	Placebo: TENS with machine off Untreated: no TENS Experimental: TENS with machine on (Co-intervention: analgesics on demand)	
Outcomes	Pain (VAS)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'sealed envelope'
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 27

Conn 1986 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Corver 2006		
Methods	Design: three group parallel trial Purpose: study the effect of house dust mite impermeable mattress covers on the devel- opment of respiratory symptoms, atopic eczema, and mite-sensitization in children born to mothers with allergy	
Participants	Patients: pregnant women in third trimester with allergy Baseline comparability: yes (several factors), no for gender of children	
Interventions	Placebo: house dust mite permeable mattress (cotton) covers Untreated: no mattress covers Experimental: house dust mite impermeable mattress (polyester-cotton)covers (Co-intervention: NS)	
Outcomes	Wheezing at least once Recurrent wheezing Night cough without a cold Runny nose without a cold Atopic dermatitis House dust mite allergen level on bed Total IgE House dust mite specific IgE	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'participants were randomly allocated in a double blind fashion'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available

Corver 2006 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 695
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Costello 2006

Methods	Design: three group parallel trial Purpose: study the effect of ethyl vinyl chloride spray on the pain associated with can- nulation in children
Participants	Patients: children (9 to18 years) undergoing cannulation Baseline comparability: yes (age, gender ratio)
Interventions	Placebo: isopropyl alcohol spray Untreated: no spray Experimental: ethyl vinyl chloride spray (Co-intervention: no)
Outcomes	Pain intensity VAS
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random number allocation'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The investigators and nursing staff per- formin IV cannulation were blinded to the cannister's contents'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	

Costello 2006 (Continued)

No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 90
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Not clearly concealed allocation

Coyne 1995

Methods	Design: three group parallel trial Purpose: examine the effect of transcutaneous electrical nerve stimulation (TENS) on pain
Participants	Patients: persons having a venepuncture to give blood Baseline comparability: yes
Interventions	Placebo: placebo TENS Untreated: no TENS or placebo TENS Experimental: TENS (Co-intervention: NS)
Outcomes	Pain (VAS)
Notes	Standard deviation of 10 cm visual analogue pain scale, means calculated from F-test statistic.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	

Coyne 1995 (Continued)

No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 42
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Crosby 1994

Methods	Design: four group parallel trial Purpose: examine the effect of iron supplement on acute blood loss anaemia after surgery
Participants	Patients: postoperative out-patients Baseline comparability: yes for age and sex.
Interventions	Placebo: NS Untreated: no placebo or iron Experimental: iron supplement at two doses (Co-intervention: no)
Outcomes	Hb concentration (mg Hgl/dl) (59 days after surgery) Haematocrit Serum-iron Serum-ferritin
Notes	

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'computer-generated table of random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Consenting patients were randomized into four groups in a double-blind fashion'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available

Crosby 1994 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 59
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Cupal 2001

Methods	Design: three group parallel trial Purpose: examine the effect of relaxation + guided imagery (and attention-placebo)on physical and psychological aspects of rehabilitation following orthopedic surgery
Participants	Patients: patients having had performed anterior cruciate ligament reconstruction Baseline comparability: NS
Interventions	Placebo: over a period of 6 months, 10 sessions of 30 to 40 minutes of encouragement, support and reminders to visualise a peaceful scene daily Untreated: no sessions Experimental: sessions of structured relaxation and guided imagery (Co-intervention: physical therapy)
Outcomes	Pain (11 point scale, 0 to 10) Re-injury anxiety Knee strength (ratio of injured knee to the uninjured knee)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'random block'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/re- laxation)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Cupal 2001 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Davidson 1980

Methods	Design: five group parallel trial Purpose: examine the effect of psychological treatments on compulsive nail biting
Participants	Patients: out-patients regarding nail biting a serious problem and a source of personal shame Baseline comparability: yes
Interventions	Placebo: factual information on nails, diseases of nails and of theories about pathological nail biting Untreated: waiting list Experimental: two types of psychological intervention separately, and one combined. (Co-intervention: NS)
Outcomes	Length of nails (mm) and estimated frequency of nail biting (per day) Estimated control over nail biting Cosmetic appearance rate
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ psychological intervention)

Davidson 1980 (Continued)

Blinding? Outcome assessor	Yes	'Post-test and follow-up sessions were con- ducted by an experimenter who had no knowledge of the groups to which subjects had been assigned during treatment'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

De Sanctis 2001

Methods	Design: three group parallel trial Purpose: examine the effect of Essaven gel in patients with venous microangiopathy and venous ulceration	
Participants	Patients: out-patients with microangiopathy and venous ulcers Baseline comparability: yes (age, gender ratio)	
Interventions	Placebo: Gel not containing Essaven Untreated: no gel Experimental: Gel containing Essaven (Co-intervention: elastic stockings)	
Outcomes	Ulcer healing rates Total symptom score (based on Pain, edema, alternation in social life and working handicaps, cost of care, deambulation) Microcirculatory parameters (flux, CO2, O2)	
Notes	No patient in either group had healed ulcers. For computing reasons we have entered data as one patient in each group had a healed ulcer.	
Risk of bias		
Item	Authors' judgement	Description

De Sanctis 2001 (Continued)

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'The randomization process was controlled by an external statistical controller accord- ing to GCP rules'
Blinding? Treatment provider	Yes	'Operators were unaware of the contents of the tube, which was numbered'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 19
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Defrin 2005

Methods	Design: six group parallel trial Purpose: study the effect of segmental versus innocuous electrical stimulation for chronic pain relief
Participants	Patients: out-patients needing screening flexible endoscopy Baseline comparability: yes (age, gender)
Interventions	Placebo: stimulation with interferential current (IF) device off Untreated: no IF device treatment Experimental: stimulation with IF device on (Co-intervention: analgesic medication. Patients were asked not to change regime during the study)
Outcomes	Pain (VAS) Pain relief (%) Morning stiffness (VAS) Range of motion (Goniometry) Pain threshold
Notes	

Defrin 2005 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ electrical stimulus device)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 17
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Dibble 2007

Methods	Design: three group parallel trial Purpose: study the effect of acupressure on chemo-therapy induced nausea
Participants	Patients: cancer patients receiving chemotherapy Baseline comparability: yes
Interventions	Placebo: needling in S13 point theoretically inert for nausea Untreated: no needling Experimental: needling in P6 (Co-intervention: antiemetic drugs)
Outcomes	Nausea intensity (NRS) Rhodes Index of Nausea (3 items) Rhodes index of nausea and vomiting (1 item) Functional status (NRS)

Dibble 2007 (Continued)

	State-Trait Anxiety Inventory	
Notes	Data provided from authors: mean nausea NRS (0 to 10) evening after getting chemo- therapy.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The researchers endeavoured to keep the research assistant masked as to the active point'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	No protocol available. Data provided from authors
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 100
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Ditto 2003

Methods	Design: three group parallel trial Purpose: study the effect of applied muscle tension on blood donation reactions
Participants	Patients: English speaking blood donors Baseline comparability: yes (age, gender)
Interventions	Placebo: applied muscle tension training for 2 minutes Untreated: no training Experimental: applied muscle tension training for 15 minutes

Ditto 2003 (Continued)

	(Co-intervention: no)
Outcomes	Blood donations reactions inventory score Proportion of cases in which donation chairs were reclined Proportion of full blood portion donated Doner's estimate of the probability of giving blood again Pain Anxiety Heart rate Blood pressure
Notes	Trialists assumed that at least 5 minutes of applied muscle tension training was needed for an effect.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ap- plied muscle tension)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 389
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Ditto 2006

Methods	Same as Ditto 2003
Participants	Patients: french speaking blood donors Baseline comparability: yes (age, gender)
Interventions	Same as Ditto 2003
Outcomes	Same as Ditto 2003
Notes	Same trial as Ditto 2003 but results for French speaking donors reported separately

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/applied muscle tension)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statistically significant)or skew- ness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 295
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Doty 1975

Methods	Design: five group parallel trial Purpose: to examine the effect of social skills training on the interpersonal interaction of chronic psychiatric patients
Participants	Patients: chronic psychiatric in-patients Baseline comparability: probably (stratified by level of daily interaction)

Doty 1975 (Continued)

Interventions	Placebo: sessions with transactional game followed by lectures by the therapist Untreated: no sessions Experimental: -sessions with social skills training (role playing) -sessions with incentive condition (re-enforcement by reward) -combination (Co-intervention: yes, most patients received psychotropic drugs; type, dose and group distribution NS)
Outcomes	% alone: the % of the time the individual was observed more than 4 feet away from another person. % silent: the % of the time the person was silent in a group discussion
Notes	Relevant outcome data not accessible

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/so- cial skills training)
Blinding? Outcome assessor	Yes	'The observers were blind to both the na- ture of the dependent variable to be ex- tracted from their recordings and the group assignments'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Double 1993	
Methods	Design: three group, three period cross-over trial Purpose: to examine the effect of discontinuation of antiparkinsonian medication in patients maintained on neuroleptics
Participants	Patients: psychiatric in-patients on concomitant antiparkinsonian and neuroleptic med- ication for over one year Baseline comparability: not relevant
Interventions	Placebo: capsules with no antiparkinsonian medication Untreated: no capsules Experimental: capsules with antiparkinsonian medication (type and dose individual but fixed through trial) (Co-intervention: yes, neuroleptics, fixed dose through trial except for three patients)
Outcomes	Number of patients with relapse of parkinsonian symptoms (= need for escape medica- tion) Extrapyramidal Symptom Rating Scale (ESRS)
Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The medication periods were assigned blindly'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 44

Double 1993 (Continued)

Clearly concealed allocation + trial size >	No	Trial size < 49
49 + drop-out max 15%?		

Dundee 1986

Methods	Design: three group parallel trial Purpose: examine the prophylactic effect of acupuncture on perioperative nausea
Participants	Patients: surgical in-patients undergoing minor gynaecological procedures Baseline comparability: 'broadly comparable', but no data presented
Interventions	Placebo: needling on the lateral elbow crease, a point that is not on any recognized acupuncture line Untreated: no needling Experimental: needling at the P6 point (Neiguan) (Co-intervention: 10 mg nalbuphene as routine premedication)
Outcomes	Number of patients with nausea
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Yes	'These assessments were performed by an observer who was unaware of which pa- tients had undergone acupuncture'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 50

Dundee 1986 (Continued)

Clearly concealed allocation + trial size > No 49 + drop-out max 15%? Drop-out > 15% or NS

Methods	Design: four group parallel trial Purpose: examine the effect of a multiple-component treatment approach on smoking reduction
Participants	Patients: smokers Baseline comparability: yes
Interventions	Placebo: non-directive discussions Untreated: no discussions Experimental: -rapid smoking (smoked every 6 seconds until unable to continue) -package treatment (rapid smoking, applied relaxation, covert sensitization, systematic desensitization, self-reward and punishment etc) (Co-intervention: NS)
Outcomes	Number of abstinent smokers Mean number of cigarettes smoked / day
Notes	The trial consisted of a primary intervention phase and a secondary booster phase. Only the allocation to the booster treatment was explicitly described as random. Contact with authors clarified that allocation in the primary phase was also random.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ package treatment)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Elliott 1978 (Continued)

No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Erdogmus 2007		
Methods	Design: three group parallel trial Purpose: study the effect of physiotherapy	
Participants	Out-patients having had a disc herniation operation Baseline comparability: yes (except for body mass index)	
Interventions	Placebo: sessions with neck massage Untreated: no sessions Experimental: sessions with physiotherapy-based rehabilitation (Co-intervention: yes)	
Outcomes	Low Back Pain Rating Scale Overall satisfaction Socioeconomic parameters State Trait Anxiety Inventory	
Notes	SDs were obtained from the reported CIs	
Risk of bias		

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'block randomization (SAS) was performed by the Department of Medical Statistics'
Allocation concealment?	Yes	'sequentially numbered, sealed opaque en- velopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ physiotherapy)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available

Erdogmus 2007 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 80
Clearly concealed allocation + trial size >	Vac	All three categories fulfilled

Espie 1989

Methods	Design: six group parallel trial Purpose: examine the effect of psychological treatments on chronic insomnia
Participants	Patients: out-patients suffering from chronic sleep-onset insomnia Baseline comparability: yes (age, sex, duration of insomnia)
Interventions	Placebo: imaginary belief treatment: neutral images paired with bed time activities. Untreated: waiting list Experimental: -relaxation therapy -stimulus control -paradoxical intervention -tailored therapy condition (reported in another publication) (Co-intervention: hypnotics, fixed ordination and withdrawal scheme, compliance NS)
Outcomes	Sleep latency (min) Sleep quality
Notes	

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'predetermined list of random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ psychological intervention)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS

Espie 1989 (Continued)

Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 27
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Etringer 1982

Methods	Design: three group parallel trial Purpose: examine the effect of 'participant modelling' (snake handling) therapy on snake phobia
Participants	Patients: individuals who were unable to hold a snake for 10 sec Baseline comparability: yes
Interventions	Placebo: sessions of 'graduated subliminal modelling'. Patients were exposed to blank slides and told they were subliminal pictures of snakes. Untreated: no sessions Experimental: sessions of 'participant modelling' (Co-intervention: NS)
Outcomes	Behavioral avoidance test (18 successive steps of snake interaction tasks). Fear arousal accompanying approach. Anticipatory fear. Self-efficacy expectations

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ participant modelling)
Blinding? Outcome assessor	Yes	'The assessors were kept blind as to each subject's particular treatment condition'

Etringer 1982 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 25
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Etter 2002

Methods	Design: three group parallel trial Purpose: test the effect of nicotine replacement therapy, and placebo, in reducing cigarette consumption in smokers willing to intend to reduce number of smoked cigarettes but not to quit
Participants	Patients: cigarette smokers unwilling to quit, but intending to reduce smoking by half Baseline comparability: not for gender (54% male in nicotine group and 44% in no treatment group); yes for age, cigarette consumption, intention to reduce consumption (and several other variables)
Interventions	Placebo: transdermal patch, gum, or inhaler without nicotine (and information leaflet) mailed every other week at the choice of the patient for 6 months Untreated: no transdermal patch, gum, inhaler or leaflet Experimental: transdermal patch, gum, inhaler with nicotine (and information leaflet) (Co-intervention: information booklet after three months)
Outcomes	Mean number of cigarettes smoked per day after 6 months Score of smoking intensity (0 to 100) Score of total smoke inhalation per day (0 to 10) Mean number of reduction of smoked cigarettes per day Smoking cessation rate
Notes	Not 1:1 randomisation. The combination of baseline inequality for gender, and lack of clear description of concealment of allocation indicate possible selection bias. In the no treatment group 7% did not provide information on smoking habits; in the placebo group it was 3%. For these individuals the baseline values were computed as the end result. Because the dropout rate was higher in the no-treatment group this may have resulted in an inflated estimate of the mean number of smoked cigarettes, and thus a too optimistic estimate of the effect of placebo on smoking reduction.

Etter 2002 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer generated list of random num- bers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ drug)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	No	See notes
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 658
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Faas 1993

Methods	Design: three group parallel trial Purpose: examine the prophylactic effect of physical exercise and advice on daily living on recurrence of acute low back pain
Participants	Patients: out-patients visiting a GP with acute low back pain Baseline comparability: yes
Interventions	Placebo: sessions with ultrasound at lowest possible frequency Untreated: no sessions (standard therapy) Experimental: sessions with exercise and advice on daily living (Co-intervention: analgesics on demand, dose NS)

Faas 1993 (Continued)

Outcomes	Number of patients with recurrent low back pain episodes
	Duration of recurrent low back pain episodes
	Functional health status
	Mobility problems
	Influence on daily life
	In-between consultation of the GP

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'sealed envelope'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ex- ercise)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 317
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Fanti 2003

Methods	Design: three group parallel trial Purpose: study the effect of acupuncture on discomfort, pain and anxiety during colonoscopy
Participants	Patients: patients scheduled to undergo colonoscopy Baseline comparability: yes (age, pre-colonoscopy anxiety)

Fanti 2003 (Continued)

Interventions	Placebo: needling and electrical stimulation on sites not regarded analgesic acupuncture sites Untreated: no needling Experimental: needling and electrical stimulation on sites regarded analgesic acupuncture sites (L14, S36, SP6, SP9) (Co-intervention: midazolam 15 minutes before procedure and as required)
Outcomes	Escape medication (midazolam) Pain at 4 times during the procedure (5-point scale) Procedure acceptability (5-point scale) Patient satisfaction Technical difficulty of the procedure (physician and nurse) Satisfaction with sedation (physician and nurse) Total procedural time

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer-generated sequence of numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Fiorellini 2005			
Methods		Design: three group parallel trial Purpose: evaluate the efficacy of bone induction for the placement of dental implants using recombinant human bone morphogenetic protein-2.	
Participants	· · · ·	Patients: patients requiring local alveolar ridge preservation/augmentation of buccal wall defects following extraction of maxillary teeth. Baseline comparability: NS	
Interventions	Untreated: No-treatment Experimental: recombinant huma	Placebo: bioabsorbable collagen sponge (ACS) alone Untreated: No-treatment Experimental: recombinant human bone morphogenetic protein-2 delivered on a ACS. (Co-intervention: preoperative antibiotics and 0.12% chlohexidine rinse (15ml))	
Outcomes	Alveolar bone height and bone wi Alveolar bone volume (CT scan) Bone density (CT scan) Bone biopsy	Bone density (CT scan)	
Notes			
Risk of bias			
Item	Authors' judgement	Description	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Two sequential cohorts of 40 patients each were randomized in a double-masked man- ner'
Blinding? Outcome assessor	Yes	' three independent masked CT scan re- viewers'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	No	N = 37
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Fisher 2006

Design: three group parallel trial Purpose: study the feasibility of running a randomised trial aimed at evaluating specific and non-specific effects in homeopathy
Out-patients with dermatitis Baseline comparability: yes (age, gender)
Placebo: lactose pills Untreated: no pills Experimental: homeopathic pills (Co-intervention: NS)
Overall symptoms Skin symptoms Itching Sleep DLQI (dermatology life quality index) Use of steroids

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'randomisation list'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'double-blind placebo'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 27

Fisher 2006 (Continued)

Clearly concealed allocation + trial size >	No	Trial size < 49
49 + drop-out max 15%?		

Forster	1994
---------	------

Methods	Design: three group parallel trial Purpose: examine the effect of transcutaneous nerve stimulation (TENS) on pain
Participants	Patients: postoperative in-patients (coronary artery bypass surgery) Baseline comparability: yes
Interventions	Placebo: TENS with machine turned off Untreated: no TENS Experimental: TENS with machine turned on (Co-intervention: analgesics as deemed appropriate by staff)
Outcomes	Pain (verbal numerical scale) Lung function parameters
Notes	

Risk of bias Authors' judgement Description Item NS Adequate sequence generation? Unclear Allocation concealment? Unclear NS Blinding? Unclear NS Treatment provider Unclear Blinding? Not relevant as patient reported outcome Outcome assessor No Incomplete outcome data addressed? Drop-out > 15% or NS All outcomes Free of selective reporting? Unclear No protocol available Free of other bias? Yes No signs of variance inequality or skewness? No Either variance inequality (F-test statistically significant) or skewness (1.64 standard deviations exceeds the mean) Trial size > 49? No N = 30Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Forster 1994 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Foster 2004		
Methods	Design: three group parallel trial Purpose: study the effect of the Trager appr	roach on chronic headache
Participants	Patients: outpatients with chronic headache Baseline comparability: yes	
Interventions	Placebo: attention treatment by physician including physical exam (15 to 20 minutes) Untreated: no treatment Experimental: Trager approach (movement based educational process to increase body awareness, learn relaxation skills, and practise pain-free, balanced movement) (Co-intervention: medication)	
Outcomes	The headache quality of life instrument Headache frequency, duration, and intensity Medication use	
Notes		

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ Trager)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)

Foster 2004 (Continued)

Trial size > 49?	No	N = 18
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Foster 2007		
Methods	Design: three group parallel trial Purpose: study the effect of acupuncture on osteoarthrosis of the knee	
Participants	Patients: older outpatients with osteoarthrosis of the knee Baseline comparability: yes	
Interventions	Placebo: needling with a non-penetrating blunt needle Untreated: no needling Experimental: needling at with a proper acupuncture needle (Co-intervention: exercise and advice)	
Outcomes	WOMAC pain sub-scale WOMAC scale Function and general improvement	
Notes		

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'a computed generated randomisation'. We assume 'a computer generated randomisa- tion'
Allocation concealment?	Yes	After inclusion of patients into the trials the 'physiotherapist telephoned an admin- istrator at the research centre to receive a computed generated randomisation group.'
Blinding? Treatment provider	No	Acupuncturist knew type of acupuncture
Blinding? Outcome assessor	Unclear	Not relevant as patient-reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop out <15%

Foster 2007 (Continued)

Free of selective reporting?	Yes	Protocol published. No sign of outcome se- lection bias for the primary outcome
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	SD x 1.67 >mean
Trial size > 49?	Yes	N = 217
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three criteria fulfilled

Frank 1990

Item	Authors' indrement	Description
Risk of bias		
Notes		
Outcomes	Number of patients with relapse of depression Time to recurrence of depression	
Interventions	Placebo: continuous treatment with -tablets containing no imipramine (content NS) plus psychotherapy sessions -tablets containing no imipramine (content NS) plus visits to a medication clinic Untreated: continuous treatment with psychotherapy but without any tablets Experimental: continuous treatment with -imipramine tablets and psychotherapy sessions -imipramine tablets and visits to a medication clinic -continuous treatment with imipramine tablets without psychotherapy sessions (Co-intervention: NS)	
Participants	Patients: stable out-patients with unipolar depression having improved markedly after imipramine medication and psychotherapy Baseline comparability: yes	
Methods	Design: five group parallel trial Purpose: examine the effect of psychotherapy, imipramine and placebo on relapse of depression	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'both the patients and the members of their treatment team remained blind to whether they were receiving active medica-

Frank 1990 (Continued)

		tion or placebo'
Blinding? Outcome assessor	Yes	Partly blinded
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 52
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Frankel 1978

Methods	Design: three group parallel trial Purpose: examine the effect of biofeedback on arterial hypertension
Participants	Patients: out-patients with essential arterial hypertension Baseline comparability: yes
Interventions	Placebo: sessions of discussions of past and present problems with no behavioural tech- niques taught Untreated: no sessions Experimental: training sessions for behavioural techniques (Co-intervention: NS)
Outcomes	Diastolic blood pressure (mm Hg) Multiple personality, depression and activity tests
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random number table'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ biofeedback)

Frankel 1978 (Continued)

Blinding? Outcome assessor	Yes	' nurses (who was blind to the patient's experimental status)'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
No signs of variance inequality or skewness? Trial size > 49?	Yes	tically significant)and no skewness (1.64 standard deviations does not exceed the

Frega 1994

Methods	Design: three group parallel trial Purpose: to evaluate the pain ca neoplasia	Purpose: to evaluate the pain caused by laser vaporization of intraepithelial cervical	
Participants	Patients: women with intraepithe Baseline comparability: NS	Patients: women with intraepithelial cervical neoplasia Baseline comparability: NS	
Interventions	Placebo: tablet without naproxen Untreated: no tablet Experimental: tablet with naproxe (Co-intervention: NS)	Untreated: no tablet Experimental: tablet with naproxen	
Outcomes	Pain (VAS)	Pain (VAS)	
Notes			
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	

Frega 1994 (Continued)

Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 42
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Fuchs 1977

Methods	Design: three group parallel trial Purpose: examine the effect of self-control behaviour therapy on depression
Participants	Patients: female out-patients with depression as defined by a multiple cut-off procedure of the Minnesota Multi phasic Personality Inventory (D more than 69) Baseline comparability: yes (depression scores)
Interventions	Placebo: sessions of discussion on past and present problems with no behavioural tech- niques taught Untreated: no sessions Experimental: sessions of behavioural techniques training (Co-intervention: NS)
Outcomes	Beck Depression inventory Minnesota Multi phasic Personality Inventory (depression scale and total evaluation) Group interaction activity and response elicitation Pleasant events activity and reinforcement potential Self-evaluation Common associates test Concepts test
Notes	The standard deviation (SD) on the improvement of the mean on Beck Depression Inventory was not reported. The SD was calculated from a F-test statistic.

Fuchs 1977 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- haviour therapy)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Gluckman 1980

Methods	Design: three group parallel trial Purpose: study the effect of a remedial program on visual-motor perception in children with spina bifida
Participants	Patients: Children with spina bifida who were able to respond to verbal and paper-and- pencil task Baseline comparability: yes
Interventions	Placebo: sessions with stimulating environment (jig-saw puzzles, drawing, colouring,
	reading etc) Untreated: no sessions Experimental: sessions with a program of development of visual perception (Co-intervention: NS)

Gluckman 1980 (Continued)

Notes	Outcome not reported so that meta-analysis is possible.		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	
Blinding? Treatment provider	Unclear	NS	
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome	
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS	
Free of selective reporting?	No	Outcome not reported so that meta-analy- sis is possible.	
Free of other bias?	Yes		
Trial size > 49?	No	N = 24	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

Godfrey 1973

Methods	Design: three group, three period cross-over trial Purpose: to examine the effect of placebo on exercise induced asthma
Participants	Patients: children with bronchial asthma Baseline comparability: not relevant
Interventions	Placebo (according to active drug): -injections of saline -inhalations of saline -inhalations of lactose with sodium sulphate Untreated: no injections or inhalations Experimental: -inhalations of salbutamol -injections of atropine -inhalation of cromoglycate (Co-intervention: NS)

Godfrey 1973 (Continued)

Outcomes	Fall in % peak expiratory flow (PEF) rate Number of patients with a drop in PEF rate of at least 15%	
Notes	Data originally came from three small cross-over trials. The outcome data was not avail- able from the first period only, and was calculated as deriving from one parallel group trial.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15 % or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	No	Data originally came from three small cross-over trials. The outcome data was not available from the first period only, and was calculated as deriving from one parallel group trial.
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 88
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15 % or NS

Goldstein 2000

Methods

Design: three group parallel trial

Purpose: study the effect of eye movement desensitization and reprocessing (EMDR) on panic disorder with agoraphobia

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Goldstein 2000 (Continued)

Participants	Patients: out-patients with panic disorder with agoraphobia Baseline comparability: NS
Interventions	Placebo: sessions with a credible attention-placebo ('association and relaxation therapy') Untreated: no sessions Experimental: sessions with EMDR (Co-intervention: anxiolytic drugs in moderate doses)
Outcomes	Frequency of panic attacks Daily and weekly expectancy of panic attack Daily highest anxiety Daily average anxiety The agoraphobic cognitions questionnaire Body sensations questionnaire Brief body sensations interpretations Panic appraisal inventory The mobility inventory Beck depression inventory Beck anxiety inventory Brief symptom inventory Social adjustment scale (self-report) Distress questionnaire
Notes	After completion of waiting-list period the no treatment group was randomised to placebo and active treatment. Results from the placebo group also included patients who originally were in the no-treatment group. Contact with the authors made it clear that the data from the originally randomised patients had been lost.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ EMDR)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	No protocol available. Contact to the au- thors made it clear that the data from the originally randomised patients had been

Goldstein 2000 (Continued)

		lost.
Free of other bias?	Yes	
Trial size > 49?	No	N = 27
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Goodenough 1997

Methods	Design: three group parallel trial Purpose: examine the effect of placebo medication and suggestion on acute pain associ- ated with venepuncture
Participants	Patients: children undergoing venepuncture in a hospital setting Baseline comparability: NS
Interventions	Placebo: cream with no analgesic component and no suggestion of analgesic effect Untreated: no cream Experimental: cream with no analgesic component but with the suggestion of analgesic effect (Co-intervention: NS)
Outcomes	Pain (facial pain scale) Anxiety
Natas	

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ placebo+suggestion)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available

Goodenough 1997 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 78
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Gracely 1979

Methods	Design: three group parallel trial Purpose: examine the effect of placebo medication and naloxone on acute pain
Participants	Patients: postoperative in-patients after extraction of molars Baseline comparability: NS
Interventions	Placebo: injection with naloxone vehicle Untreated: no injection Experimental: injection with naloxone (Co-intervention: NS)
Outcomes	Pain
Notes	Data reported in a way not extractable for meta-analysis. Original data lost (personal communication Gracely RH)

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random table generated by a shuffle pro- gram'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Two groups of 12 subjects received double- blind intravenous injections of either 10mg naloxone or naloxone vehicle (placebo)'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS

Gracely 1979 (Continued)

Free of selective reporting?	No	No protocol available. Data reported in a way not extractable for meta-analysis. Original data lost (personal communica- tion Gracely RH)
Free of other bias?	Yes	
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Gracely 1983

Methods	Design: three group parallel trial Purpose: examine the influence of hidden infusion of naloxone on the effect of fentanyl and placebo in acute pain
Participants	Patients: postoperative in-patients after extraction of molars Baseline comparability: NS
Interventions	Placebo: injection with saline Untreated: no injection Experimental: injection with fentanyl (Co-intervention: pre-treatment hidden infusion of either naloxone or naloxone vehicle)
Outcomes	Pain (McGill pain rating index)
Notes	The trial report does not explicitly state that allocation was random, however personal communication with authors established that this is likely to have been the case.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random table generated by a shuffle pro- gram'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Hidden infusions of naloxone (10 mg) or naloxone vehicle were administered dou- ble-blind'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Gracely 1983 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 29
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Grammer 1984

Methods	Design: three group parallel trial Purpose: examine whether patients with allergic rhinitis would have lower or higher symptom scores depending upon the presence of asthma
Participants	Patients: out-patients with allergic, ragweed rhinitis Baseline comparability: NS
Interventions	Placebo: injections without ragweed (caramelised glucose) Untreated: no injections Experimental: injections with polymerised ragweed (Co-intervention: histamine, dosage part of composite outcome score)
Outcomes	Rhinitis symptom-medication scores (sneeze, nasal congestion, histamine medication)
Notes	Relevant outcome data not accessible
Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Grammer 1984 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	No	N = 31
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

GRECHO 1989

Methods	Design: four group parallel trial Purpose: examine the effect of two homoeopathic preparations on postoperative ileus
Participants	Patients: postoperative in-patients (after abdominal surgery) Baseline comparability: yes (sex, age, type and duration of operation)
Interventions	Placebo: granule with no homoeopathic content Untreated: no granule Experimental: homoeopathic preparations 'opium' or 'raphanus' (Co-intervention: use of laxatives higher in placebo than untreated)
Outcomes	Time from abdominal closure to first stool and first flatus (hours)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' in a controlled, double-blind therapeu- tic trial'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop out > 15% or NS
Free of selective reporting?	Unclear	No protocol available

GRECHO 1989 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 300
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop out > 15% or NS

Guglielmi 1982

Methods	Design: three group parallel trial Purpose: examine the effect of skin temperature biofeedback on Raynaud's disease
Participants	Patients: out-patients with primary Raynaud's disease Baseline comparability: yes (age and severity of attack)
Interventions	Placebo: biofeedback training focused at relaxing forehead muscles Untreated: no training Experimental: biofeedback training focused at increasing finger temperature (Co-intervention: no)
Outcomes	Number of patients with attacks Duration of attacks Severity of attacks Extent of hand involvement Number of symptoms experienced Pain Impairment Length of time spent in laboratory to relieve the attack Amount of relief obtained from laboratory training

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' a double-blind design was adopted'

Guglielmi 1982 (Continued)

Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hall 1974

Risk of bias	
Notes	33 out of 84 patients were college students. The standard deviation (SD) of the mean % reduction of body weight was not reported. The SD was calculated from the reported F-test statistic.
Outcomes	Weight loss (percentage of initial body weight)
Interventions	Placebo: sessions with relaxation training Untreated: no sessions Experimental: -sessions with combined self-management technique: based on re-enforcement princi- ples -sessions with simple self-management technique: based on re-enforcement principles (Co-intervention: information booklet on nutrition)
Participants	Patients: overweight adults Baseline comparability: NS
Methods	Design: four group parallel trial Purpose: examine the effect of two self-management treatments on obese persons

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Hall 1974 (Continued)

Blinding? Treatment provider	No	Not described as double-blind (placebo/ self-management technique)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 45
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hallström 1988

Methods	Design: three group parallel trial Purpose: examine the effect of propranolol on tranquillizer dependence	
Participants	Patients: out-patients who had not succeeded in stopping tranquilliser medication despite attempts Baseline comparability: yes for diazepam intake	
Interventions	Placebo: tablets without propranolol Untreated: no tablets Experimental: tablets of propranolol (Co-intervention: NS)	
Outcomes	Abstinence 50% reduction of medication Time to abstinence Pulse rates	
Notes	Relevant outcome data not accessible	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS

Hallström 1988 (Continued)

Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Patients were also treated under double blind conditions'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	No	N = 18
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hanson 1976

Methods	Design: five group parallel trial Purpose: examine the effect of self-management behavioural therapy on weight loss
Participants	Patients: media-recruited obese persons Baseline comparability: yes (weight)
Interventions	Placebo: sessions of deep muscle relaxation therapy Untreated: no sessions (waiting list) Experimental: sessions with -behavioural training with standard therapist contact -behavioural therapy with low therapist contact -behavioural therapy with high therapist contact (Co-intervention: antihypertensive medication, fixed ordination scheme: NS)
Outcomes	Weight loss (percentage of initial body weight)
Notes	
Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Hanson 1976 (Continued)

Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural therapy)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 21
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hargreaves 1989

Methods	Design: three group parallel trial Purpose: examine the effect of transcutaneous electrical nerve stimulation (TENS) on acute pain associated with wound dressing	
Participants	Patients: postoperative patients needing surgical wound dressing. Baseline comparability: NS	
Interventions	Placebo: TENS with no current passing to electrodes Untreated: no TENS Experimental: TENS with current passing to electrodes (Co-intervention: analgesics administered at the same rate for all groups)	
Outcomes	Pain (VAS)	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Hargreaves 1989 (Continued)

Blinding? Treatment provider	Yes	'the experimenter was unaware of the assigned intervention during the initial preparation of each subject for the study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Harrison 1975

Methods	Design: three group parallel trial Purpose: examine the effect of doxycycline treatment on infertility		
Participants	Patients: couples suffering from infertility of unknown origin Baseline comparability: yes (age, duration of infertility)		
Interventions	Placebo: tablet without doxycycline Untreated: no tablet Experimental: tablet with doxycycline (Co-intervention: NS)		
Outcomes	Number of women who got pregnant		
Notes			
Risk of bias			
Item	Authors' judgement Description		
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	

Harrison 1975 (Continued)

Blinding? Treatment provider	Yes	'Double-blind Trial with Doxycycline'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 58
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Hashish 1986

Methods	Design: five group parallel trial Purpose: examine the effect of ultrasound and placebo on pain and swelling	
Participants	Patients: postoperative in-patients (after removal of impacted third molars) Baseline comparability: NS	
Interventions	Placebo: ultrasound with machine off Untreated: no ultrasound Experimental: ultrasound at three levels of intensity (Co-intervention: analgesics, fixed ordination scheme)	
Outcomes	Pain (VAS) and facial swelling (cubic cm) Trismus C-reactive protein	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Hashish 1986 (Continued)

Blinding? Treatment provider	Yes	' in a double-blind controlled study'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 75
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Hashish 1988

Design: five group parallel trial Purposes examine the mechanism of placebo effects in ultracound treatment		
Purpose: examine the mechanism of placebo effects in ultrasound treatment		
Patients: postoperative in-patients (after removal of impacted third molars) Baseline comparability: NS		
Placebo a: ultrasound without massage and machine off Placebo b: ultrasound with massage and machine off Untreated: no ultrasound or massage Experimental a: ultrasound without massage and machine on Experimental b: ultrasound with massage and machine on (Co-intervention: analgesics on demand)		
Pain (VAS) and facial swelling (cubic cm) C-reactive protein Trismus Plasma cortisol Anxiety		
Risk of bias		
Authors' judgement	Description	
	Purpose: examine the mechanism of placeb Patients: postoperative in-patients (after ref Baseline comparability: NS Placebo a: ultrasound without massage and m Untreated: no ultrasound or massage Experimental a: ultrasound without massage Experimental b: ultrasound without massage a (Co-intervention: analgesics on demand) Pain (VAS) and facial swelling (cubic cm) C-reactive protein Trismus Plasma cortisol Anxiety	

Hashish 1988 (Continued)

Adequate sequence generation?	Yes	'random number tables'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'In a placebo-controlled double-blind clin- ical trial'
Blinding? Outcome assessor	Yes	'All assessments and measurements were performed by an investigator (I.H.) who was unaware of the treatment group to which the patient has been allocated'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Hawkins 1995

Methods	Design: three group parallel trial Purpose: examine the effect of hypnosis and placebo on nausea and vomiting in children receiving chemotherapy
Participants	Patients: in-patients with cancer in need of nausea-inducing chemotherapy Baseline comparability: chemotherapy type and dose NS
Interventions	Placebo: sessions with psychologists who talked with the children about what they liked Untreated: no sessions Experimental: sessions with hypnosis (Co-intervention: NS)
Outcomes	Nausea (VAS) Vomiting
Notes	The number of patients in each group was not reported. The number was estimated to n = 10 (total patient number 30 divided by 3 groups)

Hawkins 1995 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ hypnosis)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	No protocol available. The number of pa- tients in each group was not reported. The number was estimated to n=10 (total pa- tient number 30 divided by 3 groups)
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Heinzl 1981

Methods	Design: four group parallel trial Purpose: examine the effect of prostaglandin E2-alpha on cervical dilatation
Participants	Patients: in-patients undergoing first trimester abortion Baseline comparability: yes
Interventions	Placebo: intra-cervically placed gel without prostaglandin Untreated: no gel or tablet Experimental: -intra-cervically placed gel with prostaglandin E2-alpha -tablet with prostaglandin E2-alpha (Co-intervention: Valium on fixed scheme and analgesic on demand, distribution NS)

Heinzl 1981 (Continued)

Outcomes	Successful cervical dilatation (number of patients with dilatation of cervical os > Hegar no. 6)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Yes	'The investigating doctor had no idea what treatment, if any, the patients had received'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 262
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Helms 1987

Methods	Design: four group parallel trial Purpose: examine the effect of acupuncture on dysmenorrhoea
Participants	Patients: out-patients with primary dysmenorrhoea Baseline comparability: yes, however somewhat lower pretreatment pain scores.
Interventions	Placebo: needling at points not recognized as acupuncture points (lateral thighs and arms) Untreated a): no needling, minimum contact (our control group) b): no needling, visit by investigator Experimental: needling in correct acupuncture points (Co-intervention: analgesics)

Helms 1987 (Continued)

Outcomes	Pain (scores) Use of analgesic medication Proportion of improved patients	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers table'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 22
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hong 1993

Methods	Design: six group parallel trial Purpose: examine the effect of different physical medicine modalities on pain threshold of a myofascial trigger point
Participants	Patients: out-patients with myofascial pain syndrome Baseline comparability: yes (sex, age, pain duration)
Interventions	Placebo: sham ultrasound Untreated: no ultrasound Experimental:

Hong 1993 (Continued)

	-spray and stretch -hydrocollator -ultrasound -massage (Co-intervention: NS)
Outcomes	Pain (Index of threshold change (ITS), based on measurements with a pressure algometer)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 37
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hossmann 1981

Methods	Design: four period, four group, cross-over trial Purpose: examine the effect of hospitalisation (habituation to the medical environment and rest in hospital bed) and placebo on arterial hypertension
Participants	Patients: patients with untreated essential hypertension

Hossmann 1981 (Continued)

Interventions	Placebo: oval pink tablet Untreated: no tablet Experimental: hospitalisation (Co-intervention: NS)
Outcomes	Diastolic arterial blood pressure (mm Hg) Systolic arterial blood pressure (mm Hg) Heart rate Plasma renin activity Plasma norepinephrine activity Anxiety scores Urinary catecholamines

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hovell 2003

Methods	Design: three group parallel trial Purpose: study the effect of adherence coaching to treatment adherence for TB	
Participants	Patients: adolescents with TB Baseline comparability: yes	
Interventions	Placebo: sessions with self-esteem counselling (12 sessions, 9 months) Untreated: no sessions Experimental: sessions with adherence counselling (Co-intervention: TB medication)	
Outcomes	Cumulative number of pills Proportion of TB treatment completers (180 pills within 9 moths) Interaction of alcohol consumption and lack of treatment adherence	
Notes	We have multiplied the results by negative 1 to change the direction of the summary statistics.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ coaching)
Blinding? Outcome assessor	Unclear	Not relevant as outcome was patient re- ported (number of pills)
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 194
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Hruby 2006

Methods	Design: three group parallel trial Purpose: study the effect TENS for pain associated with cystoscopy
Participants	Patients: outpatients needing flexible cystoscopy Baseline comparability: yes (age, gender)
Interventions	Placebo: sessions with TENS device not producing nerve stimulation Untreated: no sessions Experimental: sessions TENS device not producing nerve stimulation (Co-intervention: lidocaine gel)
Outcomes	Pain (VAS) Vital signs International prostate symptom score
Notes	It is unclear wether the spread of the mean VAS pain score refer to standard errors or standard deviations. We assume that they are standard deviations as their size (1.50 and 2.05) are comparable to the standard deviations for other mean VAS pain scores.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	No protocol available. It is unclear wether the spread of the mean VAS pain score refer to standard errors or standard deviations. We assume that they are standard devia- tions as their size (1.50 and 2.05) are com- parable to the standard deviations for other mean VAS pain scores.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)

Hruby 2006 (Continued)

Trial size > 49?	Yes	N = 100
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS
Hutton 1991		

Methods	Design: three group parallel trial Purpose: examine the effect of antihistamine decongestant and placebo on common cold symptoms in children
Participants	Patients: paediatric primary care unit out-patients (0.5 to 5 years) with common cold symptoms Baseline comparability: NS
Interventions	Placebo: medication containing no antihistamines Untreated: no medication Experimental: medication containing antihistamines (brompheniramine, phenylephrine and phenylpropanolamine) (Co-intervention: instructions to avoid, however 9/30 in untreated group took NSAID, 0/24 in placebo group)
Outcomes	Number of children with improved rhinorrhoea (parental assessment) Individual cold symptoms (breathing problems, fever, cough, decreased appetite, crank- iness, sleeping disturbance, vomiting) General assessment
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Neither parents and guardians nor inves- tigators were aware of the drug-placebo as- signment'
Blinding? Outcome assessor	Unclear	Not relevant as patient (parents) reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available

Hutton 1991 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 54
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Hyland 2006

Methods	Design: three group parallel trial Purpose: study the effect of calcaneal taping on plantar heel pain
Participants	Patients: outpatients with plantar heel pain Baseline comparability: no (age, body mass)
Interventions	Placebo: Cover-Roll stretch bandage and leucotape that did not attempt to control the alignment/position of the calcaneus. The tape was 'simply being overlaid on the skin'. Untreated: no tape Experimental: calcaneal taping 'repositioning the calcaneal alignment closer to neutral'. (Co-intervention: NS)
Outcomes	Pain VAS (0 to 10) PSFS (patient-specific function scale)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers table'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ taping)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	

Hyland 2006 (Continued)

No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Hyman 1986

Methods	Design: four group parallel trial Purpose: examine the effect of behaviour therapy, hypnosis and placebo on smoking cessation
Participants	Patients: smokers wanting to quit Baseline comparability: yes
Interventions	Placebo: sessions with general discussions of topics of concern to the participant Untreated: no sessions Experimental: -hypnosis sessions: negative aspects of smoking were repeated while patient was in trance -behavioural therapy sessions: focused smoking technique where participants were to concentrate on the aversive aspects of smoking (Co-intervention: NS)
Outcomes	Number of abstinent smokers (based on thiocyanate concentration) Number of abstinent smokers (based on self report) Mean smoking rate
Notes	

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- haviour therapy)
Blinding? Outcome assessor	Unclear	NS

Hyman 1986 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 30
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Irjala 1993

Methods	Design: three group parallel trial Purpose: examine the relationship between quality of sleep the night before surgery and several biochemical cerebro-spinal fluid indicators
Participants	Patients: in-patients in need of surgery Baseline comparability: yes (age, sex, weight, height)
Interventions	Placebo: tablet with no midazolam or temazepam Untreated: no tablet Experimental: -tablet with midazolam -tablet with temazepam (Co-intervention: no)
Outcomes	Quality of sleep Concentrations of 3,4-dihydroxyphenylglycol, 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxyphenylacetic acid, homovanillic acid, tryptophan, 5-hydroxyindoleacetic acid and cortisol
Notes	Relevant outcome data not accessible: data lost (personal communication Irjala J)

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' the anaesthetist (J.I.) was not aware of the groupings'

Irjala 1993 (Continued)

Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible: data lost (personal communication Irjala J)
Free of other bias?	Yes	
Trial size > 49?	No	N = 35
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Irvin 1996

Methods	Design: three group parallel trial Purpose: examine the effect of relaxation therapy on postmenopausal symptoms
Participants	Patients: postmenopausal women attending an out-patient clinic Baseline comparability: yes
Interventions	Placebo: sessions of leisure reading Untreated: no sessions Experimental: sessions of video instructed relaxation therapy (Co-intervention: NS)
Outcomes	Hot flashes: intensity (numerical rating scale) Hot flashes: frequency Profile of Mood State (anxiety, depression, anger, vigour, fatigue, confusion) Spielberger State-Trait Anxiety Inventory
Notes Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers table'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/re- laxation therapy)

Irvin 1996 (Continued)

Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 22
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Jacobs 1971

Methods	Design: five group parallel trial Purpose: examine the effect of different drugs, in addition to a supportive treatment program, on cessation of smoking	
Participants	Patients: male smokers wanting to quit Baseline comparability: yes (prognostic variables)	
Interventions	Placebo: tablet with no drug Untreated: no tablet Experimental: tablet with lobeline, dextroamphetamine or imipramine Untreated: no tablet (Co-intervention: supportive treatment program, mostly group sessions)	
Outcomes	Number of abstinent smokers (cessation or reduction to < 10% of baseline value)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Jacobs 1971 (Continued)

Blinding? Treatment provider	Yes	' administering five drug conditions in a random and double-blind fashion'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 54
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Jacobson 1978

Methods	Design: four group parallel trial Purpose: examine the effect of behavioural therapy on marital discord	
Participants	Patients: couples with marital discord Baseline comparability: yes	
Interventions	Placebo: sessions of discussions with no behavioural elements or problem solving training Untreated: no sessions Experimental: -sessions of behavioural therapy + problem solving skills training based on good faith principles -sessions of behavioural therapy + problem solving skills training based on quid pro quo principles (Co-intervention: NS)	
Outcomes	Marital happiness scale Marital adjustment scale Negative behaviour Positive behaviour	
Notes		
Risk of bias		
Item	Authors' judgement	Description

Jacobson 1978 (Continued)

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ therapy)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 13
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Jakes 1992

Methods	Design: five group parallel trial Purpose: examine the effect of auditory masking and group cognitive therapy on tinnitus
Participants	Patients: out-patients suffering from tinnitus Baseline comparability: yes (outcome variables)
Interventions	Placebo: auditory masking with noise at hearing threshold Untreated: no masking Experimental: -auditory masking with variable noise level -group cognitive therapy -group cognitive therapy and auditory masking with variable noise level (Co-intervention: NS)
Outcomes	Tinnitus Effects Questionnaire (insomnia, emotional distress, auditory perceptional dif- ficulties) Interference with daily activities Crown Crisp Experimental Index

Jakes 1992 (Continued)

Relevant outcome data not	t accessible: data	lost (personal	communication Jakes SC)	

Risk of bias

Notes

-		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible: data lost (personal communication Jakes SC)
Free of other bias?	Yes	
Trial size > 49?	No	N = 28
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Kaptchuk 2008

Methods	Design: three group parallel trial Purpose: study the effect of placebo treatment and patient-practioner relationship
Participants	Patients: outpatients with irritable bowel syndrome Baseline comparability: yes
Interventions	Placebo: sessions of needling with a sham needle that does not penetrate the skin and limited patient-provider interaction ('placebo acupuncture alone') Untreated: no session Experimental: sessions of needling with a sham needle that does not penetrate the skin and extensive patient-provider interaction (placebo acupuncture augmented by warmth, attention and confidence') (Co-intervention: NS)
Outcomes	Global improvement scale scores (1 to 7 point) Proportion of patients with adequate relief Symptom severity scale

Kaptchuk 2008 (Continued)

Quality of life scale

Notes

Risk of hias

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'sequentially numbered opaque sealed en- velopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No primary outcomes mentioned in the protocol.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 175
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Karst 2007

Methods	Design: four group parallel trial Purpose: study the effect of auricular acupuncture on dental procedural anxiety
Participants	Patients: outpatients undergoing dental extraction Baseline comparability: yes
Interventions	Placebo: needling with non penetrative needle at points not regarded having effect on anxiety (finger and liver points) Untreated: no needling

Karst 2007 (Continued)

	Experimental: -needling at ' relaxation, tranquillizer, and master cerebral points in the external ear '. -midazolam, intranasal (average dose 4mg) (Co-intervention: NS)
Outcomes	Spielberger state-trait anxiety inventory VAS Sedation score Quality of dental condition Physiological status

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'list of random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 29
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Karunakaran 1997	
Methods	Design: three group parallel trial Purpose: examine the effect of sulfonylurea therapy on patients with increased fasting plasma glucose
Participants	Patients: out-patients with increased but not diabetic fasting plasma glucose Baseline comparability: yes
Interventions	Placebo: tablets containing no sulfonylurea Untreated: no tablets Experimental: tablets containing sulfonylurea (Co-intervention: reinforced or basic health advice in a factorial design)
Outcomes	Fasting plasma glucose (mmol/l) Haemoglobin A1c Plasma insulin Beta-cell function Weight Blood lipids Arterial blood pressure
Notes	Data from placebo and no-treatment groups pooled in the original trial report. Contact with researchers provided unpooled data.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' double-blind placebo'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Data from placebo and no-treatment groups pooled in the original trial re- port. Contact with researchers provided unpooled data.
Free of other bias?	No	See notes

Karunakaran 1997 (Continued)

No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 115
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Kendall 1979

Methods	Design: four group parallel trial Purpose: examine the effect of cognitive-behavioural and patient education interventions on the anxiety related to cardiac catheterization
Participants	Patients: in-patients undergoing cardiac catheterization Baseline comparability: yes
Interventions	Placebo: pre-catheterization session where patients' feelings were discussed, avoiding coping skills, procedures or factual information Untreated: no sessions (observational group) Experimental: sessions with: -cognitive-behavioural training in anxiety coping strategies -patient education: factual information on heart diseases and the procedure of cardiac catherization (Co-intervention: NS)
Outcomes	Anxiety (Spielberger state trait anxiety inventory) Pain Anger
Notes	

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ac- tive)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Kendall 1979 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 22
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Kerr 2003

Methods	Design: three group parallel trial Purpose: study the effect of penicillin troches for recurrent aphthous ulcers
Participants	Patients: outpatients with recurrent aphthous ulcers Baseline comparability: yes (age, gender, ulcer age)
Interventions	Placebo: sessions with TENS device not producing nerve stimulation Untreated: no sessions Experimental: sessions TENS device producing nerve stimulation (Co-intervention: installation of 4% lidocaine gel)
Outcomes	Proportion of patients with healed ulcers Proportion of patients with no pain

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	urn randomisation 'the subject drawing a single envelope from a pool of sealed blank envelopes'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Both the investigators and treatment group subjects were blinded'
Blinding? Outcome assessor	Unclear	NS

Kerr 2003 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 69
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Killeen 2004

Methods	Design: three group parallel trial Purpose: study the effect of naltrexone for alcohol dependence
Participants	Patients: outpatients with alcohol dependence Baseline comparability: yes (age, gender)
Interventions	Placebo: NS (12 weeks) Untreated: no placebo or naltrexone Experimental: naltrexone (Co-intervention: various individual or group programs)
Outcomes	Alcohol consumption (time line follow-back: average drinks per day, percent days drink- ing, drinks per drinking days, heavy drinking days) Percentage with at least one heavy drinking episode Craving (obsessive compulsive drinking scale) Various explorative analyses
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	urn randomisation
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS

Killeen 2004 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 59
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Killen 1990

Methods	Design: 4 x 3 group parallel trial (see notes) Purpose: examine the effect of behavioural intervention (3 types) and pharmacological intervention (4 types) in smoking relapse prevention
Participants	Patients: tobacco smokers abstinent for more than 48 hours and volunteering for a self- help program Baseline comparability: yes
Interventions	Placebo: gum with no nicotine Untreated: no gum Experimental: -nicotine gum ad libitum -nicotine gum with fixed regimen (Co-intervention: NS)
Outcomes	Number of abstinent smokers
Notes	As the behavioural treatments showed no significant difference the 3 x 4 factorial design was collapsed into a four group parallel trial.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Assignment to gum condition was double- blind'

Killen 1990 (Continued)

Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 618
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Kilmann 1987

Methods	Design: five group parallel trial Purpose: study the effect of three different psychological interventions on secondary erectile dysfunction	
Participants	Patients: men with secondary erectile dysfunction Baseline comparability: yes	
Interventions	Placebo: sessions with factual information on sexual education and relationship enhance- ment Untreated: no sessions Experimental: -sessions with communication technique training -sessions with sexual technique training -sessions with combination treatment (Co-intervention: NS)	
Outcomes	Coital success in % Marital adjustment test Sexual interaction inventory Sexual anxiety inventory Sexual pleasure rating	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS

Kilmann 1987 (Continued)

Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ psychological interventions)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 8
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Klerman 1974

Methods	Design: 2 x 3 factorial design (high and low personal interaction versus amitriptyline, placebo, no treatment) Purpose: examine the effect of amitriptyline, placebo and psychotherapy treatment on relapse of depression
Participants	Patients: out-patients with neurotic depression having improved markedly after 1 to 2 months amitrityline medication Baseline comparability: yes
Interventions	Placebo: -continuous treatment with tablets containing no amitriptyline (content NS) Untreated: -tablet treatment discontinued (observational group) Experimental: -continuous treatment with amitriptyline tablets (Co-intervention: no)
Outcomes	Number of patients with relapse of depression Residual symptoms of depression Social adjustment

Klerman 1974 (Continued)

Notes	As the high and low personal interaction treatments showed no significant difference the $2 \ge 3$ factorial design was collapsed into a three group parallel trial.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' in a double-blind controlled manner'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS
Kober 2002		
Mathada	Designs three group negalist trial	

Methods	Design: three group parallel trial Purpose: study the analgesic effect of accupressure
Participants	Patients: victims of minor trauma under transport to hospital Baseline comparability: yes (age, gender)
Interventions	Placebo: stimulation on sites not regarded analgesic acupressure sites Untreated: no stimulation Experimental: stimulation on sites regarded analgesic acupressure sites (Di4, KS9, KS6, BL60, LG20) (Co-intervention: no)
Outcomes	Pain (100 mm VAS) Anxiety (100 VAS) Heart frequency

Kober 2002 (Continued)

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	'opened an envelope'
Blinding? Treatment provider	Yes	' we conducted a prospective, random- ized, double-blinded study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 41
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Kokol 2005

Methods	Design: three group parallel trial Purpose: study the effect of 685 nm laser and placebo on venous leg ulcers
Participants	Patients: out-patients with venous leg ulcers Baseline comparability: yes
Interventions	Placebo: polychromatic red light Untreated: no light Experimental: 685 nm laser light (red) (Co-intervention: standard venous leg ulcers treatments)
Outcomes	Area of leg ulcers (photographs)

Kokol 2005 (Continued)

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' weder vom Arzt noch vom Patienten unterschieden werden kann'
Blinding? Outcome assessor	Yes	'Erst nach Ende der Nachbeobachtungen- sphase (Tag 90) wurden die verwendeten als A und B be zeichneten Geräte decodiert (entblindet), um die Ergebnisse nicht zu beeinflussen'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 26
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Kotani 2001

Methods	Design: three group parallel trial Purpose: study the effect of insertion of intradermal needles into painful points on intractable scar pain
Participants	Patients: out-patients with intractable abdominal scar pain Baseline comparability: yes
Interventions	Placebo: intradermal needling into nonpainful points Untreated: no needling Experimental: intradermal needling into painful points (Co-intervention: diclofenac until 24 hours before pain evaluation)

Kotani 2001 (Continued)

Outcomes	Number of analgesic tablets per week Proportion of patients with global pain relief (50% reduction or more) Pain, continuous (VAS) Pain, lancinating (VAS) Pain area (square cm)
	Threshold pressure

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random number table'
Allocation concealment?	Yes	'sequentially sealed opaque envelopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ needling into painful points)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 47
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Lamazza 1986		
Methods	Design: three group parallel trial Purpose: examine the effect of pinaverium bromide (antispasmodic and analgesic drug) in the premedication of endoscopic retrograde cholangio-pancreaticography (ERCP) and on the motor activity of the sphincter of Oddi	
Participants	Patients: with biliary and pancreatic disease and in need of a ERCP Baseline comparability: NS	
Interventions	Placebo: tablet with no pinaverium bromide Untreated: no tablet Experimental: tablet with pinaverium bromide (Co-intervention: diazepam injection, 10 to 20 mg)	
Outcomes	Patient's tolerance of procedure Time for procedure Sphincter of Oddi pressure and wave pattern	
Notes	Relevant outcome data not accessible	
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'A double-blind study was carried out'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	No	N = 12
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Lander 1993			
Methods	Design: three group parallel trial Purpose: examine the effect of transcutaneous electrical nerve stimulation (TENS) for children's pain on blood sampling		
Participants	Patients: children attending out-patient clinics undergoing venepuncture Baseline comparability: yes (age, sex, expected pain, anxiety)		
Interventions	Placebo: TENS with machine off Untreated: no TENS Experimental: TENS with machine on (Co-intervention: NS)		
Outcomes	Pain (VAS, Faces Affective Pain Scale)	Pain (VAS, Faces Affective Pain Scale)	
Notes			
Risk of bias			
Item	Authors' judgement Description		
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Yes	'sealed envelopes'	
Blinding? Treatment provider	No	Not	
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome	
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%	
Free of selective reporting?	Unclear	No protocol available	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)	
Trial size > 49?	Yes	N = 340	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled	

Larson 2005	
Methods	Design: three group parallel trial Purpose: study the risk of vomiting and regurgitation in children with diarrhoea treated with Zink or placebo
Participants	Patients: children with diarrhoea (short stay ward or outpatient clinic) Baseline comparability: yes
Interventions	Placebo: dispersible tablet without Zink Untreated: no tablet Experimental: dispersible tablet with Zink (Co-intervention: standard treatment for diarrhoea)
Outcomes	Proportion of patients that vomit Proportion of patients that regurgitatee

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'numbered' and 'opaque envelopes'
Blinding? Treatment provider	Yes	'This randomized, double-blind, placebo- controlled clinical trial'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	Yes	N =1066
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Lee 2005

Methods	Design: two group parallel trial Purpose: study the effect of placebo on cough
Participants	Patients: out-patients with cough and signs of upper respiratory infection Baseline comparability: NS
Interventions	Placebo: capsule with vitamin E Untreated: no capsule (Co-intervention: no)
Outcomes	Changes in cough frequency per 15 minutes Cough suppression time
Notes	Mean changes in cough frequency per 15 minutes calculated from individual patient data in Figure 1

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Yes	'microphone connected to a pen recorder'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 54
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Leibing 2002

Methods	Design: three group parallel trial Purpose: study the analgesic effect of acupuncture for low-back pain	
Participants	Patients: out-patients with non-radiating low-back pain of more than 6 months duration Baseline comparability: yes	
Interventions	Placebo: needling on sites not regarded analgesic acupuncture sites Untreated: no needling Experimental: needling on sites regarded analgesic acupressure sites (Co-intervention: active physiotherapy)	
Outcomes	Pain (100 mm VAS) Pain disability (pain disability index) Psychological distress Spine flexion	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 79
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Levine 1984		
Methods	Design: 8 group parallel trial (incomplete 3 x 3 factorial design) Purpose: examine the effect of open and hidden infusion of placebo on pain	
Participants	Patients: postoperative in-patients (after removal of impacted third molars) Baseline comparability: NS	
Interventions	Placebo: open infusion of vehicle by bedside investigator Untreated: patient unaware of infusion of vehicle (either by machine or hidden investi- gator) Experimental: infusions of naloxone and morphine (8 and 12 mg) (Co-intervention: NS)	
Outcomes	Pain (VAS)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Each patient was randomly assigned to re- ceive, after surgery, a double-blind injec- tion'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 36
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Methods	Design: three group parallel trial	Design: three group parallel trial	
	Purpose: examine the effect of investigating cardiovascular parameters in cancer patients receiving antiemetic cannabis treatment		
Participants	Patients: cancer patients receiving nausea inducing chemotherapy Baseline comparability: NS		
Interventions	Placebo: NS Untreated: no placebo or cannabis Experimental: -cannabis (three doses) -prochlorperazine (Co-intervention: yes, chemotherapy)		
Outcomes	Emetic events Psychological events Heart rate Blood pressure Intraocular pressure		
Notes	Relevant outcome data not accessible		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	
Blinding? Treatment provider	Unclear	NS	
Blinding? Outcome assessor	Unclear	NS	
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS	
Free of selective reporting?	No	Relevant outcome data not accessible	
Free of other bias?	Yes		
Trial size > 49?	No	N = 48	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

Licciardone 2003			
Methods	Design: three group parallel trial Purpose: study the effect of osteopathic manipulative treatment techniques for chronic low-back pain		
Participants	Patients: out-patients with chronic low-back pain Baseline comparability: yes		
Interventions	Placebo: simulated osteopathic manipulative treatment techniques Untreated: no simulated osteopathic manipulative treatment techniques Experimental: osteopathic manipulative treatment techniques (Co-intervention: 'usual or other low back care')		
Outcomes	Back pain (VAS) SF-36 health survey (physical functioning subscale) SF-36 health survey (all subscales) Roland-Morris disability questionnaire Lost work or school days Satisfaction with back care		
Notes	We selected back pain as the relevant outcome (and not the SF-36 which was the basis for the power calculation), because also back pain was described as a 'main outcome', and because pain (and not quality of life) is mentioned in the aims section and the title. We extracted pain data (at six months) from Figure 3		

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'sequentially sealed envelopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ manipulation)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)

Licciardone 2003 (Continued)

Trial size > 49?	No	N = 34
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Lick 1975		
Methods	Design: four group parallel trial Purpose: examine the effect of behavioural therapy and placebo on snake and spider phobia	
Participants	Patients: out-patients suffering from phobia against snakes and spiders Baseline comparability: yes	
Interventions	Placebo: -with feedback: patients told that pictures with phobic stimulus would be flickered too rapidly for the conscious mind to register and phobic responses would be detected by a 'polygraph' that would deliver a mild but uncomfortable electrical shock. In fact only light was shown and no machine detected any phobias. The rate of shocks associated with lights was programmed to be reduced from 90% in the first session to 10% in the last session. The patients were shown outprints and explained that treatment was 'going well'. - without feedback: similar procedure, but no outprints were shown and patients told that the machine reduced the number of shocks independently of their response. Patients were also 'assured throughout treatment that things were going well' Untreated: no behavioural or placebo procedure (waiting-list) Experimental: systematic desensitization procedure (Co-intervention: NS)	
Outcomes	Percentage of fear remaining (index) and pulse rate at confrontation with snake or spider Behavioural approach test Behavioural inhibition test Reaction to picture test Global behavioural improvement Therapy expectancy Warmth and competence of therapist	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS

Lick 1975 (Continued)

Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural therapy)
Blinding? Outcome assessor	Yes	' experimenter who was blind to the con- ditions that the subjects had been assigned'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 18
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Lick 1977

c insomnia ep)
re designed to induce expectancy (waiting list) difference in % days in which patients took
ry

Risk of bias

Lick 1977 (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/re- laxation therapy)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	No	See notes
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Limoges 2004

Methods	Design: three group parallel trial Purpose: study the effect of TENS during sigmoidoscopy
Participants	Patients: out-patients needing screening endoscopy Baseline comparability: yes
Interventions	Placebo: session with TENS machine off Untreated: no session Experimental: session with TENS machine turned on (Co-intervention: NS)
Outcomes	Pain intensity (1-5) Bloating Nausea Pain or burning or tingling at electrode site Pain compared with previous sigmoidoscopy

Limoges 2004 (Continued)

Notes	,
-------	---

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	(but endoscopist and patients were blinded)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 60
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Unclear allocation concealment

Lin 2002

Methods	Design: three group parallel trial Purpose: study the analgesic effect of electroacupuncture
Participants	Patients: postoperative patients (hysterectomy) Baseline comparability: yes
Interventions	Placebo: needling without electrical stimulation at ST-36 Untreated: no needling Experiemental: needling with electrical stimulation at ST-36 (Co-intervention: pethidine and morphine at request)

Lin 2002 (Continued)

Outcomes	Use of morphine (mg at 8, 16 and 24 hours) Pain Time to first pethidine dose Heart rate Blood pressure Oxygen saturation	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'computer-generated'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed
Lincoln 2003		

Methods	Design: three group parallel trial Purpose: study the effect of cognitive behavioral psychotherapy for post-stroke depression
Participants	Patients: out-patients with a recent stroke and depression Baseline comparability: yes

Lincoln 2003 (Continued)

Interventions	Placebo: sessions with conversations focusing on daily events and physical effects of stroke and life changes Untreated: no sessions Experimental: sessions with cognitive behavioural psychotherapy (Co-intervention: NS)
Outcomes	Beck depression inventory Wakefield self-assessment of depression inventory Extended activities of daily living scale London handicap scale Satisfaction with care rating
Notes	Standard deviation for the mean scores on the Beck depression inventory were not reported. We took the standard deviation from another trial (Verduyn C 2003).

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'computer generated'
Allocation concealment?	Yes	'sealed in opaque, consecutively numbered envelopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ cognitive behavioral psychotherapy)
Blinding? Outcome assessor	Yes	'Outcome assessments were administered by an assistant psychologist, who was blind to the group allocation'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	No protocol available. Standard deviation for the mean scores on the Beck depression inventory were not reported. We took the standard deviation from another trial (Ver- duyn C 2003).
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 80

Lincoln 2003 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled
Linde 2005		
Methods	Design: three group parallel trial Purpose: study the effect of acupuncture on migraine	
Participants	Patients: out-patients with migraine headache Baseline comparability: yes	
Interventions	Placebo: needling at places not regarded true acupuncture sites Untreated: no needling Experimental: needling at places regarded true acupuncture sites (Co-intervention: standard headache treatment according to the guideline of the German Migraine and Headache Society)	
Outcomes	Number of headache days of moderate or severe intensity until week 9-12 Number of migraine headaches Total number of headache days Proportion of treatment responders Number of days with medication Pain disability index Scale for assessing the emotional aspects of pain Algemeine Depressionskalla SF-36	
Notes		

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random list generated with Sample Size 2.0'
Allocation concealment?	Yes	'centralized telephone randomization pro- cedure'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%

Linde 2005 (Continued)

Free of selective reporting?	Yes	Primary outcome specified in protocol
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 157
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Lindholm 1996

Methods	Design: multi centre 2 x 3 factorial design (normal or intensive advice x pravastatin, placebo or no drug) Purpose: examine the effect of pharmacological and non-pharmacological strategies on cardiovascular risk
Participants	Patients: out-patients with increased risk of cardiovascular disease and moderately in- creased serum-cholesterol Baseline comparability: yes
Interventions	Placebo: tablet with no pravastatin (with usual or intense advice) Untreated: no pharmacological intervention (with usual or intense advice) Experimental: pravastatin (with usual or intense advice) (Co-intervention: usual health care advice on diet conducted by a GP or intense health care advice where usual advice is supplemented by group sessions)
Outcomes	Serum-cholesterol (mmol/l) Serum-cholesterol: high and low density lipoprotein Serum-triglycerides Blood-glycose Blood pressure Framingham risk score

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'A prospective, double-blind, randomized, controlled trial'

Lindholm 1996 (Continued)

Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 453
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly stated

Liossi 2003

Methods	Design: four group parallel trial Purpose: study the effect of hypnosis on procedure-related pain	
Participants	Patients: children (6 to 16 years) with cancer Baseline comparability: yes	
Interventions	Placebo: attention control treatment ('development of rapport, nonmedical play, non- medical verbal interaction'. Therapist was 'supportive, warm, encouraged the child to express freely their interests, and formed a close relationship with the child.' Untreated: no hypnosis Experimental: -direct hypnosis (hypnotic indiction by reference to request for numbness and imagining 'numbing medicine', etc) -indirect hypnosis (hypnotic induction by reference to 'the setting sun metaphor' and the 'Mexican food metaphor') (Co-intervention: standard medical care)	
Outcomes	Pain (6 point scale) Anxiety Observed distress	
Notes		
Risk of bias		
Item	Authors' judgement	Description

Liossi 2003 (Continued)

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 40
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Longo 1988

Methods	Design: three group parallel trial Purpose: examine the effect of psycho-social intervention on recurrence of genital herpes simplex
Participants	Patients: media and healthcare-referred persons with recurrent genital herpes simplex with 4 or more attacks a year Baseline comparability: yes
Interventions	Placebo: -sessions of social support consisting of discussions of interpersonal conflicts without any relaxation techniques or stress management. Untreated: no sessions (waiting-list) Experimental: sessions of relaxation techniques and stress management + playing a re- laxation tape during herpes attacks (Co-intervention: NS)
Outcomes	Herpes attack: severity (index) Herpes attack: frequency and duration Zung Depression Scale

Longo 1988 (Continued)

	Profile of Mood States UCLA Loneliness Scale Multidimensional Health Locus of Control Scales	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ psycho-social intervention)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 19
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Lorr 1961

Methods	Design: five group parallel trial Purpose: examine the effect of pharmacological treatment in addition to psychotherapy in patients with anxiety and hostility
Participants	Patients: out-patients with anxiety and hostility admitted to a veteran's Mental Hygiene Clinic for psychotherapy Baseline comparability: NS

Lorr 1961 (Continued)

Interventions	Placebo: tablet containing lactose but not chlorpromazine, meprebomate or phenobar- bital Untreated: no tablet (observational group) Experimental: -tablets with chlorpromazine -tablet with meprobamate -tablet with phenobarbital (Co-intervention: sessions of individual psychotherapy)
Outcomes	Anxiety (index) Hostility Discomfort
Notes	42% drop-outs. The standard deviation (SD) of the anxiety score was not reported. The SD was calculated from the reported F-test statistic.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'12-week double-blind study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 80
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Macaluso 1995

Methods	Design: three group parallel trial Purpose: examine the effect of fentanyl as premedication
Participants	Patients: in-patients undergoing same day surgery Baseline comparability: yes
Interventions	Placebo: oralet without fentanyl Untreated: no oralet Experimental: oralet with fentanyl (Co-intervention: NS)
Outcomes	Anxiety (Spielberger state trait anxiety inventory) Heart rate Volume and pH of gastric contents Arterial pressure Respiratory frequency Oxygen saturation

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'by computer program'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'All investigators were blinded to the type of oralet patients in Groups I and II con- sumed'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 60
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Malcolm 1980

Methods	Design: three group parallel trial Purpose: examine the effect of nicotine chewing gum treatment on smoking
Participants	Patients: smokers Baseline comparability: yes
Interventions	Placebo: chewing gum without nicotine Untreated: no chewing gum Experimental: chewing gum with nicotine (Co-intervention: NS)
Outcomes	Number of abstinent smokers (based on carboxyhaemoglobin levels) Number of abstinent smokers (based on self report)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The trial was double blind between the gum groups'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 121
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Markland 1993

Methods	Design: three group parallel trial Purpose: examine the effect of a relaxation tape session on preoperative anxiety	
Participants	Patients: in-patients undergoing day-case surgery Baseline comparability: yes, except for diastolic blood pressure	
Interventions	Placebo: session where patients listen to a recorded short story Untreated: no session Experimental: session where patients listen to a recorded relaxation procedure (Co-intervention: NS)	
Outcomes	Anxiety (Spielberger state trait anxiety inventory) Heart rate Blood pressure Anaesthesia measures (dose of sedative, time to settle the patient, mean concentration per min of isoflurane, anaesthetist's score)	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/re- laxation procedure)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 14
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Matros 2006

Methods	Design: three group parallel trial Purpose: study the effect of gum chewing on postoperative ileus	
Participants	Patients: in-patients having had performed abdominal surgery Baseline comparability: yes (age, gender)	
Interventions	Placebo: Acupressure bracelet used on an inert location Untreated: no chewing gum or bracelet Experimental: chewing gum (Co-intervention: standard postoperative care)	
Outcomes	Time to first flatus Time to first bowel movement Time to ready for discharge Time to actual discharge	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	'computer-generated'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ chewing gum)
Blinding? Outcome assessor	Unclear	NS

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant) and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 44
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Mattarei 1985

Methods	Design: two period, two group, cross-over trial Purpose: examine the effect of placebo on arterial hypertension
Participants	Patients: out-patients with untreated mild essential hypertension Baseline comparability: NS
Interventions	Placebo: capsule Untreated: no capsule (Co-intervention: no)
Outcomes	Diastolic blood pressure in mm Hg after 4 weeks Systolic blood pressure in mm Hg
Notes	The outcome data was not available.
Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	The outcome data was not available.
Free of other bias?	Yes	
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

May 1988

Methods

Design: four group, four period cross-over trial Purpose: examine the effect of terbutaline, isotonic saline, ambient air and no-treatment on chronic airway obstruction in asthmatics

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

May 1988 (Continued)

Participants	Patients: asthmatic out-patients with reversible chronic airway obstruction Baseline comparability: no carry-over effect
Interventions	Placebo: -inhalation of air from a noisy nebulizer -inhalation of isotonic saline from a noisy nebulizer Untreated: inhalation of air through a mouthpiece disconnected from the nebulizer Experimental: inhalation of terbutaline from a noisy nebulizer (Co-intervention: use of corticosteroids or bronchodilator drugs prohibited)
Outcomes	Change in forced expiratory volume in 1 second (FEV1) Change in forced vital capacity (FVC)
Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The treatment was given double-blind'
Blinding? Outcome assessor	Yes	' but the nurse in charge of spirometry did not know whether or not the patient was receiving treatment'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 48

May 1988 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
McLachlan 1991		
Methods	Design: three group parallel trial Purpose: examine the effect of the aluminium chelator desferrioxamine on progression of Alzheimer's disease	

Placebo: tablets containing lecithin and no desferrioxamine Untreated: no tablets or injections (observational group)

Experimental: injections with desferrioxamine

atrophy, no cerebral infarcts) Baseline comparability: NS

(Co-intervention: NS)

sessment)

Patients: out-patients with probable Alzheimer's disease (memory problems, cerebral

Activities of daily living (ADL, rate of decline of video recorder home-behavioural as-

Outcomes

Participants

Interventions

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'table of random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ desferrioxamine)
Blinding? Outcome assessor	Yes	' trained raters who were not told about the nature of the study'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

McLachlan 1991 (Continued)

Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

McMillan 1994

Methods	Design: four group parallel trial Purpose: examine the prophylactic antiemetic effect of transcutaneous electrical stimu- lation (TENS) of the P6 (Neiguan) acupuncture point
Participants	Patients: in-patients in need of major surgery and at risk of opoid analgesic-induced nausea Baseline comparability: yes (type of analgesic)
Interventions	Placebo: TENS with machine turned off Untreated: no TENS Experimental: TENS with machine turned on (Co-intervention: pharmacological analgesic and anti-emetic medication)
Outcomes	Number of patients with nausea Number of patients with vomiting
Notes	Inconsistent data reporting in original trial report clarified by contact with author. Not 1:1 randomisation.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)

McMillan 1994 (Continued)

Trial size > 49?	Yes	N = 72
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed
Medici 2002		
Methods	Design: three group parallel trial Purpose: examine the effect of real and sham acupuncture on bronchial asthma	
Participants	Patients: out-patients with chronic asthma Baseline comparability: yes	
Interventions	Placebo: needling at 11 sites not regarded true acupuncture sites Untreated: no needling Experimental: needling at 11 sites 'believed to have an anti-asthmatic effect'. (Co-intervention: standard pharmacological inhalation therapy)	
Outcomes	Proportion of patients scoring 1 to 4 on a VAS for nausea Proportion of patients scoring 1 to 4 on a VAS for difficulty of swallowing gastroscopy Proportion of patients scored 1 to 4 by gastrocopist on a VAS for nausea/retching Proportion of patient who accept re-gastroscopy	
Notes		

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)

Medici 2002 (Continued)

Trial size > 49?	No	N = 41
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Mehl-Madrona 2007

Methods	Design: Five group parallel trial Purpose: To study the effect of acupuncture, craniosacral therapy, acupuncture and craniosacral therapy, attention control and waiting list control on asthma.
Participants	Patients: out-patients with chronic asthma Baseline comparability: NS
Interventions	Placebo: Attention control Untreated: waiting list control Experimental: Acupuncture, craniosacral, acupuncture and craniosacral. (Co-intervention: Standard medical management)
Outcomes	Pulmonary function Asthma quality of life questionnaire. Profile of mood states. Beck depression inventory. Beck anxiety inventory. Medication form.

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'random number generating program'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Yes	'The respiratory therapist performing pul- monary function testing was blind to the assignments of the subjects'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	No	N = ?

Mehl-Madrona 2007 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Melchart 2005		
Methods	Design: three group parallel trial Purpose: study the effect of acupuncture on tension type headache	
Participants	Patients: out-patients with tension type headache Baseline comparability: yes for most aspects, however 'some differences in previous use of acupuncture and in parts of the pain questionnaire'.	
Interventions	Placebo: needling at places not regarded true acupuncture sites Untreated: no needling Experimental: needling at places regarded true acupuncture sites (Co-intervention: standard headache treatment)	
Outcomes	Days with headache Hours with headache Headache scores Days with more than mild headache Days with analgesic drugs Number of days with medication Pain disability index SF-36 Algemeine Depressionskala Scale for assessing the emotional aspects of pain Average pain (1 to 10 scale)	
Notes	Average days with analgesic drugs in placebo group was 2.6 (SD: 2.6), and in the no- treatment group 4.4 (SD: 4.1) at week 12.	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random list generated with sample size 2.0 by the statistician'
Allocation concealment?	Yes	'centralized telephone randomization pro- cedure'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Melchart 2005 (Continued)

Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Yes	Primary outcome specified in protocol
Free of other bias?	Unclear	Average days with analgesic drugs in placebo group was 2.6 (SD: 2.6), and in the no-treatment group 4.4 (SD:4.1).
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 120
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Moffet 1996

Methods	Design: three group parallel trial Purpose: examine the effect of pulsed short wave therapy (PSW) on chronic pain
Participants	Patients: out-patients with chronic pain associated with osteoarthritis of hip or knee Baseline comparability: yes
Interventions	Placebo: PSW with machine off Untreated: no PSW Experimental: PSW with machine on (Co-intervention: NS)
Outcomes	Pain (numerical/verbal rating scale)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'minimisation method'
Allocation concealment?	Yes	'minimisation method'
Blinding? Treatment provider	Yes	' double blind randomised controlled trial'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Moffet 1996 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 49
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size is not 50 or more

Molsberger 2002

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture on chronic low back pain
Participants	Patients: patients with low back pain of more than 6 weeks duration Baseline comparability: yes (age, pain)
Interventions	Placebo: superficial needling at sites not regarded acupuncture sites (12 sessions over 4 weeks) Untreated: no needling Experimental: needling at acupuncture sites (Co-intervention: conservative orthopaedic treatment (physiotherapy, exercise, back school, mud packs, infrared heat therapy, and diclofenac on demand))
Outcomes	Proportion of patients with 50% reduction of 100 mm pain VAS at one month Proportion of patients with 50% reduction of 100 mm pain VAS at follow-up Proportion of patients with excellent or good ratings on a four-point box scale
Notes	According to protocol we extracted the post treatment outcome data at one month, overruling a secondary principle of extracting the primary outcome of a trial (follow up data at three months). The effect of placebo was neutral at post treatment (RR = 1.16, 0.86 to 1.56), but positive at follow-up (RR = 0.64, 0.43 to 0.95). The drop out rate in the two groups was $(3+7)/121 = 8\%$ at one month, and $(19+23)/121 = 35\%$ at three months.
Risk of bias	

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer generated randomisation list'

Molsberger 2002 (Continued)

Allocation concealment?	Yes	'central telephone randomisation'
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	No	See notes
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 111
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Moreland 2006

Methods	Design: three group parallel trial Purpose: examine the effect of a blood glucose monitoring manual in adults with diabetes	
Participants	Patients: out-patients with diabetes Baseline comparability: yes	
Interventions	Placebo: session of diabetes education and a blood glucose meter ('attention control') Untreated: no session Experimental: session of diabetes education based on a blood glucose manual and a blood glucose meter (Co-intervention: standard diabetes care)	
Outcomes	Frequency of blood glucose measurements Glycaemic control Knowledge of HbA1c Affect regarding blood glucoses results	
Notes	We have multiplied the results by negative 1 to change the direction of the effect in the analyses.	
Risk of bias		
Item	Authors' judgement	Description

Moreland 2006 (Continued)

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ manual)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 149
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS and unclear allo- cation concealment

Morey 2006

Methods	Design: three group parallel trial Purpose: examine the effect of exercise health counselling
Participants	Patients: elderly out-patients with chronic illnesses Baseline comparability: yes
Interventions	Placebo: sessions of disease management or prevention unrelated to physical activity and with no efforts made to modify behaviour ('attention control') Untreated: no sessions Experimental: sessions aiming at providing patient centred motivational, behavioural, and cognitive techniques to increase physical activity (Co-intervention: NS)
Outcomes	Physical activity (CHAMPS questionnaire) -weekly frequency -caloric expenditure -estimated total minutes (estimated moderate minutes + estimated walk/bike minutes)
Notes	

Risk of bias

Morey 2006 (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'computer-generated'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (atten- tion control placebo/exercise health coun- selling)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 80
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Morton 1993

Methods	Design: four group, four period cross-over trial Purpose: examine the prophylactic effect of acupuncture on exercise induced asthma
Participants	Patients: female out-patients suffering from exercise induced asthma Baseline comparability: not relevant
Interventions	Placebo: acupuncture with laser beam off Untreated: no acupuncture Experimental: -acupuncture with laser beam on -salbutamol inhalation (Co-intervention: corticosteroids in 3 participants)
Outcomes	Forced expiratory volume after 1 second (FEV1) as % of pretreatment value Proportion with bronchoconstriction (15% reduction in FEV1)

Morton 1993 (Continued)

Notes	The outcome data was treated as if coming from a parallel trial	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	The outcome data from this cross-over trial was treated as if coming from a parallel trial
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 26
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Murphy 1982

Methods	Design: 2 x 2 factorial design with two additional control groups Purpose: examine the effect of behavioural therapy with spouse involvement on weight loss
Participants	Patients: self-referred couples with at least one obese person Baseline comparability: yes (weight, sex, age)
Interventions	Placebo: sessions with supportive group discussions about different weight loss programs Untreated: no sessions Experimental: sessions of behavioural therapy where the -person is alone and without spouse involvement by contract -person is alone in therapy and with spouse involvement by contract -couple is in therapy but without spouse involvement by contract

Murphy 1982 (Continued)

	-couple is in therapy and with spouse involvement by contract (Co-intervention: corticosteroids in 3 subjects)	
Outcomes	Weight loss (pounds)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural therapy)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 17
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Mussell 1988

Methods	Design: five period cross-over trial Purpose: examine the effect of trachea-noise biofeedback in asthma
Participants	Patients: 'asthmatics were recruited with informed consent' Baseline comparability: not relevant
Interventions	Placebo: inhaled saline Type of untreated: no inhalation or biofeedback Type of experimental: -salbutamol inhalation

Mussell 1988 (Continued)

	-biofeedback wrong information -biofeedback correct information (Co-intervention: no asthma medication)		
Outcomes	Forced expiratory volume after 1 second (FEV1)		
Notes	Relevant outcome data not accessible	Relevant outcome data not accessible	
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	
Blinding? Treatment provider	Yes	'the active and placebo bronchodilator inhaler given double blind'	
Blinding? Outcome assessor	Unclear	NS	
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS	
Free of selective reporting?	No	Relevant outcome data not accessible	
Free of other bias?	Yes		
Trial size > 49?	No	N = 16	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

Najnigier 1997

Methods	Design: three group parallel trial Purpose: examine the preventive effect of ondansetron on postoperative nausea
Participants	Patients: in-patients undergoing laparoscopic cholecystectomy Baseline comparability: NS
Interventions	Placebo: tablets without ondansetron Untreated: no tablets Experimental: tablets with ondansetron (Co-intervention: NS)

Najnigier 1997 (Continued)

Outcomes	Number of patients with nausea Number of patients with vomiting	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	Very likely a double-blind study
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 60
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Nandi 1976

Methods	Design: three group parallel trial Purpose: examine the effect of imipramine on depression in patients not spontaneously seeking treatment
Participants	Patients: out-patients with clinical depression identified through a door to door survey in a rural community Baseline comparability: yes (score on Hamilton's depressive rating scale)
Interventions	Placebo: tablets without imipramine (lactose) Untreated: no tablets (observational group) Experimental: tablets with imipramine (Co-intervention: NS)

Nandi 1976 (Continued)

Outcomes	Score on Hamilton's rating scale	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 18
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Naumann 1989

Methods	Design: three group parallel trial Purpose: examine the effect of transcutaneous electrical nerve stimulation (TENS) and placebo on postoperative pain
Participants	Patients: postoperative patients Baseline comparability: NS
Interventions	Placebo: TENS with no current Untreated: no TENS Experimental: TENS with current (Co-intervention: standard pharmacological analgesic care)

Naumann 1989 (Continued)

Outcomes	Number of analgesic injections	
Notes	Outcome not reported so that meta-analysis is possible.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Der Versuchsaufbau entsprach Doppel- blindbedingungen'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Outcome not reported so that meta-analy- sis is possible.
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 117
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS
Nawrocki 1997		
Methods	Design: three group parallel trial Purpose: examine the effect of transurethral microwave thermotherapy (TUMT) on benign prostatic hyperplasia	
Participants	Patients: out-patients suffering from benign prostatic hyperplasia Baseline comparability: NS	
Interventions	Placebo: TUMT with no microwave emission Untreated: no TUMT Experimental: TUMT with machine on (Co-intervention: NS)	

Outcomes American Urologist Association's symptom score and Minimum urethral opening pressure (mm H20) Maximum urinary flow rate

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Nawrocki 1997 (Continued)

	Post-void residual urine volume Maximum detrusor pressure	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'selecting numbered balls from a sealed bag'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The treatment of the first two groups was 'double-blind''
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 82
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Nicassio 1974

Methods	Design: four group parallel trial Purpose: examine the effect of two different relaxation techniques on insomnia
Participants	Patients: media recruited out-patients suffering from insomnia Baseline comparability: yes (time to fall asleep)
Interventions	Placebo: sessions of self relaxation without any technique being taught Untreated: no sessions Experimental: sessions of taught techniques of relaxation: -autogenic training (focusing on heaviness and warmth of legs and arms)

Nicassio 1974 (Continued)

	-progressive relaxation (muscle tension-release cycles) (Co-intervention: no)
Outcomes	Sleep latency (minutes) Hours slept Number of awakenings Overall quality of the night's sleep (fatigue, depression, ability to relax, feeling of anxiety, ability to function at work and irritability during day) Pupillography

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/re- laxation techniques)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 16
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Nocella 1982			
Methods	Design: three group parallel trial Purpose: examine the effect of cognitive-behavior modification on coping with dental procedure stress		
Participants	Patients: children attending a dental clinic for a painful procedure Baseline comparability: yes (sex, procedure)		
Interventions	Placebo: one session where a child received the full attention of the experimenter without implementing strategies for stress coping Untreated: no session Experimental: one session where stress coping strategies of a cognitive-behavioral nature were given (co-intervention: NS)		
Outcomes	Frequency (per min) of behaviour expressing stress (facial grimaces, restlessness, moving legs and arms, sitting up, gripping chair and verbalizations)		
Notes			
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	
Blinding? Treatment provider	No	Not described as double-blind (placebo/ cognitive-behavior intervention)	
Blinding? Outcome assessor	Yes	' each child's behavior was categorized by a judge who was blind to treatment condi- tions'	
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS	
Free of selective reporting?	Unclear	No protocol available	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)	
Trial size > 49?	No	N = 20	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

O'Brien 1996

Methods	Design: three group parallel trial Purpose: examine the effect of acupressure on nausea associated with pregnancy
Participants	Patients: pregnant women with nausea Baseline comparability: yes for baseline nausea
Interventions	Placebo: acupressure on a neutral point (not P6) Untreated: no acupressure Experimental: acupressure on the point P6 (Co-intervention: antiemetic medication, dietary and activity recommendations. The acupressure group used less antiemetic medication than the two other groups).
Outcomes	Nausea (Rhodes inventory of nausea and vomiting) Vomiting
Notes	

Risk of bias

Item	Authors' judgement	Description
item	Authors Judgement	Description
Adequate sequence generation?	Unclear	'group assignments were computer gener- ated'
Allocation concealment?	Yes	'numbered sealed envelopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupressure)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 107
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Parker 1995	
Methods	Design: three group parallel trial Purpose: examine the effect of stress management on clinical outcomes of rheumatoid arthritis (RA)
Participants	Patients: out-patients with RA Baseline comparability: yes
Interventions	Placebo: sessions where a education programme was discussed with each patient Untreated: no sessions Experimental: sessions with stress management (Co-intervention: standard RA treatment, 74% of patients in placebo and 77% in un- treated group continued on stable medication).
Outcomes	Pain (VAS) McGill Pain Questionnaire Hassles scale Daily Stress Inventory Arthritis Helplessness Index Center for Epidemiologic Studies Depression Scale State-Trait Anxiety inventory Arthritis Self-Efficacy Scale Coping Strategy Questionnaire Arthritis impact Measurement Scale Disease Activity
Notes	Relevant outcome data not accessible in trial report but retrieved by contact with authors.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ stress-management)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out <15%
Free of selective reporting?	No	Relevant outcome data not accessible in trial report but retrieved by contact with authors.
Free of other bias?	Yes	

Parker 1995 (Continued)

No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 94
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Parker 2003

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive-behavioural therapy on depression with rheumatoid arthritis	Purpose: examine the effect of cognitive-behavioural therapy on depression associated	
Participants	Patients: in-patients with rheumatoid arthritis Baseline comparability: no (age)		
Interventions	Placebo: general patient education program Untreated: no program Experimental: cognitive behavioural program (10 weekly visits) (Co-intervention: standard medical care and anti-depressive medication)		
Outcomes	Center for epidemiological studies-depression scale (CES-D) Hamilton rating scale for depression Geriatric depression scale Symptom checklist 90-R Coping strategies questionnaire Daily stress inventory Hassles scale State-trait anxiety inventory Arthritis helplessness index Arthritis self-efficiency scale Arthritis impact measurement scale 2 multidimensional assessment of fatigue Pain (VAS) McGill pain questionnaire Rapid assessment of disease activity in rheumatology Erythrocyte sedimentation rate	Center for epidemiological studies-depression scale (CES-D) Hamilton rating scale for depression Geriatric depression scale Symptom checklist 90-R Coping strategies questionnaire Daily stress inventory Hassles scale State-trait anxiety inventory Arthritis helplessness index Arthritis self-efficiency scale Arthritis self-efficiency scale Arthritis impact measurement scale 2 multidimensional assessment of fatigue Pain (VAS) McGill pain questionnaire Rapid assessment of disease activity in rheumatology	
Notes	Standard deviation for mean CES-D scores not reported. Standard deviation another study (Kozora 2006): 7.5.	Standard deviation for mean CES-D scores not reported. Standard deviation taken from another study (Kozora 2006): 7.5.	
Risk of bias			
τ.	Anthon? in Longont Description		

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS

Parker 2003 (Continued)

Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ cognitive behavioural therapy)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	No protocol available. Standard deviation for mean CES-D scores not reported. Stan- dard deviation taken from another study (Kozora 2006): 7.5.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 27
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Pearl 1956

Methods	Design: three group parallel trial Purpose: examine the effect of reserpine on schizophrenic patients	
Participants	Patients: in-patients with schizophrenia Baseline comparability: NS	
Interventions	Placebo: NS Untreated: no reserpine or placebo Experimental: reserpine (Co-intervention: institutionalised patients, beside that NS)	
Outcomes	Multidimensional Scale for Rating Psychiatric Patients	
Notes	Relevant outcome data not accessible	
Risk of bias		
Item	Authors' judgement	Description

Pearl 1956 (Continued)

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Except for the ward psychiatrist and nurse, no personnel involved were aware of pa- tient's treatment. Persons dispensing the placebo were told it was a variant of reser- pine'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 100
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Pelham 1992

Methods	Design: three group, multi-period cross-over trial (number of periods NS) Purpose: examine the perception of what influenced mood and behaviour (causal attri- bution)in boys treated for attention deficit hyperactivity disorder by methylphenidate or placebo
Participants	Patients: boys with attention deficit hyperactivity disorder attending a summer camp Baseline comparability: not relevant
Interventions	Placebo: tablet with no methylphenidate Untreated: no tablet Experimental: tablet with methylphenidate (Co-intervention: -summer camp treatment program (behavioural therapy principles) -same boys also participated in trials with other drugs on days not included in the present study)
Outcomes	Behaviour rating scales, including ratings of "Did you have a good day?" Attribution rating scales (what the children themselves thought influenced behaviour or mood) Mood/self-esteem rating scales Forced-Choice Questions

Pelham 1992 (Continued)

Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' designed to examine ADHD boys' causal attributions in a double-blind, within-subject, placebo-controlled medi- cation trial'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 76
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Quahagen 1995

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive training program for patients with dementia
Participants	Patients: out-patients with possible or confirmed diagnosis of Alzheimer's disease Baseline comparability: yes
Interventions	Placebo: passive cognitive stimulation where patients did not engage in training activities Untreated: no training Experimental: active cognitive stimulation where patients did engage in training activities

Quahagen 1995 (Continued)

	(Co-intervention: NS)	
Outcomes	Cognitive functioning (Mattis dementia rating scale) Behavioural functioning (Memory and behaviour problems checklist, part A)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ cognitive training program)
Blinding? Outcome assessor	Yes	' research assistants who, with rare ex- ception, were blinded to the condition to which the family had been assigned'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 53
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Rabkin 1990

Methods	Design: two group parallel trial Purpose: examine the effect of continuous placebo treatment on relapse of chronic mild depression
Participants	Patients: out-patients with chronic, mild depression having improved markedly after a 10 day placebo medication Baseline comparability: yes

Rabkin 1990 (Continued)

Interventions	Placebo: continuous treatment with a tablet (content NS) Untreated: discontinued treatment with tablet (Co-intervention: NS)	
Outcomes	Number of patients with relapse of depression	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Treatment provider was not blinded
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Rawling 2001

Methods	Design: three group parallel trial Purpose: examine the effect of fentanyl and placebo on the pain related to abortion
Participants	Patients: women undergoing abortion Baseline comparability: yes
Interventions	Placebo: saline injections Untreated: no injections Experimental: fentanyl injections (Co-intervention: ibuprofen or acetaminophen, and lorazepam)

Rawling 2001 (Continued)

Outcomes	Pain (11 point numerical pain scale, 0 to 10) after removal of speculum	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Yes	'sequentially numbered, opaque envelopes'
Blinding? Treatment provider	Yes	'Physicians, clinic staff, and women in the study did not know the contents of the sy- ringes'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 185
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Reading 1982

Methods	Design: three group parallel trial Purpose: examine the effect of preoperative interview and placebo interview on postop- erative pain and recovery
Participants	Patients: women undergoing elective laparoscopy Baseline comparability: yes (age)
Interventions	Placebo: preparation interview with neutral questions about hospitalisation in general Untreated: no preparation interview Experimental: preparation interview presenting 'information in a reassuring /supportive

Reading 1982 (Continued)

	way' (Co-intervention: analgesics on demand, type and dose NS, 7 from placebo and 9 from untreated group required pain medication)	
Outcomes	Pain (numerical/verbal rating scale) Time to return to health and work	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/in- terview)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 38
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Ristikankare 1999

Methods	Design: three group parallel trial Purpose: examine the tolerance and technical difficulty (and cardiorespiratory adverse effects) of sedative premedication during colonoscopy
Participants	Patients: out-patients undergoing colonoscopy Baseline comparability: yes (age, gender)

Ristikankare 1999 (Continued)

Interventions	Placebo: saline injections Untreated: no injections Experimental: midazolam injections (Co-intervention: NS)	
Outcomes	Overall difficulty of colonoscopy, patient's report post procedure and after 2 weeks (100 mm VAS) Abdominal pain, patient's report (100 mm VAS) Discomfort, patient's report (100 mm VAS) Overall difficulty of colonoscopy, observer's report (100 mm VAS) Abdominal pain, observer's report (100 mm VAS) Discomfort, observer's report (100 mm VAS) Oxygen saturation in % Arterial blood pressure R-R intervals on continuous ECG readings	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'An injection was administered for 30 to 60 seconds in a double-blind manner'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 122
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Methods	Design: three group parallel group trial Purpose: study the effect of sedation and topical pharyngeal anaesthesia on cardiorespi- ratory safety during gastroscopy	
Participants	Patients: patients undergoing gastroscopy Baseline comparability: yes	
Interventions	Placebo: spray (NS) and injection (saline) Untreated: no spray or sedation injection Experimental: topical lidocaine spray or midazolam injection) (Co-intervention: NS)	
Outcomes	Heart rate Blood pressure (diastolic and systolic) Saturation of Oxygen	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The patient, the endoscopist, and the endoscopy nurse were all blinded as to whether the patient received effective drug or placebo'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 128
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Robinson 2001		
Methods	Design: three group parallel trial Purpose: examine the analgesic effect of transcutaneous electrical nerve stimulation (TENS) during colonoscopy	
Participants	Patients: out-patients undergoing colonoscopy Baseline comparability: yes	
Interventions	Placebo: TENS without current Untreated: no TENS Experimental: TENS with current (Co-intervention: midazoalam, and escape analgesic drugs)	
Outcomes	Breakthrough analgesia (mg nalbuphrine) Patient reported pain (100 point scale) Endoscopist rated pain (100 point scale) Post-procedure evaluation questionnaire (physical discomfort, psychological distress, sat- isfaction)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'envelopes shuffled'
Allocation concealment?	Yes	'sealed envelopes'
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Yes	'Assesments were conducted by an assistant psychologist (CW) who did not attend the colonoscopy and was blind to study group'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 23

Robinson 2001 (Continued)

Clearly concealed allocation + trial size > No 49 + drop-out max 15%?

Trial size < 49

Roongpisutinp 1999	
Methods	Design: three group parallel trial Purpose: examine the effect of dexfenfluramine on weight loss and thermogenesis in obese individuals
Participants	Patients: out-patients with body mass index > 25 kilograms per square meter Baseline comparability: yes
Interventions	Placebo: capsules for three months Untreated: no capsules Experimental: capsules with dexfenfluramine (Co-intervention: 8 week behavioural weight loss program)
Outcomes	Weight loss Other weight outcomes (waist/hip ratio, biceps fold, subscapular fold, arm circumfer- ence, etc) Daily activity and changes in behaviour Side effects
Notes	13 of 32 patients in the no treatment group dropped out.

Roongpisuthip 1999

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Patients in group I were randomly strati- fied into 2 subgroups in a double-blind, placebo-controlled manner'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	

Roongpisuthip 1999 (Continued)

No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 37
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Roscoe 2002

Methods	Design: three period, Latin square, cross-over trial Purpose: examine the effect of acustimulation on chemotherapy-induced nausea
Participants	Patients: cancer patients receiving chemotherapy who previously have experienced mod- erate or severe chemotherapy-induced nausea
Interventions	Placebo: acustimulation wrist-band without stimulation of point PC-6 Untreated: no acustimulation write band Experimental: acustimulation wrist band with stimulation on point PC-6 (Co-intervention: 'antiemetic pills')
Outcomes	Antiemetic use (pills per day) Nausea Acute nausea Delayed nausea
Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available

Roscoe 2002 (Continued)

Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 54
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Roscoe 2005

Methods	Design: three group parallel trial Purpose: examine the effect of acustimulation on chemotherapy-induced nausea in women with breast cancer		
Participants	1	Patients: patients about to receive their second chemotherapy treatment who experienced nausea or vomiting after the first treatment	
Interventions	Placebo: acustimulation wrist-band without stimulation Untreated: no acustimulation wrist band Experimental: acustimulation wrist band with stimulation (Co-intervention: standard clinical antiemetic prophylaxis, including a 5-HT ₃ receptor antagonist)		
Outcomes	Acute nausea (7-point scale) Delayed nausea Vomiting Quality of life Antiemetic medication		
Notes	SE values were provided in the original publication and these values were converted to SDs.		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	

NS

Allocation concealment?

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Unclear

Roscoe 2005 (Continued)

Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 64
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Rosen 1976

Methods	Design: five group parallel trial Purpose: examine the effect of three types of behavioural therapy on snake phobia
Participants	Patients: out-patients suffering from snake phobia Baseline comparability: yes
Interventions	Placebo: -posted instructions of factual information about snakes ('systematic re-learning') Untreated: no behavioural or placebo procedure (waiting-list) Experimental: -systematic desensitization procedure by posted instructions -systematic desensitization procedure by therapist -systematic desensitization procedure by minimal therapist contact through telephone (Co-intervention: No)
Outcomes	Anxiety score and heart rate and at slide provocation test Snake Attitude Questionnaire (SNAQ) Behavioural Approach test Fear Survey Schedule Rate of fear change
Notes	38% drop-outs

Rosen 1976 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' a self-administered double-blind placebo control'
Blinding? Outcome assessor	Yes	' follow-up assessments were conducted by assistants blind to subjects' group assignment'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 14
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Rossi 1982

Methods	Design: three group, three period cross-over trial Purpose: examine the effect of labetalol on hypertension
Participants	Patients: in-patients with essential hypertension Baseline comparability: yes
Interventions	Placebo: tablet without labetalol Untreated: no tablet Experimental: tablet with labetalol (Co-intervention: No)
Outcomes	Diastolic blood pressure (mm Hg)

Rossi 1982 (Continued)

Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.			
Risk of bias	Risk of bias			
Item	Authors' judgement	Description		
Adequate sequence generation?	Unclear	NS		
Allocation concealment?	Unclear	NS		
Blinding? Treatment provider	Unclear	NS		
Blinding? Outcome assessor	Unclear	NS		
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%		
Free of selective reporting?	Unclear	No protocol available		
Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.		
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)		
Trial size > 49?	No	N = 12		
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49		

Roughan 1981

Methods	Design: three group parallel trial Purpose: examine the effect of pelvic floor exercises on orgasmic potential
Participants	Patients: female out-patients not having had an orgasm for two years Baseline comparability: NS
Interventions	Placebo: instruction to do relaxation exercises Untreated: no exercises (waiting-list)

Roughan 1981 (Continued)

	Experimental: instructions to do pelvic floor exercises (Co-intervention: no psychological counselling)	
Outcomes	Number of women having had orgasm	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ex- ercise instructions)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 26
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Rowbotham 1996

Methods	Design: three group, four period cross-over trial Purpose: examine the effect of lidocaine patches on post-herpetic neuralgia
Participants	Patients: out-patients with post-herpetic neuralgia Baseline comparability: not relevant
Interventions	Placebo: patch with vehicle but no lidocaine Untreated: no patch (observational group) Experimental: patch with vehicle and lidocaine (two periods) (Co-intervention: oral analgesics as prescribed before entering the trial, including escape medication, dose NS)

Rowbotham 1996 (Continued)

Outcomes	Pain (VAS) Side effects Blood lidocaine	
Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.	
Risk of bias		
Item	Authors' judgement Description	
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' double-blind controlled study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 70
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Rupert 1978

Methods	Design: factorial design, 3 (biofeedback, placebo, no biofeedback)x 2 (instructions to increase or decrease heart rate) + 1 (no treatment) Purpose: examine the effect of biofeedback on anxiety and heart rate
Participants	Patients: psychiatric in-patients deemed to have a high degree of anxiety problems by their physician Baseline comparability: yes (anxiety scores, heart rate)

Rupert 1978 (Continued)

Interventions	Placebo: biofeedback sessions with false positive feedback Untreated: no sessions (observational) Experimental: biofeedback sessions with correct feedback (Co-intervention: anxiolytics, fixed dosage.)		
Outcomes	Anxiety Heart rate		
Notes	Relevant outcome data not accessible		
Risk of bias	Risk of bias		
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	
Blinding? Treatment provider	Unclear	NS	
Blinding? Outcome assessor	Unclear	NS	
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS	
Free of selective reporting?	No	Relevant outcome data not accessible	
Free of other bias?	Yes		
Trial size > 49?	No	N = 16	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

Rybarczyk 1990

Methods	Design: four group parallel trial Purpose: examine the effect of stress management interventions on preoperative anxiety
Participants	Patients: older male in-patients undergoing major surgery Baseline comparability: yes (anxiety scores)
Interventions	Placebo: session of present focus interview prompting discussions on positive activities in the patient's present life Untreated: no session

Rybarczyk 1990 (Continued)

	Experimental: -session of general reminiscence interview prompting patient to recall positive events from the first half of their life -session of challenge reminiscence interview prompting the patient to recall successfully met challenges (Co-intervention: NS)
Outcomes	Anxiety (Spielberger State-trait Anxiety Inventory) Coping self-efficacy inventory Physiological and postoperative adjustment measures
Notes	Relevant outcome data not accessible in trial report but retrieved by contact with authors.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ stress management interventions)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15 % or NS
Free of selective reporting?	No	Relevant outcome data not accessible in trial report but retrieved by contact with authors.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 49
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15 % or NS

Röschke 2000

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture on major depression
Participants	Patients: inpatients with depression (score > 17 on 21 item Hamilton depression scale) Baseline comparability: yes for age and score on Hamilton depression scale; no for gender
Interventions	Placebo: whole body needling in sites not regarded true acupuncture points for 30 minutes 3 times weekly for 4 weeks Untreated: no acupuncture Experimental: whole body acupuncture sessions (Co-intervention: mianserin at fixed doses; diazepam 'if required' but actual medication the first four weeks was roughly comparable between groups)
Outcomes	Self-rating scale (Bf-S) Global assessment scale (GAS) Bech-Rafaelsen melancholia Scale (BRMS) Clinical global impressions scale (CGI) Need of diazepam medication
Notes	SD for GAS and Self-rating scale not reported. Authors were contacted and provided the data.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	SD for GAS and Self-rating scale not re- ported. Authors were contacted and pro- vided the data.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)

Röschke 2000 (Continued)

Trial size > 49?	No	N = 48		
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49		
Rösler 2003	Rösler 2003			
Methods	Design: three group parallel trial Purpose: examine the effect of single needle acupuncture in suppressing gag-reflex during transesophageal echocardiography (TEE)			
Participants	Patients: acupuncture naive patients with presumed cardioembolic stroke or transient ischemic attack Baseline comparability: yes			
Interventions	Placebo: needling in the Chengjiang point (CV24) during TEE Untreated: no needling Experimental: needling 'at a sham point' (tip of the chin (Co-intervention: 0.5% tetracaine spray)			
Outcomes	Gag-reflex (10 point VAS)			
Notes				
Risk of bias	Risk of bias			
Item	Authors' judgement	Description		
Adequate sequence generation?	Unclear	'computer-evoked'		
Allocation concealment?	Unclear	NS		

Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the

Rösler 2003 (Continued)

		mean)
Trial size > 49?	No	N = 27
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Sanders 1990

Methods	Design: three group parallel trial Purpose: examine the effect of chiropractic spinal manipulation on acute low back pain
Participants	Patients: out-patients with acute low back pain Baseline comparability: no, stratified for sex
Interventions	Placebo: light physical touch by investigator at L4/L5-S1 region Untreated: no touch or manipulation Experimental: low amplitude high velocity manipulation of L4/L5-S1 region (Co-intervention: no)
Outcomes	Pain (5-point NRS) Plasma B-endorphin concentration
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'table of random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ manipulation)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64

Sanders 1990 (Continued)

		standard deviations does not exceed the mean)
Trial size > 49?	No	N = 12
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Schallreuter 2002

Methods	Design: three group parallel trial Purpose: examine the effect of pseudocatalase cream and placebo on repigmentation in vitiligo
Participants	Patients: out-patients with vitiligo Baseline comparability: NS
Interventions	Placebo: cream with no pseudocatalase Untreated: no cream Experimental: cream with pseudocatalase (Co-intervention: climatotherapy)
Outcomes	No or minimal repigmentation (photographs graded 0 to 3)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)

Schallreuter 2002 (Continued)

Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Scharf 2006		
Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture in patients with osteoarthritis	
Participants	Patients: patients with symptomatic osteoarthritis of the knee Baseline comparability: yes (age, gender, pain duration)	
Interventions	Placebo: acupuncture on sites not regarded acupuncture sites Untreated: no acupuncture Experimental: acupuncture on sites regarded acupuncture sites (Co-intervention: standard medical care (physiotherapy and NSAIDs)).	
Outcomes	Success rate (at least 36% change from baseline WOMAC scores) WOMAC (Western Ontario and McMaster Universities osteoarthritis)index Physical and mental health (SF-36) Global patient assessment	
Notes	Patients in the no-treatment group took more medication, and received more sessions of physiotherapy (median 10) than the other groups (median 6).	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'block randomization with block size of 6, stratified by center, was computer-gener- ated by an independent statistician'
Allocation concealment?	Yes	'Centralised telephone procedure'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupressure)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Yes	Primary outcome specified in protocol

Scharf 2006 (Continued)

Free of other bias?	Unclear	See notes
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 681
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three criteria fulfilled

Scharff 2002

Methods	Design: three group parallel trial Purpose: examine the effect of minimal-contact thermal biofeedback and attention- placebo on children's migraine
Participants	Patients: children 7 to 17 years with migraine (minimum average 5 attacks a month) referred by neurologists Baseline comparability: yes (age, gender, headache index, days with headache, etc)
Interventions	Placebo: four 1-hour sessions within a period of 6 weeks with 'handcooling' sham biofeed- back and general discussion about 'their lives and headache' Untreated: no sessions Experimental: sessions of thermal biofeedback ('hand warming') (Co-intervention: ibuprofen and acetaminophen for headache. Instruction of 'not to change' medication habits)
Outcomes	Incidence of patients with decrease in headache index of 50% or more Pain (Headache Index, 4-point Likert scale) Temperature change Treatment credibility Child depression index (CDI) State-trait anxiety inventory for children (STAIC)
Notes	We have presented the outcome as no improvement for consistency of direction of outcomes. We excluded one patient from the numerators of both the placebo and no-treatment groups to be able to compute the result, as relative risk cannot be calculated when all patients in a group have a negative outcome.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'randomization table stratified by two age groups'
Allocation concealment?	Unclear	NS

Scharff 2002 (Continued)

Blinding? Treatment provider	No	Not described as double-blind (placebo/ biofeedback)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 23
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49, unclear allocation conceal- ment

Seer 1980

Methods	Design: three group parallel trial Purpose: examine the effect of meditation on hypertension
Participants	Patients: out-patients with essential arterial hypertension Baseline comparability: NS
Interventions	Placebo: relaxation sessions Untreated: no relaxation or meditation sessions Experimental: meditation sessions (Co-intervention: no)
Outcomes	Diastolic blood pressure (mm Hg) Heart rate
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS

Seer 1980 (Continued)

Blinding? Outcome assessor	Yes	' trained psychologist who was blind to all experimental conditions'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis-
		tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	tically significant)and no skewness (1.64 standard deviations does not exceed the

Senediak 1985

Methods	Design: four group parallel trial Purpose: examine the effect of r reduction programme	Purpose: examine the effect of rapid versus gradual scheduling of behavioural weight	
Participants	Patients: obese children Baseline comparability: yes		
Interventions	Untreated: no sessions (waiting l		
Outcomes	Weight (kg) % overweight Subcapsular skin fold thickness Normal % skin fold thickness Caloric intake Activity output Expectancy and programme eval	% overweight Subcapsular skin fold thickness Normal % skin fold thickness Caloric intake	
Notes			
Risk of bias			
Item	Authors' judgement	Authors' judgement Description	

Senediak 1985 (Continued)

Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural programme)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 21
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Shen 2000

Methods	Design: three group parallel trial Purpose: examine the effect of electroacupuncture for chemotherapy-induced emesis
Participants	Patients: female patients receiving chemotherapy Baseline comparability: yes for age, no for emesis with prior chemotherapy
Interventions	Placebo: superficial needling at a location different from PC6 or ST36, no 'de Qi', or electrical stimulation ('minimal needling') Untreated: no needling Experimental: needling at PC6 or ST36, de Qi -sensation, and electrical stimulation (Co-intervention: standard antiemetic regime and escape medication)
Outcomes	Use of antiemetic medication Total number of emesis episodes Proportion of emesis free days
Notes	Overall antiemetic escape medication was not reported. We report the use of prochlor- perazine as outcome, which we consider the relevant drug.

Shen 2000 (Continued)

Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random number table'
Allocation concealment?	Yes	'serially numbered, sealed, opaque en- velopes'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ electroacupuncture)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	No protocol available. Overall antiemetic escape medication was not reported. We report the use of prochlorperazine as out- come, which we consider the relevant drug.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 67
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Sibilio 1957

Methods	Design: three group parallel trial Purpose: examine the effect of promazine on the behaviour of chronic schizophrenics
Participants	Patients: woman chronic schizophrenic in-patients Baseline comparability: yes
Interventions	Placebo: capsule with no promazine Untreated: no capsule Experimental: capsule with promazine (Co-intervention: no)

Sibilio 1957 (Continued)

Outcomes	Behaviour change on Gardner Behavior Chart	
Notes	Relevant outcome data not accessible	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The double-blind technique was em- ployed throughout the study'
Blinding? Outcome assessor	Yes	'Those attendants who rated the patients' behavioral adjustment did not dispense medication and were unaware of the exper- imental group to which a patient was as- signed'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 62
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Sinaiko 1991

Methods	Design: four group parallel trial Purpose: examine the effect of low sodium diet or potassium supplementation on ado- lescent blood pressure
Participants	Patients: adolescents with systolic blood pressure above 109 mm Hg (boys) and 108 mm Hg (girls) Baseline comparability: yes
Interventions	Placebo: capsules Untreated: no capsules Experimental: - capsules with potassium -low sodium diet

Sinaiko 1991 (Continued)

	(Co-intervention: NS)		
Outcomes	Diastolic blood pressure (mm Hg) at three years Systolic blood pressure		
Notes	Data from the no-treatment group r authors. Randomisation not 1:1.	Data from the no-treatment group not published. Additional data received from the authors. Randomisation not 1:1.	
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	NS	
Allocation concealment?	Unclear	NS	
Blinding? Treatment provider	Yes	'The capsule treatment is a double-masked design'	
Blinding? Outcome assessor	Unclear	NS	
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS	
Free of selective reporting?	No	Data from the no-treatment group not published. Additional data received from the authors. Randomisation not 1:1.	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)	
Trial size > 49?	Yes	N = 87	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS	

Sipich 1974

Methods	Design: five group parallel trial Purpose: examine the effect of 'covert sensitization' on smoking behaviour
Participants	Patients: smokers Baseline comparability: yes (number of smoked cigarettes)

Sipich 1974 (Continued)

Interventions	Placebo: sessions of listening to illusory subliminal messages Untreated: -no sessions with continuous monitoring of smoking rates -no sessions with pre-post monitoring of smoking rates Experimental: -covert sensitization sessions (visualization of feelings of nausea and vomiting as imag- ining themselves smoking) -self control suggestion sessions (told to quit by their own effort) (Co-intervention: NS)
Outcomes	Mean number of cigarettes smoked per day
Notes	Standard deviation of untreated and placebo means estimated from t-test of baseline- post intervention change in the placebo group

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ covert sensitization)
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	No protocol available. Standard deviation of untreated and placebo means estimated from t-test of baseline-post intervention change in the placebo group
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Sommerness 1955

Methods	Design: three group parallel trial Purpose: examine the effect of reserpine on the behaviour of chronic mentally ill patients
Participants	Patients: chronic mentally ill men Baseline comparability: yes
Interventions	Placebo: pill with no reserpine Untreated: no pill Experimental: pill with reserpine (Co-intervention: yes, no group difference)
Outcomes	Behaviour change Blood pressure Weight
Notes	Relevant outcome data not accessible

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers table'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The hospital pharmacist alone knew which group received reserpine or placebo'
Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Relevant outcome data not accessible
Free of other bias?	Yes	
Trial size > 49?	Yes	N = 60
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Spanos 1995

Methods	Design: four group parallel trial Purpose: examine the effect of hypnosis on smoking reduction	
Participants	Patients: smokers Baseline comparability: yes (number of cigarettes smoked)	
Interventions	Placebo: sessions of listening to illusory subliminal messages Untreated: no sessions Experimental: -sessions of hypnosis -sessions called 'cognitive restructuring' with procedures identical to the hypnosis group but with no mention of hypnosis and no hypnotic induction (Co-intervention: NS)	
Outcomes	Mean number of cigarettes smoked per day	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ hypnosis)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 25
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Sprott 1993

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture on fibromyalgia	
Participants	Patients: in-patients suffering from fibromyalgia Baseline comparability: NS	
Interventions	Placebo: laser acupuncture with laser off Untreated: no acupuncture Experimental: laser acupuncture with laser on (Co-intervention: physio-, thermo- and electrotherapy. Fixed scheme at start of treat- ment. Paracetamol on demand, intake NS)	
Outcomes	Pain (VAS and pain threshold) Number of positive tender points	
Notes	Standard deviations (SD) on 10 cm pain visual analogue scale data not reported. SD estimated from another pain RCT (Lander 1993: SD ~ 3 cm)	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	No protocol available. Standard deviations (SD) on 10 cm pain visual analogue scale data not reported. SD estimated from an- other pain RCT (Lander 1993: SD ~ 3 cm)
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)

Trial size > 49?

N = 20

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

No

Sprott 1993 (Continued)

Stabholz 1991

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Methods	Design: three group parallel trial Purpose: examine the effect of sustained release delivery system of chlorhexidine on oral hygiene of patients with Down's syndrome
Participants	Patients: institutionalised with Down's syndrome Baseline comparability: NS
Interventions	Placebo: teeth coating without chlorhexidine Untreated: no teeth coating Experimental: teeth coating with chlorhexidine (Co-intervention: penicillin before scaling and polishing teeth, normal oral hygiene)
Outcomes	Plaque index Gingival index Papillary bleeding Plaque bacterial counts
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'The study was double-blind'
Blinding? Outcome assessor	Yes	' the examiner was not aware which treat- ment was given'
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64

Stabholz 1991 (Continued)

		standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Steinsbekk 2004

Methods	Design: four group parallel trial Purpose: examine the effect of homeopathy for upper respiratory infections (URTI) in children
Participants	Patients: children with upper respiratory infection Baseline comparability: yes (age, gender)
Interventions	Placebo: lactose pill Untreated: no pill Experimental: -Self-selected ultramolecular homeopathic pill -treatment by homeopath (Co-intervention: no)
Outcomes	Total URTI score Days with URTI Days with antibiotics Days with analgesic/antipyretic Visits to medical doctor Days with other illness, noises from the chest, or work absence due to ill child (all outcomes also as binary: proportion of children with days of)

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer'
Allocation concealment?	Yes	'central'
Blinding? Treatment provider	Yes	'This trial was of double-blind, randomized parallel group placebo controlled design'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Steinsbekk 2004 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 176
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Stewart 1991

Methods	Design: four group parallel trial Purpose: examine the effect of cognitive-behavioural therapy on oral hygiene
Participants	Patients: veteran out-patients with normal oral hygiene Baseline comparability: yes
Interventions	Placebo: sessions of lectures on non-disease aspects of dentistry Untreated: no sessions Experimental: sessions of cognitive-behavioural therapy (Co-intervention: NS)
Outcomes	Brushing frequency (per week) and Plaque Index Flossing frequency
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ cognitive-behavioural therapy)
Blinding? Outcome assessor	Yes	'The dentist that rated plaque levels was blind to each subject's assigned experimen- tal group'

Stewart 1991 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 50
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Drop-out > 15% or NS

Stransky 1989

Methods	Design: three group parallel trial Purpose: examine the effect of vitamin B6 on carpal tunnel syndrome
Participants	Patients: out-patients suffering from carpal tunnel syndrome Baseline comparability: NS
Interventions	Placebo: tablet without vitamin B6 (content: dextrose) Untreated: no tablet Experimental: tablet with vitamin B6 (Co-intervention: NS)
Outcomes	Number of patients who improved in symptoms Improvement in median and ulnar nerve conduction latency
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'We undertook a randomized, double- blind, placebo-controlled study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Stransky 1989 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	TT 1	
No signs of variance mequancy of skewness:	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 9

Straub 2001

Methods	Design: three group parallel trial Purpose: examine the effect of chiropractic care on jet lag
Participants	Patients: junior elite athletes Baseline comparability: NS
Interventions	Placebo: sham chiropractic manipulations for 19 days Untreated: no chiropractic sessions Experimental: chiropractic sessions (Co-intervention: NS)
Outcomes	Sleep disturbance (duration of sleep in hours, sleep onset in minutes, numbers of sleep bouts, movement and fragmentation index) Jet lag rating Mood (Profile of Mood States questionnaire)
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'table of random numbers'
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (chiroprac- tic manipulation/placebo manipulation)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome

Straub 2001 (Continued)

Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 10
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Sumaya 2001

Methods	Design: three group, three period, cross-over trial Purpose: examine the effect of bright light treatment on depression in institutionalised older adults
Participants	Patients: institutionalised older adults with moderate to severe depression (baseline scores on the Geriatric Depression Scale 11 to 20) Baseline comparability: not relevant
Interventions	Placebo: sessions with light treatment with 300 Lux for 30 minutes per day for 1 week Untreated: no light treatment Experimental: light treatment with 10,000 Lux (Co-intervention: NS)
Outcomes	Geriatric Depression Scale at day 5 of each treatment period
Notes	The outcome data was not available from the first period only, and was calculated as deriving from a parallel group trial.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS

Sumaya 2001 (Continued)

Blinding? Outcome assessor	Unclear	NS
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	The outcome data from this cross-over trial was not available from the first period only, and was calculated as deriving from a par- allel group trial.
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Tan 1982

Methods	Design: three group parallel trial Purpose: examine the effect of prophylactic behavioural-cognitive training on procedural acute pain
Participants	Patients: out-patients having to undergo a painful diagnostic procedure (knee arthro- gram) Baseline comparability: yes
Interventions	Placebo: procedural information and pain experience discussion without any pain control skills training Untreated: no information or training Experimental: behavioural-cognitive skills training for pain control (Co-intervention: NS)
Outcomes	Pain: McGill pain questionnaire Pain: radiologist's rating and videotaped pain behaviour Fear (self report and radiologist's rating) Discomfort (self report and radiologist's rating)
Notes	

Risk of bias

Tan 1982 (Continued)

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 24
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Tan 1986

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive-behaviour therapy on psycho-social problems and seizure control in epileptic patients
Participants	Patients: epileptic out-patients with psycho-social problems (anxiety, depression)and inadequate seizure control Baseline comparability: yes
Interventions	Placebo: sessions of supportive group counselling or discussion with no specific cognitive- behaviour therapy Untreated: no sessions Experimental: sessions of behavioural-cognitive therapy (Co-intervention: -'professional counselling or psychiatric treatment' to all but 6 patients -anticonvulsant medication. The difference in serum-level between the groups was not significant.)

Tan 1986 (Continued)

Outcomes	Number of patients with improvement in seizure frequency (frequency diary) Seizure rating by blinded observer Global rating of psycho-social adjustment	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural cognitive training)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 19
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trials size < 49

Tarcin 2004

Methods	Design: three group parallel trial Purpose: examine the effect of acustimulation in patients undergoing gastroscopy
Participants	Patients: out-patients undergoing gastroscopy Baseline comparability: yes (age, gender)
Interventions	Placebo: -electrical device attached to electrodes and acustimulation performed on a site not regarded acupuncture site -electrical device attached to electrodes but no acustimulatiuon performed Untreated: no electrical device attached nor acustimulation performed Experimental: acustimulation on point P6

Tarcin 2004 (Continued)

	(Co-intervention: no)
Outcomes	Proportion of patients scoring 1 to 4 on a VAS for nausea Proportion of patients scoring 1 to 4 on a VAS for difficulty of swallowing gastroscopy Proportion of patients scored 1 to 4 by gastrocopist on a VAS for nausea/retching Proportion of patient who accept re-gastroscopy
Notes	The results from the two placebo groups were combined

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acustimulation)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 235
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Tarrier 1998

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive behaviour therapy on positive symptoms in patients with chronic schizophrenia
Participants	Patients: people with chronic schizophrenia Baseline comparability: yes

Tarrier 1998 (Continued)

Interventions	Placebo: sessions of supportive counselling Untreated: no sessions Experimental: sessions of behavioural cognitive therapy (Co-intervention: standard care including medication, fixed dose)
Outcomes	Number of patients with improvement of positive symptoms by 50% or more Mean number and intensity of positive psychotic symptoms on Present state examination and Brief psychiatric rating scale

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	'stratified block randomised procedure'
Allocation concealment?	Yes	'sealed envelopes' ' carried out by a third party'
Blinding? Treatment provider	No	Not described as double-blind (placebo/be- havioural cognitive therapy)
Blinding? Outcome assessor	Yes	'Effort was made to blind the independent assessors' ' suggesting that blinding was satisfactory'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 54
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Tashjian 2006

Methods

Design: three group parallel trial Purpose: examine the effect of zolpidem on postoperative pain

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Tashjian 2006 (Continued)

Participants	Patients: out-patients undergoing knee arthroscopy Baseline comparability: yes (age, gender, preoperative pain score)
Interventions	Placebo: gelatin pills with no zolpidem Untreated: no pills Experimental: pills with zolpidem (Co-intervention: yes (ibuprofen + hydrocodone/acetaminophen))
Outcomes	Pain (0 to 10 VAS; mean daily postoperative) Pain (mean morning and evening postoperative) Fatigue (0 to 10 VAS; mean daily postoperative) Fatigue (mean morning and evening postoperative)

Notes

Risk	of	bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	' the surgeon was unaware if the patient was given zolpidem or placebo'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 43
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Theroux 1993	
Methods	Design: three group parallel trial Purpose: examine the effect of intranasal midazolam in facilitating suturing of lacerations in children
Participants	Patients: preschool children with lacerations visiting an emergency department Baseline comparability: yes
Interventions	Placebo: nasal spray without midazolam Untreated: no nasal spray Experimental: nasal spray with midazolam (Co-intervention: NS)
Outcomes	Anxiety (cry score) Parent satisfaction Heart rate Blood pressure Respiratory rate Pulse oximetry Cry score Motion score Struggle score
Notes	Data from placebo and no-treatment groups pooled. Contact with researchers provided unpooled data

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Allocation concealment?	Unclear	NS
Blinding? Treatment provider	Yes	'Blinding was maintained for the physician by having them leave the bedside for a short interval'
Blinding? Outcome assessor	Yes	'Cry was assessed by the physician' (See above)
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15% or NS
Free of selective reporting?	No	Data from placebo and no-treatment groups pooled. Contact with researchers provided unpooled data
Free of other bias?	Yes	

Theroux 1993 (Continued)

No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 32
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Thomas 1987

Methods	Design: 2 x 2 factorial design (positive or negative consultation x placebo tablet or no tablet) Purpose: examine the effect of positive consultation style and placebo tablet
Participants	Patients: out-patients attending a GP clinic with symptoms but without any physical signs and in whom no definite diagnosis could be made Baseline comparability: yes
Interventions	Placebo: tablet containing thiamine Untreated: no tablet Experimental: -positive consultation: firm diagnosis + good prognosis -negative consultation: no diagnosis and uncertain prognosis (Co-intervention: NS)
Outcomes	Number of patients who improved Doctor-patient contact Degree of communication Number of days before improvement Need for further treatment
Notes	

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	NS
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available

Thomas 1987 (Continued)

Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 200
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Thomas 1999

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive-behavioural intervention, and placebo, on pain associated with sickle cell disease
Participants	Patients: out-patients with sickle cell disease (type HbSS) Baseline comparability: yes (age, gender, hospital admissions for painful crises, etc)
Interventions	Placebo: one hourly session per week for two months of general discussions of the problems of living with sickle cell disease (attention-placebo) Untreated: no sessions Experimental: sessions of cognitive-behavioural therapy (Co-intervention: NS)
Outcomes	Pain (Short form of McGill pain questionnaire) General health questionnaire Coping strategies questionnaire Pain self-efficacy questionnaire Beliefs about pain control questionnaire Number of hospital and emergency admissions Duration of hospital stay
Notes	The result is probably unreliable because 38 of 97 patients dropped out (39%). In addition, 23 of 56 patients treated with placebo or active sessions were excluded because of failure to attend sessions or to complete assessments, no such exclusions described for no-treatment group.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random number table and was restricted to blocks of four'
Allocation concealment?	Unclear	'a sequence of labeled cards contained in sealed numbered envelopes'

Thomas 1999 (Continued)

Blinding? Treatment provider	No	Not described as double-blind (cognitive- behavioural intervention/placebo)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	Drop-out > 15%. The result is proba- bly unreliable because 38 of 97 patients dropped out (39%). In addition, 23 of 56 patients treated with placebo or active ses- sions were excluded because of failure to attend sessions or to complete assessments, no such exclusions described for no-treat- ment group.
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 40
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Thomas 2002a

Methods	Design: 2x2 factorial design with an additional randomisation for one arm Purpose: examine the effect of a home based exercise programme on knee pain, and to determine the contribution of the contact with a therapist in explaining the outcome
Participants	Patients: out-patients with knee pain recruited through a postal questionnaire Baseline comparability: yes (age, gender, pain, weight, etc)
Interventions	Placebo: tablet with dolomite (calcium and magnesium)twice weekly for two years Untreated: no tablets Experimental: -exercise (20-30 minutes daily, initiated by four 30 minutes' instruction sessions within the first two months in the patients' home, and follow up visits every six months). -telephone (monthly telephone contact) (Co-intervention: no information on use of analgesic drugs)
Outcomes	Pain (WOMAC osteoarthritis index, 0 to 20) Knee stiffness Disability

Thomas 2002a (Continued)

	General physical function (SF-36) Hospital anxiety and depression scale Isometric quadriceps muscle strength
Notes	Not 1:1 randomisation. Dropout rate: 23.7%. Results not presented for placebo and no- treatment, but authors provided additional data.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer generated lists in permuted blocks of 10, stratified by sex and age'
Blinding? Treatment provider	No	Not described as double-blind (home based exercise/placebo)
Blinding? Outcome assessor	Unclear	Patient reported outcome (interviewer was blinded)
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	No	No protocol available. Results not pre- sented for placebo and no-treatment, but authors provided additional data.
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 156
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Thomas 2002b

Methods	Same trial as Thomas 2002a, but results are presented as two subanalyses because there was one group of patients randomised to placebo or no treatment (see above), and another group randomised to telephone contact, exercise and placebo versus telephone contact and exercise.
Participants	See Thomas 2002a

Thomas 2002b (Continued)

Interventions	Placebo: dolomite (calcium and magnesium)twice weekly for two years Untreated: no tablets Experimental: see Thomas 2002a (Co-intervention: exercise and telephone contact)		
Outcomes	See Thomas 2002a		
Notes	See Thomas 2002a	See Thomas 2002a	
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Yes	'computer generated lists in permuted blocks of 10, stratified by sex and age'	
Blinding? Treatment provider	No	Not described as double-blind (home based exercise/placebo)	
Blinding? Outcome assessor	Unclear	Patient reported outcome (interviewer was blinded)	
Incomplete outcome data addressed? All outcomes	No		
Free of selective reporting?	No	No protocol available. Results not pre- sented for placebo and no-treatment, but authors provided additional data.	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)	
Trial size > 49?	Yes	N = 233	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No		

Tremeau 1992

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture on cervical maturation
Participants	Patients: women in 37th to 38th week of pregnancy and a Bishop score < 4 Baseline comparability: yes (Bishop score)

Tremeau 1992 (Continued)

Interventions	Placebo: acupuncture in relevant sites Untreated: no acupuncture (observational) Experimental: acupuncture 1 cm from relevant sites (Co-intervention: standard care)		
Outcomes	Bishop score		
Notes			
Risk of bias	Risk of bias		
Item	Authors' judgement	Description	
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)	
Blinding? Outcome assessor	Yes	' par un obstétricien ou une sage-femme, ne connaissant ni l'un, ni l'autre, le groupe de tirage au sort de la patiente'	
Incomplete outcome data addressed? All outcomes	No		
Free of selective reporting?	Unclear	No protocol available	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)	
Trial size > 49?	Yes	N = 64	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No		

Tritrakarn 2000

Methods	Design: five group parallel trial Purpose: examine the analgesic effect of EMLA cream (lidocaine and prilocaine)on pain associated with extracorporeal lithotripsy, and if effective, to examine which component (the cutaneous anaesthesia, the cream or the occlusive dressing) contributes to the anal- gesia
Participants	Patients: out-patients undergoing pain inducing extracorporeal lithotripsy because of renal stones Baseline comparability: yes

Tritrakarn 2000 (Continued)

Interventions	Placebo: no occlusive dressing -occlusive dressing without cream Untreated: no dressing or cream Experimental: 3 groups received occlusive dressing with and without cream (Co-intervention: no)	
Outcomes	Pain (numerical verbal pain scale, 0 to 100)	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Blinding? Treatment provider	Yes	' A randomized, double-blind, crossover study'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 82
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Tsay 2003

Methods	Design: three group parallel trial Purpose: examine the effect of acupressure on quality of sleep
Participants	Patients: in-patients with end stage renal disease Baseline comparability: yes
Interventions	Placebo: acupressure on sites not regarded acupressure sites Untreated: no acupressure Experimental: acupressure on sites regarded acupressure sites

Tsay 2003 (Continued)

	(Co-intervention: standard medical care)
Outcomes	Pittsburgh sleep quality index Sleep log
Notes	The trial report does not state the number of patients allocated to each group. We assumed that out of 98 patients in the three-armed trial 32 patients entered the placebo group and 32 patients the no-treatment group

Risk of bias

Item	Authors' judgement	Description
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	No	No protocol available. The trial report does not state the number of patients allocated to each group. We assumed that out of 98 patients in the three-armed trial 32 patients entered the placebo group and 32 patients the no-treatment group
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 64
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Tsay 2004

Methods	Design: three group parallel trial Purpose: examine the effect of acupressure on fatigue in patients with end-stage renal disease
Participants	Patients: patients with end-stage renal disease Baseline comparability: yes
Interventions	Placebo: acupressure on sites not regarded acupressure sites Untreated: no acupressure Experimental: acupressure on sites regarded acupressure sites

Tsay 2004 (Continued)

	(Co-intervention: standard medical care)	
Outcomes	Revised Piper fatigue Scale Fatigue (100 mm VAS) Pittsburgh Sleep Quality Index Beck Depression Inventory	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 71
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Tuomilehto 1980

Methods	Design: three group parallel trial Purpose: examine the effect of high fibre intervention (guar gum) on serum lipoproteins and body weight
Participants	Patients: out-patients with hypercholesterolaemia Baseline comparability: NS
Interventions	Placebo: granule with no guar gum (wheat flower) Untreated: no granule Experimental: granule with guar gum (Co-intervention: diet instructions: decrease alcohol and fat, increase complex carbohy- drates)

Tuomilehto 1980 (Continued)

Outcomes	Serum-cholesterol: total (mmol/l) Serum-cholesterol: high density lipoprotein Serum-triglyceride Weight Blood pressure		
Notes			
Risk of bias			
Item	Authors' judgement	Description	
Blinding? Treatment provider	Yes	' studied in a double-blind controlled trial'	
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome	
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%	
Free of selective reporting?	Unclear	No protocol available	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)	
Trial size > 49?	No	N = 22	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

Turner 1979

Methods	Design: five group parallel trial Purpose: examine the effect of paradoxical intention therapy on insomnia
Participants	Patients: out-patients suffering from insomnia Baseline comparability: yes (sleep parameters)
Interventions	Placebo: sessions of 'quasi-desensitization' (neutral images paired with bedtime activity) Untreated: no sessions (waiting list) Experimental: sessions of -paradoxical intention therapy: instructions to remain awake as long as possible and presented with the true theoretical background

Turner 1979 (Continued)

	-stimulus control: practical advice on bed time activities -progressive relaxation: training in relaxation techniques (Co-intervention: hypnotics, comparable doses between groups)
Outcomes	Sleep latency (min) Returning to sleep difficulty Restedness rating Falling asleep difficulty Hours of sleep Drug usage per week

Notes

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind (placebo/ paradoxical intention)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 20
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Tyler 1946

Methods	Design: three group parallel trial Purpose: examine the prophylactic effect of placebo and various drugs on seasickness
Participants	Patients: soldiers undergoing amphibious training Baseline comparability: NS

Tyler 1946 (Continued)

Interventions	Placebo: lactose capsules Untreated: no capsules Experimental: various belladonna alkaloid and barbiturate preparations (Co-intervention: NS)
Outcomes	Number of patients with seasickness
Notes	The randomisation procedure was in principle open to selection bias, however, the allocation took place openly under full military discipline so we do not think selection bias was likely.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'cards from deck so stacked as to ensure a random distribution'
Allocation concealment?	Unclear	See notes
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 563
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Vlaeyen 1996

Methods	Design: three group parallel trial Purpose: examine the effect of cognitive therapy on fibromyalgia
Participants	Patients: out-patients with fibromyalgia Baseline comparability: yes
Interventions	Placebo: sessions of group discussions on pain experience + educational programme on pain Untreated: no sessions

Vlaeyen 1996 (Continued)

	Experimental: sessions of cognitive therapy + educational programme on pain (Co-intervention: NS)
Outcomes	Pain (McGill pain questionnaire) Pain: coping, control, behaviour % positive responders Relaxation Tension Catastrophing Activity Obsessive-compulsive Fear Depression

Notes

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind (placebo/ cognitive therapy)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	Yes	N = 79
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Walton 1993

Methods

Design: three group parallel trial

Purpose: examine the prophylactic effect of penicillin on post treatment symptoms following root canal treatment for asymptomatic periapical pathosis

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Walton 1993 (Continued)

Participants	Patients: out-patients undergoing root canal treatment Baseline comparability: NS	
Interventions	Placebo: tablets without penicillin Untreated: no tablets Experimental: tablets with penicillin (Co-intervention: NS)	
Outcomes	Number of patients in pain Swelling Side effects	
Notes		
Risk of bias		
Item	Authors' judgement Description	
Blinding? Treatment provider	No	Not described as double-blind

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 54
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Wang 1997

Methods	Design: four group parallel trial Purpose: examine the effect of transcutaneous acupoint electrical stimulation (TAES) on postoperative analgesic requirement
Participants	Patients: patients having undergone lower abdominal surgical procedures Baseline comparability: yes

Wang 1997 (Continued)

Interventions	Placebo: TAES without electrical stimulation Untreated: no TAES Experimental: TAES with electrical stimulation (low and high) (Co-intervention: standard operational procedures)
Outcomes	Total opoid requirement (in equivalents of mg hydromorphone)in 24 hours Morphine (mg) delivered by PCA (patient controlled analgesia)device Number of times patients used PCA device (patient controlled analgesia) Supplemental opioid analgesics (i.m.) Supplemental oral analgesics Duration of PCA Duration of use of TAES Duration of stay in postanaesthesia care unit Duration of hospital stay Pain, 100 mm VAS Fatigue, 100 mm VAS Follow-up questionnaire

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'computer-generated randomization se- quence'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ TAES)
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	Yes	N = 51
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	

Watzl 1986

Methods	Design: 2 x 2 factorial design Purpose: examine the effect of strict control and placebo on relapse rate of abstinent alcoholics
Participants	Patients: woman in-patients attending an alcoholism clinic Baseline comparability: yes
Interventions	Placebo: injections with saline Untreated: no injections Experimental: -strict external control of alcohol abstinence -no strict external control of alcohol abstinence (Co-intervention: stay at a clinic with unspecified 'complex and extensive treatment program', e.g. in a few cases patients received 'liver preparation')
Outcomes	Number of abstinent drinkers

Notes

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind (placebo/ex- perimental)
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	Yes	N = 70
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Allocation not clearly concealed

Weingaertner 1971

Methods	Design: three group parallel trial Purpose: examine the effect of aversive stimulation (self-administered electric shocks) on hallucinatious schizophrenic patients
Participants	Patients: schizophrenic in-patients (men) with auditory hallucinations Baseline comparability: yes

Weingaertner 1971 (Continued)

Interventions	Placebo: patients equipped with a device that did not produce an electric shock and instructed to activate it when hallucinating (told that some people could not feel the shock) Untreated: not equipped with a device to induce electric shock Experimental: equipped with a device that did produce an electric shock and instructed to activate it when hallucinating (Co-intervention: -medication (type and dose NS, four patients changed) -other experimental intervention (type NS, interference deemed implausible by authors) -group and milieu therapy (type, frequency NS))
Outcomes	Brief Psychiatric Rating Scale: hallucination scale Patient Data Sheet Symptom checklist Ward personnel comments

Notes

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind (placebo/ electric shock)
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 30
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Werntoft 2001

Methods	Design: three group parallel trial Purpose: examine the effect of acupressure on nausea and vomiting during pregnancy
Participants	Patients: pregnant women with nausea without treatment Baseline comparability: not for week of pregnancy (yes for age, week of pregnancy at start of nausea)

Werntoft 2001 (Continued)

Interventions	Placebo: acupressure waistband at the upper side of the wrist (not P6) for two weeks Untreated: no acupressure Experimental: acupressure waistband at P6 (Co-intervention: no)
Outcomes	Nausea (100 mm VAS) after 2 weeks Vomiting
Notes	The drop-out rate was 25% (20 out of 80). Trial probably stopped prematurely before inclusion of the planned 300 women

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	each woman 'drew an envelope from a box'
Allocation concealment?	Yes	The drawn envelopes had 'the same ap- pearance but different content', and 'The women were asked not to open the enve- lope until returning home'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupressure)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	No	N = 40
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Whittaker 1963			
Methods	Design: three group parallel trial Purpose: examine the effect of discontinuing medication with perphenazine in schizophrenia		
Participants	Patients: chronic schizophrenic in-patients on perphenazine Baseline comparability: for age and length of hospital stay		
Interventions	Placebo: liquid solution with no perphenazine (content NS) Untreated: no liquid solution (observational group) Experimental: liquid solution with perphenazine (Co-intervention: no other psychotropic drugs allowed)		
Outcomes	Number of patients with major relapse: need for known active medication Minor relapse: deterioration on symptom scales (psychiatric rating scale & Fergus Falls Behaviour Rating Scale)		
Notes			
Risk of bias	Risk of bias		
Item	Authors' judgement Description		
Blinding? Treatment provider	Yes	'the trial was blind in that only the phar- macist knew which bottles were active'	
Incomplete outcome data addressed? All outcomes	No		
Free of selective reporting?	Unclear	No protocol available	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)	
Trial size > 49?	No	N = 26	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49	

Wilcock 2008

Methods	Design: three group cross-over trial Purpose: examine the effect of nebulised furosemide and placebo on breathlessness
Participants	Patients: patients with cancer and breathlessness Baseline comparability: cross-over trial

Wilcock 2008 (Continued)

Interventions	Placebo: inhalation of saline Untreated: no inhalation Experimental: inhalation of furosemide (Co-intervention: standard cancer treatment
Outcomes	Number reading test (number read per breath) Number reading test (total number) Arm exercise test Duration of arm test Borg Score at maximum equivalent work load Change in spirometric values
Notes	Cross-over trial. data from 1 period not available.

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	Yes	'The object of the current randomised, double-blind, placebo-controlled, cross- over study'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Unclear	Cross-over trial. Data from 1 period not available.
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 30
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Williams 1988

Methods	Design: three group parallel trial Purpose: examine the effect of hypnosis on smoking cessation
Participants	Patients: smokers that had attended one smoking program before Baseline comparability: NS

Williams 1988 (Continued)

Interventions	Placebo: one session in which the reason for smoking and attempts to stop were discussed Untreated: no session Experimental: single hypnosis session (Co-intervention: NS)
Outcomes	Number of abstinent smokers Mean number of cigarettes smoked per week
Notes	All 20 patients in the placebo and 20 patients in the no-treatment group smoked at post intervention. Data extracted as if one patient in each group did not smoke. This was done due to overcome software incapacity in computing data with no successes.

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind (placebo/ hypnosis)
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)
Trial size > 49?	No	N = 40
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Wilson 1980

Methods	Design: three group parallel trial Purpose: examine the effect of disulfiram and placebo implants on alcoholism
Participants	Patients: alcoholics Baseline comparability: NS
Interventions	Placebo: implants without disulfiram Untreated: no implants Experimental: implants with disulfiram (Co-intervention: NS)

Wilson 1980 (Continued)

Outcomes	Number of abstinent drinkers Mean time to first alcoholic consumption		
Notes	Patients were randomised to placebo and no treatment in a 4:1 ratio		
Risk of bias	Risk of bias		
Item	Authors' judgement	Description	
Blinding? Treatment provider	Yes	'Assignment to the disulfiram and placebo conditions was double-blind'	
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome	
Incomplete outcome data addressed? All outcomes	No		
Free of selective reporting?	Unclear	No protocol available	
Free of other bias?	Yes		
No signs of variance inequality or skewness?	Unclear	Not relevant (binary outcome)	
Trial size > 49?	Yes	N = 50	
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No		

Witt 2005

Methods	Design: three group parallel trial Purpose: examine the effect of acupuncture for osteoarthritis of the knee
Participants	Patients: patients with symptomatic osteoarthritis of the knee Baseline comparability: yes (WOMAC score)
Interventions	Placebo: acupuncture on sites not regarded acupuncture sites Untreated: no acupuncture Experimental: acupuncture on sites regarded acupuncture sites (Co-intervention: standard medical care. All patients were allowed to take non-steroid anti-inflammatory drugs if necessary)
Outcomes	WOMAC (Western Ontario and McMaster Universities osteoarthritis)index Disability (Pain disability index) Physical and mental health (SF-36) Pain (questionnaire for assessing the emotional aspects of pain) Depression (ADS depression scale)

Witt 2005 (Continued)

	Days with limited function Days in pain (patient diary) Days with medication in weeks 5-8 (patient diary)
Notes	Patients in the no-treatment group took medication on 5.8 days whereas the placebo group did so on 4.6 days (weeks 5 to 8). SE values were provided in the original publication and these values were converted to SD for analysis in the review.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random list generated with Samp Size 2.0'
Allocation concealment?	Yes	'centralised telephone randomisation pro- cedure'
Blinding? Treatment provider	No	Not described as double-blind (placebo/ acupuncture)
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Yes	Primary outcome specified in protocol
Free of other bias?	Unclear	Patients in the no-treatment group took medication on 5.6 days whereas the placebo group did so on 4.6 days (weeks 5 to 8).
No signs of variance inequality or skewness?	Yes	No variance inequality (F-test not statis- tically significant)and no skewness (1.64 standard deviations does not exceed the mean)
Trial size > 49?	Yes	N = 140
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	Yes	All three categories fulfilled

Wo	ciechow	ski	1984
WU	CICCIIOW	21/1	1,01

Methods	Design: five group parallel trial Purpose: to demonstrate a) therapist bias and b) that a double blind design is feasible in psychotherapy
Participants	Patients: women out-patients with tension headache Baseline comparability: no (pre treatment headache index score)
Interventions	Placebo: sessions with 'concentration therapy' and -positive therapist expectations -negative therapist expectations Untreated: no sessions Experimental: sessions with muscular relaxation therapy and -positive therapist expectations -negative therapist expectations (Co-intervention: NS)
Outcomes	Pain (Headache index score) Global therapist judgement of improvement Global patient judgement of improvement

Notes

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	Yes	'the double blind design'
Blinding? Outcome assessor	Unclear	Not relevant as patient reported outcome
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant) or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 21
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Woods 2005

Methods	Design: three group parallel trial Purpose: examine the effect of therapeutic touch on patients with dementia
Participants	Patients: patients with Alzheimer's disease Baseline comparability: yes (age, gender, degree of dementia)
Interventions	Placebo: mimic treatment that resembled therapeutic touch to the naive observer (no attempt to enter 'a quiet meditative state instead the practitioner did mental calcula- tions). Untreated: no therapeutic touch Experimental: therapeutic touch (Co-intervention: standard medical care).
Outcomes	Modified Agitated Behavior Rating Scale (ABRS) Revised Memory and Behavior checklist

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random numbers table'
Allocation concealment?	Unclear	'Envelopes containing group assignments were opened just prior to the intervention to ensure blinding of all concerned during the pre-test measurement'
Blinding? Treatment provider	Yes	'Using a double-blind (masked), three- group experimental pre-test/post-test de- sign'
Blinding? Outcome assessor	Yes	'Six blind observers collected all of the data on a Behavior Monitoring Chart (BMC)'
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	No	Either variance inequality (F-test statisti- cally significant)or skewness (1.64 standard deviations exceeds the mean)
Trial size > 49?	No	N = 38

Woods 2005 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Yan 2005		
Methods	Design: three group parallel trial Purpose: study the effect of segmental vs. innocuous electrical stimulation for chronic pain relief	

Participants	Patients: patients with first acute stroke Baseline comparability: NS
Interventions	Placebo: stimulation from electrical stimulation device with disconnected circuit and standard rehabilitation Untreated: standard rehabilitation only Experimental: functional electrical stimulation and standard rehabilitation (Co-intervention: standard rehabilitation program)
Outcomes	Composite spasticity scale (CSS) Maximum isometric voluntary contraction (MIVC) Walking ability (Up and Go (TUG) test)

Notes

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	'random number produced by Jensen's computerized method of minimization'
Blinding? Treatment provider	No	Described as single-blind (placebo/electri- cal stimulus device)
Blinding? Outcome assessor	Yes	' the assessor was blinded to the nature of intervention'
Incomplete outcome data addressed? All outcomes	Yes	Drop-out < 15%
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
Trial size > 49?	No	N = 28

Yan 2005 (Continued)

Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49
Yates 1988		
Methods	Design: three group parallel trial Purpose: examine the effect of chiropractic	treatment on blood pressure
Participants	Patients: out-patients with hypertension an Baseline comparability: NS	d thoracic subluxation
Interventions	manipulative procedure Untreated: no session Experimental: session with a 'chiropractic manipulative procedure	ng device' without it performing the essential adjusting device' performing the essential and untreated group received hypertensive
Outcomes	Diastolic blood pressure reduction (mm Hş Anxiety	g)
Notes		

Risk of bias

Item	Authors' judgement	Description
Blinding? Treatment provider	No	Not described as double-blind (placebo/ chiropractic procedure)
Incomplete outcome data addressed? All outcomes	No	
Free of selective reporting?	Unclear	No protocol available
Free of other bias?	Yes	
No signs of variance inequality or skewness?	Unclear	Not relevant (not naturally positive contin- uous outcomes e.g. change)
Trial size > 49?	No	N = 14
Clearly concealed allocation + trial size > 49 + drop-out max 15%?	No	Trial size < 49

Outcomes: The first outcome listed is the one extracted for the review (all major outcomes for each trial are listed).

Placebo interventions for all clinical conditions (Review)

NS: not stated. VAS: visual analogue scale. EMG: electromyography. GP: general practitioner. Hb: haemoglobin

Characteristics of excluded studies [ordered by study ID]

The 'placebo intervention' was 'compressed air with freon' which, sprayed on skin, lowers temperature: impure placebo. All patients underwent a placebo run-in period and only those not responding were included: not relevant participants.
Dropout was > 50%.
Randomisation was not described in the original paper. In a subsequent correspondence the authors described he method of randomisation: 'put three pieces of paper into a hat, each with the number 1, 2 or 3 and then lrew a number each time a subject arrived and then assigned them accordingly '. There was no concealment of allocation. The number of patients in the placebo group was 105, in the no-treatment group 75.
Pain was induced experimentally.
Not explicitly a randomised trial.
Not a randomised study.
nclusion of patients to no-treatment groups started later than inclusion to active/placebo.
Patients received payment.
No explicit randomisation between placebo and no-treatment.
low self-esteem is not regarded a clinical problem.
Male nursing home residents were not randomised, but 'assigned to the groups'. The proportion of males liffered between the compared groups from 10% to 24%.
Allocation to placebo and no-treatment was not explicitly random.
Pain was induced experimentally.
The outcome in this study of chronic schizophrenia was reaction-time which we regard not clinically relevant.
The outcome was not clinical.
The trial studied the impact of vitamin supplements on the intelligence of normal schoolchildren, not regarded clinical study.
A a bin a bi

Bergmann 1994	No untreated group.
Beutler 1988	The 'placebo' intervention consisted in 'paranormal healing at a distance', directed at a patient behind a screen, however the patients in the no treatment group also sat behind a screen, so the patient in both groups experienced the same: unacceptable no treatment group.
Bierman 1997	The outcome in this alcohol addiction trial was 'sleep quality': regarded not clinically relevant.
Björkstén 1986	Randomisation not mentioned.
Blackwell 1972	Participants were 'medical students': not a clinical study.
Blanchard 1978	6/30 patients were reallocated after randomisation.
Borden 1989	The clinically relevant outcomes (parents' and teachers' ratings) were not blinded.
Borkovec 1975	The participants were college students screened by group test program and receiving research credit for partic- ipation: not a clinical setting.
Bornstein 1973	The accumulated weight loss of the patients in the placebo group was 'positively reinforced': impure placebo.
Bouchet 1996	The participants were normal subjects.
Brown 1999	Pain was induced experimentally.
Buckalew 1972	The participants were normal subjects.
Bullock 1999	Drop out rate > 50%.
Bush 1985	Allocation of participants to the different groups of the trial was not concealed.
Butler 1984	The placebo intervention consisted in ordering difficult tasks for social phobics and practicing these tasks in ascending order: impure placebo.
Carlson 1993	The outcomes were 1) a questionnaire assessing the boys' attributions and 2) performance at an experimental word puzzle test: regarded not clinically relevant.
Carpenter 1994	Subjects were paid for participation.
Chambless 1984	Drop-out rate > 50%.
Chen 1999	Unclear wether the trial was randomised. Authors contacted by e-mail for clarification but did not respond.
Cole 1983	Randomisation not stated.
Corletto 1999	Placebo group got active treatment after 40 days.

Corson 1994	The placebo intervention implied pain inducing needle sticks: not a pure placebo intervention.
Cottraux 1986	Placebo group received not only a placebo intervention but also advice to reduce alcohol intake which is associated with smoking: impure placebo.
Cram 1980	The no treatment group sessions ('chart headaches only') also included discussions of 'situational themes': unacceptable no treatment group.
Cristofalo 1999	Normal subjects (athletes with no diagnosis of asthma).
Cullhed 1961	Allocation by day of admission.
Dahlquist 1986	Placebo group children were removed from parents. This was probably in itself anxiety inducing: impure placebo.
Daley 2007	According to the protocol patients received money for entering the trial.
Diamond 1995	The placebo used was saline. It is likely that saline has a physiological effect on congested nose, and is sold 'over the counter' in Denmark for this purpose: impure placebo.
Disney 1988	Not explicitly a randomised trial.
Dobia 1985	The 'placebo intervention' was relaxation therapy which was an integrated part of the experimental intervention: not a relevant placebo procedure.
Dundee 1988	Patients allocated by day of admittance.
Egbert 1964	The 'placebo' intervention in post-operative patients having had intra-abdominal surgery included instructions concerning pain modulating behaviour, e.g. how actively to relax abdominal muscles: impure placebo.
Eickholz 2002	Split mouth design. Teeth were randomised, not patients or treatment periods.
Elkin 1985	No untreated group.
Feather 1972	A non-clinical experimental setting where pain was induced by heat.
Fevery 1990	The trial was designed to measure outcome after 6, 12 and 24 months. The placebo intervention was only comparable to the no treatment group the first 8 weeks: not a relevant comparison.
Fillmore 1992	A non-clinical experimental setting with normal subjects.
Fillmore 1994	A non-clinical experimental setting with normal subjects.
Fillmore 1994b	A non-clinical experimental setting with normal subjects.
Flor 1983	Untreated group received co-intervention not given to the placebo group.

Fuller 1986	No untreated group.
Gam 1998	The placebo group received massage and exercise, the no treatment group did not: differential co-intervention.
Gelfand 1963	The subjects in this non-clinical experimental pain trial were nursing students.
Goodale 1990	No clear indication in the trial report that 'the reading group' constituted a placebo group.
Gowdey 1967	'Normal subjects': not a clinical problem.
Gregorio 1996	The trial was designed to measure outcome after 6, 12 and 18 months. The placebo intervention was only comparable to the no treatment group the first 6 weeks: not a relevant comparison.
Gregory 1983	The study was 'designed to investigate whether elderly hospitalized people can improve their performance if they are permitted a second attempt at the Set Test, a verbal fluency task': not a therapeutical clinical study.
Gryll 1978	The allocation of participants was not explicitly stated to be random.
Haake 2007	No no-treatment group. The group receiving acupuncture was not treated with conventional treatment given to the no-acupuncture group.
Hale 1986	Allocation of participants was done in 'orderly sequence' following randomisation of the first patient.
Hall 1994	'Subjects reimbursed \$20 at weeks 3 and 8 and \$35 at week 12': participants paid.
Hargreaves 1983	This laboratory study was an uncontrolled trial.
Hayden 1996	The placebo used was saline. It is likely that saline has a physiological effect on congested nose, and is sold 'over the counter' in Denmark for this purpose: impure placebo.
Herth 2000	Placebo not explicitly mentioned.
Hogarty 1973	No untreated group.
Huber 1986	The clinician who decided to remove the placenta knew which patients were in the untreated group: not blindly assessed.
Jensen 1991	The trial was a 'laboratory study' with normal subjects: not a clinical study.
Kalman 1998	The placebo group received dietary advice which was withheld from the no-treatment group.
Kanner 1999	The placebo treatment included 'intensive smoking-cessation sessions' which was withheld from the the no- treatment group.
Kelley 1976	Subjects were normal children: not a clinical study.

Khandwala 1997	According to personal communication with trial report authors, the vehicle was under suspicion of having an effect that was not only due to placebo and is actually sold 'over the counter' in the USA: impure placebo.
Klosko 1990	Patients in the untreated group continued on anxiolytic medication. Patients in the placebo group discontinued their medication. The groups in this anxiety trial are not comparable.
Korner 1982	No randomisation to placebo and untreated.
Lasagna 1954	The study was not randomised.
Levine 1980	The outcome was test anxiety which is not considered a clinically relevant outcome.
Liberman 1964	Not a randomised study.
Lopez 1999	Randomisation was conducted 'with due precaution to avoid differences among the subgroups in the children's mean ages and IQs'.
Lorr 1962	Drop-out rate > 50%.
Lujan 1992	The headache was induced: an experimental setting.
Lynn 1983	The placebo procedure is described as being of 'an active nature': impure placebo.
Manner 1987	7/20 placebo treated patients receive sedative anticholinergic premedication (glycopyrrolate)compared to 0/18 untreated patients. Also unclear whether the untreated patients were part of the randomization: differential co-intervention.
Marchand 1993	Patients were allocated through 'pseudo-random assignment'. Contact to the authors clarified that this meant that randomisation was based on drawing pieces of paper with group assignments from a hat. There was no concealment of allocation.
McGrath 1988	Suggestions to reduce impact of possible triggers in 'untreated group': unacceptable no treatment group.
Meehan 1985	The no treatment group took prescribed and escape analgesics, the placebo group only escape analgesics.
Montgomery 1996	A non-clinical experimental study with normal subjects.
Nikolaou 1998	Not a randomised trial.
Peart 1977	No randomisation to untreated and placebo.
Penman 1956	Post-randomisation reallocations took place.
Pollo 2001	Allocation to placebo and no-treatment was not explicitly random.
Price 1999	Healthy volunteers. Pain was induced experimentally.

Rampes 1997	Drop-out rate 33/58=56% [> 50%].
Reich 1990	The participants were normal older subjects: not a clinical study.
Robertson 1991	'All subjects were paid'.
Rodriguez 1997	Post randomisation patient re-allocation took place: 69 patients were randomised to the untreated group and but results were collected from 78 patients.
Roehrich 1993	This alcohol study had neuropsychological and psychological test variables as outcomes: regarded not clinically relevant.
Roelofs 2000	Paid healthy volunteers. Pain was induced experimentally.
Roos 1969	The placebo intervention was designed to include active components: not a pure placebo.
Roth 1986	Normal subjects.
Rustøen 1998	Placebo not explicitly mentioned.
Sarles 1977	Not a randomised trial.
Sartor 1980	Not properly randomised.
Shaw 1974	The placebo intervention consisted of listening to 'audiotapes designed to help persons cope with everyday fears and anxieties': not a pure placebo.
Sheikh 1986	The participants were older 'normal' volunteers with 'age associated memory impairment' : not a clinical study.
Silvestri 1977	Anxiety is the only outcome considered clinically relevant in this trial of the effect of implosive therapy for emotionally disturbed retardates, however, anxiety was not recorded in the no treatment group.
Skovlund 1991	No untreated group.
Smith 2002	The so-called 'no treatment' group (but not the placebo group) received advice about changes in diet and the use of vitamin B6.
Spanos 1988	'All were paid \$15 for their participation'.
Staats 1998	Pain induced by 'hand exposure to ice water': not a clinical study.
Stanley 1989	Not blindly assessed.
Suchman 1992	Not blindly assessed.
Tashkin 1977	Not a randomised trial.

Taylor 1977	Anti-hypertensive drugs were given at variable dose as co-intervention. More patients in the placebo group than in the untreated group were increased in dose: differential co-intervention.
Vacc 1980	The investigation studied the effect of various interventions on maladaptive behaviour of otherwise normal children: not regarded a clinical study.
Van Damme 1998	Healthy volunteers.
Volweider 1981	Placebo procedure included physical exercise: not a pure placebo.
Weber 1975	Averaged Electroencephalic audiometry (AEA) thresholds was the outcome in this study of CNS stimulant medication on children with minimal brain damage: outcome regarded not clinically relevant.
Weintraub 1992	The placebo period (week 160 to 190) was followed by the untreated period (week 190 to 210), (no randomi- sation).
Windle 2001	Allocation of patients by alternation.
Winnan 1982	The Bernstein test is a diagnostic test. Pain was induced by infusion of acid: not a therapeutic clinical study.
Worner 1992	Drop out rate > 50%.
Zeisset 1968	The outcome was 'interview anxiety' which was not considered clinically relevant as a measure for general anxiety.

Impure placebos: interventions with clearly specified contents or procedures that have an effect which, with considerable likelihood, goes beyond the effect of the treatment ritual. Such interventions are mostly 1) physical or pharmacological vehicles (see, e.g., Khandwala 1997), or 2) psychological 'placebos' with clear behavioural-cognitive therapeutical elements (see, e.g., Bornstein 1973) or direct health related advice (see, e.g., Cottraux 1986).

Characteristics of studies awaiting assessment [ordered by study ID]

Shin 2005

Methods	Randomised trial
Participants	Women with hyperemesis gravidarum
Interventions	P6 acupuncture; placebo acupuncture; no acupuncture
Outcomes	Unclear
Notes	Reported in Korean

Placebo interventions for all clinical conditions (Review)

Characteristics of ongoing studies [ordered by study ID]

Barret 2007

Trial name or title	PEP trial
Methods	Randomised trial
Participants	Out-patients with common cold
Interventions	Placebo Standard and enhanced patient-provider interaction Echinacea
Outcomes	Area under time severity curve based on the Wisconsin Upper Respiratory Symptom Survey
Starting date	NS
Contact information	bruce.barret@fammed.wisc.edu
Notes	

DATA AND ANALYSES

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Binary outcomes	44	6041	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.99]
2 Continuous outcomes	158	10525	Std. Mean Difference (IV, Random, 95% CI)	-0.23 [-0.28, -0.17]

Comparison 1. Main analysis: overall pooled analyses

Comparison 2. Main analysis: patient-reported or observer-reported outcomes

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Patient-reported binary outcomes	31	4046	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.00]
2 Observer-reported binary outcomes	13	1995	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.85, 1.02]
3 Patient-reported continuous outcomes	109	8000	Std. Mean Difference (IV, Random, 95% CI)	-0.26 [-0.32, -0.19]
4 Observer-reported continuous outcomes	49	2513	Std. Mean Difference (IV, Random, 95% CI)	-0.13 [-0.24, -0.02]

Comparison 3. Main analysis: clinical conditions investigated in three trials or more

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Binary outcomes	21		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Pain (incidence)	6	1207	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.77, 1.11]
1.2 Depression (relapse prevention)	3	152	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.78, 1.34]
1.3 Nausea	6	732	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.82, 1.07]
1.4 Smoking (relapse, self report or biochemical measure)	6	887	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.73, 1.10]
2 Continuous outcomes	119		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 Pain (VAS, ordinal scales, McGill score, escape medication, WOMAC index; absolute or improvement)	60	4154	Std. Mean Difference (IV, Random, 95% CI)	-0.28 [-0.36, -0.19]
2.2 Insomnia (sleep onset latency in min, Pittsburgh sleep quality index change)	6	164	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.50, 0.12]

Placebo interventions for all clinical conditions (Review)

2.3 Hypertension (diastolic, mm Hg; absolute or improvement)	10	308	Std. Mean Difference (IV, Random, 95% CI)	-0.17 [-0.46, 0.12]
2.4 Nausea (VAS, Rhodes Inventory of Nausea and Vomiting, escape medication)	7	452	Std. Mean Difference (IV, Random, 95% CI)	-0.25 [-0.46, -0.04]
2.5 Smoking (cigarettes per day, self report)	3	703	Std. Mean Difference (IV, Random, 95% CI)	-0.53 [-1.29, 0.23]
2.6 Phobia (fear of snakes and spiders: snake slides test, behavioral avoidance test;	3	57	Std. Mean Difference (IV, Random, 95% CI)	-0.63 [-1.17, -0.08]
absolute or improvement)				
2.7 Asthma (bronchoconstriction: FEV1 or PEF; absolute or improvement)	4	203	Std. Mean Difference (IV, Random, 95% CI)	-0.35 [-0.70, -0.01]
2.8 Obesity (kg, pounds,%; absolute or improvement)	8	188	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.57, 0.17]
2.9 Depression (Hamilton's score, Beck Depression Inventory, Geriatric Depression	8	324	Std. Mean Difference (IV, Random, 95% CI)	-0.25 [-0.55, 0.05]
Scale, Bf-S scale) 2.10 Anxiety (modified versions of Spielberger's anxiety inventory, situational anxiety	7	286	Std. Mean Difference (IV, Random, 95% CI)	-0.16 [-0.48, 0.16]
scale, cry score) 2.11 Dementia (various scales)	3	111	Std. Mean Difference (IV, Random, 95% CI)	-0.18 [-0.55, 0.20]

Comparison 4. Supplementary analysis: adverse effects

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Binary outcomes	1	1066	Risk Ratio (M-H, Random, 95% CI)	1.36 [0.95, 1.95]
1.1 Vomiting	1	1066	Risk Ratio (M-H, Random, 95% CI)	1.36 [0.95, 1.95]
2 Continuous outcomes	2	152	Std. Mean Difference (IV, Random, 95% CI)	0.25 [-0.74, 1.23]
2.1 Cardiorespiratory safety during gastroscopy (heart rate per min)	1	128	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.53, 0.16]
2.2 Respiratory depressant response (liter per min)	1	24	Std. Mean Difference (IV, Random, 95% CI)	0.83 [-0.01, 1.67]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Patient-reported outcomes that are non-observable	12	2393	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.84, 1.06]
2 Patient-reported outcomes that are observable	19	1653	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.82, 1.02]
3 Observer-reported outcomes involving patient's cooperation	4	144	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.77, 1.09]
4 Observer-reported outcomes not involving patient's cooperation	5	428	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.06]
5 Laboratory outcomes	4	1423	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.74, 1.17]
6 Patient-reported outcomes that are non-observable	83	6004	Std. Mean Difference (IV, Random, 95% CI)	-0.28 [-0.36, -0.20]
7 Patient-reported outcomes that are observable	26	1996	Std. Mean Difference (IV, Random, 95% CI)	-0.21 [-0.31, -0.11]
8 Observer-reported outcomes involving patient's cooperation	22	878	Std. Mean Difference (IV, Random, 95% CI)	-0.26 [-0.41, -0.12]
9 Observer-reported outcomes not involving patient's cooperation	22	906	Std. Mean Difference (IV, Random, 95% CI)	-0.12 [-0.29, 0.05]
10 Laboratory outcomes	5	729	Std. Mean Difference (IV, Random, 95% CI)	0.16 [0.01, 0.30]

Comparison 5. Effect modification subgroup analysis: type of outcomes

Comparison 6. Effect modification subgroup analysis: the purpose of the trials

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 To study the effect of placebo was an explicit trial purpose	11	1163	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.78, 1.04]
2 To study the effect of placebo was not an explicit trial purpose	33	4878	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.88, 1.01]
3 To study the effect of placebo was an explicit trial purpose	28	2027	Std. Mean Difference (IV, Random, 95% CI)	-0.34 [-0.46, -0.22]
4 To study the effect of placebo was not an explicit trial purpose	130	8486	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.26, -0.14]

Placebo interventions for all clinical conditions (Review)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Psychological placebos	9	298	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.75, 1.04]
2 Physical placebos	11	2536	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.81, 1.01]
3 Pharmacological placebos	24	3207	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.05]
4 Psychological placebos	53	2546	Std. Mean Difference (IV, Random, 95% CI)	-0.22 [-0.31, -0.12]
5 Physical placebos	61	3922	Std. Mean Difference (IV, Random, 95% CI)	-0.31 [-0.41, -0.22]
6 Pharmacological placebos	44	4045	Std. Mean Difference (IV, Random, 95% CI)	-0.10 [-0.20, -0.01]

Comparison 7. Effect modification subgroup analysis: type of placebo interventions

Comparison 8. Effect modification subgroup analysis: patient information

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Binary outcomes: patients not informed that the trial involved placebo	7	1085	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.83, 1.12]
2 Binary outcomes: patients informed that the trial involved placebo (or not stated)	37	4956	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.87, 0.99]
3 Continuous outcomes: patients not informed that the trial involved placebo	23	1692	Std. Mean Difference (IV, Random, 95% CI)	-0.39 [-0.53, -0.26]
4 Continuous outcomes: patients informed that the trial involved placebo (or not stated)	135	8821	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.25, -0.13]

Comparison 9. Effect modification subgroup analysis: placebo as add-on treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Add-on treatment: yes	17	1912	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.85, 1.07]
2 Add-on treatment: no or not stated	27	4129	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.89, 1.00]
3 Add-on treatment: yes	71	5423	Std. Mean Difference (IV, Random, 95% CI)	-0.23 [-0.31, -0.15]
4 Add-on treatment: no or not stated	87	5090	Std. Mean Difference (IV, Random, 95% CI)	-0.22 [-0.30, -0.14]

Placebo interventions for all clinical conditions (Review)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1 Placebo intervention provider blinded: yes	19	2707	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.91, 1.05]	
2 Placebo intervention provider blinded: no or not stated	25	3334	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.83, 0.99]	
3 Placebo intervention provider blinded: yes	42	3069	Std. Mean Difference (IV, Random, 95% CI)	-0.15 [-0.27, -0.02]	
4 Placebo intervention provider blinded: no or not stated	116	7444	Std. Mean Difference (IV, Random, 95% CI)	-0.26 [-0.32, -0.19]	

Comparison 10. Risk of bias subgroup analysis: blinding of placebo treatment providers

Comparison 11. Risk of bias subgroup analysis: blinding of observer

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Blinding of observer: yes	2	316	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.68, 1.07]
2 Blinding of observer: not stated	11	1679	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.87, 1.06]
3 Blinding of observer: yes	20	669	Std. Mean Difference (IV, Random, 95% CI)	-0.23 [-0.42, -0.05]
4 Blinding of observer: not stated	29	1844	Std. Mean Difference (IV, Random, 95% CI)	-0.07 [-0.20, 0.06]

Comparison 12. Risk of bias subgroup analysis: variance inequality and skewness

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 No signs of unequal variance or skewness	72	4378	Std. Mean Difference (IV, Random, 95% CI)	-0.24 [-0.33, -0.15]
2 Signs of either unequal variance or skewness	52	4108	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.30, -0.11]

Placebo interventions for all clinical conditions (Review)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Selection of outcome: primary trial outcome clearly indicated	31	4775	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.00]
2 Selection of outcome: primary trial outcome not clearly indicated (or not selected)	13	1265	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.89, 1.01]
3 Selection of outcome: primary trial outcome clearly indicated	85	6028	Std. Mean Difference (IV, Random, 95% CI)	-0.26 [-0.34, -0.19]
4 Selection of outcome: primary trial outcome not clearly indicated (or not selected)	73	4485	Std. Mean Difference (IV, Random, 95% CI)	-0.17 [-0.25, -0.09]

Comparison 13. Risk of bias subgroup analysis: selection of outcome

Comparison 14. Risk of bias subgroup analysis: format of outcome

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Outcome was final values	118	7866	Std. Mean Difference (IV, Random, 95% CI)	-0.21 [-0.28, -0.14]
2 Outcome was change from baseline	40	2659	Std. Mean Difference (IV, Random, 95% CI)	-0.27 [-0.37, -0.16]

Comparison 15. Risk of bias subgroup analysis: concealed allocation

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Concealed allocation adequate	8	1554	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.76, 1.02]
2 Concealed allocation unclear	36	4487	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.90, 1.01]
3 Concealed allocation adequate	20	2241	Std. Mean Difference (IV, Random, 95% CI)	-0.34 [-0.46, -0.22]
4 Concealed allocation unclear	138	8272	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.26, -0.14]

Placebo interventions for all clinical conditions (Review)

Comparison 16. Risk of bias subgroup analysis: trial size

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Trial size >49	27	5586	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.88, 1.01]
2 Trial size 49 or less	17	455	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.80, 1.04]
3 Trial size >49	65	8050	Std. Mean Difference (IV, Random, 95% CI)	-0.22 [-0.29, -0.14]
4 Trial size 49 or less	93	2463	Std. Mean Difference (IV, Fixed, 95% CI)	-0.24 [-0.32, -0.16]

Comparison 17. Risk of bias subgroup analysis: dropouts

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Dropout rates no more than 15%	24	3687	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 0.99]
2 Dropout rates >15%, or not stated	20	2354	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.86, 1.06]
3 Dropout rates no more than 15%	64	4973	Std. Mean Difference (IV, Random, 95% CI)	-0.25 [-0.34, -0.16]
4 Dropout rates > 15%, or not stated	94	5540	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.27, -0.13]

Comparison 18. Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1 Binary outcomes	5	1438	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.76, 1.08]	
1.1 Pain (incidence)	3	1109	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.67, 1.19]	
1.2 Schizophrenia (lack of	1	54	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.77, 1.17]	
50% improvement) 1.3 Nausea	1	275	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.75, 1.12]	
2 Continuous outcomes	11	1610	Std. Mean Difference (IV, Random, 95% CI)	-0.38 [-0.55, -0.22]	
2.1 Pain (various scales, see table of included studies for details)	7	1181	Std. Mean Difference (IV, Random, 95% CI)	-0.45 [-0.69, -0.21]	
2.2 Nausea (Rhodes inventory of nausea and vomiting, escape medication)	2	174	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.49, 0.11]	
2.3 Irritable bowel syndrome (Global improvement scale)	1	175	Std. Mean Difference (IV, Random, 95% CI)	-0.41 [-0.71, -0.11]	
2.4 Depression (Beck depression inventory)	1	80	Std. Mean Difference (IV, Random, 95% CI)	-0.23 [-0.67, 0.21]	
3 Pain heterogeneity	7	1181	Std. Mean Difference (IV, Random, 95% CI)	-0.45 [-0.69, -0.21]	

Placebo interventions for all clinical conditions (Review)

3.1 GAT	4	544	Std. Mean Difference (IV, Random, 95% CI)	-0.68 [-0.85, -0.50]
3.2 Not GAT	3	637	Std. Mean Difference (IV, Random, 95% CI)	-0.13 [-0.28, 0.03]

Analysis I.I. Comparison I Main analysis: overall pooled analyses, Outcome I Binary outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: I Main analysis: overall pooled analyses

Outcome: I Binary outcomes

Risk Ratio	Weight	Risk Ratio	No-treatment	Placebo	Study or subgroup
M-H,Random,95% Cl		M-H,Random,95% Cl	n/N	n/N	
1.31 [0.88, 1.94]	1.7 %	+	38/326	50/328	Adriaanse 1995
0.82 [0.44, 1.53]	0.8 %		11/20	9/20	Alkaissi 1999
0.92 [0.75, 1.12]	3.8 %	-	82/136	77/139	Alkaissi 2002
0.66 [0.36, 1.19]	0.8 %		9/14	11/26	Aune 1998
1.36 [0.83, 2.24]	1.1 %		9/15	9/11	Berg 1983
1.00 [0.45, 2.23]	0.5 %		6/12	6/12	Blackman 1964
0.67 [0.42, 1.07]	1.3 %		20/29	13/28	Carter 2003
0.94 [0.88, 1.01]	6.5 %	-	360/416	227/279	Corver 2006
1.01 [0.74, 1.38]	2.3 %	+	8/9	9/10	De Sanctis 2001
1.00 [0.23, 4.42]	0.1 %		3/22	3/22	Double 1993
1.00 [0.68, 1.46]	1.7 %	-	17/25	17/25	Dundee 1986
0.37 [0.19, 0.71]	0.7 %		6/6	6/18	Elliott 1978
0.95 [0.81, 1.10]	4.8 %	+	108/155	107/162	Faas 1993
0.89 [0.61, 1.29]	1.8 %		9/10	8/10	Fanti 2003
1.00 [0.60, 1.65]	1.1 %		14/26	14/26	Frank 1990
1.09 [0.87, 1.36]	3.4 %		11/12	12/12	Guglielmi 1982
1.03 [0.83, 1.28]	3.5 %	+	25/30	24/28	Harrison 1975
0.77 [0.64, 0.94]	3.9 %		92/132	70/130	Heinzl 1981
0.39 [0.17, 0.91]	0.4 %		16/30	5/24	Hutton 1991
0.61 [0.40, 0.93]	1.5 %		15/15	9/15	Hyman 1986
1.95 [1.04, 3.65]	0.8 %		12/39	9/15	Jacobs 1971
0.95 [0.79, 1.15]	4.1 %	+	32/36	28/33	Kerr 2003
1.03 [0.94, 1.14]	5.9 %	+	219/309	226/309	Killen 1990

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	(Continued Risk Ratio M-H,Random,95% Cl
Klerman 1974	17/25	16/25		1.6 %	1.06 [0.71, 1.58]
Malcolm 1980	40/63	44/58		3.2 %	0.84 [0.66, 1.06]
McMillan 1994	14/26	24/46		1.3 %	1.03 [0.66, 1.62]
Molsberger 2002	38/58	30/53	+	2.4 %	1.16 [0.86, 1.56]
Najnigier 1997	21/30	24/30	-+	2.5 %	0.88 [0.65, 1.17]
Rabkin 1990	4/27	12/23		1.0 %	0.99 [0.58, 1.70]
Roughan 1981	9/12	9/14	<u> </u>	1.1 %	1.17 [0.70, 1.94]
Schallreuter 2002	3/10	4/10		0.2 %	0.75 [0.22, 2.52]
Scharf 2006	179/365	224/316	-	5.3 %	0.69 [0.61, 0.78]
Scharff 2002	11/12	12/12	-	3.4 %	0.92 [0.74, 1.15]
Stransky 1989	1/5	1/4	·	0.1 %	0.80 [0.07, 9.18]
Tan 1986	8/10	8/9	_+_	1.7 %	0.90 [0.61, 1.32]
Tarcin 2004	58/158	27/77	_ 	1.8 %	1.05 [0.73, 1.51]
Tarrier 1998	22/26	25/28	+	3.7 %	0.95 [0.77, 1.17]
Thomas 1987	47/100	50/100		2.6 %	0.94 [0.71, 1.25]
Tyler 1946	89/260	106/303	+	3.4 %	0.98 [0.78, 1.23]
Walton 1993	19/24	21/30	- -	2.3 %	1.13 [0.83, 1.54]
Watzl 1986	15/34	7/36		0.5 %	2.27 [1.06, 4.88]
Whittaker 1963	3/13	7/13		0.3 %	0.43 [0.14, 1.30]
Williams 1988	19/20	19/20	+	5.0 %	1.00 [0.87, 1.15]
Wilson 1980	31/40	10/10		3.6 %	0.80 [0.65, 0.99]
Fotal (95% CI)	3000	3041	•	100.0 %	0.93 [0.88, 0.99]
otal events: 1607 (Placeb	I; Chi ² = 78.77, df	ment) = 43 (P = 0.00071); l ² =459	6		

Analysis I.2. Comparison I Main analysis: overall pooled analyses, Outcome 2 Continuous outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: I Main analysis: overall pooled analyses

Outcome: 2 Continuous outcomes

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		0.8 %	-0.09 [-0.56, 0.38]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		0.5 %	-0.14 [-0.80, 0.52]
Allen 1998	11	-2.9 (7.9)	П	-6.1 (10.9)		0.4 %	0.32 [-0.52, 1.17]
Allen 2006	45	12 (9.6)	44	19 (9.6)		0.9 %	-0.72 [-1.15, -0.29]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.5 %	0.38 [-0.30, 1.06]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)	_ <u>_</u>	0.7 %	0.08 [-0.44, 0.60]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)	·	0.4 %	0.34 [-0.52, .2]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.2 %	0.56 [-0.60, 1.72]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.3 %	-0.32 [-1.28, 0.64]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		0.8 %	-0.12 [-0.60, 0.35]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		0.3 %	-1.07 [-1.94, -0.20]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	-+-	1.3 %	-0.17 [-0.43, 0.10]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		0.7 %	0.13 [-0.39, 0.64]
Blades 2001	40	-16 (6)	40	-16 (6)		0.9 %	0.0 [-0.44, 0.44]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		0.4 %	-0.70 [-1.53, 0.13]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		0.6 %	-0.28 [-0.90, 0.33]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.4 %	-0.30 [-1.15, 0.56]
Bosley 1989	13	86 (10)	14	89 (10)		0.4 %	-0.29 [-1.05, 0.47]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		0.8 %	-0.14 [-0.61, 0.33]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.4 %	-0.41 [-1.22, 0.40]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		1.1 %	-0.62 [-0.96, -0.29]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.5 %	-0.18 [-0.88, 0.51]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.2 %	0.48 [-0.72, 1.67]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	<u> </u>	0.7 %	0.10 [-0.45, 0.66]
Chenard 1991	12	29 (19)	16	30 (19)		0.4 %	-0.05 [-0.80, 0.70]
Classen 1983	15	11.3 (8.3)	15	4.4 (6.1)		0.5 %	-0.4 [-1.14, 0.31]

-2 -1 0 Favours placebo I 2

Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continued) Std. Mean Difference IV.Random,95% Cl
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.2 %	0.29 [-0.95, 1.53]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.4 %	-0.92 [-1.72, -0.12]
Costello 2006	48	33 (25)	42	31 (25)	_ 	0.9 %	0.08 [-0.33, 0.49]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		0.6 %	0.13 [-0.47, 0.74]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)	<u> </u>	0.7 %	0.08 [-0.44, 0.59]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.3 %	0.0 [-0.88, 0.88]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.3 %	-0.94 [-1.88, -0.01]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.3 %	-0.39 [-1.35, 0.58]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	<u> </u>	1.0 %	-0.12 [-0.51, 0.27]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	+	1.5 %	-0.02 [-0.22, 0.17]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	1.4 %	-0.06 [-0.28, 0.17]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)	<u> </u>	0.9 %	-0.36 [-0.80, 0.08]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)	.	0.4 %	-0.65 [-1.43, 0.13]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		0.4 %	-0.33 [-1.12, 0.46]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)		1.6 %	-0.41 [-0.57, -0.26]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.4 %	-0.13 [-0.89, 0.63]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.5 %	-0.54 [-1.27, 0.19]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	·	0.3 %	-0.98 [-2.02, 0.06]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)		1.3 %	-0.06 [-0.33, 0.21]
Frankel 1978	7	93 (5)	8	95 (3)		0.3 %	-0.47 [-1.50, 0.57]
Frega 1994	21	20 (16)	21	23 (16)		0.6 %	-0.18 [-0.79, 0.42]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.3 %	-0.97 [-1.91, -0.03]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		0.9 %	-0.72 [-1.15, -0.29]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)	<u> </u>	0.9 %	-0.28 [-0.73, 0.16]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.4 %	-0.54 [-1.30, 0.21]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	1.4 %	-0.03 [-0.25, 0.20]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		0.6 %	-0.17 [-0.76, 0.41]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)		0.4 %	-0.19 [-1.05, 0.67]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		0.7 %	-0.16 [-0.72, 0.39]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		0.8 %	-0.82 [-1.32, -0.32]
Hashish 1988	25	42 (25)	25	60 (23)		0.6 %	-0.74 [-1.31, -0.16]

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	←	0.3 %	-1.58 [-2.61, -0.55]
Helms 1987	11	103 (91)	11	79 (99)		0.4 %	0.24 [-0.60, 1.08]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.5 %	-0.53 [-1.19, 0.13]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		0.4 %	-0.18 [-0.98, 0.62]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)		1.3 %	-0.06 [-0.34, 0.22]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)	<u> </u>	1.0 %	0.21 [-0.19, 0.60]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.3 %	-0.21 [-1.09, 0.67]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.4 %	-0.35 [-1.19, 0.50]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)	•	0.2 %	-1.17 [-2.39, 0.04]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		1.2 %	-0.41 [-0.71, -0.11]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.4 %	-1.07 [-1.89, -0.25]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.0 %	0.31 [-0.05, 0.68]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.4 %	-0.23 [-1.07, 0.61]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		0.7 %	-0.28 [-0.81, 0.24]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.2 %	0.04 [-1.35, 1.42]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		0.6 %	0.19 [-0.42, 0.80]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		0.4 %	0.23 [-0.56, 1.02]
Kotani 2001	23	15 (4.5)	24	18 (6)		0.6 %	-0.55 [-1.14, 0.03]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)		1.5 %	-0.12 [-0.33, 0.09]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		0.7 %	-0.79 [-1.34, -0.23]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		0.9 %	-0.59 [-1.04, -0.14]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		0.5 %	-0.3 [-1.0 , 0.38]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.5 %	-0.49 [-1.17, 0.20]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)	•	0.3 %	-1.08 [-2.09, -0.07]
Lick 1977	10	66 (25)	10	63 (32)	_	0.3 %	0.10 [-0.78, 0.98]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	_ <u>_</u>	0.8 %	0.04 [-0.47, 0.55]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		0.7 %	-0.51 [-1.07, 0.05]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		0.9 %	-0.23 [-0.67, 0.21]
Linde 2005	76	-2.2 (2.7)	76	-0.8 (2.2)		1.2 %	-0.57 [-0.89, -0.24]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	-	1.6 %	0.15 [-0.04, 0.33]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)	<u>+</u>	0.6 %	-0.49 [-1.12, 0.14]

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.3 %	0.0 [-0.90, 0.90]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)		0.9 %	0.08 [-0.36, 0.52]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		0.7 %	-0.41 [-0.93, 0.10]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.3 %	0.03 [-1.01, 1.08]
Matros 2006	23	76 (36.3)	21	72 (28.3)		0.6 %	0.12 [-0.47, 0.71]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		0.7 %	-0.02 [-0.59, 0.54]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.3 %	0.04 [-0.86, 0.93]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)	<u> </u>	0.6 %	-0.31 [-0.93, 0.32]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		1.0 %	-0.70 [-1.07, -0.33]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		0.6 %	-0.49 [-1.06, 0.08]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)		1.1 %	0.06 [-0.28, 0.40]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		0.9 %	-0.19 [-0.63, 0.25]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		0.4 %	-0.14 [-0.91, 0.63]
Murphy 1982	6	-16.5 (9.3)	П	-0.8 (6.4)	*	0.2 %	-1.99 [-3.24, -0.74]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.3 %	-0.33 [-1.27, 0.61]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		0.8 %	-1.37 [-1.85, -0.89]
Nicassio 1974	7	7.29 (33.7)	9	99.25 (35.3)		0.3 %	0.19 [-0.80, 1.18]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.3 %	-0.02 [-0.90, 0.85]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		1.0 %	-0.15 [-0.53, 0.23]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)	_ 	1.0 %	0.10 [-0.31, 0.50]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.4 %	0.26 [-0.50, 1.02]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		0.9 %	-0.12 [-0.57, 0.33]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		0.7 %	-0.24 [-0.78, 0.30]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)		1.3 %	-0.06 [-0.35, 0.23]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		0.6 %	-0.40 [-1.05, 0.24]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	+	1.1 %	0.20 [-0.16, 0.55]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.4 %	-0.11 [-0.93, 0.72]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)	<u> </u>	0.5 %	-0.1 [-0.75, 0.54]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		0.7 %	-0.15 [-0.69, 0.38]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		0.8 %	-0.30 [-0.80, 0.19]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.2 %	-0.67 [-1.80, 0.46]

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Rossi 1982	6	107 (17)	6	108 (20)		0.2 %	-0.05 [-1.18, 1.08]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		0.8 %	-0.72 [-1.20, -0.23]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		0.7 %	-0.16 [-0.73, 0.40]
Rschke 2000	24	23 (16.2)	24	26 (16)		0.7 %	-0.18 [-0.75, 0.38]
Rsler 2003	13	5.92 (3.41)	4	6 (2.98)		0.4 %	-0.02 [-0.78, 0.73]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.2 %	-0.13 [-1.26, 1.00]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.4 %	-1.12 [-1.94, -0.30]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.4 %	-0.04 [-0.90, 0.81]
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)	_	0.8 %	-0.25 [-0.73, 0.23]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		0.9 %	0.21 [-0.24, 0.67]
Sipich 1974	10	8 (14)	10	32.5 (14)	←	0.3 %	-1.68 [-2.73, -0.63]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		0.4 %	0.22 [-0.56, .0]
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.3 %	0.16 [-0.72, 1.04]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		0.3 %	-0.69 [-1.60, 0.22]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)		1.2 %	-0.16 [-0.46, 0.14]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		0.7 %	-0.28 [-0.83, 0.28]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.2 %	0.27 [-0.98, 1.52]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		0.3 %	0.21 [-0.67, 1.09]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.4 %	-0.55 [-1.36, 0.27]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		0.6 %	0.05 [-0.55, 0.65]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		0.5 %	0.48 [-0.22, 1.19]
Thomas 1999	14	13.4 (10.28)	26	16.5 (9.73)		0.5 %	-0.31 [-0.96, 0.35]
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		1.2 %	-0.27 [-0.59, 0.04]
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)		1.4 %	0.12 [-0.14, 0.37]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		0.8 %	0.14 [-0.36, 0.65]
Tritrakarn 2000	41	49 (16)	41	61 (17)		0.9 %	-0.72 [-1.17, -0.27]
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)	<u> </u>	0.8 %	-0.08 [-0.57, 0.41]
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		0.8 %	-0.60 [-1.07, -0.12]
Tuomilehto 1980		9.04 (1.36)	11	8.67 (1.56)		0.4 %	0.24 [-0.60, 1.08]
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.3 %	-0.45 [-1.34, 0.44]
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)		0.9 %	0.0 [-0.44, 0.44]

Favours placebo Favours no-treatment

2

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

	Placebo	Ν	o-treatment		Std. Mean Difference	Weight	(Continue) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% C
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		0.7 %	-0.40 [-0.96, 0.15
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		0.5 %	-0.10 [-0.81, 0.62
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)	·	0.6 %	-0.26 [-0.88, 0.37
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)	<u> </u>	0.5 %	0.05 [-0.66, 0.77
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		1.1 %	-0.84 [-1.19, -0.50
Wojciechowski 1984	9	264 (122)	12	238 (190)	<u> </u>	0.4 %	0.15 [-0.71, 1.02
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		0.6 %	-0.20 [-0.83, 0.44
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44) ←		0.2 %	-0.97 [-2.10, 0.16
otal (95% CI)	5188		5337		•	100.0 %	-0.23 [-0.28, -0.17

-2 -1 0 I 2

Favours placebo Favours no-treatment

Analysis 2.1. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome I Patient-reported binary outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 2 Main analysis: patient-reported or observer-reported outcomes

Outcome: I Patient-reported binary outcomes

Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl	No-treatment n/N	Placebo n/N	Study or subgroup
0.82 [0.44, 1.53]	1.3 %		11/20	9/20	Alkaissi 1999
0.92 [0.75, 1.12]	5.7 %	-	82/136	77/139	Alkaissi 2002
0.66 [0.36, 1.19]	1.4 %		9/14	11/26	Aune 1998
1.36 [0.83, 2.24]	1.8 %	<u> </u>	9/15	9/11	Berg 1983
1.00 [0.45, 2.23]	0.8 %		6/12	6/12	Blackman 1964
0.67 [0.42, 1.07]	2.0 %	<u> </u>	20/29	3/28	Carter 2003
0.94 [0.88, 1.01]	8.9 %	-	360/416	227/279	Corver 2006
1.00 [0.68, 1.46]	2.8 %		17/25	17/25	Dundee 1986

0.1 0.2 0.5 2 5 10 Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	(Continue) Risk Ratic M-H,Random,95% Cl
Elliott 1978	6/18	6/6	<u> </u>	1.2 %	0.37 [0.19, 0.71]
Faas 1993	107/162	108/155	+	6.9 %	0.95 [0.81, 1.10]
Frank 1990	14/26	14/26		1.8 %	1.00 [0.60, 1.65
Guglielmi 1982	9/12	11/12	-+-	2.9 %	0.82 [0.57, 1.18
Hutton 1991	5/24	16/30		0.7 %	0.39 [0.17, 0.91
Jacobs 1971	9/15	12/39		1.3 %	1.95 [1.04, 3.65
Klerman 1974	17/25	16/25	<u> </u>	2.6 %	1.06 [0.71, 1.58
McMillan 1994	14/26	24/46		2.2 %	1.03 [0.66, 1.62
Molsberger 2002	38/58	30/53	+	3.8 %	1.16 [0.86, 1.56
Najnigier 1997	21/30	24/30	-+-	3.9 %	0.88 [0.65, 1.17
Rabkin 1990	14/27	12/23		1.6 %	0.99 [0.58, 1.70
Roughan 1981	9/12	9/14		1.8 %	1.17 [0.70, 1.94
Scharf 2006	179/365	224/316	•	7.6 %	0.69 [0.61, 0.78
Scharff 2002	/ 2	12/12	-	5.2 %	0.92 [0.74, 1.15
Stransky 1989	1/5	1/4	·	0.1 %	0.80 [0.07, 9.18
Tan 1986	8/10	8/9		2.7 %	0.90 [0.61, 1.32
Tarcin 2004	58/158	27/77		2.9 %	1.05 [0.73, 1.51
Thomas 1987	47/100	50/100		4.0 %	0.94 [0.71, 1.25
Tyler 1946	89/260	106/303	+	5.1 %	0.98 [0.78, 1.23
Walton 1993	19/24	21/30	<u>+-</u>	3.6 %	1.13 [0.83, 1.54
Watzl 1986	15/34	7/36		0.9 %	2.27 [1.06, 4.88
Williams 1988	19/20	19/20	+	7.1 %	1.00 [0.87, 1.15
Wilson 1980	31/40	10/10	-	5.5 %	0.80 [0.65, 0.99
Fotal (95% CI) otal events: 1109 (Placeb leterogeneity: Tau ² = 0.0	, ,	2043 ment) = 30 (P = 0.002); I ² =48%	•	100.0 %	0.93 [0.86, 1.00]

0.1 0.2 0.5 2 5 10

Favours placebo Favours no-treatment

Analysis 2.2. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome 2 Observer-reported binary outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 2 Main analysis: patient-reported or observer-reported outcomes

Outcome: 2 Observer-reported binary outcomes

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		4.5 %	1.31 [0.88, 1.94]
De Sanctis 2001	9/10	8/9	+	6.6 %	1.01 [0.74, 1.38]
Double 1993	3/22	3/22		0.4 %	1.00 [0.23, 4.42]
Fanti 2003	8/10	9/10		4.9 %	0.89 [0.61, 1.29]
Harrison 1975	24/28	25/30	+	10.6 %	1.03 [0.83, 1.28]
Heinzl 1981	70/130	92/132	+	12.3 %	0.77 [0.64, 0.94]
Hyman 1986	9/15	15/15		4.1 %	0.61 [0.40, 0.93]
Kerr 2003	28/33	32/36	+	13.0 %	0.95 [0.79, 1.15]
Killen 1990	226/309	219/309	+	21.2 %	1.03 [0.94, 1.14]
Malcolm 1980	40/63	44/58		9.7 %	0.84 [0.66, 1.06]
Schallreuter 2002	3/10	4/10		0.6 %	0.75 [0.22, 2.52]
Tarrier 1998	22/26	25/28	+	11.4 %	0.95 [0.77, 1.17]
Whittaker 1963	3/13	7/13		0.7 %	0.43 [0.14, 1.30]
Total (95% CI)	99 7	998	•	100.0 %	0.93 [0.85, 1.02]
	226/309 40/63 3/10 22/26 3/13 997 p), 521 (No-treatme	219/309 44/58 4/10 25/28 7/13 998		21.2 % 9.7 % 0.6 % 11.4 % 0.7 %	1.03 [0.94, 1.14] 0.84 [0.66, 1.06] 0.75 [0.22, 2.52] 0.95 [0.77, 1.17] 0.43 [0.14, 1.30]

Heterogeneity: Tau² = 0.01; Chi² = 17.84, df = 12 (P = 0.12); $I^2 = 33\%$

Test for overall effect: Z = 1.54 (P = 0.12)

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

Analysis 2.3. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome 3 Patient-reported continuous outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 2 Main analysis: patient-reported or observer-reported outcomes

Outcome: 3 Patient-reported continuous outcomes

-

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)	-	1.1 %	-0.09 [-0.56, 0.38]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		0.7 %	-0.14 [-0.80, 0.52]
Andersen 1990	18	35 (27.15)	16	25 (23.6)	<u> </u>	0.7 %	0.38 [-0.30, 1.06]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		1.0 %	0.08 [-0.44, 0.60]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.4 %	-0.32 [-1.28, 0.64]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)	-	0.5 %	-1.07 [-1.94, -0.20]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	+	1.8 %	-0.17 [-0.43, 0.10]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.0 %	0.13 [-0.39, 0.64]
Blanchard 1990a	13	8.3 (13.6)	П	22.5 (25.1)	- _	0.5 %	-0.70 [-1.53, 0.13]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		0.8 %	-0.28 [-0.90, 0.33]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.1 %	-0.14 [-0.61, 0.33]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		1.6 %	-0.62 [-0.96, -0.29]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.7 %	-0.18 [-0.88, 0.51]
Chenard 1991	12	29 (19)	16	30 (19)		0.6 %	-0.05 [-0.80, 0.70]
Classen 1983	15	11.3 (8.3)	15	4.4 (6.)		0.6 %	-0.41 [-1.14, 0.31]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)	_ _	0.5 %	-0.92 [-1.72, -0.12]
Costello 2006	48	33 (25)	42	31 (25)	-	1.3 %	0.08 [-0.33, 0.49]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	<u> </u>	0.8 %	0.13 [-0.47, 0.74]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.5 %	0.0 [-0.88, 0.88]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.4 %	-0.94 [-1.88, -0.01]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.4 %	-0.39 [-1.35, 0.58]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	-	1.4 %	-0.12 [-0.51, 0.27]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	-	2.1 %	-0.02 [-0.22, 0.17]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	2.0 %	-0.06 [-0.28, 0.17]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		1.2 %	-0.36 [-0.80, 0.08]

-4 -2 0 Favours placebo 2 4

Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Differenc IV.Random,95% Cl	e Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)	-+	0.6 %	-0.65 [-1.43, 0.13]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	2.3 %	-0.41 [-0.57, -0.26]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.6 %	-0.13 [-0.89, 0.63]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.6 %	-0.54 [-1.27, 0.19]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.3 %	-0.98 [-2.02, 0.06]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	1.8 %	-0.06 [-0.33, 0.21]
Frega 1994	21	20 (16)	21	23 (16)	<u> </u>	0.8 %	-0.18 [-0.79, 0.42]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.4 %	-0.97 [-1.91, -0.03]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.2 %	-0.28 [-0.73, 0.16]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.6 %	-0.54 [-1.30, 0.21]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		0.9 %	-0.16 [-0.72, 0.39]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		1.0 %	-0.82 [-1.32, -0.32]
Hashish 1988	25	42 (25)	25	60 (23)		0.9 %	-0.74 [-1.31, -0.16]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		0.3 %	-1.58 [-2.61, -0.55]
Helms 1987	11	103 (91)	11	79 (99)		0.5 %	0.24 [-0.60, 1.08]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.7 %	-0.53 [-1.19, 0.13]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	1.8 %	-0.06 [-0.34, 0.22]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.4 %	0.21 [-0.19, 0.60]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.5 %	-0.21 [-1.09, 0.67]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.5 %	-0.35 [-1.19, 0.50]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.3 %	-1.17 [-2.39, 0.04]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		1.7 %	-0.41 [-0.71, -0.11]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.5 %	-1.07 [-1.89, -0.25]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.5 %	-0.23 [-1.07, 0.61]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		1.0 %	-0.28 [-0.81, 0.24]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.2 %	0.04 [-1.35, 1.42]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		0.8 %	0.19 [-0.42, 0.80]
Kotani 2001	23	15 (4.5)	24	18 (6)		0.8 %	-0.55 [-1.14, 0.03]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	2.1 %	-0.12 [-0.33, 0.09]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.2 %	-0.59 [-1.04, -0.14]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		0.7 %	-0.31 [-1.01, 0.38]

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.7 %	-0.49 [-1.17, 0.20]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.4 %	-1.08 [-2.09, -0.07]
Lick 1977	10	66 (25)	10	63 (32)	<u> </u>	0.5 %	0.10 [-0.78, 0.98]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	-	1.0 %	0.04 [-0.47, 0.55]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		1.2 %	-0.23 [-0.67, 0.21]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		1.5 %	-0.56 [-0.90, -0.22]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		0.8 %	-0.49 [-1.12, 0.14]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.4 %	0.0 [-0.90, 0.90]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	+	1.2 %	0.08 [-0.36, 0.52]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		1.0 %	-0.41 [-0.93, 0.10]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.3 %	0.03 [-1.01, 1.08]
Matros 2006	23	76 (36.3)	21	72 (28.3)		0.8 %	0.12 [-0.47, 0.71]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		0.8 %	-0.31 [-0.93, 0.32]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)	-	1.4 %	-0.70 [-1.07, -0.33]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		0.9 %	-0.49 [-1.06, 0.08]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	1.5 %	0.06 [-0.28, 0.40]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		1.2 %	-0.19 [-0.63, 0.25]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)	<u> </u>	1.1 %	-1.37 [-1.85, -0.89]
Nicassio 1974	7	7.29 (33.7)	9	99.25 (35.3)	<u> </u>	0.4 %	0.19 [-0.80, 1.18]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)	-	1.4 %	-0.15 [-0.53, 0.23]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		1.3 %	0.10 [-0.31, 0.50]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.6 %	0.26 [-0.50, 1.02]
Pelham 1992	38	-8.72 (1.73)	38	-8.5 (.6)		1.2 %	-0.12 [-0.57, 0.33]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	1.7 %	-0.06 [-0.35, 0.23]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		0.7 %	-0.40 [-1.05, 0.24]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	+-	1.5 %	0.20 [-0.16, 0.55]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		1.0 %	-0.15 [-0.69, 0.38]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.1 %	-0.30 [-0.80, 0.19]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.3 %	-0.67 [-1.80, 0.46]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		1.1 %	-0.72 [-1.20, -0.23]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)	_ _	0.9 %	-0.16 [-0.73, 0.40]

Favours no-treatment

Favours placebo

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Reler 2003 13 5.92 (3.41) 14 6 (2.98) 0.6 % -0.02 [-0.78, 0.7] Sanders 1990 6 2.03 (0.42) 6 2.08 (0.28) 0.3 % -0.13 [-1.26, 1.6] Sipich 1974 10 8 (14) 10 32.5 (14) 0.3 % -1.68 [-2.73, 0.6] Spanos 1995 13 2.1.39 (9.7) 12 19.08 (10.33) 0.5 % 0.22 [-0.56, 1.0] Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.0] Steinsbeck 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.1] Stewart 1991 25 -14.3 (5.5) 25 -12.8 (5.2) 0.9 % -0.28 [-0.83, 0.2] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.	Beler 2003 13 5.92 (34) 14 6 (2.98) 06 6 % -0.02 [-0.78, 02] Sanders 1990 6 2.03 (0.42) 6 2.08 (0.28) 0.3 % -0.13 [-1.26, 14] Spich 1974 10 8 (14) 10 32.5 (14) 0.3 % -0.16 [-0.72, 10] Spich 1974 10 8 (14) 10 32.5 (14) 0.3 % -0.16 [-0.72, 10] Spich 1974 10 8 (14) 10 32.5 (14) 0.3 % -0.16 [-0.72, 10] Spich 1973 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 10] Steinbelok 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % 0.16 [-0.72, 10] Steinbelok 2001 5 5.58 (0.31) 5 6.01 (0.69) 0.2 % 0.27 [-0.80, 02] Tan 1982 12 13.0 (6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 02] Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 02] Thomas 2002b 11.4 -1.21 (35.2) 11.9 -1.61 (3.31) 1.9	Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continu Std. Mean Differenc IV,Random,95% (
Sanders 1990 6 203 (042) 6 208 (028) 0.3 % -0.13 [-1.24, 12 Spich 1974 10 8 (14) 10 325 (14) 0.3 % -1.68 [-2.73, 02 Spanos 1995 13 21.39 (9.7) 12 19.08 (10.33) 0.5 % 0.22 [-0.56, 14 Spert 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 14 Steinsbek 2004 102 41.48 (58.88) 7.4 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.0 Steraub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5 Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2 Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2 Thomas 2002a 78 0.87 (30.3) 78 -0.06 (2.88) 1.6 % -0.27 [-5.90, 0.2 Tirtakam 2000 4.1 4.9 (1.6) 4.1 6.1 (17) 1.2 % -0.27 [-5.90, 0.2 Tirtakam 2000 4.1 4.9 (16) 5.71 (18.2) 1.1 % 0.06 (-1.07, 0.1 </td <td>Sinders 1990 6 203 (042) 6 208 (028) 0.3 % -0.13 [-1.26, 1.4] Spich 1974 10 8 (14) 10 325 (14) 0.3 % -1.68 [-2.73, 0.4] Spanos 1995 13 21.39 (9.7) 12 19.08 (10.3) 0.5 % 0.22 [-0.56, 1.4] Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.6] Stendesk 2004 102 44.48 (58.88) 74 52.99 (45.2) -1.7 % -0.16 [-0.46, 0.0] Stendesk 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) -1.1 % -0.66 (-1.07, 0.1] Tarsy 2003 32 9.23 (43.6) 32 9.56 (4) -1.1 % -0.26 [-0.32, -0.1] Turner 1979 10 44.2 (4.1.26) 10 5.98 (2.9) -0.4</td> <td>Rschke 2000</td> <td>24</td> <td>23 (16.2)</td> <td>24</td> <td>26 (16)</td> <td>-+</td> <td>0.9 %</td> <td>-0.18 [-0.75, 0.38</td>	Sinders 1990 6 203 (042) 6 208 (028) 0.3 % -0.13 [-1.26, 1.4] Spich 1974 10 8 (14) 10 325 (14) 0.3 % -1.68 [-2.73, 0.4] Spanos 1995 13 21.39 (9.7) 12 19.08 (10.3) 0.5 % 0.22 [-0.56, 1.4] Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.6] Stendesk 2004 102 44.48 (58.88) 74 52.99 (45.2) -1.7 % -0.16 [-0.46, 0.0] Stendesk 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) -1.1 % -0.66 (-1.07, 0.1] Tarsy 2003 32 9.23 (43.6) 32 9.56 (4) -1.1 % -0.26 [-0.32, -0.1] Turner 1979 10 44.2 (4.1.26) 10 5.98 (2.9) -0.4	Rschke 2000	24	23 (16.2)	24	26 (16)	-+	0.9 %	-0.18 [-0.75, 0.38
Spich 1974 10 8 (14) 10 325 (14) 0.3 % -1.68 [-273, 0.4 Spanos 1995 13 21.39 (97) 12 19.08 (10.33) 0.5 % 0.22 [-0.56, 1.4 Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.4 Steinsbelk 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % 0.16 [-0.72, 1.4 Steinsbelk 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5 Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5 Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2 Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2 Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) - 1.6 % -0.27 [-0.17, 0.2 Thomas 2002b 114 -1.2 (3.52) 119 -1.6 (3.31) -1.9 % -0.26 [-0.37, 0.4 Thrankam 2000 41 49 (16) 41 61 (17)	Spich 1974 10 8 (14) 10 325 (14) 0.3 % -1.68 [-273, 0.4 Spanos 1995 13 21.39 (97) 12 19.08 (10.33) 0.5 % 0.22 [-0.56, 1.6] Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.6] Steinsbelk 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % 0.16 [-0.46, 0.1] Steinsbelk 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % 0.16 [-0.46, 0.1] Steinsbelk 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.22 % 0.22 [-0.88, 0.3] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 0.87 (303) 78 -0.06 (2.88) - 1.6 % -0.27 [-1.7, 0.2] Thomas 2002b 114 -1.2 (3.52) 119 -1.6 (1.31) - 1.9 % 0.12 [-0.14, 0.2] Tan 2000 41 49 (16) <td>Rsler 2003</td> <td>13</td> <td>5.92 (3.41)</td> <td> 4</td> <td>6 (2.98)</td> <td></td> <td>0.6 %</td> <td>-0.02 [-0.78, 0.73</td>	Rsler 2003	13	5.92 (3.41)	4	6 (2.98)		0.6 %	-0.02 [-0.78, 0.73
Spanos 1995 13 21.39 (9.7) 12 19.08 (10.3) 0.5 % 0.22 [-0.56, 1.0] Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.0] Steinsbelk 2004 102 44.48 (58.88) 7.4 52.99 (45.2) 1.7.% -0.16 [-0.46, 0.1] Stewart 1991 2.5 -1.43 (5.5) 2.5 -1.28 (5.2) 0.9 % -0.28 [-0.83, 0.2] Straub 2001 5 -5.85 (0.31) 5 -601 (0.69) 0.2 % 0.27 [-0.98, 1.6] Tan 1982 12 13 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-1.7, 0.2] Thomas 2002b 11.4 -1.21 (3.52) 11.9 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Thrakam 2000 41 49 (16) 41 61 (17) -1.2 % -0.72 [-1.7, 0.2] Thrakam 2000 41 49 (16) 10 5.8 (2.2.9)	Spanos 1995 13 21.39 (9.7) 12 1908 (10.3) 0.5 % 0.22 [-0.56, 1.0] Sportt 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.72, 1.0] Steinsbekk 2004 102 44.48 (58.88) 7.4 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.1] Steinsbekk 2004 102 44.48 (58.88) 7.4 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.1] Steinsbekk 2001 5 5.85 (0.31) 5 -601 (0.69) 0.2 % 0.27 [-0.98, 1.6] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 7.8 -0.87 (30.3) 7.8 -0.06 (2.88) - 1.6 % -0.27 [-1.7, 0.2] Thomas 2002b 11.4 -1.21 (3.52) 11.9 -1.61 (3.31) - 1.9 % 0.12 [-0.14, 0.2] Thrakam 2000 41 4.9 (16) 41 61 (17) - 1.2 % -0.72 [-1.7, 0.2] Thomas 2002b 11.4 <td< td=""><td>Sanders 1990</td><td>6</td><td>2.03 (0.42)</td><td>6</td><td>2.08 (0.28)</td><td></td><td>0.3 %</td><td>-0.13 [-1.26, 1.00</td></td<>	Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.3 %	-0.13 [-1.26, 1.00
Sprott 1993 10 7.9 (3) 10 7.4 (3) 0.5 % 0.16 [-0.7, 1.0] Steinsbekk 2004 102 44.48 (58.88) 7.4 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.1] Steinsbekk 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 15] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 15] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Thomas 1999 1.4 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % 0.31 [-0.96, 0.2] Thomas 2002a 7.8 -0.87 (3.03) 7.8 -0.06 (2.88) - 1.6 % -0.27 [-0.59, 0.4] Thomas 2002b 11.4 -1.21 (3.52) 11.9 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tritrakam 2000 4.1 4.9 (1.6) 4.1 6.1 (17) - 1.2 % -0.72 [-1.17, 0.2] Tan 1979 10 44.2 (4.1.26) 10	Sprott 1993 10 79 (3) 10 7.4 (3) 0.5 % 0.16 [-0.7, 1.6] Steinsbekk 2004 102 44.48 (58.88) 7.4 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.1] Steinsbekk 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tashjan 2006 19 3.4 (2.2) 2.4 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.4] Thomas 1999 1.4 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % 0.31 [-0.96, 0.2] Thomas 2002a 7.8 -0.87 (3.03) 7.8 -0.06 (2.88) - 1.6 % -0.27 [-0.57, 0.4] Thomas 2002b 11.4 -1.21 (3.52) 11.9 -1.61 (3.31) - 1.9 % 0.12 [-0.14, 0.2] Tasy 2003 3.2 9.23 (4.36) 3.2 9.56 (4) - 1.1 % -0.06 [-1.07, 0.1] Valeyen 1996 3.9 0.4 (Sipich 1974	10	8 (14)	10	32.5 (14)	<u> </u>	0.3 %	-1.68 [-2.73, -0.63
Steinsbeckk 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.10] Stewart 1991 25 -14.3 (5.5) 25 -12.8 (5.2) 0.9 % -0.28 [-0.83, 0.2] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tashjian 2006 19 3.4 (2.2) 2.4 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.4] Thomas 1999 14 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (303) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.4] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Titrakam 2000 41 49 (16) 41 61 (17) - 1.2 % -0.27 [-1.17, -0.2] Tisay 2003 32 9.26 (4) 1.1 % -0.08 [-5.7, 0.4] - 1.1 % -0.06 [-1.07, -0.1] Tumer 1979 10 44.2 (41.26) <td>Steinsbekk 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.10] Stewart 1991 25 -14.3 (5.5) 25 -12.8 (5.2) 0.9 % -0.28 [-0.83, 0.2] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tashjian 2006 19 3.4 (2.2) 24 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.4] Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (303) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.0] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tasay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-5.7, 0.4] Turner 1977 10 44.2 (41.26) 10 59.8 (2.2) 0.4 % -0.45 [-1.34, 0.4] Valeyen 1996 39 0.4 (1.8) 40 0.4 (1.8)<td>Spanos 1995</td><td>13</td><td>21.39 (9.7)</td><td>12</td><td>19.08 (10.33)</td><td></td><td>0.5 %</td><td>0.22 [-0.56, 1.01</td></td>	Steinsbekk 2004 102 44.48 (58.88) 74 52.99 (45.2) 1.7 % -0.16 [-0.46, 0.10] Stewart 1991 25 -14.3 (5.5) 25 -12.8 (5.2) 0.9 % -0.28 [-0.83, 0.2] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tashjian 2006 19 3.4 (2.2) 24 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.4] Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (303) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.0] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tasay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-5.7, 0.4] Turner 1977 10 44.2 (41.26) 10 59.8 (2.2) 0.4 % -0.45 [-1.34, 0.4] Valeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) <td>Spanos 1995</td> <td>13</td> <td>21.39 (9.7)</td> <td>12</td> <td>19.08 (10.33)</td> <td></td> <td>0.5 %</td> <td>0.22 [-0.56, 1.01</td>	Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		0.5 %	0.22 [-0.56, 1.01
Stewart 1991 25 -143 (5.5) 25 -12.8 (5.2) 0.9 % -0.28 [-0.83, 0.7] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.7] Tashjan 2006 19 3.4 (2.2) 2.4 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.6] Thomas 1999 1.4 13.4 (10.28) 2.6 1.65 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.6] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tritrakam 2000 4.1 4.9 (16) 4.1 6.1 (17) - 1.2 % -0.72 [-1.17, 0.2] Tsay 2003 3.2 9.23 (4.36) 3.2 9.56 (4) - 1.1 % -0.08 [-0.57, 0.4] Turner 1977 10 44.2 (4.12.6) 10 59.8 (2.2.9) 0.4 % -0.45 [-1.34, 0.4] 0.4 % 0.45 [-1.34, 0.4] 0.6 [-0.70, 0.1] 0.5 %	Stewart 1991 25 -143 (5.5) 25 -12.8 (5.2) 0.9 % -0.28 [-0.83, 0.7] Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.5] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.7] Tashjan 2006 19 3.4 (2.2) 2.4 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.6] Thomas 1999 1.4 13.4 (10.28) 2.6 1.65 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.6] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tritrakam 2000 4.1 4.9 (16) 4.1 6.1 (17) - 1.2 % -0.72 [-1.17, 0.2] Tsay 2003 3.2 9.23 (4.36) 3.2 9.56 (4) - 1.1 % -0.08 [-0.57, 0.4] Turner 1977 10 44.2 (4.12.6) 10 59.8 (2.2.9) 0.4 % -0.45 [-1.34, 0.4] 0.4 % 0.45 [-1.34, 0.4] 0.6 [-0.70, 0.1] 0.5 %	Sprott 1993	10	7.9 (3)	10	7.4 (3)	_ 	0.5 %	0.16 [-0.72, 1.04
Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.2] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tashjian 2006 19 3.4 (2.2) 2.4 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.6] Thomas 1999 1.4 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.2] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tratrakam 2000 41 49 (16) 41 61 (17) 1.2 % -0.72 [-1.17, -0.2] Tasy 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-0.57, 0.4] Turner 1979 10 44.2 (41.26) 10 59.8 (2.29) 0.4 % -0.45 [-1.34, 0.4] Waleyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.00 [-0.44, 0.4] Wojciechowski 1984 9 2.64 (122) 12 2.38 (190)	Straub 2001 5 -5.85 (0.31) 5 -6.01 (0.69) 0.2 % 0.27 [-0.98, 1.2] Tan 1982 12 1.3 (0.6) 12 1.7 (0.8) 0.5 % -0.55 [-1.36, 0.2] Tashjian 2006 19 3.4 (2.2) 2.4 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.6] Thomas 1999 1.4 13.4 (10.28) 2.6 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.2] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-0.97, 0.2] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tratrakam 2000 41 49 (16) 41 61 (17) 1.2 % -0.72 [-1.17, -0.2] Tasy 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-0.57, 0.4] Turner 1979 10 44.2 (41.26) 10 59.8 (2.29) 0.4 % -0.45 [-1.34, 0.4] Waleyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.00 [-0.44, 0.4] Wojciechowski 1984 9 2.64 (122) 12 2.38 (190)	Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	-	1.7 %	-0.16 [-0.46, 0.14
Tan 1982121.3 (0.6)121.7 (0.8)0.5 %-0.55 [-1.36, 0.2]Tashjian 2006193.4 (2.2)2.43.3 (1.75)0.8 %0.05 [-0.55, 0.4]Thomas 19991.413.4 (10.28)2.61.65 (9.73)0.7 %-0.31 [-0.96, 0.2]Thomas 2002a7.8-0.87 (3.03)7.8-0.06 (2.88)1.6 %-0.27 [-0.59, 0.0]Thomas 2002b1.14-1.21 (3.52)1.19-1.61 (3.31)1.9 %0.12 [-0.14, 0.2]Tritrakam 20004.14.9 (16)4.16.1 (17)1.2 %-0.72 [-1.17, -0.2]Tsay 20033.29.23 (4.36)3.29.56 (4)1.1 %-0.08 [-0.57, 0.4]Turner 19791044.2 (41.26)105.9.8 (2.2.9)0.4 %-0.45 [-1.34, 0.4]Valeyen 19963.90.4 (1.8)400.4 (1.8)1.2 %0.00 [-0.44, 0.4]Verntoft 2001205.9 (2.4)206.5 (2.2)0.8 %-0.26 [-0.82, -0.1]Wojciechowski 19849264 (122)1.22.38 (190)0.5 %0.15 [-0.71, 1.0]Wojciechowski 19849264 (122)1.22.38 (190)0.5 %0.15 [-0.71, 1.0]Total (95% CI)39034097100.0 %-0.26 [-0.32, -0.1]tetrogeneity: Tau ² = 0.04; Ch ² = 186.96, df = 108 (P<0.00001); l ² = 42%-4-2024	Tan 1982121.3 (0.6)121.7 (0.8)0.5 %-0.55 [-1.36, 0.2]Tashjian 2006193.4 (2.2)2.43.3 (1.75)0.8 %0.05 [-0.55, 0.4]Thomas 19991.413.4 (10.28)2.61.65 (9.73)0.7 %-0.31 [-0.96, 0.2]Thomas 2002a7.8-0.87 (3.03)7.8-0.06 (2.88)1.6 %-0.27 [-0.59, 0.0]Thomas 2002b1.14-1.21 (3.52)1.19-1.61 (3.31)1.9 %0.12 [-0.14, 0.2]Tritrakam 20004.14.9 (16)4.16.1 (17)1.2 %-0.72 [-1.17, -0.2]Tsay 20033.29.23 (4.36)3.29.56 (4)1.1 %-0.08 [-0.57, 0.4]Turner 19791044.2 (41.26)105.9.8 (2.2.9)0.4 %-0.45 [-1.34, 0.4]Valeyen 19963.90.4 (1.8)400.4 (1.8)1.2 %0.00 [-0.44, 0.4]Verntoft 2001205.9 (2.4)206.5 (2.2)0.8 %-0.26 [-0.82, -0.1]Wojciechowski 19849264 (122)1.22.38 (190)0.5 %0.15 [-0.71, 1.0]Wojciechowski 19849264 (122)1.22.38 (190)0.5 %0.15 [-0.71, 1.0]Total (95% CI)39034097100.0 %-0.26 [-0.32, -0.1]tetrogeneity: Tau ² = 0.04; Ch ² = 186.96, df = 108 (P<0.00001); l ² = 42%-4-2024	Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		0.9 %	-0.28 [-0.83, 0.28
Tashijan 2006 19 3.4 (2.2) 24 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.4] Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.3] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-0.59, 0.6] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.3] Tritrakan 2000 41 49 (16) 41 61 (17) 1.2 % -0.77 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-0.57, 0.4] Tumer 1979 10 44.2 (41.26) 10 59.8 (2.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.02 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) 1.5 % -0.26 [-0.32, -0.19] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Total (959% CL) 3903 4097 100.0 % -0.26 [-0.32, -0.1	Tashijan 2006 19 3.4 (2.2) 24 3.3 (1.75) 0.8 % 0.05 [-0.55, 0.4] Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.3] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 1.6 % -0.27 [-0.59, 0.6] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.3] Tritrakan 2000 41 49 (16) 41 61 (17) 1.2 % -0.77 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-0.57, 0.4] Tumer 1979 10 44.2 (41.26) 10 59.8 (2.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.02 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) 1.5 % -0.26 [-0.32, -0.19] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Total (959% CL) 3903 4097 100.0 % -0.26 [-0.32, -0.1	Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)	<u> </u>	0.2 %	0.27 [-0.98, 1.52
Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.3] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 16.% -0.27 [-0.59, 0.0] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tritrakam 2000 41 49 (16) 41 61 (17) 1.2 % -0.72 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) 1.1 % -0.06 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.38, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % 0.15 [-0.71, 1.0] teterogeneity: Tau ² = 0.04; Chi ² = 186.96; df = 108 (P<0.00001); i ²	Thomas 1999 14 13.4 (10.28) 26 16.5 (9.73) 0.7 % -0.31 [-0.96, 0.3] Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) 16.% -0.27 [-0.59, 0.0] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.2] Tritrakam 2000 41 49 (16) 41 61 (17) 1.2 % -0.72 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) 1.1 % -0.06 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.38, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % 0.15 [-0.71, 1.0] teterogeneity: Tau ² = 0.04; Chi ² = 186.96; df = 108 (P<0.00001); i ²	Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.5 %	-0.55 [-1.36, 0.27
Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) - I.6 % -0.27 [-0.59, 0.0] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) I.9 % 0.12 [-0.14, 0.3] Tritrakam 2000 41 49 (16) 41 61 (17) - I.2 % -0.72 [-1.17, -0.7] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) - I.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) - I.1 % -0.06 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Waeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) - 1.2 % 0.0[-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.32, -0.1] Objecthowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Objecthowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Interrogeneity: Tau ² = 0.04;	Thomas 2002a 78 -0.87 (3.03) 78 -0.06 (2.88) - I.6 % -0.27 [-0.59, 0.0] Thomas 2002b 114 -1.21 (3.52) 119 -1.61 (3.31) I.9 % 0.12 [-0.14, 0.3] Tritrakam 2000 41 49 (16) 41 61 (17) - I.2 % -0.72 [-1.17, -0.7] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) - I.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) - I.1 % -0.06 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Waeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) - 1.2 % 0.0[-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.32, -0.1] Objecthowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Objecthowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Interrogeneity: Tau ² = 0.04;	Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)	+	0.8 %	0.05 [-0.55, 0.65
Thomas 2002b 114 -1.21 (352) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.3] Tritrakam 2000 41 49 (16) 41 61 (17) - 1.2 % -0.72 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) - 1.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) - 1.1 % -0.08 [-0.57, 0.4] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.88, 0.3] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] teterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); I ² = 42% - - - - 4 -2 0 2 4 - - - -	Thomas 2002b 114 -1.21 (352) 119 -1.61 (3.31) 1.9 % 0.12 [-0.14, 0.3] Tritrakam 2000 41 49 (16) 41 61 (17) - 1.2 % -0.72 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) - 1.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) - 1.1 % -0.08 [-0.57, 0.4] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.88, 0.3] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] teterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); I ² = 42% - - - - 4 -2 0 2 4 - - - -	Thomas 1999	14	3.4 (0.28)	26	16.5 (9.73)		0.7 %	-0.31 [-0.96, 0.35
Tritrakam 2000 41 49 (16) 41 61 (17) - 1.2 % -0.72 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) - 1.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) - 1.1 % -0.06 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.00 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % 0.15 [-0.71, 1.0] total (95% CI) 3903 4097 0.5 % 0.15 [-0.71, 1.0] 100.0 % -0.26 [-0.32, -0.1] 100.0 % -0.26 [-0.32, -0.1] eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% - - - 2 4	Tritrakam 2000 41 49 (16) 41 61 (17) - 1.2 % -0.72 [-1.17, -0.2] Tsay 2003 32 9.23 (4.36) 32 9.56 (4) - 1.1 % -0.08 [-0.57, 0.4] Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) - 1.1 % -0.06 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.00 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % 0.15 [-0.71, 1.0] total (95% CI) 3903 4097 0.5 % 0.15 [-0.71, 1.0] 100.0 % -0.26 [-0.32, -0.1] 100.0 % -0.26 [-0.32, -0.1] eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% - - - 2 4	Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		1.6 %	-0.27 [-0.59, 0.04
Tsay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % $-0.08 [-0.57, 0.4]$ Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) 1.1 % $-0.60 [-1.07, -0.1]$ Turner 1979 10 44.2 (41.26) 10 59.8 (2.29) 0.4 % $-0.45 [-1.34, 0.4]$ Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % $-0.26 [-0.88, 0.3]$ Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % $-0.84 [-1.19, -0.5]$ Vojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] teterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 4	Tsay 2003 32 9.23 (4.36) 32 9.56 (4) 1.1 % $-0.08 [-0.57, 0.4]$ Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) 1.1 % $-0.60 [-1.07, -0.1]$ Turner 1979 10 44.2 (41.26) 10 59.8 (2.29) 0.4 % $-0.45 [-1.34, 0.4]$ Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % $-0.26 [-0.88, 0.3]$ Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % $-0.84 [-1.19, -0.5]$ Vojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] teterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 4	Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	+	1.9 %	0.12 [-0.14, 0.37
Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) 1.1% -0.60 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4% -0.45 [-1.34, 0.4% Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 0.4% -0.45 [-1.34, 0.4% Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8% -0.26 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) -1.5% -0.84 [-1.19, -0.5] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5% 0.15 [-0.71, 1.0] total (95% CI) 3903 4097 100.0% -0.26 [- -0.32 , -0.19 eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); I ² = 42\% -4 -2 0 2 4	Tsay 2004 35 4.7 (1.51) 36 5.71 (1.82) 1.1% -0.60 [-1.07, -0.1] Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4% -0.45 [-1.34, 0.4% Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 0.4% -0.45 [-1.34, 0.4% Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8% -0.26 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) -1.5% -0.84 [-1.19, -0.5] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5% 0.15 [-0.71, 1.0] total (95% CI) 3903 4097 100.0% -0.26 [- -0.32 , -0.19 eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); I ² = 42\% -4 -2 0 2 4	Tritrakarn 2000	41	49 (16)	41	61 (17)		1.2 %	-0.72 [-1.17, -0.27
Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) + 1.5 % -0.84 [-1.19, -0.5] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] botal (95% CI) 3903 4097 100.0 % -0.26 [-0.32, -0.1] eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% - - - - -4 -2 0 2 4 - - - -	Turner 1979 10 44.2 (41.26) 10 59.8 (22.9) 0.4 % -0.45 [-1.34, 0.4] Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2 % 0.0 [-0.44, 0.4] Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8 % -0.26 [-0.88, 0.3] Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) - 1.5 % -0.84 [-1.19, -0.5] Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] botal (95% CI) 3903 4097 100.0 % -0.26 [-0.32, -0.1] eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% - - - - -4 -2 0 2 4 - - - -	Tsay 2003	32	9.23 (4.36)	32	9.56 (4)	-	1.1 %	-0.08 [-0.57, 0.4
Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2% 0.0 [- 0.44 , 0.4 Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8% -0.26 [- 0.88 , 0.3 Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) 1.5% -0.84 [- 1.19 , -0.5% Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5% 0.15 [- 0.71 , 1.0 Total (95% CI) 3903 4097 100.0 % -0.26 [- 0.32 , -0.19 eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 -4 -2 0 2 4	Vlaeyen 1996 39 0.4 (1.8) 40 0.4 (1.8) 1.2% 0.0 [- 0.44 , 0.4 Werntoft 2001 20 5.9 (2.4) 20 6.5 (2.2) 0.8% -0.26 [- 0.88 , 0.3 Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) 1.5% -0.84 [- 1.19 , -0.5% Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5% 0.15 [- 0.71 , 1.0 Total (95% CI) 3903 4097 100.0 % -0.26 [- 0.32 , -0.19 eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 -4 -2 0 2 4	Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.1 %	-0.60 [-1.07, -0.12
Werntoft 2001 20 $5.9 (2.4)$ 20 $6.5 (2.2)$ 0.8 % $-0.26 [-0.88, 0.3]$ Witt 2005 73 $35.8 (16.2)$ 67 $49.6 (16.3)$ + 1.5% $-0.84 [-1.19, -0.5]$ Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % $0.15 [-0.71, 1.0]$ iotal (95% CI) 3903 4097 100.0 % $-0.26 [-0.32, -0.19]$ eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% - - - est for overall effect: Z = 7.78 (P < 0.00001)	Werntoft 2001 20 $5.9 (2.4)$ 20 $6.5 (2.2)$ 0.8 % $-0.26 [-0.88, 0.3]$ Witt 2005 73 $35.8 (16.2)$ 67 $49.6 (16.3)$ + 1.5% $-0.84 [-1.19, -0.5]$ Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % $0.15 [-0.71, 1.0]$ iotal (95% CI) 3903 4097 100.0 % $-0.26 [-0.32, -0.19]$ eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% - - - est for overall effect: Z = 7.78 (P < 0.00001)	Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.4 %	-0.45 [-1.34, 0.44
Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) $-$ 1.5 % -0.84 [-1.19, -0.5 Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [- 0.71 , 1.0 Votal (95% CI) 3903 4097 100.0 % -0.26 [- 0.32 , - 0.19] eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 4	Witt 2005 73 35.8 (16.2) 67 49.6 (16.3) $-$ 1.5 % -0.84 [-1.19, -0.5 Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [- 0.71 , 1.0 Votal (95% CI) 3903 4097 100.0 % -0.26 [- 0.32 , - 0.19] eterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 4	Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	1.2 %	0.0 [-0.44, 0.44
Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Total (95% CI) 3903 4097 100.0 % -0.26 [-0.32, -0.1] leterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 4	Wojciechowski 1984 9 264 (122) 12 238 (190) 0.5 % 0.15 [-0.71, 1.0] Total (95% CI) 3903 4097 100.0 % -0.26 [-0.32, -0.1] leterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% -4 -2 0 2 4	Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		0.8 %	-0.26 [-0.88, 0.37
Sotal (95% CI) 3903 4097 leterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² =42% 100.0 % -0.26 [-0.32, -0.19 est for overall effect: Z = 7.78 (P < 0.00001)	Sotal (95% CI) 3903 4097 leterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² =42% 100.0 % -0.26 [-0.32, -0.19 est for overall effect: Z = 7.78 (P < 0.00001)	Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		1.5 %	-0.84 [-1.19, -0.50
Neterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² =42% est for overall effect: $Z = 7.78$ (P < 0.00001) -4 -2 0 2 4	Neterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² =42% est for overall effect: $Z = 7.78$ (P < 0.00001) -4 -2 0 2 4	Wojciechowski 1984	9	264 (122)	12	238 (190)		0.5 %	0.15 [-0.71, 1.02
Leterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% est for overall effect: $Z = 7.78$ (P < 0.00001) -4 -2 0 2 4	Leterogeneity: Tau ² = 0.04; Chi ² = 186.96, df = 108 (P<0.00001); l ² = 42% est for overall effect: $Z = 7.78$ (P < 0.00001) -4 -2 0 2 4	otal (95% CI)	3903		4097		•	100.0 %	-0.26 [-0.32, -0.19
		eterogeneity: $Tau^2 = 0$.	.04; Chi ² =			-42%			

Analysis 2.4. Comparison 2 Main analysis: patient-reported or observer-reported outcomes, Outcome 4 **Observer-reported continuous outcomes.**

Review: Placebo interventions for all clinical conditions

Comparison: 2 Main analysis: patient-reported or observer-reported outcomes

Outcome: 4 Observer-reported continuous outcomes

-

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% Cl
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		1.4 %	0.32 [-0.52, 1.17]
Allen 2006	45	12 (9.6)	44	19 (9.6)		3.5 %	-0.72 [-1.15, -0.29]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)	_ +- _	1.3 %	0.34 [-0.52, .2]
Antonio 1999	6	79.7 (12.2)	6	72.6 (.2)		0.8 %	0.56 [-0.60, 1.72]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		3.1 %	-0.12 [-0.60, 0.35]
Blades 2001	40	-16 (6)	40	-16 (6)	+	3.4 %	0.0 [-0.44, 0.44]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		1.3 %	-0.30 [-1.15, 0.56]
Bosley 1989	13	86 (10)	4	89 (10)		1.6 %	-0.29 [-1.05, 0.47]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		1.5 %	-0.41 [-1.22, 0.40]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)	_ •	0.7 %	0.48 [-0.72, 1.67]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		2.5 %	0.10 [-0.45, 0.66]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.7 %	0.29 [-0.95, 1.53]
Crosby 1994	26	3.6 (.25)	33	13.5 (1.25)	_	2.8 %	0.08 [-0.44, 0.59]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		1.5 %	-0.33 [-1.12, 0.46]
Frankel 1978	7	93 (5)	8	95 (3)		1.0 %	-0.47 [-1.50, 0.57]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		3.4 %	-0.72 [-1.15, -0.29]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	5.6 %	-0.03 [-0.25, 0.20]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		2.4 %	-0.17 [-0.76, 0.41]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)	-	1.3 %	-0.19 [-1.05, 0.67]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)	<u> </u>	1.5 %	-0.18 [-0.98, 0.62]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		4.0 %	0.31 [-0.05, 0.68]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)	_ 	1.5 %	0.23 [-0.56, 1.02]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)	_+	2.5 %	-0.79 [-1.34, -0.23]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		2.5 %	-0.51 [-1.07, 0.05]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)		6.1 %	0.15 [-0.04, 0.33]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	(Continued) Std. Mean Difference IV.Random,95% CI
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)	-	2.5 %	-0.02 [-0.59, 0.54]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		1.2 %	0.04 [-0.86, 0.93]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		1.6 %	-0.14 [-0.91, 0.63]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)		0.7 %	-1.99 [-3.24, -0.74]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		1.1 %	-0.33 [-1.27, 0.61]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		1.3 %	-0.02 [-0.90, 0.85]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		2.6 %	-0.24 [-0.78, 0.30]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)	_	1.4 %	-0.11 [-0.93, 0.72]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		2.1 %	-0.11 [-0.75, 0.54]
Rossi 1982	6	107 (17)	6	108 (20)		0.8 %	-0.05 [-1.18, 1.08]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		1.4 %	-1.12 [-1.94, -0.30]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		1.3 %	-0.04 [-0.90, 0.81]
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		3.0 %	-0.25 [-0.73, 0.23]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		3.2 %	0.21 [-0.24, 0.67]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		1.2 %	-0.69 [-1.60, 0.22]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		1.3 %	0.21 [-0.67, 1.09]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		1.8 %	0.48 [-0.22, 1.19]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)	-+-	2.9 %	0.14 [-0.36, 0.65]
Tuomilehto 1980	11	9.04 (1.36)	П	8.67 (1.56)	_ 	1.4 %	0.24 [-0.60, 1.08]
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)	_+_	2.5 %	-0.40 [-0.96, 0.15]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		1.8 %	-0.10 [-0.81, 0.62]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		1.8 %	0.05 [-0.66, 0.77]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		2.1 %	-0.20 [-0.83, 0.44]
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)		0.8 %	-0.97 [-2.10, 0.16]
otal (95% CI) eterogeneity: Tau ² = 0. st for overall effect: Z			1228 P = 0.01); I ² =339	6	•	100.0 %	-0.13 [-0.24, -0.02]

-4 -2 0 2 4

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 3.1. Comparison 3 Main analysis: clinical conditions investigated in three trials or more, Outcome I Binary outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 3 Main analysis: clinical conditions investigated in three trials or more

Outcome: I Binary outcomes

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
l Pain (incidence)					
Faas 1993	107/162	108/155	-	20.5 %	0.95 [0.81, 1.10]
Fanti 2003	8/10	9/10	+	12.0 %	0.89 [0.61, 1.29]
Molsberger 2002	38/58	30/53	+	14.5 %	1.16 [0.86, 1.56]
Scharf 2006	179/365	224/316	-	21.4 %	0.69 [0.61, 0.78]
Scharff 2002	/ 2	12/12	-	17.5 %	0.92 [0.74, 1.15]
Walton 1993	19/24	21/30	+	14.1 %	1.13 [0.83, 1.54]
Subtotal (95% CI)	631	576	•	100.0 %	0.92 [0.77, 1.11]
Heterogeneity: Tau ² = 0.04; C Test for overall effect: Z = 0.8 2 Depression (relapse preven	6 (P = 0.39)	5 (P = 0.00095); I ² =76%			
Frank 1990	14/26	14/26	+	28.7 %	1.00 [0.60, 1.65]
Klerman 1974	17/25	16/25	+	45.8 %	1.06 [0.71, 1.58]
Rabkin 1990	14/27	12/23	+	25.5 %	0.99 [0.58, 1.70]
Subtotal (95% CI)	78	74	•	100.0 %	1.03 [0.78, 1.34]
Total events: 45 (Placebo), 42 Heterogeneity: Tau ² = 0.0; Ch Test for overall effect: $Z = 0.1$ 3 Nausea	$ni^2 = 0.05, df = 2$ (F	P = 0.97); I ² =0.0%			
Alkaissi 1999	9/20	11/20	_	4.4 %	0.82 [0.44, 1.53]
Alkaissi 2002	77/139	82/136	-	42.3 %	0.92 [0.75, 1.12]
Dundee 1986	17/25	17/25	+	12.0 %	1.00 [0.68, 1.46]
McMillan 1994	14/26	24/46	+	8.5 %	1.03 [0.66, 1.62]
Najnigier 1997	21/30	24/30	-	19.9 %	0.88 [0.65, 1.17]
Tarcin 2004	58/158	27/77	+	12.9 %	1.05 [0.73, 1.51]
Subtotal (95% CI) Total events: 196 (Placebo), 14 Heterogeneity: Tau ² = 0.0; Ch	398 85 (No-treatment)	334	•	100.0 %	0.94 [0.82, 1.07]

0.01 0.1 I Favours placebo

10 100

Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	(Continued) Risk Ratio M-H,Random,95% Cl
Test for overall effect: $Z = 0.9$	93 (P = 0.35)				
4 Smoking (relapse, self repo	rt or biochemical m	easure)			
Elliott 1978	6/18	6/6		7.3 %	0.37 [0.19, 0.71]
Hyman 1986	9/15	15/15		3. %	0.61 [0.40, 0.93]
Jacobs 1971	9/15	12/39	-	7.8 %	1.95 [1.04, 3.65]
Killen 1990	226/309	219/309	+	26.5 %	1.03 [0.94, 1.14]
Malcolm 1980	40/63	44/58	-	20.5 %	0.84 [0.66, 1.06]
Williams 1988	19/20	19/20	+	24.9 %	1.00 [0.87, 1.15]
Subtotal (95% CI)	440	447	•	100.0 %	0.89 [0.73, 1.10]
Total events: 309 (Placebo), 3	815 (No-treatment)				
Heterogeneity: $Tau^2 = 0.04$; ($Chi^2 = 20.92, df = 5$	6 (P = 0.00084); I ² =76%			
Test for overall effect: $Z = 1.0$	08 (P = 0.28)				
			0.01 0.1 10 100		

Analysis 3.2. Comparison 3 Main analysis: clinical conditions investigated in three trials or more, Outcome 2 Continuous outcomes.

Favours placebo

Favours no-treatment

Review: Placebo interventions for all clinical conditions

Comparison: 3 Main analysis: clinical conditions investigated in three trials or more

Outcome: 2 Continuous outcomes

Study or subgroup	Placebo N	No Mean(SD)	o-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
l Pain (VAS, ordinal scale	es, McGill scon	e, escape medication	, WOMAC inc	lex; absolute or in	provement)		
Alfano 2001	24	6.2 (2.8)	4	6.6 (2.7)		1.3 %	-0.14 [-0.80, 0.52]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		1.2 %	0.38 [-0.30, 1.06]
Benedetti 1995	13	-2 (1.15)	H	-0.8 (1) -		0.8 %	-1.07 [-1.94, -0.20]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)		3.3 %	-0.17 [-0.43, 0.10]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.8 %	0.13 [-0.39, 0.64]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		0.9 %	-0.70 [-1.53, 0.13]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		1.4 %	-0.28 [-0.90, 0.33]

-2 -1 0 I 2 Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		2.0 %	-0.14 [-0.61, 0.33]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		2.8 %	-0.62 [-0.96, -0.29]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	<u> </u>	1.6 %	0.10 [-0.45, 0.66]
Chenard 1991	12	29 (19)	16	30 (19)		1.1 %	-0.05 [-0.80, 0.70]
Classen 1983	15	11.3 (8.3)	15	14.4 (6.1)		1.1 %	-0.4 [-1.14, 0.3]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.9 %	-0.92 [-1.72, -0.12]
Costello 2006	48	33 (25)	42	31 (25)	<u> </u>	2.3 %	0.08 [-0.33, 0.49]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		1.4 %	0.13 [-0.47, 0.74]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.8 %	0.0 [-0.88, 0.88]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.7 %	-0.39 [-1.35, 0.58]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		2.1 %	-0.36 [-0.80, 0.08]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		1.1 %	-0.54 [-1.27, 0.19]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	•	0.6 %	-0.98 [-2.02, 0.06]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)		3.3 %	-0.06 [-0.33, 0.21]
Frega 1994	21	20 (16)	21	23 (16)		1.4 %	-0.18 [-0.79, 0.42]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)	_+ <u>+</u>	2.1 %	-0.28 [-0.73, 0.16]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		1.0 %	-0.54 [-1.30, 0.21]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		1.6 %	-0.16 [-0.72, 0.39]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		1.8 %	-0.82 [-1.32, -0.32]
Hashish 1988	25	42 (25)	25	60 (23)		1.5 %	-0.74 [-1.31, -0.16]
Helms 1987	11	103 (91)	11	79 (99)	<u> </u>	0.9 %	0.24 [-0.60, 1.08]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.3 %	-0.53 [-1.19, 0.13]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		2.4 %	0.21 [-0.19, 0.60]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.8 %	-0.21 [-1.09, 0.67]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		1.4 %	0.19 [-0.42, 0.80]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.5 %	-0.55 [-1.14, 0.03]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)		3.7 %	-0.12 [-0.33, 0.09]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		2.1 %	-0.59 [-1.04, -0.14]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		1.2 %	-0.3 [-1.0 , 0.38]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		1.2 %	-0.49 [-1.17, 0.20]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	<u> </u>	1.8 %	0.04 [-0.47, 0.55]

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

(Continued . . .)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continue) Std. Mean Difference IV,Random,95% C
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		1.6 %	-0.51 [-1.07, 0.05
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		2.7 %	-0.56 [-0.90, -0.22
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.4 %	-0.49 [-1.12, 0.14
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		2.5 %	-0.70 [-1.07, -0.33
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)	_ _	1.6 %	-0.49 [-1.06, 0.08
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		2.3 %	0.10 [-0.31, 0.50
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)		3.1 %	-0.06 [-0.35, 0.23
Reading 1982	18	1.6 (1.3)	20	2.3 (2)	_	1.3 %	-0.40 [-1.05, 0.24
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.9 %	-0.11 [-0.93, 0.72
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)	<u> </u>	1.9 %	-0.72 [-1.20, -0.23
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.5 %	-0.13 [-1.26, 1.00
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.8 %	0.16 [-0.72, 1.04
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.9 %	-0.55 [-1.36, 0.27
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)	<u> </u>	1.4 %	0.05 [-0.55, 0.65
Thomas 1999	14	13.4 (10.28)	26	16.5 (9.73)		1.3 %	-0.31 [-0.96, 0.35
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		2.9 %	-0.27 [-0.59, 0.04
Thomas 2002b	114	-1.21 (3.52)	119	-1.61 (3.31)	_ _	3.3 %	0.12 [-0.14, 0.37
Tritrakarn 2000	41	49 (16)	41	61 (17)		2.1 %	-0.72 [-1.17, -0.27
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)		2.1 %	0.0 [-0.44, 0.44
, Wang 1997	25	10.7 (7.3)	26	3.4 (5.8)	.	1.6 %	-0.40 [-0.96, 0.15
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		2.7 %	-0.84 [-1.19, -0.50
Wojciechowski 1984	9	264 (122)	12	238 (190)		0.8 %	0.15 [-0.71, 1.02
Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: $Z =$			2105 P = 0.00062); I ² =	41%	•	1 00.0 %	-0.28 [-0.36, -0.19
2 Insomnia (sleep onset la	`	,	o quality index ch	ange)			
Ascher 1979	8	50.63 (44.13)		62.44 (25.25)		10.4 %	-0.32 [-1.28, 0.64
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		15.8 %	-0.65 [-1.43, 0.13
Lick 1977	10	66 (25)	10	63 (32)		12.4 %	0.10 [-0.78, 0.98
Nicassio 1974	7	7.29 (33.7)	9	99.25 (35.3)		9.7 %	0.19 [-0.80, 1.18
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		39.7 %	-0.08 [-0.57, 0.41
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		12.0 %	-0.45 [-1.34, 0.44
Subtotal (95% CI)	81		83		•	100.0 %	-0.19 [-0.50, 0.12

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	e Weight	(Continue Std. Mean Differenc IV,Random,95% (
Heterogeneity: Tau ² = 0.0				Ticul(3D)			14,1 4110011,7 570 0
Test for overall effect: $Z =$,, 1 0.070				
B Hypertension (diastolic,	mm Hg; abs	olute or improvem	ent)				
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		8.8 %	0.34 [-0.52, 1.21
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		18.7 %	-0.12 [-0.60, 0.35
Bosley 1989	13	86 (10)	14	89 (10)		10.6 %	-0.29 [-1.05, 0.47
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		5.2 %	0.48 [-0.72, 1.67
Frankel 1978	7	93 (5)	8	95 (3)		6.6 %	-0.47 [-1.50, 0.57
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		9.8 %	-0.18 [-0.98, 0.62
Rossi 1982	6	107 (17)	6	108 (20)	_	5.7 %	-0.05 [-1.18, 1.08
Seer 1980	14	92.5 (9.8)	13	104.5 (11)	B	9.5 %	-1.12 [-1.94, -0.30
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		19.5 %	0.21 [-0.24, 0.67
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	• 	5.7 %	-0.97 [-2.10, 0.16
Subtotal (95% CI)	168		140		•	100.0 %	-0.17 [-0.46, 0.12
est for overall effect: Z = Nausea (VAS, Rhodes Ir Dibble 2007	`	Vausea and Vomitir	ng, escape med 5 I	,		21.1 %	-0.12 [-0.51, 0.2]
	,	3.13 (2.9)		3.5 (3.1)		21.1 %	-0.12 [-0.51, 0.27
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	← →───	3.9 %	-1.58 [-2.61, -0.55
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		22.2 %	-0.15 [-0.53, 0.23
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		12.9 %	-0.15 [-0.69, 0.38
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		14.7 %	-0.30 [-0.80, 0.19
Shen 2000	33	40.7 (12.35)	34	43.7 (.3)		15.3 %	-0.25 [-0.73, 0.23
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		9.9 %	-0.26 [-0.88, 0.37
Subtotal (95% CI) eterogeneity: Tau2 = 0.0	223 and the second s	21. df = 6 (P = 0.3)	229		•	100.0 %	-0.25 [-0.46, -0.04
est for overall effect: Z = Smoking (cigarettes per	2.34 (P = 0	.019)					
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	-	44.9 %	-0.41 [-0.57, -0.26
Sipich 1974	10	8 (14)	10	32.5 (14)	←∎	24.4 %	-1.68 [-2.73, -0.63
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		30.7 %	0.22 [-0.56, 1.01
Subtotal (95% CI)	292		411			100.0 %	-0.53 [-1.29, 0.23
leterogeneity: $Tau^2 = 0.3$			2); I ² =75%				
	nd spiders: s	nake slides test, bel			e or improvement)		
est for overall effect: Z = Phobia (fear of snakes a		1.1.00.00					0.32 E L L 2 0 4/
	13	-11.39 (3.95)	12	-10.08 (3.68)		47.5 %	-0.33 [-1.12, 0.46

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continue) Std. Mean Difference IV,Random,95% Cl
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)	←	29.3 %	-1.08 [-2.09, -0.07]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)	_	23.2 %	-0.67 [-1.80, 0.46
Subtotal (95% CI)	31	()	26	~ /		100.0 %	-0.63 [-1.17, -0.08]
Heterogeneity: $Tau^2 = 0.0$;	-	32, df = 2 (P = 0.				10000 /0	
Test for overall effect: Z =	2.26 (P = 0	0.024)					
7 Asthma (bronchoconstri				,		25 7 0/	
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)	- 1	35.7 %	-0.72 [-1.15, -0.29]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		25.6 %	-0.02 [-0.59, 0.54]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		22.5 %	-0.31 [-0.93, 0.32]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		16.2 %	-0.14 [-0.91, 0.63
Subtotal (95% CI)	104		99		•	100.0 %	-0.35 [-0.70, -0.01]
Heterogeneity: $Tau^2 = 0.0$			$(.23); ^2 = 3 \%$				
Test for overall effect: Z = 8 Obesity (kg, pounds,%; a		,					
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		8.2 %	0.56 [-0.60, 1.72
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		13.0 %	-0.30 [-1.15, 0.56
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		7.4 %	0.29 [-0.95, 1.53
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		20.2 %	-0.17 [-0.76, 0.41
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)	_	12.8 %	-0.19 [-1.05, 0.67
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)	•	7.3 %	-1.99 [-3.24, -0.74
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		18.3 %	-0.11 [-0.75, 0.54
Senediak 1985	П	47.52 (8.38)	10	47.87 (7.53)		12.9 %	-0.04 [-0.90, 0.8
Subtotal (95% CI)	98		90		•	100.0 %	-0.20 [-0.57, 0.17]
Heterogeneity: $Tau^2 = 0.0^{\circ}$			0.17 ; $1^2 = 32\%$				
Test for overall effect: Z = 9 Depression (Hamilton's :	`	,	ntory Geriatric D	enression Scale	Bf-S scale)		
Allen 1998		-2.9 (7.9)		-6.1 (10.9)		9.3 %	0.32 [-0.52, 1.17
Allen 2006	45	12 (9.6)	44	19 (9.6)		20.2 %	-0.72 [-1.15, -0.29
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		7.9 %	-0.97 [-1.91, -0.03
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		19.8 %	-0.23 [-0.67, 0.21
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		7.9 %	-0.33 [-1.27, 0.61
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)	_	10.8 %	0.26 [-0.50, 1.02
Rschke 2000	24	23 (16.2)	24	26 (16)		15.5 %	-0.18 [-0.75, 0.38
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		8.7 %	0.21 [-0.67, 1.09
Subtotal (95% CI)	165		159		•	100.0 %	-0.25 [-0.55, 0.05

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continued Std. Mean Difference IV,Random,95% Cl
Heterogeneity: $Tau^2 = 0.07$	7; Chi ² = 1	I.42, df = 7 (P = 0). 2); ² =39%	. ,			
Test for overall effect: Z =	I.60 (P = 0	D.11)					
10 Anxiety (modified versi	ions of Spie	lberger's anxiety ir	ventory, situatio	onal anxiety scale, c	ry score)		
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		10.8 %	-1.07 [-1.89, -0.25]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		10.5 %	-0.23 [-1.07, 0.61]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)		21.8 %	0.08 [-0.36, 0.52]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		19.0 %	-0.41 [-0.93, 0.10]
Markland 1993	7	37.29 (.77)	7	36.86 (11.91)	_	7.5 %	0.03 [-1.01, 1.08]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		17.3 %	-0.16 [-0.73, 0.40]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		13.2 %	0.48 [-0.22, 1.19]
Subtotal (95% CI)	151		135		•	100.0 %	-0.16 [-0.48, 0.16]
Heterogeneity: Tau ² = 0.07 Test for overall effect: Z =).12); 12 =41%				
II Dementia (various scale	es)	,					
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)	_	17.5 %	0.04 [-0.86, 0.93]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		47.9 %	-0.24 [-0.78, 0.30]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		34.5 %	-0.20 [-0.83, 0.44]
Subtotal (95% CI)	55		56		-	100.0 %	-0.18 [-0.55, 0.20]
Heterogeneity: $Tau^2 = 0.0;$	$Chi^2 = 0.2$	27, df = 2 (P = 0.8	7); I ² =0.0%				
Test for overall effect: $Z =$	0.92 (P = 0	0.36)					
				ı			
				-2	-1 0 1 2 urs placebo Favours no-tr		

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 4.1. Comparison 4 Supplementary analysis: adverse effects, Outcome I Binary outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 4 Supplementary analysis: adverse effects

Outcome: I Binary outcomes

Study or subgroup	Placebo n/N	No-treatment n/N			Risk Ratio ndom,95% (CI	Weight	Risk Ratio M-H,Random,95% Cl
l Vomiting Larson 2005	64/533	47/533					100.0 %	1.36 [0.95, 1.95]
Total (95% CI) Total events: 64 (Placebo) Heterogeneity: not applic: Test for overall effect: Z =	able	533			•		100.0 %	1.36 [0.95, 1.95]
	1.70 (F = 0.090)		0.2 Favours	0.5 s placebo	1 2 Favours 1	5 no-treatmen	t	

Analysis 4.2. Comparison 4 Supplementary analysis: adverse effects, Outcome 2 Continuous outcomes.

Review: Placebo interve	entions for a	II clinical conditi	ons					
Comparison: 4 Supplem	nentary analy	ysis: adverse effe	ects					
Outcome: 2 Continuou	s outcomes							
Study or subgroup	Placebo		No-treatment	M (CD)		lean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Ranc	lom,95% Cl		IV,Random,95% CI
I Cardiorespiratory safety	during gastr	roscopy (heart i	rate per min)		_			
Ristikankare 2006	64	97 (16)	64	100 (16)			57.4 %	-0.19 [-0.53, 0.16]
Subtotal (95% CI)	64		64		-		57.4 %	-0.19 [-0.53, 0.16]
Heterogeneity: not applica	ble							
Test for overall effect: Z =	1.05 (P = 0	0.29)						
2 Respiratory depressant r	response (lit	er per min)						
Benedetti 1999a	12	-8.04 (1.16)	12	-9 (1.07)		•	42.6 %	0.83 [-0.01, 1.67]
Subtotal (95% CI)	12		12				42.6 %	0.83 [-0.01, 1.67]
Heterogeneity: not applica	ble							
Test for overall effect: $Z =$	I.94 (P = 0	0.053)						
Total (95% CI)	76		76				100.0 %	0.25 [-0.74, 1.23]
Heterogeneity: $Tau^2 = 0.4$	I; Chi ² = 4.	81, df = 1 (P =	0.03); l ² =79%					
Test for overall effect: $Z =$	0.49 (P = 0	0.62)						
				1	•			
				-	-0.5	0 0.5 I		
				Favo	urs placebo	Favours no-th	eatment	

Placebo interventions for all clinical conditions (Review)

Analysis 5.1. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 1 Patientreported outcomes that are non-observable.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: I Patient-reported outcomes that are non-observable

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Dundee 1986	17/25	17/25	-	5.9 %	1.00 [0.68, 1.46]
Faas 1993	107/162	108/155	-	13.1 %	0.95 [0.81, 1.10]
McMillan 1994	14/26	24/46		4.7 %	1.03 [0.66, 1.62]
Molsberger 2002	38/58	30/53		7.8 %	1.16 [0.86, 1.56]
Najnigier 1997	21/30	24/30		8.0 %	0.88 [0.65, 1.17]
Roughan 1981	9/12	9/14	_ 	3.9 %	1.17 [0.70, 1.94]
Scharf 2006	179/365	224/316	•	14.2 %	0.69 [0.61, 0.78]
Scharff 2002	11/12	2/ 2	+	10.3 %	0.92 [0.74, 1.15]
Tarcin 2004	58/158	27/77	-	6.2 %	1.05 [0.73, 1.51]
Thomas 1987	47/100	50/100	-	8.3 %	0.94 [0.71, 1.25]
Tyler 1946	89/260	106/303	+	10.2 %	0.98 [0.78, 1.23]
Walton 1993	19/24	21/30		7.5 %	1.13 [0.83, 1.54]
Total (95% CI)	1232	1161	•	100.0 %	0.95 [0.84, 1.06]
Total events: 609 (Placebo	o), 652 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	02; Chi ² = 24.68, df	$= (P = 0.0); ^2 = 55\%$			
Test for overall effect: Z =	= 0.94 (P = 0.35)				

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

Analysis 5.2. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 2 Patientreported outcomes that are observable.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 2 Patient-reported outcomes that are observable

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Alkaissi 1999	9/20	11/20		2.5 %	0.82 [0.44, 1.53]
Alkaissi 2002	77/139	82/136	-	11.2 %	0.92 [0.75, 1.12]
Aune 1998	11/26	9/14		2.8 %	0.66 [0.36, 1.19]
Berg 1983	9/11	9/15	<u> </u>	3.7 %	1.36 [0.83, 2.24]
Blackman 1964	6/12	6/12		1.6 %	1.00 [0.45, 2.23]
Carter 2003	13/28	20/29		4.1 %	0.67 [0.42, 1.07]
Corver 2006	227/279	360/416	_	17.4 %	0.94 [0.88, 1.01]
Elliott 1978	6/18	6/6		2.3 %	0.37 [0.19, 0.71]
Frank 1990	14/26	14/26		3.6 %	1.00 [0.60, 1.65]
Guglielmi 1982	9/12	11/12		5.8 %	0.82 [0.57, 1.18]
Hutton 1991	5/24	16/30		1.5 %	0.39 [0.17, 0.91]
acobs 1971	9/15	12/39		2.5 %	1.95 [1.04, 3.65]
Klerman 1974	17/25	16/25		5.2 %	1.06 [0.71, 1.58]
Rabkin 1990	14/27	12/23		3.3 %	0.99 [0.58, 1.70]
Stransky 1989	1/5	1/4		0.2 %	0.80 [0.07, 9.18]
Tan 1986	8/10	8/9		5.4 %	0.90 [0.61, 1.32]
Watzl 1986	15/34	7/36		1.8 %	2.27 [1.06, 4.88]
Williams 1988	19/20	19/20	+	14.1 %	1.00 [0.87, 1.15]
Wilson 1980	31/40	10/10	-#-	10.8 %	0.80 [0.65, 0.99]
Total (95% CI)	771	882	•	100.0 %	0.92 [0.82, 1.02]
Total events: 500 (Placebo Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	b), 629 (No-treatme)2; Chi ² = 31.80, df	nt)			
			0.1 0.2 0.5 1 2 5 10		
			Favours placebo Favours no-treatme	ent	

Placebo interventions for all clinical conditions (Review)

Analysis 5.3. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 3 Observerreported outcomes involving patient's cooperation.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 3 Observer-reported outcomes involving patient's cooperation

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Double 1993	3/22	3/22		1.4 %	1.00 [0.23, 4.42]
Fanti 2003	8/10	9/10		22.8 %	0.89 [0.61, 1.29]
Tarrier 1998	22/26	25/28	=	73.2 %	0.95 [0.77, 1.17]
Whittaker 1963	3/13	7/13		2.6 %	0.43 [0.14, 1.30]
Total (95% CI)	71	73	•	100.0 %	0.92 [0.77, 1.09]
Total events: 36 (Placebo)), 44 (No-treatment)				
Heterogeneity: $Tau^2 = 0.0$); $Chi^2 = 2.5 I$, $df = 2$	3 (P = 0.47); $ ^2 = 0.0\%$			
Test for overall effect: Z =	= 0.97 (P = 0.33)				
			0.1 0.2 0.5 1 2 5 10		

Favours placebo Favours no-treatment

Analysis 5.4. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 4 Observerreported outcomes not involving patient's cooperation.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 4 Observer-reported outcomes not involving patient's cooperation

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% CI		M-H,Random,95% Cl
De Sanctis 2001	9/10	8/9	+	15.6 %	1.01 [0.74, 1.38]
Harrison 1975	24/28	25/30	+	24.7 %	1.03 [0.83, 1.28]
Heinzl 1981	70/130	92/132	+	28.4 %	0.77 [0.64, 0.94]
Kerr 2003	28/33	32/36	+	30.0 %	0.95 [0.79, 1.15]
Schallreuter 2002	3/10	4/10		1.3 %	0.75 [0.22, 2.52]
Total (95% CI)	211	217	•	100.0 %	0.92 [0.80, 1.06]
Total events: 134 (Placebo	o), 161 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	1; Chi ² = 6.10, df =	4 (P = 0.19); $ ^2 = 34\%$			
Test for overall effect: Z =	= 1.13 (P = 0.26)				
			0.1 0.2 0.5 2 5 10		
			Favours placebo Favours no-treatmer	ıt	

ravours placebo ravou

Placebo interventions for all clinical conditions (Review)

Analysis 5.5. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 5 Laboratory outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 5 Laboratory outcomes

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio M-H,Random,95% Cl
, , ,	n/N	n/N	M-H,Random,95% CI	Ū.	
Adriaanse 1995	50/328	38/326		18.4 %	1.31 [0.88, 1.94]
Hyman 1986	9/15	15/15		17.4 %	0.61 [0.40, 0.93]
Killen 1990	226/309	219/309	+	36.5 %	1.03 [0.94, 1.14]
Malcolm 1980	40/63	44/58	-	27.7 %	0.84 [0.66, 1.06]
Total (95% CI)	715	708	•	100.0 %	0.93 [0.74, 1.17]
Total events: 325 (Placebo	o), 316 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	04; Chi ² = 9.97, df =	3 (P = 0.02); I ² =70%			
Test for overall effect: Z =	= 0.62 (P = 0.53)				
			0.1 0.2 0.5 1 2 5 10		

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

Analysis 5.6. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 6 Patientreported outcomes that are non-observable.

Review: Placebo interventions for all clinical conditions

-

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 6 Patient-reported outcomes that are non-observable

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		1.0 %	-0.14 [-0.80, 0.52]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.9 %	0.38 [-0.30, 1.06]
Benedetti 1995	13	-2 (1.15)	П	-0.8 (1)		0.6 %	-1.07 [-1.94, -0.20]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	-	2.2 %	-0.17 [-0.43, 0.10]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.3 %	0.13 [-0.39, 0.64]
Blanchard 1990a	13	8.3 (13.6)	П	22.5 (25.1)	_ _	0.7 %	-0.70 [-1.53, 0.13]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		1.1 %	-0.28 [-0.90, 0.33]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.4 %	-0.14 [-0.61, 0.33]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		1.9 %	-0.62 [-0.96, -0.29]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.9 %	-0.18 [-0.88, 0.51]
Chenard 1991	12	29 (19)	16	30 (19)		0.8 %	-0.05 [-0.80, 0.70]
Classen 1983	15	11.3 (8.3)	15	14.4 (6.1)		0.8 %	-0.4 [-1.14, 0.3]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.7 %	-0.92 [-1.72, -0.12]
Costello 2006	48	33 (25)	42	31 (25)	-	1.6 %	0.08 [-0.33, 0.49]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	<u> </u>	1.1 %	0.13 [-0.47, 0.74]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.6 %	0.0 [-0.88, 0.88]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.5 %	-0.39 [-1.35, 0.58]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	-+-	1.7 %	-0.12 [-0.51, 0.27]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	+	2.5 %	-0.02 [-0.22, 0.17]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	2.4 %	-0.06 [-0.28, 0.17]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		1.5 %	-0.36 [-0.80, 0.08]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.8 %	-0.54 [-1.27, 0.19]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	.	0.5 %	-0.98 [-2.02, 0.06]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	2.2 %	-0.06 [-0.33, 0.21]
Frega 1994	21	20 (16)	21	23 (16)		1.1 %	-0.18 [-0.79, 0.42]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Fuchs 1977	10	14.3 (7)	10	21.4 (7)	<u> </u>	0.6 %	-0.97 [-1.91, -0.03]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.5 %	-0.28 [-0.73, 0.16]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.8 %	-0.54 [-1.30, 0.21]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		1.2 %	-0.16 [-0.72, 0.39]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		1.4 %	-0.82 [-1.32, -0.32]
Hashish 1988	25	42 (25)	25	60 (23)	_ 	1.1 %	-0.74 [-1.31, -0.16]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		0.5 %	-1.58 [-2.61, -0.55]
Helms 1987		103 (91)	П	79 (99)	_ 	0.7 %	0.24 [-0.60, 1.08]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.0 %	-0.53 [-1.19, 0.13]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.7 %	0.21 [-0.19, 0.60]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.6 %	-0.21 [-1.09, 0.67]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.7 %	-0.35 [-1.19, 0.50]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.4 %	-1.17 [-2.39, 0.04]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)	-	2.1 %	-0.41 [-0.71, -0.11]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.7 %	-1.07 [-1.89, -0.25]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.7 %	-0.23 [-1.07, 0.61]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		1.1 %	0.19 [-0.42, 0.80]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.1 %	-0.55 [-1.14, 0.03]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	2.4 %	-0.12 [-0.33, 0.09]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.5 %	-0.59 [-1.04, -0.14]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		0.9 %	-0.31 [-1.01, 0.38]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.9 %	-0.49 [-1.17, 0.20]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)	- _	0.5 %	-1.08 [-2.09, -0.07]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	-	1.3 %	0.04 [-0.47, 0.55]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		1.5 %	-0.23 [-0.67, 0.21]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		1.9 %	-0.56 [-0.90, -0.22]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.0 %	-0.49 [-1.12, 0.14]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	+	1.5 %	0.08 [-0.36, 0.52]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		1.3 %	-0.41 [-0.93, 0.10]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.5 %	0.03 [-1.01, 1.08]
Matros 2006	23	76 (36.3)	21	72 (28.3)	<u> </u>	1.1 %	0.12 [-0.47, 0.71]

-4 -2 0 2 Favours no-treatment

4

Favours placebo

(Continued . . .)

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo	M (CD)	No-treatment		Std. Mean Difference	Weight	(Continue Std. Mean Difference
Melchart 2005	N 57	Mean(SD)	N 63	Mean(SD)	IV,Random,95% Cl 	1.8 %	IV,Random,95% C -0.70 [-1.07, -0.33
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		1.2 %	-0.49 [-1.06, 0.08
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		1.2 %	-1.37 [-1.85, -0.89
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)	_	1.8 %	-0.15 [-0.53, 0.23
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		1.0 %	0.10 [-0.31, 0.50
Parker 2003	13	. ,	14			0.8 %	0.10 [-0.51, 0.50
		16.2 (7.5)		14.2 (7.5)	1		-
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)		2.1 %	-0.06 [-0.35, 0.23
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		1.0 %	-0.40 [-1.05, 0.24
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		1.8 %	0.20 [-0.16, 0.55
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.4 %	-0.30 [-0.80, 0.19
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.4 %	-0.67 [-1.80, 0.46
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		1.4 %	-0.72 [-1.20, -0.23
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		1.2 %	-0.16 [-0.73, 0.40
Rschke 2000	24	23 (16.2)	24	26 (16)		1.2 %	-0.18 [-0.75, 0.38
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.8 %	-0.02 [-0.78, 0.73
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.4 %	-0.13 [-1.26, 1.00
Sprott 1993	10	7.9 (3)	10	7.4 (3)	<u> </u>	0.6 %	0.16 [-0.72, 1.04
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.7 %	-0.55 [-1.36, 0.27
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		1.1 %	0.05 [-0.55, 0.65
Thomas 1999	14	3.4 (0.28)	26	16.5 (9.73)		1.0 %	-0.31 [-0.96, 0.35
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)	-	2.0 %	-0.27 [-0.59, 0.04
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	+	2.2 %	0.12 [-0.14, 0.37
Tritrakarn 2000	41	49 (16)	41	61 (17)		1.5 %	-0.72 [-1.17, -0.27
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.4 %	-0.60 [-1.07, -0.12
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	1.5 %	0.0 [-0.44, 0.44
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		1.9 %	-0.84 [-1.19, -0.50
Wojciechowski 1984	9	264 (122)	12	238 (190)	<u> </u>	0.6 %	0.15 [-0.71, 1.02
	2979		3025		•	100.0 %	-0.28 [-0.36, -0.20

Favours placebo

Favours no-treatment

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 5.7. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 7 Patientreported outcomes that are observable.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 7 Patient-reported outcomes that are observable

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)	_	4.1 %	-0.09 [-0.56, 0.38]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		3.4 %	0.08 [-0.44, 0.60]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)	·	1.0 %	-0.32 [-1.28, 0.64]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)	- _	1.1 %	-0.94 [-1.88, -0.01]
Espie 1989	4	63.5 (30.6)	13	96.5 (63.5)	_ _	1.6 %	-0.65 [-1.43, 0.13]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	-	24.3 %	-0.41 [-0.57, -0.26]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		1.7 %	-0. 3 [-0.89, 0.63]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	10.3 %	-0.06 [-0.34, 0.22]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		3.4 %	-0.28 [-0.81, 0.24]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.5 %	0.04 [-1.35, 1.42]
Lick 1977	10	66 (25)	10	63 (32)	_	1.2 %	0.10 [-0.78, 0.98]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		1.2 %	0.0 [-0.90, 0.90]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		2.4 %	-0.3 [-0.93, 0.32]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	7.5 %	0.06 [-0.28, 0.40]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		4.7 %	-0.19 [-0.63, 0.25]
Nicassio 1974	7	7.29 (33.7)	9	99.25 (35.3)		1.0 %	0.19 [-0.80, 1.18]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)	-	4.5 %	-0.12 [-0.57, 0.33]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		3.3 %	-0.15 [-0.69, 0.38]
Sipich 1974	10	8 (14)	10	32.5 (14)		0.9 %	-1.68 [-2.73, -0.63]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	_ 	1.5 %	0.22 [-0.56, .0]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	-	9.3 %	-0.16 [-0.46, 0.14]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		3.0 %	-0.28 [-0.83, 0.28]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)	·	0.6 %	0.27 [-0.98, 1.52]
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		3.8 %	-0.08 [-0.57, 0.41]
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		1.2 %	-0.45 [-1.34, 0.44]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo	No-	treatment		Std. M	lean Difference	Weight	(Continued) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rand	om,95% Cl		IV,Random,95% CI
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		-	2.4 %	-0.26 [-0.88, 0.37]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:		= 26.68, df = 25 (P = 0 = 0.000034)	1072 .37); I ² =6%	-4 Favou	-2 rs placebo	0 2 4 Favours no-tro	100.0 %	-0.21 [-0.31, -0.11]

Analysis 5.8. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 8 Observerreported outcomes involving patient's cooperation.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 8 Observer-reported outcomes involving patient's cooperation

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% CI
Allen 1998	11	-2.9 (7.9)		-6.1 (10.9)		2.8 %	0.32 [-0.52, 1.17]
Allen 2006	45	12 (9.6)	44	19 (9.6)	-#-	8.6 %	-0.72 [-1.15, -0.29]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		3.0 %	-0.41 [-1.22, 0.40]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		5.8 %	0.10 [-0.45, 0.66]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		3.1 %	-0.33 [-1.12, 0.46]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)	-#-	8.5 %	-0.72 [-1.15, -0.29]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)	-#-	5.8 %	-0.79 [-1.34, -0.23]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		5.6 %	-0.51 [-1.07, 0.05]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		5.6 %	-0.02 [-0.59, 0.54]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		2.5 %	0.04 [-0.86, 0.93]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		3.3 %	-0.14[-0.91, 0.63]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		2.3 %	-0.33 [-1.27, 0.61]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		2.6 %	-0.02 [-0.90, 0.85]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		6.0 %	-0.24 [-0.78, 0.30]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		2.9 %	-0.11 [-0.93, 0.72]

-4 -2 0 2 Favours placebo Favours no-treatment

4

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continued) Std. Mean Difference IV,Random,95% Cl
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		7.2 %	-0.25 [-0.73, 0.23]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	_ 	2.6 %	0.21 [-0.67, 1.09]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	+	3.9 %	0.48 [-0.22, 1.19]
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		5.8 %	-0.40 [-0.96, 0.15]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		3.8 %	-0.10 [-0.81, 0.62]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		3.8 %	0.05 [-0.66, 0.77]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		4.6 %	-0.20 [-0.83, 0.44]
Total (95% CI)	442		436		•	100.0 %	-0.26 [-0.41, -0.12]
Heterogeneity: $Tau^2 = 0$.02; Chi ² =	24.79, df = 21 (F	$P = 0.26$; $ ^2 = 5\%$				
Test for overall effect: Z	= 3.49 (P =	0.00048)					

Analysis 5.9. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 9 Observerreported outcomes not involving patient's cooperation.

-4 -2

Favours placebo

0

2

4

Favours no-treatment

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 9 Observer-reported outcomes not involving patient's cooperation

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		3.4 %	0.34 [-0.52, .2]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		2.0 %	0.56 [-0.60, 1.72]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)	-	8.4 %	-0.12 [-0.60, 0.35]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		3.4 %	-0.30 [-1.15, 0.56]
Bosley 1989	13	86 (10)	14	89 (10)		4.2 %	-0.29 [-1.05, 0.47]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		1.9 %	0.48 [-0.72, 1.67]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		1.8 %	0.29 [-0.95, 1.53]
Frankel 1978	7	93 (5)	8	95 (3)		2.5 %	-0.47 [-1.50, 0.57]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	16.8 %	-0.03 [-0.25, 0.20]
					-4 -2 0 2 4		

Favours placebo Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Mean(SD) -0.47 (7.83) -0.88 (3.83)	N 22	Mean(SD) 0.92 (7.83)	IV,Random,95% Cl	6.3 %	IV,Random,95% C
~ /		0.92 (7.83)		6.3 %	-017[-076_04]
-0.88 (3.83)					-0.17 [-0.70, 0.11
	10	-0.26 (2.2)		3.4 %	-0.19 [-1.05, 0.67
94.15 (4.84)	12	95.05 (4.84)		3.8 %	-0.18 [-0.98, 0.62
9.5 (10.5)	10	7.3 (6.6)	_ 	3.9 %	0.23 [-0.56, 1.02
-16.5 (9.3)	11	-0.8 (6.4)		1.7 %	-1.99 [-3.24, -0.74
-3.3 (4.24)	19	-2.9 (3.05)		5.4 %	-0.11 [-0.75, 0.54
107 (17)	6	108 (20)		2.1 %	-0.05 [-1.18, 1.08
92.5 (9.8)	13	104.5 (11)	_ _	3.7 %	-1.12 [-1.94, -0.30
47.52 (8.38)	10	47.87 (7.53)		3.4 %	-0.04 [-0.90, 0.81
66.5 (9.7)	27	64.1 (13.9)		8.9 %	0.21 [-0.24, 0.67
1.4 (0.5)	10	1.8 (0.6)	· _+	3.1 %	-0.69 [-1.60, 0.22
-0.89 (1.27)	25	-1.08 (1.38)	-	7.8 %	0.14 [-0.36, 0.65
-1.43 (2.53)	7	0.71 (1.44)		2.1 %	-0.97 [-2.10, 0.16
	425		•	100.0 %	-0.12 [-0.29, 0.05
26.94, df = 21 (l	$P = 0.17$; $I^2 = 22\%$				
0.16)					
	-16.5 (9.3) -3.3 (4.24) 107 (17) 92.5 (9.8) 47.52 (8.38) 66.5 (9.7) 1.4 (0.5) -0.89 (1.27) -1.43 (2.53) 26.94, df = 21 (f	$\begin{array}{c} -16.5 \ (9.3) & 11 \\ -3.3 \ (4.24) & 19 \\ 107 \ (17) & 6 \\ 92.5 \ (9.8) & 13 \\ 47.52 \ (8.38) & 10 \\ 66.5 \ (9.7) & 27 \\ 1.4 \ (0.5) & 10 \\ -0.89 \ (1.27) & 25 \\ -1.43 \ (2.53) & 7 \\ \hline \begin{array}{c} 425 \\ 26.94, \ df = 21 \ (P = 0.17); \ l^2 = 22\% \end{array}$	-16.5 (9.3) 11 -0.8 (6.4) -3.3 (4.24) 19 -2.9 (3.05) 107 (17) 6 108 (20) 92.5 (9.8) 13 104.5 (11) 47.52 (8.38) 10 47.87 (7.53) 66.5 (9.7) 27 64.1 (13.9) 1.4 (0.5) 10 1.8 (0.6) -0.89 (1.27) 25 -1.08 (1.38) -1.43 (2.53) 7 0.71 (1.44) 425 26.94, df = 21 (P = 0.17); I ² = 22%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 5.10. Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 10 Laboratory outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 5 Effect modification subgroup analysis: type of outcomes

Outcome: 10 Laboratory outcomes

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	N Mean(SD) N Mean(SD) IV,Random,95% Cl		IV,Random,95% CI		IV,Random,95% CI		
Blades 2001	40	-16 (6)	40	-16 (6)	+	11.0 %	0.0 [-0.44, 0.44]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)	+	8.0 %	0.08 [-0.44, 0.59]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)	-	15.7 %	0.31 [-0.05, 0.68]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	•	62.3 %	0.15 [-0.04, 0.33]
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)	+	3.0 %	0.24 [-0.60, 1.08]
Total (95% CI)	362		367		•	100.0 %	0.16 [0.01, 0.30]
Heterogeneity: Tau ² =	0.0; Chi ² =	I.32, df = 4 (P =	0.86); l ² =0.0%				
Test for overall effect: 2	Z = 2.10 (P =	= 0.036)					

-10 -5 0 5 10

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

Analysis 6.1. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 1 To study the effect of placebo was an explicit trial purpose.

Review: Placebo interventions for all clinical conditions

Comparison: 6 Effect modification subgroup analysis: the purpose of the trials

Outcome: I To study the effect of placebo was an explicit trial purpose

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Frank 1990	14/26	4/26		6.3 %	1.00 [0.60, 1.65]
Hutton 1991	5/24	16/30		2.6 %	0.39 [0.17, 0.91]
Hyman 1986	9/15	15/15		8.4 %	0.61 [0.40, 0.93]
Klerman 1974	17/25	16/25	-	8.9 %	1.06 [0.71, 1.58]
Rabkin 1990	14/27	12/23		5.8 %	0.99 [0.58, 1.70]
Schallreuter 2002	3/10	4/10		1.3 %	0.75 [0.22, 2.52]
Scharff 2002	11/12	2/ 2	-	16.6 %	0.92 [0.74, 1.15]
Thomas 1987	47/100	50/100	-	13.3 %	0.94 [0.71, 1.25]
Tyler 1946	89/260	106/303	+	16.4 %	0.98 [0.78, 1.23]
Watzl 1986	15/34	7/36		3.2 %	2.27 [1.06, 4.88]
Wilson 1980	31/40	10/10	-	17.3 %	0.80 [0.65, 0.99]
Total (95% CI)	573	590	•	100.0 %	0.90 [0.78, 1.04]
Total events: 255 (Placebo Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	02; Chi ² = 16.13, df	,			

0.1 0.2 0.5 1 2 5 10 Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

Analysis 6.2. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 2 To study the effect of placebo was not an explicit trial purpose.

Review: Placebo interventions for all clinical conditions

Comparison: 6 Effect modification subgroup analysis: the purpose of the trials

Outcome: 2 To study the effect of placebo was not an explicit trial purpose

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		2.1 %	1.31 [0.88, 1.94]
Alkaissi 1999	9/20	11/20		1.0 %	0.82 [0.44, 1.53]
Alkaissi 2002	77/139	82/136	-	4.7 %	0.92 [0.75, 1.12]
Aune 1998	11/26	9/14	<u> </u>	1.0 %	0.66 [0.36, 1.19]
Berg 1983	9/11	9/15		1.4 %	1.36 [0.83, 2.24]
Blackman 1964	6/12	6/12		0.6 %	1.00 [0.45, 2.23]
Carter 2003	3/28	20/29		1.6 %	0.67 [0.42, 1.07]
Corver 2006	227/279	360/416	-	8.0 %	0.94 [0.88, 1.01]
De Sanctis 2001	9/10	8/9	+	2.9 %	1.01 [0.74, 1.38]
Double 1993	3/22	3/22		0.2 %	1.00 [0.23, 4.42]
Dundee 1986	17/25	17/25		2.2 %	1.00 [0.68, 1.46]
Elliott 1978	6/18	6/6		0.9 %	0.37 [0.19, 0.71]
Faas 1993	107/162	108/155	+	5.9 %	0.95 [0.81, 1.10]
Fanti 2003	8/10	9/10		2.3 %	0.89 [0.61, 1.29]
Guglielmi 1982	12/12	11/12		4.3 %	1.09 [0.87, 1.36]
Harrison 1975	24/28	25/30	+	4.4 %	1.03 [0.83, 1.28]
Heinzl 1981	70/130	92/132	-	4.9 %	0.77 [0.64, 0.94]
Jacobs 1971	9/15	12/39		1.0 %	1.95 [1.04, 3.65]
Kerr 2003	28/33	32/36	+	5.1 %	0.95 [0.79, 1.15]
Killen 1990	226/309	219/309	+	7.3 %	1.03 [0.94, 1.14]
Malcolm 1980	40/63	44/58		4.0 %	0.84 [0.66, 1.06]
McMillan 1994	14/26	24/46		1.7 %	1.03 [0.66, 1.62]
Molsberger 2002	38/58	30/53	+	3.0 %	1.16 [0.86, 1.56]
Najnigier 1997	21/30	24/30	-	3.1 %	0.88 [0.65, 1.17]
Roughan 1981	9/12	9/14		1.4 %	1.17 [0.70, 1.94]

 0.1
 0.2
 0.5
 2
 5
 10

 Favours placebo
 Favours no-treatment

(Continued . . .)

Placebo interventions for all clinical conditions (Review)

/365	224/316			M-H,Random,95% Cl
		•	6.6 %	0.69 [0.61, 0.78]
1/5	/4 ←		0.1 %	0.80 [0.07, 9.18]
8/10	8/9	<u> </u>	2.1 %	0.90 [0.61, 1.32]
/158	27/77	<u> </u>	2.3 %	1.05 [0.73, 1.51]
2/26	25/28	+	4.6 %	0.95 [0.77, 1.17]
9/24	21/30	<u> </u>	2.9 %	1.13 [0.83, 1.54]
3/13	7/13		0.3 %	0.43 [0.14, 1.30]
9/20	19/20	+	6.2 %	1.00 [0.87, 1.15]
427	2451	•	100.0 %	0.94 [0.88, 1.01]
`````				
	$= 0.00075$ ); $ ^2 = 50\%$			
	8/10 //158 2/26 9/24 3/13 9/20 <b>427</b> (No-treatment) : 63.53, df = 32 (P = 0.076)	x1/158       27/77         x2/26       25/28         9/24       21/30         3/13       7/13         9/20       19/20         427       2451         (No-treatment)       : 63.53, df = 32 (P = 0.00075); l ² = 50%	x/158       27/77         x/2/26       25/28         9/24       21/30         3/13       7/13         9/20       19/20         427       2451         (No-treatment)       63.53, df = 32 (P = 0.00075); l ² =50%	1/158     27/77     2.3 %       1/2/26     25/28     4.6 %       9/24     21/30     2.9 %       3/13     7/13     0.3 %       9/20     19/20     6.2 %       427     2451     100.0 %       (No-treatment)     63.53, df = 32 (P = 0.00075); l ² = 50%

0.1 0.2 0.5 2 5 10

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Analysis 6.3. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 3 To study the effect of placebo was an explicit trial purpose.

Review: Placebo interventions for all clinical conditions

-

Comparison: 6 Effect modification subgroup analysis: the purpose of the trials

Outcome: 3 To study the effect of placebo was an explicit trial purpose

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% CI
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		1.8 %	0.34 [ -0.52, 1.21 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		4.6 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		1.7 %	-1.07 [ -1.94, -0.20 ]
Chenard 1991	12	29 (19)	16	30 (19)		2.3 %	-0.05 [ -0.80, 0.70 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		1.7 %	0.0 [ -0.88, 0.88 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	-	12.3 %	-0.41 [ -0.57, -0.26 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		2.2 %	-0.13 [ -0.89, 0.63 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)	-	5.3 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		5.0 %	-0.28 [ -0.73, 0.16 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		2.2 %	-0.54 [ -1.30, 0.21 ]
Hashish 1986	25	6 (  .7)	50	30 (18.9)		4.3 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)		3.5 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		1.3 %	-1.58 [ -2.61, -0.55 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		2.0 %	-0.18 [ -0.98, 0.62 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)	-8-	8.0 %	-0.41 [ -0.71, -0.11 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)	_ <u></u>	2.1 %	0.23 [ -0.56, 1.02 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		3.7 %	-0.79 [ -1.34, -0.23 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		2.6 %	-0.31 [ -1.01, 0.38 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		1.3 %	-1.08 [ -2.09, -0.07 ]
Lick 1977	10	66 (25)	10	63 (32)		1.7 %	0.10 [ -0.78, 0.98 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		3.6 %	-0.02 [ -0.59, 0.54 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		3.1 %	-0.31 [ -0.93, 0.32 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.5  ( .6 )		5.0 %	-0.12 [ -0.57, 0.33 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	8.3 %	-0.06 [ -0.35, 0.23 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		2.9 %	-0.40 [ -1.05, 0.24 ]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo	Ν	lo-treatment		Std. M	ean Difference	Weight	( Continued) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rando	om,95% Cl	-	IV,Random,95% CI
Thomas 1999	14	3.4 ( 0.28)	26	16.5 (9.73)	+-	_	2.8 %	-0.3  [ -0.96, 0.35 ]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)			2.4 %	-0.10 [ -0.81, 0.62 ]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)	_	<u> </u>	2.4 %	0.05 [ -0.66, 0.77 ]
Total (95% CI)	931		1096		٠		100.0 %	-0.34 [ -0.46, -0.22 ]
Heterogeneity: $Tau^2 =$	0.03; Chi ² =	37.56, df = 27 (P =	0.09); l ² =28%					
Test for overall effect: Z	Z = 5.51 (P <	(100000)						
					-4 -2 (	) 2 4		
				Fa	vours placebo	Favours no-tr	eatment	

# Analysis 6.4. Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 4 To study the effect of placebo was not an explicit trial purpose.

Review: Placebo interventions for all clinical conditions

Comparison: 6 Effect modification subgroup analysis: the purpose of the trials

Outcome: 4 To study the effect of placebo was not an explicit trial purpose

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.0 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		0.6 %	-0.14 [ -0.80, 0.52 ]
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		0.4 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		1.1 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)	+	0.6 %	0.38 [ -0.30, 1.06 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		0.9 %	0.08 [ -0.44, 0.60 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.3 %	0.56 [ -0.60, 1.72 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.4 %	-0.32 [ -1.28, 0.64 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	+	1.6 %	-0.17 [ -0.43, 0.10 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		0.9 %	0.13 [ -0.39, 0.64 ]
Blades 2001	40	-16 (6)	40	-16 (6)	+	1.1 %	0.0 [ -0.44, 0.44 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		0.5 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)	· · · · · · ·	0.7 %	-0.28 [ -0.90, 0.33 ]

-2 0 2 4 placebo Favours no-treatment

Favours placebo

-4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	( Continued) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)	_+	0.4 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	3	86 (10)	14	89 (10)		0.5 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)	+	1.0 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.5 %	-0.41 [ -1.22, 0.40 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		1.4 %	-0.62 [ -0.96, -0.29 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.6 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)	<b>·</b>	0.2 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	<u> </u>	0.8 %	0.10 [ -0.45, 0.66 ]
Classen 1983	15	11.3 (8.3)	15	14.4 (6.1)		0.6 %	-0.4  [ -1.14, 0.3  ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)	<del></del>	0.2 %	0.29 [ -0.95, 1.53 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)	<u> </u>	0.5 %	-0.92 [ -1.72, -0.12 ]
Costello 2006	48	33 (25)	42	31 (25)	+	1.1 %	0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	_ <del></del>	0.7 %	0.13 [ -0.47, 0.74 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)		0.9 %	0.08 [ -0.44, 0.59 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.4 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.4 %	-0.39 [ -1.35, 0.58 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	+	1.2 %	-0.12 [ -0.51, 0.27 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	-	1.9 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	1.8 %	-0.06 [ -0.28, 0.17 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		1.1 %	-0.36 [ -0.80, 0.08 ]
Espie 1989	4	63.5 (30.6)	13	96.5 (63.5)		0.5 %	-0.65 [ -1.43, 0.13 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		0.5 %	-0.33 [ -1.12, 0.46 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.6 %	-0.54 [ -1.27, 0.19 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	<b>-</b> _	0.3 %	-0.98 [ -2.02, 0.06 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	1.6 %	-0.06 [ -0.33, 0.21 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.3 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		0.7 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.4 %	-0.97 [ -1.91, -0.03 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	1.8 %	-0.03 [ -0.25, 0.20 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		0.8 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)		0.4 %	-0.19 [ -1.05, 0.67 ]

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)	-+	0.8 %	-0.16 [ -0.72, 0.39 ]
Helms 1987	П	103 (91)	П	79 (99)	_ <del></del>	0.4 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.6 %	-0.53 [ -1.19, 0.13 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	1.6 %	-0.06 [ -0.34, 0.22 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.2 %	0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)	<u> </u>	0.4 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.4 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.2 %	-1.17 [ -2.39, 0.04 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.5 %	-1.07 [ -1.89, -0.25 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.3 %	0.31 [ -0.05, 0.68 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.4 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		0.9 %	-0.28 [ -0.81, 0.24 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.2 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		0.7 %	0.19 [ -0.42, 0.80 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		0.8 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	1.8 %	-0.12 [ -0.33, 0.09 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.0 %	-0.59 [ -1.04, -0.14 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.6 %	-0.49 [ -1.17, 0.20 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	+	0.9 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		0.8 %	-0.5  [ -1.07, 0.05 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)	-+	1.1 %	-0.23 [ -0.67, 0.21 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		1.4 %	-0.56 [ -0.90, -0.22 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	1.9 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		0.7 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)	<u> </u>	0.4 %	0.0 [ -0.90, 0.90 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	-	1.1 %	0.08 [ -0.36, 0.52 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		0.9 %	-0.41 [ -0.93, 0.10 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)	<u> </u>	0.3 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)	<u> </u>	0.7 %	0.12 [ -0.47, 0.71 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)	<u> </u>	0.4 %	0.04 [ -0.86, 0.93 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		1.3 %	-0.70 [ -1.07, -0.33 ]

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo		No-treatment	M (CD)	Std. Mean Difference	Weight	( Continued) Std. Mean Difference
Moffet 1996	N 22	Mean(SD) 24.04 (18.56)	N 27	Mean(SD) 34.56 (23.2)	IV,Random,95% Cl	0.8 %	IV,Random,95% Cl -0.49 [ -1.06, 0.08 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	1.4 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		1.1 %	-0.19 [ -0.63, 0.25 ]
Morton 1993	13	22.11 (16.38)	12	24.53 (16.38)		0.5 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)		-0.8 (6.4)		0.2 %	-1.99 [ -3.24, -0.74 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.2 %	-0.33 [ -1.27, 0.61 ]
Nawrocki 1997		· · · ·		. ,			
	40	9.5 (6)	42	17 (4.8)		1.0 %	-1.37 [ -1.85, -0.89 ]
Nicassio 1974	7	117.29 (133.7)	9	99.25 (35.3)		0.3 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.4 %	-0.02 [ -0.90, 0.85 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		1.2 %	-0.15 [ -0.53, 0.23 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		1.2 %	0.10 [ -0.31, 0.50 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.5 %	0.26 [ -0.50, 1.02 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		0.8 %	-0.24 [ -0.78, 0.30 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		1.3 %	0.20 [ -0.16, 0.55 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.5 %	-0.11 [ -0.93, 0.72 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		0.7 %	-0.11 [ -0.75, 0.54 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		0.9 %	-0.15 [ -0.69, 0.38 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		0.9 %	-0.30 [ -0.80, 0.19 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)	<u> </u>	0.3 %	-0.67 [ -1.80, 0.46 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.3 %	-0.05 [ -1.18, 1.08 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		1.0 %	-0.72 [ -1.20, -0.23 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		0.8 %	-0.16 [ -0.73, 0.40 ]
Rschke 2000	24	23 (16.2)	24	26 (16)		0.8 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.5 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)	<u> </u>	0.3 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.5 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)	<u> </u>	0.4 %	-0.04 [ -0.90, 0.81 ]
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		1.0 %	-0.25 [ -0.73, 0.23 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)	+-	1.0 %	0.21 [ -0.24, 0.67 ]
Sipich 1974	10	8 (14)	10	32.5 (14)		0.3 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	<u> </u>	0.5 %	0.22 [ -0.56, 1.01 ]

Favours no-treatment

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup F	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued Std. Mean Difference IV,Random,95% Cl
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.4 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)	<u> </u>	0.4 %	-0.69 [ -1.60, 0.22 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	+	1.5 %	-0.16 [ -0.46, 0.14 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)	_+_	0.8 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.2 %	0.27 [ -0.98, 1.52 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	_ <del></del>	0.4 %	0.21 [ -0.67, 1.09
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.5 %	-0.55 [ -1.36, 0.27 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)	+	0.7 %	0.05 [ -0.55, 0.65 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	+	0.6 %	0.48 [ -0.22, 1.19
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		1.4 %	-0.27 [ -0.59, 0.04
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	+	1.7 %	0.12 [ -0.14, 0.37
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)	+-	0.9 %	0.14 [ -0.36, 0.65
Tritrakam 2000	41	49 (16)	41	61 (17)		1.1 %	-0.72 [ -1.17, -0.27
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)	+	0.9 %	-0.08 [ -0.57, 0.41
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.0 %	-0.60 [ -1.07, -0.12
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)	<del></del>	0.4 %	0.24 [ -0.60, 1.08
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)	<u> </u>	0.4 %	-0.45 [ -1.34, 0.44
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	1.1 %	0.0 [ -0.44, 0.44
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		0.8 %	-0.40 [ -0.96, 0.15
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		0.7 %	-0.26 [ -0.88, 0.37
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		1.3 %	-0.84 [ -1.19, -0.50
Wojciechowski 1984	9	264 (122)	12	238 (190)	_ <del></del>	0.4 %	0.15 [ -0.71, 1.02
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		0.7 %	-0.20 [ -0.83, 0.44
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	<b>-</b> _	0.3 %	-0.97 [ -2.10, 0.16
<b>otal (95% CI)</b> eterogeneity: Tau ² = 0.04 st for overall effect: Z =			<b>4229</b> (P<0.00001); I ² =	41%	,	100.0 %	-0.20 [ -0.26, -0.14

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Analysis 7.1. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome I Psychological placebos.

Review: Placebo interventions for all clinical conditions

Comparison: 7 Effect modification subgroup analysis: type of placebo interventions

Outcome: I Psychological placebos

Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
n/N	n/N	M-H,Random,95% CI		M-H,Random,95% Cl
3/28	20/29		7.7 %	0.67 [ 0.42, 1.07 ]
6/18	6/6		4.8 %	0.37 [ 0.19, 0.71 ]
12/12	/ 2	+	14.7 %	1.09 [ 0.87, 1.36 ]
9/15	15/15		8.8 %	0.61 [ 0.40, 0.93 ]
9/12	9/14		6.9 %	1.17 [ 0.70, 1.94 ]
11/12	12/12	+	14.7 %	0.92 [ 0.74, 1.15 ]
8/10	8/9		9.5 %	0.90 [ 0.61, 1.32 ]
22/26	25/28	-	15.3 %	0.95 [ 0.77, 1.17 ]
19/20	19/20	+	17.6 %	1.00 [ 0.87, 1.15 ]
153	145	•	100.0 %	0.88 [ 0.75, 1.04 ]
5 (No-treatme	ent)			
$hi^2 = 22.18, df$	= 8 (P = 0.005); I ² =64%			
(P = 0.12)				
	n/N 13/28 6/18 12/12 9/15 9/12 11/12 8/10 22/26 19/20 <b>153</b> 5 (No-treatments) 5 (No-treatments)	n/N         n/N $13/28$ $20/29$ $6/18$ $6/6$ $12/12$ $11/12$ $9/15$ $15/15$ $9/12$ $9/14$ $11/12$ $12/12$ $8/10$ $8/9$ $22/26$ $25/28$ $19/20$ $19/20$ $153$ $145$ $5$ (No-treatment) $12^2 = 22.18$ , df = $8$ (P = $0.005$ ); $1^2 = 64\%$	n/N         n/N         M-H,Random,95% Cl           13/28         20/29         -           6/18         6/6         -           12/12         11/12         -           9/15         15/15         -           9/12         9/14         -           11/12         12/12         -           8/10         8/9         -           22/26         25/28         -           19/20         19/20         -           153         145         -           5 (No-treatment)         -         - $n^2 = 22.18$ , df = 8 (P = 0.005); l^2 = 64%         -	n/N         n/N         M-H,Random,95% Cl           13/28         20/29         7.7 %           6/18         6/6         4.8 %           12/12         11/12         14.7 %           9/15         15/15         8.8 %           9/12         9/14         6.9 %           11/12         12/12         14.7 %           8/10         8/9         9.5 %           22/26         25/28         15.3 %           19/20         19/20         17.6 %           153         145         100.0 %           5 (No-treatment)         5(No-treatment)

0.1 0.2 0.5 1 2 5 10 Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

## Analysis 7.2. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 2 Physical placebos.

Review: Placebo interventions for all clinical conditions

Comparison: 7 Effect modification subgroup analysis: type of placebo interventions

Outcome: 2 Physical placebos

	n/N	n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Alkaissi 1999	9/20	11/20		2.7 %	0.82 [ 0.44, 1.53 ]
Alkaissi 2002	77/139	82/136	-	12.3 %	0.92 [ 0.75, 1.12 ]
Aune 1998	11/26	9/14		3.0 %	0.66 [ 0.36, 1.19 ]
Corver 2006	227/279	360/416	-	19.4 %	0.94 [ 0.88,  .0  ]
Dundee 1986	17/25	17/25	-	6.0 %	1.00 [ 0.68, 1.46 ]
Faas 1993	107/162	108/155	+	15.0 %	0.95 [ 0.81, 1.10 ]
Fanti 2003	8/10	9/10		6.2 %	0.89 [ 0.61, 1.29 ]
McMillan 1994	14/26	24/46		4.7 %	1.03 [ 0.66, 1.62 ]
Molsberger 2002	38/58	30/53		8.2 %	1.16 [ 0.86, 1.56 ]
Scharf 2006	179/365	224/316	-	16.4 %	0.69 [ 0.61, 0.78 ]
Tarcin 2004	58/158	27/77		6.3 %	1.05 [ 0.73, 1.51 ]
Total (95% CI)	1268	1268	•	100.0 %	0.91 [ 0.81, 1.01 ]
Total events: 745 (Placebo), 90		,			
Heterogeneity: $Tau^2 = 0.02$ ; C	$hi^2 = 24.73, df$	$= 10 (P = 0.01); 1^2 = 60\%$			

0.1 0.2 0.5 1 2 5 10 Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

### Analysis 7.3. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 3 Pharmacological placebos.

Review: Placebo interventions for all clinical conditions

Comparison: 7 Effect modification subgroup analysis: type of placebo interventions

Outcome: 3 Pharmacological placebos

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		3.4 %	1.31 [ 0.88, 1.94 ]
Berg 1983	9/11	9/15	<b>+</b>	2.3 %	1.36 [ 0.83, 2.24 ]
Blackman 1964	6/12	6/12		1.0 %	1.00 [ 0.45, 2.23 ]
De Sanctis 2001	9/10	8/9	+	4.9 %	1.01 [ 0.74, 1.38 ]
Double 1993	3/22	3/22		0.3 %	1.00 [ 0.23, 4.42 ]
Frank 1990	14/26	14/26		2.3 %	1.00 [ 0.60, 1.65 ]
Harrison 1975	24/28	25/30	+	7.5 %	1.03 [ 0.83, 1.28 ]
Heinzl 1981	70/130	92/132	-	8.5 %	0.77 [ 0.64, 0.94 ]
Hutton 1991	5/24	16/30		0.9 %	0.39 [ 0.17, 0.91 ]
Jacobs 1971	9/15	12/39		1.5 %	1.95 [ 1.04, 3.65 ]
Kerr 2003	28/33	32/36	-	9.0 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	+	13.5 %	1.03 [ 0.94, 1.14 ]
Klerman 1974	17/25	16/25	_ <del></del>	3.3 %	1.06 [ 0.71, 1.58 ]
Malcolm 1980	40/63	44/58	-	6.9 %	0.84 [ 0.66, 1.06 ]
Najnigier 1997	21/30	24/30		5.2 %	0.88 [ 0.65, 1.17 ]
Rabkin 1990	14/27	12/23		2.0 %	0.99 [ 0.58, 1.70 ]
Schallreuter 2002	3/10	4/10		0.4 %	0.75 [ 0.22, 2.52 ]
Stransky 1989	1/5	1/4	·	0.1 %	0.80 [ 0.07, 9.18 ]
Thomas 1987	47/100	50/100	-	5.5 %	0.94 [ 0.71, 1.25 ]
Tyler 1946	89/260	106/303	+	7.2 %	0.98 [ 0.78, 1.23 ]
Walton 1993	19/24	21/30	+	4.8 %	1.13 [ 0.83, 1.54 ]
Watzl 1986	15/34	7/36		1.1 %	2.27 [ 1.06, 4.88 ]
Whittaker 1963	3/13	7/13		0.5 %	0.43 [ 0.14, 1.30 ]
Wilson 1980	31/40	10/10		7.8 %	0.80 [ 0.65, 0.99 ]
Total (95% CI)	1579	1628	•	100.0 %	0.97 [ 0.89, 1.05 ]

0.1 0.2 0.5 2 5 10 Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo	No-treatment			Risk Ratio	1	Weight	( Continued) Risk Ratio
	n/N	n/N n/N		M-H,Random,95% Cl				M-H,Random,95% Cl
Total events: 753 (Placebo	o), 776 (No-treatme	nt)						
Heterogeneity: $Tau^2 = 0.0$	01; Chi ² = 33.64, df	= 23 (P = 0.07); I ² = 32%						
Test for overall effect: Z =	= 0.76 (P = 0.45)							
			i i		i i			
			0.1 0.2	2 0.5	1 2	5 10		
			Favours	placebo	Favours	no-treatment		

# Analysis 7.4. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 4 Psychological placebos.

Review: Placebo interventions for all clinical conditions

Comparison: 7 Effect modification subgroup analysis: type of placebo interventions

Outcome: 4 Psychological placebos

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		3.1 %	-0.09 [ -0.56, 0.38 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		2.7 %	0.08 [ -0.44, 0.60 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.9 %	-0.32 [ -1.28, 0.64 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		1.2 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		2.1 %	-0.28 [ -0.90, 0.33 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		1.2 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		1.4 %	-0.29 [ -1.05, 0.47 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		1.3 %	-0.41 [ -1.22, 0.40 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.6 %	0.48 [ -0.72, 1.67 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		1.1 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		1.0 %	-0.94 [ -1.88, -0.01 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	+	7.9 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	-	7.2 %	-0.06 [ -0.28, 0.17 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		1.4 %	-0.65 [ -1.43, 0.13 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		1.3 %	-0.33 [ -1.12, 0.46 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.8 %	-0.98 [ -2.02, 0.06 ]

-2 0 2 4

Favours no-treatment

Favours placebo

_4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Frankel 1978	7	93 (5)	8	95 (3)		0.8 %	-0.47 [ -1.50, 0.57 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		1.0 %	-0.97 [ -1.91, -0.03 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)	<u> </u>	2.2 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)		1.2 %	-0.19 [ -1.05, 0.67 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		0.8 %	-1.58 [ -2.61, -0.55 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	•	6.0 %	-0.06 [ -0.34, 0.22 ]
Irvin 1996	11	3.3 (0.7)	П	3.7 (1.4)		1.2 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.6 %	-1.17 [ -2.39, 0.04 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		1.2 %	-0.23 [ -1.07, 0.61 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.5 %	0.04 [ -1.35, 1.42 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.9 %	-1.08 [ -2.09, -0.07 ]
Lick 1977	10	66 (25)	10	63 (32)	<u> </u>	1.1 %	0.10 [ -0.78, 0.98 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		3.5 %	-0.23 [ -0.67, 0.21 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		2.0 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		1.1 %	0.0 [ -0.90, 0.90 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.8 %	0.03 [ -1.01, 1.08 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	4.9 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		3.5 %	-0.19 [ -0.63, 0.25 ]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)	<u> </u>	0.6 %	-1.99 [ -3.24, -0.74 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)	<u> </u>	0.9 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		1.1 %	-0.02 [ -0.90, 0.85 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)	-	3.9 %	0.10 [ -0.31, 0.50 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)	<u> </u>	1.5 %	0.26 [ -0.50, 1.02 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		2.5 %	-0.24 [ -0.78, 0.30 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		1.9 %	-0.40 [ -1.05, 0.24 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.7 %	-0.67 [ -1.80, 0.46 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		2.4 %	-0.16 [ -0.73, 0.40 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		1.3 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		1.2 %	-0.04 [ -0.90, 0.81 ]
Sipich 1974	10	8 (14)	10	32.5 (14)		0.8 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	<u> </u>	1.4 %	0.22 [ -0.56, 1.01 ]

-4 -2 0 2 4

Favours no-treatment

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Placebo	Ν	o-treatment		Std. Mean Difference	Weight	( Continued Std. Mean Difference
N	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
25	-14.3 (5.5)	25	-12.8 (5.2)	-+-	2.4 %	-0.28 [ -0.83, 0.28 ]
12	1.3 (0.6)	12	1.7 (0.8)		1.3 %	-0.55 [ -1.36, 0.27 ]
14	3.4 ( 0.28)	26	16.5 (9.73)	-+-	1.9 %	-0.31 [ -0.96, 0.35 ]
10	44.2 (41.26)	10	59.8 (22.9)		1.1 %	-0.45 [ -1.34, 0.44 ]
39	0.4 (1.8)	40	0.4 (1.8)	+	3.5 %	0.0 [ -0.44, 0.44 ]
9	264 (122)	12	238 (190)	_ <del></del>	1.1 %	0.15 [ -0.71, 1.02 ]
1242		1304		•	100.0 %	-0.22 [ -0.31, -0.12 ]
	4.12, df = 52 (P = 0			•	100.0 %	-0.22 [ -0.31,
	N 25 12 14 10 39 9 <b>1242</b>	N         Mean(SD)           25         -14.3 (5.5)           12         1.3 (0.6)           14         13.4 (10.28)           10         44.2 (41.26)           39         0.4 (1.8)           9         264 (122)           1242	N         Mean(SD)         N           25         -14.3 (5.5)         25           12         1.3 (0.6)         12           14         13.4 (10.28)         26           10         44.2 (41.26)         10           39         0.4 (1.8)         40           9         264 (122)         12	N         Mean(SD)         N         Mean(SD)           25         -14.3 (5.5)         25         -12.8 (5.2)           12         1.3 (0.6)         12         1.7 (0.8)           14         13.4 (10.28)         26         16.5 (9.73)           10         44.2 (41.26)         10         59.8 (22.9)           39         0.4 (1.8)         40         0.4 (1.8)           9         264 (122)         12         238 (190)           1242         1304	N         Mean(SD)         N         Mean(SD)         IV,Random,95% Cl           25         -14.3 (5.5)         25         -12.8 (5.2)         +           12         1.3 (0.6)         12         1.7 (0.8)         +           14         13.4 (10.28)         26         16.5 (9.73)         +           10         44.2 (41.26)         10         59.8 (22.9)         +           39         0.4 (1.8)         40         0.4 (1.8)         +           9         264 (122)         12         238 (190)         +           1242         1304         •         •	N         Mean(SD)         N         Mean(SD)         IV,Random,95% Cl           25         -14.3 (5.5)         25         -12.8 (5.2)         -         2.4 %           12         1.3 (0.6)         12         1.7 (0.8)         -         1.3 %           14         13.4 (10.28)         26         16.5 (9.73)         -         1.9 %           10         44.2 (41.26)         10         59.8 (22.9)         -         1.1 %           39         0.4 (1.8)         40         0.4 (1.8)         -         3.5 %           9         264 (122)         12         238 (190)         -         1.1 %           1242         1304         -         100.0 %         -

# Analysis 7.5. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 5 Physical placebos.

-4 -2

Favours placebo

0 2 4

Favours no-treatment

Review: Placebo interventions for all clinical conditions

Comparison: 7 Effect modification subgroup analysis: type of placebo interventions

Outcome: 5 Physical placebos

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Alfano 2001	24	6.2 (2.8)	4	6.6 (2.7)		1.3 %	-0.14 [ -0.80, 0.52 ]
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		0.9 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		2.2 %	-0.72 [ -1.15, -0.29 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)		3.1 %	-0.17 [ -0.43, 0.10 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		2.7 %	-0.62 [ -0.96, -0.29 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		1.2 %	-0.18 [ -0.88, 0.51 ]
Chenard 1991	12	29 (19)	16	30 (19)		1.1 %	-0.05 [ -0.80, 0.70 ]
Conn 1986	13	28.2 (18.4)	4	44.4 (15.7)		1.0 %	-0.92 [ -1.72, -0.12 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		1.5 %	0.13 [ -0.47, 0.74 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.8 %	-0.39 [ -1.35, 0.58 ]

-4 -2 0 2 4 Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	+	2.4 %	-0.12 [ -0.51, 0.27 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		2.1 %	-0.36 [ -0.80, 0.08 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		1.2 %	-0.54 [ -1.27, 0.19 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	3.1 %	-0.06 [ -0.33, 0.21 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)	_+_	1.7 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	6 (  .7)	50	30 (18.9)		1.9 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)	_+_	1.6 %	-0.74 [ -1.31, -0.16 ]
Helms 1987	11	103 (91)	11	79 (99)	_ <del></del>	0.9 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.3 %	-0.53 [ -1.19, 0.13 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		2.4 %	0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.9 %	-0.21 [ -1.09, 0.67 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)	+	2.9 %	-0.41 [ -0.71, -0.11 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)	<b>-</b> _	1.0 %	-1.07 [ -1.89, -0.25 ]
Kober 2002	20	66.7 (10)	21	64.4 ( 3.3)	_ <del></del>	1.5 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)	_ <del></del>	1.0 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.6 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	3.4 %	-0.12 [ -0.33, 0.09 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		2.1 %	-0.59 [ -1.04, -0.14 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)	_+_	1.3 %	-0.49 [ -1.17, 0.20 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	+	1.9 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		1.6 %	-0.51 [ -1.07, 0.05 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)	+	2.7 %	-0.56 [ -0.90, -0.22 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)		1.5 %	0.12 [ -0.47, 0.71 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		1.5 %	-0.31 [ -0.93, 0.32 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		2.5 %	-0.70 [ -1.07, -0.33 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		1.6 %	-0.49 [ -1.06, 0.08 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		1.1 %	-0.14 [ -0.91, 0.63 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		2.0 %	-1.37 [ -1.85, -0.89 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)	+	2.5 %	-0.15 [ -0.53, 0.23 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		1.0 %	-0.11 [ -0.93, 0.72 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)	+	1.7 %	-0.15 [ -0.69, 0.38 ]

-4 -2 0 2 Favours placebo

Favours no-treatment

4

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Roscoe 2005	ebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continue) Std. Mean Difference IV,Random,95% Cl
	31	2.4 (1.28)	33	2.8 (1.32)	-+	1.9 %	-0.30 [ -0.80, 0.19 ]
Rschke 2000	24	23 (16.2)	24	26 (16)	_+_	1.6 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		1.1 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.6 %	-0.13 [ -1.26, 1.00
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)	-+	2.0 %	-0.25 [ -0.73, 0.23
Sprott 1993	10	7.9 (3)	10	7.4 (3)	<u> </u>	0.9 %	0.16 [ -0.72, 1.04
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)	<del></del>	0.8 %	-0.69 [ -1.60, 0.22
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)	<del></del>	0.5 %	0.27 [ -0.98, 1.52
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	<del></del> +	0.9 %	0.21 [ -0.67, 1.09
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	<u></u>	1.2 %	0.48 [ -0.22, 1.19
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)	<u> </u>	1.9 %	0.14 [ -0.36, 0.65
Tritrakam 2000	41	49 (16)	41	61 (17)		2.1 %	-0.72 [ -1.17, -0.27
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		1.9 %	-0.08 [ -0.57, 0.41
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		2.0 %	-0.60 [ -1.07, -0.12
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		1.7 %	-0.40 [ -0.96, 0.15
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		1.2 %	-0.10 [ -0.81, 0.62
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		1.4 %	-0.26 [ -0.88, 0.37
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		2.6 %	-0.84 [ -1.19, -0.50
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)	-+-	1.4 %	-0.20 [ -0.83, 0.44
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)		0.6 %	-0.97 [ -2.10, 0.16
total (95% CI)         19           eterogeneity: Tau ² = 0.05; C         2           est for overall effect: Z = 6.64         2			<b>1954</b> (P = 0.000    );   ² :	=45%	•	100.0 %	-0.31 [ -0.41, -0.22

#### Analysis 7.6. Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 6 Pharmacological placebos.

Review: Placebo interventions for all clinical conditions

Comparison: 7 Effect modification subgroup analysis: type of placebo interventions

Outcome: 6 Pharmacological placebos

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% Cl
Andersen 1990	18	35 (27.15)	16	25 (23.6)		1.5 %	0.38 [ -0.30, 1.06 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)	_+	1.0 %	0.34 [ -0.52,  .2  ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (  .2)		0.6 %	0.56 [ -0.60, 1.72 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		2.4 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		1.0 %	-1.07 [ -1.94, -0.20 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)	_ <del></del>	2.2 %	0.13 [ -0.39, 0.64 ]
Blades 200 I	40	-16 (6)	40	-16 (6)	+	2.7 %	0.0 [ -0.44, 0.44 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)	-	2.5 %	-0.14 [ -0.61, 0.33 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	- <del>-</del>	2.0 %	0.10 [ -0.45, 0.66 ]
Classen 1983	15	.3 (8.3)	15	14.4 (6.1)		1.3 %	-0.41 [ -1.14, 0.31 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)	_ <del></del>	0.5 %	0.29 [ -0.95, 1.53 ]
Costello 2006	48	33 (25)	42	31 (25)	+	2.9 %	0.08 [ -0.33, 0.49 ]
Crosby 1994	26	13.6 (1.25)	33	3.5 ( .25)	+	2.2 %	0.08 [ -0.44, 0.59 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	-	5.5 %	-0.41 [ -0.57, -0.26 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		1.2 %	-0.13 [ -0.89, 0.63 ]
Frega 1994	21	20 (16)	21	23 (16)		1.8 %	-0.18 [ -0.79, 0.42 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		2.7 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)	-+	2.6 %	-0.28 [ -0.73, 0.16 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		1.2 %	-0.54 [ -1.30, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	4.7 %	-0.03 [ -0.25, 0.20 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		1.1 %	-0.18 [ -0.98, 0.62 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		3.3 %	0.31 [ -0.05, 0.68 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)	-+	2.2 %	-0.28 [ -0.81, 0.24 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		2.0 %	-0.79 [ -1.34, -0.23 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		1.4 %	-0.3  [ -1.0 , 0.38 ]

-4 -2 0 Favours Placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Lorr 1961       42       583 (9.91)       38       57.5 (9.91)       2.7 %       0.08 [-0.36, 0.5]         Macaluso 1995       30       -3.3 (383)       30       -1.8 (3.29)       2.2 %       -0.41 [-0.93, 0.1]         May 1988       2.4       -1.23 (0.46)       2.4       -1.22 (0.46)       1.9 %       -0.02 [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       -0.04 [-0.86, 0.5]         Nardi 1976       10       53.2 (1.12)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27, 0.6]         Peham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Rosingisuthip 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Rosingisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rosingisuthip 1999       18       -3.3 (4.27)       35       1.9 (8.7)       -2.4 %       -0.72 [-1.20, 0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7 6 4.1 (139)	Lorr 1961       42       583 (9.91)       38       57.5 (9.91)       27 %       0.08 [-0.36,         Macaluso 1995       30       -3.3 (3.83)       30       -1.8 (3.29)       22 %       -0.41 [-0.93,         May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       -0.02 [-0.59,         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86,         Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27,         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57,         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40.%       -0.06 [-0.35,         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       34.%       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rosi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -44 (8.7)       35       1.9 (8.7)       2.4 %       0.21 [-0.24,     <	Lor 1961       42       583 (991)       38       575 (991)       27 %       0.08 (-03, 0.4, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5	Lorr 1961       42       583 (991)       38       575 (991)       27 %       0.08 [-036, 05]         Macaluso 1995       30       -3.3 (383)       30       -1.18 (329)       2.2 %       -0.41 [-0.93, 0.0]         May 1988       2.4       -1.23 (0.6)       2.4       -1.22 (0.6)       1.9 %       -0.02 [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.9]         Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27, 0.6]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawing 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Rosingisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rosingisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.01 [-0.20, -0.2]         Sinako 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.8	Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continue) Std. Mean Difference IV,Random,95% Cl
Macaluso 1995       30       -3.3 (3.83)       30       -1.8 (3.29)       2.2 %       -0.41 [-0.93, 0.1         May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       -0.02 [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.5]         Nandi 1976       10       5.32 (11.2)       8       5.75 (13.8)       0.9 %       -0.33 [-1.27, 0.6]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Rowing 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.55, 0.2]         Rosi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (87)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, 0.2]         Sinaiko 1991       60       665 (9.7)       2.7 64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Tashjan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       <	Macaluso 1995       30       -33 (3.83)       30       -1.8 (3.29)       22 %       -0.41 [-0.93,         May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       19 %       -0.02 [-0.59,         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86,         Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27,         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57,         Rawling 2001       89       5.3 (4.72)       9.6       5.6 (4.9)       4.0 %       -0.06 [-0.35,         Ratikankare 1999       61       40.25 (21.5)       61       36 (21.5)       34 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rosi 1992       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -2.4 %       -0.72 [-1.20, -         Steinsbeck 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16	Macaluso 1995       30 $-3.3$ (3.83)       30 $-1.8$ (3.29)       22.% $-0.41$ [-0.93, 0.1         May 1988       24 $-1.23$ (0.46)       24 $-1.22$ (0.46)       1.9 % $-0.02$ [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.9]         Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 % $-0.33$ [-1.27, 0.6]         Pelham 1992       38 $-8.72$ (1.73)       38 $-8.51$ (1.61)       2.6 % $-0.12$ [-0.57, 0.3]         Rawling 2001       89       5.3 (47.2)       96       5.6 (4.9)       4.0 % $-0.06$ [-0.35, 0.2]         Restilankare 1999       61       40.25 (21.5)       61       36 (21.5) $-3.4$ % $0.21$ [-0.57, 0.5]         Rosi 1982       6       107 (17)       6       108 (20) $-0.6$ % $-0.51$ [-1.0, 0.2]         Steinsbeck 2004       102       44.48 (58.88)       74       52.99 (45.2) $-3.8$ % $-0.27$ [-1.20, 0.2]         Steinsbeck 2004       102       44.48 (58.88)       74       52.99 (45.2) $-3.8$ % $-0.27$ [-0.59, 0.0]         Thomas 2002a       78 $-0.87$	Macaluso 1995       30       -33 (383)       30       -18 (329)       22 %       -0.41 [-9.93, 0.10]         May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       -0.02 [-0.59, 0.5]         McLachian 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.9]         Nandi 1976       10       532 (11.2)       8       575 (13.8)       0.9 %       -0.33 [-127, 0.6]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawing 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.01 [-0.75, 0.5]         Steinsbek 2004       102       44.48 (8.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashjan 2006       19       3.4 (22)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.56, 0.2]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)	Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	-	5.2 %	0.15 [ -0.04, 0.33 ]
May 1988 $24$ $-1.23$ (0.46) $24$ $-1.22$ (0.46) $1.9\%$ $-0.02$ [ $-0.59$ , 0.5McLachlan 19918 $6.25$ ( $12.25$ ) $12$ $5.67$ ( $17.35$ ) $0.9\%$ $0.04$ [ $-0.86$ , 0.5Nandi 197610 $5.32$ ( $1.2$ )8 $57.5$ ( $13.8$ ) $0.9\%$ $0.04$ [ $-0.86$ , 0.5Pelham 199238 $-8.72$ ( $1.73$ )38 $-8.51$ ( $1.61$ ) $2.6\%$ $-0.12$ [ $-0.57$ , 0.3Rawling 200189 $5.3$ ( $4.72$ )96 $5.6$ ( $4.9$ ) $40\%$ $-0.06$ [ $-0.35, 0.2$ Rosingsuthip 199918 $-3.3$ ( $4.24$ ) $19$ $-2.9$ ( $3.05$ ) $1.6\%$ $-0.11$ [ $-0.75, 0.5$ Rosingsuthip 199918 $-3.3$ ( $4.24$ ) $19$ $-2.9$ ( $3.05$ ) $1.6\%$ $-0.11$ [ $-0.75, 0.5$ Rosin 19826 $107$ ( $17$ )6 $108$ ( $20$ ) $0.6\%$ $-0.05$ [ $-1.18, 10$ Rowbotham 199635 $-4.4$ ( $8.7$ ) $35$ $1.9$ ( $8.7$ ) $2.4\%$ $-0.72$ [ $-1.20, 0.2$ Sinaiko 199160 $66.5$ ( $9.7$ ) $2.7$ $64.1$ ( $1.39$ ) $2.6\%$ $0.21$ [ $-0.24, 0.6$ Tashjan 200619 $3.4$ ( $2.2$ ) $2.4$ $3.3$ ( $1.75$ ) $1.8\%$ $0.05$ [ $-0.55, 0.6$ Thomas 2002a78 $-0.67$ ( $3.03$ )78 $-0.06$ ( $2.88$ ) $3.8\%$ $-0.27$ [ $-0.59, 0.02$ Thomas 2002b114 $-1.21$ ( $3.52$ )119 $-1.61$ ( $3.31$ ) $4.4\%$ $0.12$ [ $-0.42, 0.00$ ]Thomas 2002b114 $-1.21$ ( $3.52$ )119 $-1.67$ ( $5.9$ ) $1.4\%$ $0.05$ [ $-0.66, 0.7$ <td>May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       $-0.02$ [-0.59,         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86,         Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 %       $-0.03$ [-0.57,         Rawing 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       $-0.06$ [-0.35,         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (424)       19       -2.9 (305)       1.6 %       $-0.11$ [-0.75,         Rosis 1982       6       107 (17)       6       108 (20)       0.6 %       0.005 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       0.072 [-12.0, -         Steinsbeck 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.44,         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (303)       78       -0.66 (288)       -1.4 %</td> <td>May 1988       24       -1.23       $(0.46)$       24       -1.22       $(0.46)$         McLachlan 1991       8       $625$ (1225)       12       $5.67$ (17.35)       $0.9\%$ $0.04$ [-0.86, 0.9         Nandi 1976       10       $5.32$ (11.2)       8       $5.75$ (13.8)       $0.9\%$ $0.04$ [-0.86, 0.9         Pelham 1992       38       $-8.72$ (1.73)       38       $-8.51$ (1.61)       $2.6\%$ $0.12$ [-0.57, 0.3         Rawling 2001       89       $5.3$ (4.72)       96       $5.6$ (4.9)       $4.0\%$ $-0.06$ [-0.35, 0.2         Rawling 2001       89       $5.3$ (4.24)       19       $-2.9$ (3.05)       $1.6\%$ $0.11$ [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       $0.6\%$ $0.05$ [-1.18, 1.0]         Rowbotham 1996       35       $-4.4$ (8.7)       $35$ $1.9$ (8.7)       $-2.4\%$ $-0.72$ [-1.20, 0.2]         Steinsbeck 2004       102       $44.48$ (58.88)       $74$ $52.99$ (45.2)       $3.9\%$ $0.16$ [-0.46, 0.1]         Tashjan 2006       19       $3.4$ (2.2)       2.4       $3.3$ (1.75)       $1.8\%$ $0.05$ [-0.50, 0.0]         Thomas 2002a       78       $-0.87$ (3.03)       <th< td=""><td>May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       -0.02 [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.2]         Nandi 1976       10       5.32 (11.2)       8       57.5 (13.8)       0.9 %       -0.02 [-0.57, 0.5]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2004       102       4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2]         Steinsbelk 2004       102       4.4 (8.7)       33       <th< td=""><td>Lorr 1961</td><td>42</td><td>58.3 (9.91)</td><td>38</td><td>57.5 (9.91)</td><td>+</td><td>2.7 %</td><td>0.08 [ -0.36, 0.52 ]</td></th<></td></th<></td>	May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 % $-0.02$ [-0.59,         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86,         Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 % $-0.03$ [-0.57,         Rawing 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 % $-0.06$ [-0.35,         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (424)       19       -2.9 (305)       1.6 % $-0.11$ [-0.75,         Rosis 1982       6       107 (17)       6       108 (20)       0.6 %       0.005 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       0.072 [-12.0, -         Steinsbeck 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.44,         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (303)       78       -0.66 (288)       -1.4 %	May 1988       24       -1.23 $(0.46)$ 24       -1.22 $(0.46)$ McLachlan 1991       8 $625$ (1225)       12 $5.67$ (17.35) $0.9\%$ $0.04$ [-0.86, 0.9         Nandi 1976       10 $5.32$ (11.2)       8 $5.75$ (13.8) $0.9\%$ $0.04$ [-0.86, 0.9         Pelham 1992       38 $-8.72$ (1.73)       38 $-8.51$ (1.61) $2.6\%$ $0.12$ [-0.57, 0.3         Rawling 2001       89 $5.3$ (4.72)       96 $5.6$ (4.9) $4.0\%$ $-0.06$ [-0.35, 0.2         Rawling 2001       89 $5.3$ (4.24)       19 $-2.9$ (3.05) $1.6\%$ $0.11$ [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20) $0.6\%$ $0.05$ [-1.18, 1.0]         Rowbotham 1996       35 $-4.4$ (8.7) $35$ $1.9$ (8.7) $-2.4\%$ $-0.72$ [-1.20, 0.2]         Steinsbeck 2004       102 $44.48$ (58.88) $74$ $52.99$ (45.2) $3.9\%$ $0.16$ [-0.46, 0.1]         Tashjan 2006       19 $3.4$ (2.2)       2.4 $3.3$ (1.75) $1.8\%$ $0.05$ [-0.50, 0.0]         Thomas 2002a       78 $-0.87$ (3.03) <th< td=""><td>May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       -0.02 [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.2]         Nandi 1976       10       5.32 (11.2)       8       57.5 (13.8)       0.9 %       -0.02 [-0.57, 0.5]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2004       102       4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2]         Steinsbelk 2004       102       4.4 (8.7)       33       <th< td=""><td>Lorr 1961</td><td>42</td><td>58.3 (9.91)</td><td>38</td><td>57.5 (9.91)</td><td>+</td><td>2.7 %</td><td>0.08 [ -0.36, 0.52 ]</td></th<></td></th<>	May 1988       24       -1.23 (0.46)       24       -1.22 (0.46)       1.9 %       -0.02 [-0.59, 0.5]         McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.2]         Nandi 1976       10       5.32 (11.2)       8       57.5 (13.8)       0.9 %       -0.02 [-0.57, 0.5]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Resulting 2004       102       4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2]         Steinsbelk 2004       102       4.4 (8.7)       33 <th< td=""><td>Lorr 1961</td><td>42</td><td>58.3 (9.91)</td><td>38</td><td>57.5 (9.91)</td><td>+</td><td>2.7 %</td><td>0.08 [ -0.36, 0.52 ]</td></th<>	Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	+	2.7 %	0.08 [ -0.36, 0.52 ]
McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.9]         Nandi 1976       10       5.32 (11.2)       8       5.75 (13.8)       0.9 %       0.04 [-0.86, 0.9]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78	McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86,         Nandi 1976       10       5.32 (11.2)       8       57.5 (13.8)       0.9 %       0.04 [-0.86,         Nandi 1976       10       5.32 (11.2)       8       57.5 (13.8)       0.9 %       0.04 [-0.86,         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57,         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35,         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -         Sinaiko 1991       60       665 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24,         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59,	McLachlan 1991       8       6.25 (12.25)       12       5.67 (17.35)       0.9 %       0.04 [-0.86, 0.5]         Nandi 1976       10       5.32 (11.2)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27, 0.6]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.072 [-1.20, 0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7 64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbeck 2004       102       44.48 (58.88)       7.4       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.66, 0.7]         Thomas 2002a       78       -0.87 (30.3)       78       -0.06 (2	McLachian 1991       8 $625$ (1225)       12 $5.67$ (17.35)       09 %       0.04 [-0.86, 09]         Nandi 1976       10 $532$ (11.2)       8 $57.5$ (13.8)       09 %       0.03 [-1.27, 0.6]         Peham 1992       38 $-8.72$ (173)       38 $-8.51$ (1.61)       2.6 % $-0.12$ [-0.57, 0.3]         Rawling 2001       89 $53$ (4.72)       96 $5.6$ (4.9)       40 % $-0.06$ [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       34 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18 $-33$ (4.24)       19 $-2.9$ (3.05)       1.6 % $-0.11$ [-0.75, 0.5]         Rowbotham 1996       35 $-4.4$ (8.7)       35 $1.9$ (8.7)       2.4 % $-0.72$ [-1.20, -0.2]         Sinako 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 % $-0.16$ [-0.46, 0.1]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.66, 0.7]         Thomas 2002b       11.4 $-1.21$ (3.52) </td <td>Macaluso 1995</td> <td>30</td> <td>-3.3 (3.83)</td> <td>30</td> <td>-1.8 (3.29)</td> <td></td> <td>2.2 %</td> <td>-0.41 [ -0.93, 0.10 ]</td>	Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		2.2 %	-0.41 [ -0.93, 0.10 ]
Nandi 1976       10       53.2 (11.2)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27, 0.6]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashjian 2006       19       3.4 (2.2)       24       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06	Nandi 1976       10       532 (11.2)       8       57.5 (13.8)       0.9 %       -0.33 [-1.27,         Pelham 1992       38       -8.72 (173)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57,         Rawling 2001       89       5.3 (472)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35,         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46,         Tashjan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (30.3)       78       -0.06 (2.88)       3.8 %       -0.27 [-5.9,         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12	Nandi 1976       10       532 (112)       8       575 (138)       09 %       -0.33 [-1.27, 0.4]         Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       665 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Thomas 2002b       114       -1.21 (3.52)       119       <	Nandi 1976       10       532 (112)       8       57.5 (13.8)       09 %       -0.33 [-1.27, 0.6]         Pelham 1992       38       -8.7 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Ristiankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.55]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.57]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       .44 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Steinsbek/ 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5	May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)	+	1.9 %	-0.02 [ -0.59, 0.54 ]
Pelham 1992 $38$ $-8.72$ (1.73) $38$ $-8.51$ (1.61) $2.6\%$ $-0.12$ [ $-0.57, 0.3$ Rawling 2001 $89$ $5.3$ ( $4.72$ ) $96$ $5.6$ ( $4.9$ ) $4.0\%$ $-0.06$ [ $-0.35, 0.2$ Ristikankare 1999 $61$ $40.25$ ( $21.5$ ) $61$ $36$ ( $21.5$ ) $3.4\%$ $0.20$ [ $-0.16, 0.5$ Roongpisuthip 1999 $18$ $-3.3$ ( $4.24$ ) $19$ $-2.9$ ( $3.05$ ) $1.6\%$ $-0.11$ [ $-0.75, 0.5$ Rossi 1982 $6$ $107$ ( $17$ ) $6$ $108$ ( $20$ ) $0.6\%$ $-0.05$ [ $-1.18, 1.0$ Rowbotham 1996 $35$ $-4.4$ ( $8.7$ ) $35$ $1.9$ ( $8.7$ ) $-2.4\%$ $0.72$ [ $-1.20, -0.2$ Sinaiko 1991 $60$ $66.5$ ( $9.7$ ) $27$ $64.1$ ( $13.9$ ) $-2.6\%$ $0.21$ [ $-0.24, 0.65$ Steinsbekk 2004 $102$ $44.48$ ( $58.88$ ) $74$ $52.99$ ( $45.2$ ) $3.9\%$ $-0.16$ [ $-0.46, 0.1$ Tashjian 2006 $19$ $3.4$ ( $2.2$ ) $2.4$ $3.3$ ( $1.75$ ) $1.8\%$ $0.05$ [ $-0.55, 0.6$ Thomas 2002a $78$ $-0.87$ ( $3.03$ ) $78$ $-0.06$ ( $2.88$ ) $3.8\%$ $-0.27$ [ $-0.59, 0.02$ Thomas 2002b $114$ $-1.21$ ( $3.52$ ) $119$ $-1.61$ ( $3.31$ ) $4.4\%$ $0.12$ [ $-0.44, 0.3$ Wilcock 2008 $15$ $-64$ ( $5.1$ ) $15$ $-6.7$ ( $5.9$ ) $1.0\%$ $0.24$ [ $-0.60, 1.02$ Wilcock 2008 $15$ $-64$ ( $5.1$ ) $15$ $-6.7$ ( $5.9$ ) $1.4\%$ $0.05$ [ $-0.20, -0.03$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 ( $P = 0.002$ ); $i^{2} = 43\%$	Pełham 1992       38       -8.72 (173)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57,         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40.%       -0.06 [-0.35,         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -         Sinaiko 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24,         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46,         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59,         Thomas 2002b       11.4       -1.21 (3.52)       11.9       -1.61 (3.31)       4.4 % <t< td=""><td>Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15</td><td>Peham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.55]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.00]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.22]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1-         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6</td><td>McLachlan 1991</td><td>8</td><td>6.25 (12.25)</td><td>12</td><td>5.67 (17.35)</td><td><u> </u></td><td>0.9 %</td><td>0.04 [ -0.86, 0.93 ]</td></t<>	Pelham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15	Peham 1992       38       -8.72 (1.73)       38       -8.51 (1.61)       2.6 %       -0.12 [-0.57, 0.3]         Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       40 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.55]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.00]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.22]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1-         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6	McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)	<u> </u>	0.9 %	0.04 [ -0.86, 0.93 ]
Rawling 2001895.3 (4.72)965.6 (4.9) $4.0\%$ $-0.06$ [ $-0.35$ , 0.2Ristikankare 199961 $40.25$ (2.1.5)6136 (2.1.5) $3.4\%$ $0.20$ [ $-0.16$ , 0.5Roongpisuthip 199918 $-3.3$ (4.24)19 $-2.9$ (3.05) $1.6\%$ $-0.11$ [ $-0.75$ , 0.5Rossi 19826107 (17)6108 (20) $0.6\%$ $-0.05$ [ $-1.18$ , 1.0Rowbotham 199635 $-4.4$ (8.7)35 $1.9$ (8.7) $-2.4\%$ $-0.72$ [ $-1.20, -0.2$ Sinaiko 19916066.5 (9.7)27 $64.1$ (13.9) $-2.6\%$ $0.21$ [ $-0.24, 0.65$ Steinsbekk 2004102 $44.48$ (58.88)74 $52.99$ (45.2) $3.9\%$ $-0.16$ [ $-0.46, 0.1$ Tashijan 200619 $3.4$ (2.2)24 $3.3$ (1.75) $1.8\%$ $0.05$ [ $-0.55, 0.6$ Thomas 2002a78 $-0.87$ (3.03)78 $-0.06$ (2.88) $3.8\%$ $-0.27$ [ $-0.59, 0.6$ Thomas 2002b114 $-1.21$ (3.52)119 $-1.61$ (3.31) $4.4\%$ $0.12$ [ $-0.40, 1.0$ Wilcock 200815 $-6.4$ (5.1)15 $-6.7$ (5.9) $1.4\%$ $0.05$ [ $-0.66, 0.7$ Wilcock 200815 $-6.4$ (5.1)15 $-6.7$ (5.9) $1.4\%$ $0.05$ [ $-0.60, 0.7$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43\% $100.0\%$ $-0.10$ [ $-0.20, -0.05$ Heterogeneity: Tau ² = 2.16 (P = 0.031) $-0.002$ ; I ² = 43\% $-0.002$ ; I ² = 43\%	Rawling 2001895.3 (4.72)965.6 (4.9) $40\%$ $-0.06$ [-0.35,Ristikankare 199961 $40.25$ (2.15)61 $36$ (21.5) $3.4\%$ $0.20$ [-0.16,Roongpisuthip 199918 $-3.3$ (4.24)19 $-2.9$ (3.05) $1.6\%$ $-0.11$ [-0.75,Rossi 19826107 (17)6108 (20) $0.6\%$ $-0.05$ [-1.18,Rowbotham 199635 $-4.4$ (87)35 $1.9$ (8.7) $$ $2.4\%$ Steinsbekk 200410244.48 (58.88)74 $52.99$ (45.2) $$ $3.9\%$ Steinsbekk 200410244.48 (58.88)74 $52.99$ (45.2) $$ $3.9\%$ Thomas 2002a78 $-0.87$ (3.03)78 $-0.06$ (2.88) $$ $3.8\%$ Thomas 2002b114 $-1.21$ (3.52)119 $-1.61$ (3.31) $-4.4\%$ $0.12$ [ $-0.14$ ,Tuomilehto 198011 $9.04$ (1.36)11 $8.67$ (1.56) $1.0\%$ $0.24$ [ $-0.60$ ,Wilcock 200815 $-6.4$ (5.1)15 $-6.7$ (5.9) $1.4\%$ $0.05$ [ $-0.20, -0.7$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); i ² = 43\%Test for overall effect: Z = 2.16 (P = 0.031) $-4$ $-2$ $2$ $4$	Rawling 2001       89       5.3 (4.72)       96       5.6 (49)       40.%       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.01 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.65, 0.6]         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.3]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6	Rawling 2001       89       5.3 (4.72)       96       5.6 (4.9)       4.0 %       -0.06 [-0.35, 0.2]         Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.01 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, 0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Wilcock 2008       15       -64 (5.1)       15       -6.7 (5.9)       1.4 %       0.02 [-0.20, -0.01]         Wilcock 2008       15       -64 (5.1)       15	Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.9 %	-0.33 [ -1.27, 0.61 ]
Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       3.4 %       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       -       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       -       3.9 %       -0.16 [-0.46, 0.1]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       -       3.8 %       -0.27 [-0.59, 0.0]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.66, 0.7]         Total (95% CI)	Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       34 %       0.20 [-0.16,         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       24 %       -0.72 [-1.20, -         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       -       2.6 %       0.21 [-0.24,         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       -       3.9 %       -0.16 [-0.46,         Tashijan 2006       19       3.4 (2.2)       24       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       -       3.8 %       -0.27 [-0.59,         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       -       4.4 %       0.12 [-0.40,         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.20, -0.         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43	Ristikankare 1999       61 $40.25$ (21.5)       61 $36$ (21.5) $3.4$ % $0.20$ [-0.16, 0.5]         Roongpisuthip 1999       18 $-3.3$ (4.24)       19 $-2.9$ (3.05)       1.6 % $-0.11$ [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20) $0.6$ % $-0.05$ [-1.18, 10]         Rowbotham 1996       35 $-4.4$ (8.7)       35 $1.9$ (8.7) $-2.4$ % $-0.72$ [-1.20, -0.2]         Sinaiko 1991       60 $66.5$ (9.7)       27 $64.1$ (13.9) $2.6$ % $0.21$ [-0.24, 0.6]         Steinsbekk 2004       102 $44.48$ (58.88)       74 $52.99$ ( $45.2$ ) $3.9$ % $-0.16$ [-0.46, 0.1]         Tashjian 2006       19 $3.4$ ( $2.2$ )       24 $3.3$ ( $1.75$ ) $1.8$ % $0.05$ [-0.55, 0.6]         Thomas 2002a       78 $-0.87$ ( $3.03$ )       78 $-0.06$ ( $2.88$ ) $3.8$ % $-0.27$ [-0.59, 0.0]         Thomas 2002b       114 $-1.21$ ( $3.52$ )       119 $-1.61$ ( $3.31$ ) $4.4$ % $0.12$ [-0.14, 0.3]         Tuomilehto 1980       11 $9.04$ ( $1.36$ )       11 $8.67$ ( $1.56$ ) $10.0$ % $-0.10$ [-0.20, $-0.07$ ] <tr< td=""><td>Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       34.4%       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       16.6%       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6%       -0.05 [-1.18, 1.00]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       24.4%       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       26.6%       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9%       -0.16 [-0.46, 0.1]         Tashijan 2006       19       3.4 (2.2)       24       3.3 (1.75)       18.8%       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8%       -0.27 [-0.90, 0.0]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0%       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.44%       0.05 [-0.66, 0.7]         teterogeneity: Tau² = 0.03; Chi² = 75.30, df = 43 (P = 0.002); l² = 43%       4.4</td><td>Pelham 1992</td><td>38</td><td>-8.72 (1.73)</td><td>38</td><td>-8.51 (1.61)</td><td>-+</td><td>2.6 %</td><td>-0.12 [ -0.57, 0.33 ]</td></tr<>	Ristikankare 1999       61       40.25 (21.5)       61       36 (21.5)       34.4%       0.20 [-0.16, 0.5]         Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       16.6%       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6%       -0.05 [-1.18, 1.00]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       24.4%       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       26.6%       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9%       -0.16 [-0.46, 0.1]         Tashijan 2006       19       3.4 (2.2)       24       3.3 (1.75)       18.8%       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8%       -0.27 [-0.90, 0.0]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0%       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.44%       0.05 [-0.66, 0.7]         teterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       4.4	Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)	-+	2.6 %	-0.12 [ -0.57, 0.33 ]
Roongpisuthip 199918 $-3.3 (4.24)$ 19 $-2.9 (3.05)$ 1.6 % $-0.11 [-0.75, 0.5]$ Rossi 19826107 (17)6108 (20)0.6 % $-0.05 [-1.18, 1.0]$ Rowbotham 199635 $-4.4 (8.7)$ 35 $1.9 (8.7)$ $-2.4 \%$ $-0.72 [-1.20, -0.2]$ Sinaiko 19916066.5 (9.7)27 $64.1 (13.9)$ $-2.6 \%$ $0.21 [-0.24, 0.6]$ Steinsbekk 2004102 $44.48 (58.88)$ 74 $52.99 (45.2)$ $3.9 \%$ $-0.16 [-0.46, 0.1]$ Tashijan 200619 $3.4 (2.2)$ 24 $3.3 (1.75)$ $1.8 \%$ $0.05 [-0.55, 0.6]$ Thomas 2002a78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ $-3.8 \%$ $-0.27 [-0.59, 0.0]$ Thomas 2002b114 $-1.21 (3.52)$ 119 $-1.61 (3.31)$ $-4.4 \%$ $0.12 [-0.14, 0.3]$ Tuomilehto 198011 $9.04 (1.36)$ 11 $8.67 (1.56)$ $1.0 \%$ $0.24 [-0.60, 1.0]$ Wilcock 200815 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ $1.4 \%$ $0.05 [-0.66, 0.7]$ Total (95% CI)19782067100.0 % $-0.10 [-0.20, -0.00]$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43\% $100.0 \%$ $-0.10 [-0.20, -0.00]$	Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75,         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18,         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       24 %       -0.72 [-1.20, -         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24,         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46,         Tashijan 2006       19       3.4 (2.2)       24       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59,         Thomas 2002b       1.14       -1.21 (3.52)       1.19       -1.61 (3.31)       4.4 %       0.12 [-0.14,         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60,         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.66,         Fortal (95% CI)       1978       2067       100.0 %       -0.10 [-0.2.0, -0.	Roongpisuthip 1999       18       -3.3 (4.24)       19       -2.9 (3.05)       1.6 %       -0.11 [-0.75, 0.5]         Rossi 1982       6       107 (17)       6       108 (20)       0.6 %       -0.05 [-1.18, 1.0]         Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       2.7       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Thomas 2002b       1.14       -1.21 (3.52)       1.19       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.3]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 0.7]         Vilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.20, -0.0]         4       -2       0       2       4	Roongpisuthip 199918 $-3.3$ (4.24)19 $-2.9$ (3.05)1.6 % $-0.11$ [ $-0.75$ , 0.5-Rossi 19826107 (17)6108 (20)0.6 % $-0.05$ [ $-1.18$ , 1.00Rowbotham 199635 $-4.4$ (8.7)35 $1.9$ (8.7)2.4 % $-0.72$ [ $-1.20$ , 0.22Sinaiko 19916066.5 (9.7)2.764.1 (13.9)2.6 %0.21 [ $-0.24$ , 0.61Steinsbekk 200410244.48 (58.88)7452.99 (45.2)3.9 % $-0.16$ [ $-0.46$ , 0.1-Tashijan 2006193.4 (2.2)2.43.3 (1.75)1.8 %0.05 [ $-0.55$ , 0.61Thomas 2002a78 $-0.87$ (3.03)78 $-0.06$ (2.88)3.8 % $-0.27$ [ $-1.20$ , 0.22Thomas 2002b114 $-1.21$ (3.52)119 $-1.61$ (3.31)4.4 % $0.12$ [ $-0.14$ , 0.32]Tuomilehto 1980119.04 (1.36)118.67 (1.56)1.0 % $0.24$ [ $-0.60$ , 1.02Wilcock 200815 $-6.4$ (5.1)15 $-6.7$ (5.9)1.4 % $0.05$ [ $-0.20$ , $-0.01$ ]Votack 200815 $-6.4$ (5.1)15 $-6.7$ (5.9)1.4 % $0.05$ [ $-0.20$ , $-0.01$ ]Ideterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); 1 ² = 43% $-2$ $Q$ $Z$ $Z$	Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	4.0 %	-0.06 [ -0.35, 0.23 ]
Rossi 19826 $107 (17)$ 6 $108 (20)$ 0.6 % $-0.05 [-1.18, 1.0]$ Rowbotham 199635 $-4.4 (8.7)$ 35 $1.9 (8.7)$ 2.4 % $-0.72 [-1.20, -0.2]$ Sinaiko 19916066.5 (9.7)27 $64.1 (13.9)$ 2.6 % $0.21 [-0.24, 0.6]$ Steinsbekk 2004102 $44.48 (58.88)$ 74 $52.99 (45.2)$ 3.9 % $-0.16 [-0.46, 0.1]$ Tashijan 200619 $3.4 (2.2)$ 24 $3.3 (1.75)$ 1.8 % $0.05 [-0.55, 0.6]$ Thomas 2002a78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ 3.8 % $-0.27 [-0.59, 0.6]$ Thomas 2002b114 $-1.21 (3.52)$ 119 $-1.61 (3.31)$ 4.4 % $0.12 [-0.14, 0.3]$ Tuomilehto 1980119.04 (1.36)11 $8.67 (1.56)$ 1.0 % $0.24 [-0.60, 1.0]$ Vilcock 200815 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ 1.4 % $0.05 [-0.20, -0.0]$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%100.0 % $-0.10 [-0.20, -0.0]$ Fest for overall effect: Z = 2.16 (P = 0.031)1.1 %1.1 %1.1 %	Rossi 19826107 (17)6108 (20)0.6 % $-0.05$ [-1.18,Rowbotham 199635-4.4 (8.7)351.9 (8.7)-2.4 % $-0.72$ [-1.20, -Sinaiko 19916066.5 (9.7)2764.1 (13.9)-2.6 %0.21 [-0.24,Steinsbekk 200410244.48 (58.88)7452.99 (45.2)3.9 %-0.16 [-0.46,Tashjian 2006193.4 (2.2)243.3 (1.75)1.8 %0.05 [-0.55,Thomas 2002a78-0.87 (3.03)78-0.06 (2.88)3.8 %-0.27 [-0.59,Thomas 2002b114-1.21 (3.52)119-1.61 (3.31)4.4 %0.12 [-0.14,Tuomilehto 1980119.04 (1.36)118.67 (1.56)1.0 %0.24 [-0.60,Wilcock 200815-6.4 (5.1)15-6.7 (5.9)1.4 %0.05 [-0.66,Total (95% CI)19782067100.0 %-0.10 [-0.20, -0.40]-4-224	Rossi 19826107 (17)6108 (20)0.6 %-0.05 [-1.18, 1.0Rowbotham 199635-4.4 (8.7)351.9 (8.7)2.4 %-0.72 [-1.20, -0.2Sinaiko 19916066.5 (9.7)2764.1 (13.9)2.6 %0.21 [-0.24, 0.6Steinsbekk 200410244.48 (58.88)7452.99 (45.2)3.9 %-0.16 [-0.46, 0.1Tashjian 2006193.4 (2.2)243.3 (1.75)1.8 %0.05 [-0.55, 0.6Thomas 2002a78-0.87 (3.03)78-0.06 (2.88)3.8 %-0.27 [-0.59, 0.0Thomas 2002b1.14-1.21 (3.52)1.19-1.61 (3.31)4.4 %0.12 [-0.14, 0.3Tuomilehto 19801.19.04 (1.36)1.18.67 (1.56)1.0 %0.24 [-0.60, 1.0Vilcock 20081.5-6.4 (5.1)1.5-6.7 (5.9)1.4 %0.05 [-0.20, -0.03]Fotal (95% CI)19782067	Rossi 1982       6 $107 (17)$ 6 $108 (20)$ 0.6 % $-0.05 [-1.18, 1.00]$ Rowbotham 1996       35 $-4.4 (8.7)$ 35 $1.9 (8.7)$ - $2.4 \%$ $-0.72 [-1.20, -0.2]$ Sinaiko 1991       60       66.5 (9.7)       27 $64.1 (13.9)$ 2.6 % $0.21 [-0.24, 0.6]$ Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 % $-0.16 [-0.46, 0.14]$ Tashjian 2006       19 $3.4 (2.2)$ 2.4 $3.3 (1.75)$ $1.8 \%$ $0.05 [-0.55, 0.62]$ Thomas 2002a       78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ $3.8 \%$ $-0.27 [-0.29, 0.02]$ Tuomilehto 1980       11 $9.04 (1.36)$ 11 $8.67 (1.56)$ $1.0 \%$ $0.24 [-0.60, 1.02]$ Wilcock 2008       15 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ $1.4 \%$ $0.05 [-0.66, 0.77]$ Fotal (95% CI)       1978       2067       100.0 % $-0.10 [-0.20, -0.01]$	Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	+-	3.4 %	0.20 [ -0.16, 0.55 ]
Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       -       2.4 %       -0.72 [-1.20, -0.2         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       -       2.6 %       0.21 [-0.24, 0.6         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       -       3.9 %       -0.16 [-0.46, 0.1         Tashjian 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       -       1.8 %       0.05 [-0.55, 0.6         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       -       3.8 %       -0.27 [-0.59, 0.6         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       -       4.4 %       0.12 [-0.14, 0.3         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.62, -0.01         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -       -       -       -       -       0.10 [-0.20, -0.01         Fest for overall effect: Z = 2.16 (P = 0.031)       -       -       -       -       - <td< td=""><td>Rowbotham 199635$-4.4 (8.7)$35$1.9 (8.7)$$2.4 \%$$-0.72 [-1.20, -5.5]$Sinaiko 19916066.5 (9.7)27$64.1 (13.9)$$2.6 \%$$0.21 [-0.24, -5.5]$Steinsbekk 2004102$44.48 (58.88)$74$52.99 (45.2)$$3.9 \%$$-0.16 [-0.46, -5.5]$Tashijan 200619$3.4 (2.2)$24$3.3 (1.75)$$1.8 \%$$0.05 [-0.55, -5.5]$Thomas 2002a78$-0.87 (3.03)$78$-0.06 (2.88)$$3.8 \%$$-0.27 [-5.59, -5.5]$Thomas 2002b114$-1.21 (3.52)$119$-1.61 (3.31)$$4.4 \%$$0.12 [-0.14, -5.5]$Tuomilehto 198011$9.04 (1.36)$11$8.67 (1.56)$$1.0 \%$$0.24 [-0.60, -5.5]$Wilcock 200815$-6.4 (5.1)$15$-6.7 (5.9)$$1.4 \%$$0.05 [-0.66, -5.6]$Fotal (95% CI)19782067Heterogeneity: Tau² = 0.03; Chi² = 75.30, df = 43 (P = 0.002); I² = 43\%Fest for overall effect: Z = 2.16 (P = 0.031)</td><td>Rowbotham 1996       $35$ $.44$ ($8.7$)       $35$ $1.9$ ($8.7$)       $-1641$ ($13.9$)         Sinaiko 1991       $60$ $665$ ($9.7$)       $27$ $64.1$ ($13.9$)       $26$ %       $0.21$ [$-0.24$, $0.6$         Steinsbekk 2004       $102$ $44.48$ ($58.88$)       $74$ $52.99$ ($45.2$)       $3.9$ %       $-0.16$ [$-0.46$, $0.1$         Tashjian 2006       $19$ $3.4$ ($2.2$)       $24$ $3.3$ ($1.75$)       $1.8$ %       $0.05$ [$-0.55$, $0.6$         Thomas 2002a       $78$ $-0.87$ ($3.03$)       $78$ $-0.06$ ($2.88$)       $-1.8$ %       $0.27$ [$-0.14$, $0.3$         Thomas 2002b       $114$ $-1.21$ ($3.52$)       $119$ $-1.61$ ($3.31$)       $-4.4$ %       $0.12$ [$-0.14$, $0.3$         Tuomilehto 1980       $11$ $9.04$ ($1.36$)       $11$ $8.67$ ($1.56$)       $1.0$ %       $0.24$ [$-0.60$, $1.0$         Wilcock 2008       $15$ $-6.4$ ($5.1$)       $15$ $-6.7$ ($5.9$)       $1.4$ %       $0.05$ [$-0.66$, $0.7$         Heterogeneity: Tau² = 0.03; Chi² = 75.30, df = 43 ($P = 0.002$); $I2 = 43\%$ $-4$ $-2$ $0$ $2$ $4$</td><td>Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.3]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.20, -0.01]         Everogeneity: Tau² = 0.03; Chi² = 75.30, df = 43 (P = 0.002); l² = 43%       4.4 -2       2       4       -2</td><td>Roongpisuthip 1999</td><td>18</td><td>-3.3 (4.24)</td><td>19</td><td>-2.9 (3.05)</td><td>-</td><td>1.6 %</td><td>-0.11 [ -0.75, 0.54 ]</td></td<>	Rowbotham 199635 $-4.4 (8.7)$ 35 $1.9 (8.7)$ $2.4 \%$ $-0.72 [-1.20, -5.5]$ Sinaiko 19916066.5 (9.7)27 $64.1 (13.9)$ $ 2.6 \%$ $0.21 [-0.24, -5.5]$ Steinsbekk 2004102 $44.48 (58.88)$ 74 $52.99 (45.2)$ $ 3.9 \%$ $-0.16 [-0.46, -5.5]$ Tashijan 200619 $3.4 (2.2)$ 24 $3.3 (1.75)$ $ 1.8 \%$ $0.05 [-0.55, -5.5]$ Thomas 2002a78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ $ 3.8 \%$ $-0.27 [-5.59, -5.5]$ Thomas 2002b114 $-1.21 (3.52)$ 119 $-1.61 (3.31)$ $ 4.4 \%$ $0.12 [-0.14, -5.5]$ Tuomilehto 198011 $9.04 (1.36)$ 11 $8.67 (1.56)$ $1.0 \%$ $0.24 [-0.60, -5.5]$ Wilcock 200815 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ $1.4 \%$ $0.05 [-0.66, -5.6]$ Fotal (95% CI)19782067Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43\%Fest for overall effect: Z = 2.16 (P = 0.031)	Rowbotham 1996 $35$ $.44$ ( $8.7$ ) $35$ $1.9$ ( $8.7$ ) $-1641$ ( $13.9$ )         Sinaiko 1991 $60$ $665$ ( $9.7$ ) $27$ $64.1$ ( $13.9$ ) $26$ % $0.21$ [ $-0.24$ , $0.6$ Steinsbekk 2004 $102$ $44.48$ ( $58.88$ ) $74$ $52.99$ ( $45.2$ ) $3.9$ % $-0.16$ [ $-0.46$ , $0.1$ Tashjian 2006 $19$ $3.4$ ( $2.2$ ) $24$ $3.3$ ( $1.75$ ) $1.8$ % $0.05$ [ $-0.55$ , $0.6$ Thomas 2002a $78$ $-0.87$ ( $3.03$ ) $78$ $-0.06$ ( $2.88$ ) $-1.8$ % $0.27$ [ $-0.14$ , $0.3$ Thomas 2002b $114$ $-1.21$ ( $3.52$ ) $119$ $-1.61$ ( $3.31$ ) $-4.4$ % $0.12$ [ $-0.14$ , $0.3$ Tuomilehto 1980 $11$ $9.04$ ( $1.36$ ) $11$ $8.67$ ( $1.56$ ) $1.0$ % $0.24$ [ $-0.60$ , $1.0$ Wilcock 2008 $15$ $-6.4$ ( $5.1$ ) $15$ $-6.7$ ( $5.9$ ) $1.4$ % $0.05$ [ $-0.66$ , $0.7$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 ( $P = 0.002$ ); $I2 = 43\%$ $-4$ $-2$ $0$ $2$ $4$	Rowbotham 1996       35       -4.4 (8.7)       35       1.9 (8.7)       2.4 %       -0.72 [-1.20, -0.2]         Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.3]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.20, -0.01]         Everogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       4.4 -2       2       4       -2	Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)	-	1.6 %	-0.11 [ -0.75, 0.54 ]
Sinaiko 19916066.5 (9.7)27 $64.1 (13.9)$ 2.6 % $0.21 [-0.24, 0.6]$ Steinsbekk 200410244.48 (58.88)74 $52.99 (45.2)$ $3.9 \%$ $-0.16 [-0.46, 0.1]$ Tashijan 200619 $3.4 (2.2)$ 24 $3.3 (1.75)$ $1.8 \%$ $0.05 [-0.55, 0.6]$ Thomas 2002a78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ $3.8 \%$ $-0.27 [-0.59, 0.6]$ Thomas 2002b114 $-1.21 (3.52)$ 119 $-1.61 (3.31)$ $4.4 \%$ $0.12 [-0.14, 0.3]$ Tuomilehto 198011 $9.04 (1.36)$ 11 $8.67 (1.56)$ $1.0 \%$ $0.24 [-0.60, 1.6]$ Wilcock 200815 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ $1.4 \%$ $0.05 [-0.66, 0.7]$ Total (95% CI)19782067100.0 % $-0.10 [-0.20, -0.03]$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43% $1.4 \%$ $0.05 [-0.66, 0.7]$	Sinaiko 1991       60       665 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24,         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46,         Tashjian 2006       19       3.4 (2.2)       24       3.3 (1.75)       1.8 %       0.05 [-0.55,         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59,         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14,         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60,         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.26, -0.         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       2.67       100.0 %       -0.10 [-0.20, -0.         -4       -2       0       2       4	Sinaiko 1991       60       66.5 (9.7)       27       64.1 (13.9)       2.6 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.1]         Tashijan 2006       19       3.4 (2.2)       2.4       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.3]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Vilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.66, 0.7]         Total (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.0]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -4       -2       0       2         -4       -2       0       2       4	Sinaiko 1991       60       665 (9.7)       27       64.1 (13.9)       26 %       0.21 [-0.24, 0.6]         Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashjian 2006       19       3.4 (2.2)       24       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.6]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.0]         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.3]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.0]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.20, -0.01]         Teorageneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -4       -2       0       2       4	Rossi 1982	6	107 (17)	6	108 (20)		0.6 %	-0.05 [ -1.18, 1.08 ]
Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2) $3.9 \%$ $-0.16$ [ $-0.46$ , 0.1         Tashjian 2006       19 $3.4 (2.2)$ 24 $3.3 (1.75)$ $1.8 \%$ $0.05$ [ $-0.55$ , 0.6         Thomas 2002a       78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ $3.8 \%$ $-0.27 [-0.59, 0.0]$ Thomas 2002b       114 $-1.21 (3.52)$ 119 $-1.61 (3.31)$ $4.4 \%$ $0.12 [-0.14, 0.3]$ Tuomilehto 1980       11 $9.04 (1.36)$ 11 $8.67 (1.56)$ $1.0 \%$ $0.24 [-0.60, 1.0]$ Wilcock 2008       15 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ $1.4 \%$ $0.05 [-0.26, 0.7]$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43\%       Test for overall effect: Z = 2.16 (P = 0.031) $-0.002$ ; I ² = 43%	Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2) $3.9 \%$ $-0.16 [-0.46,$ Tashjian 2006       19 $3.4 (2.2)$ 24 $3.3 (1.75)$ $1.8 \%$ $0.05 [-0.55,$ Thomas 2002a       78 $-0.87 (3.03)$ 78 $-0.06 (2.88)$ $3.8 \%$ $-0.27 [-0.59,$ Thomas 2002b       114 $-1.21 (3.52)$ 119 $-1.61 (3.31)$ $4.4 \%$ $0.12 [-0.14,$ Tuomilehto 1980       11 $9.04 (1.36)$ 11 $8.67 (1.56)$ $1.0 \%$ $0.24 [-0.60,$ Wilcock 2008       15 $-6.4 (5.1)$ 15 $-6.7 (5.9)$ $1.4 \%$ $0.05 [-0.26, -0.66,$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43\% $-4 -2$ $0 = 2 - 4$ $4 = 2 - 2 - 2 - 4$	Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2) $3.9\%$ $-0.16$ [ $-0.46$ , 0.1         Tashjian 2006       19 $3.4$ (2.2)       24 $3.3$ (1.75) $1.8\%$ $0.05$ [ $-0.55$ , 0.6         Thomas 2002a       78 $-0.87$ (3.03)       78 $-0.06$ (2.88) $3.8\%$ $-0.27$ [ $-0.59$ , 0.0         Thomas 2002b       114 $-1.21$ (3.52)       119 $-1.61$ (3.31) $4.4\%$ $0.12$ [ $-0.14$ , 0.3         Tuomilehto 1980       11 $9.04$ (1.36)       11 $8.67$ (1.56) $1.0\%$ $0.24$ [ $-0.60$ , 1.0         Wilcock 2008       15 $-6.4$ (5.1)       15 $-6.7$ (5.9) $1.4\%$ $0.05$ [ $-0.66$ , 0.7         Total (95% CI)       1978       2067 $100.0\%$ $-0.10$ [ $-0.20$ , $-0.00$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43\% $-4$ $-2$ $0$ $2$ $4$	Steinsbekk 2004       102       44.48 (58.88)       74       52.99 (45.2)       3.9 %       -0.16 [-0.46, 0.14]         Tashijan 2006       19       3.4 (2.2)       24       3.3 (1.75)       1.8 %       0.05 [-0.55, 0.64]         Thomas 2002a       78       -0.87 (3.03)       78       -0.06 (2.88)       3.8 %       -0.27 [-0.59, 0.04]         Thomas 2002b       114       -1.21 (3.52)       119       -1.61 (3.31)       4.4 %       0.12 [-0.14, 0.32]         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60, 1.00]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.66, 0.77]         Total (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.01]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -4       -2       0       2       4	Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		2.4 %	-0.72 [ -1.20, -0.23
Tashjian 2006       19 $3.4$ (2.2) $24$ $3.3$ (1.75) $1.8$ % $0.05$ [ $-0.55$ , $0.6$ Thomas 2002a       78 $-0.87$ ( $3.03$ )       78 $-0.06$ ( $2.88$ ) $3.8$ % $-0.27$ [ $-0.59$ , $0.6$ Thomas 2002b       114 $-1.21$ ( $3.52$ ) $119$ $-1.61$ ( $3.31$ ) $4.4$ % $0.12$ [ $-0.14$ , $0.3$ Tuomilehto 1980       11 $9.04$ ( $1.36$ )       11 $8.67$ ( $1.56$ ) $1.0$ % $0.24$ [ $-0.60$ , $1.0$ Wilcock 2008       15 $-6.4$ ( $5.1$ ) $15$ $-6.7$ ( $5.9$ ) $1.4$ % $0.05$ [ $-0.20$ , $-0.02$ ]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = $0.002$ ); l ² = 43% $2067$ $100.0$ % $-0.10$ [ $-0.20$ , $-0.02$ ]	Tashjian 2006       19 $3.4$ ( $2.2$ ) $24$ $3.3$ ( $1.75$ ) $1.8$ % $0.05$ [ $-0.55$ ,         Thomas 2002a       78 $-0.87$ ( $3.03$ )       78 $-0.06$ ( $2.88$ ) $3.8$ % $-0.27$ [ $-0.59$ ,         Thomas 2002b       114 $-1.21$ ( $3.52$ )       119 $-1.61$ ( $3.31$ ) $4.4$ % $0.12$ [ $-0.14$ ,         Tuomilehto 1980       11 $9.04$ ( $1.36$ )       11 $8.67$ ( $1.56$ ) $1.0$ % $0.24$ [ $-0.60$ ,         Wilcock 2008       15 $-6.4$ ( $5.1$ )       15 $-6.7$ ( $5.9$ ) $1.4$ % $0.05$ [ $-0.66$ ,         Fotal (95% CI)       1978       2067       100.0 % $-0.10$ [ $-0.20$ , $-0.10$ ]         -4 $-2$ $0$ $2$ $4$	Tashjian 2006       19 $3.4$ ( $2.2$ ) $24$ $3.3$ ( $1.75$ ) $1.8$ % $0.05$ [ $-0.55$ , $0.6$ Thomas 2002a       78 $-0.87$ ( $3.03$ )       78 $-0.06$ ( $2.88$ ) $3.8$ % $-0.27$ [ $-0.59$ , $0.6$ Thomas 2002b       114 $-1.21$ ( $3.52$ ) $119$ $-1.61$ ( $3.31$ ) $4.4$ % $0.12$ [ $-0.14$ , $0.3$ Tuomilehto 1980       11 $9.04$ ( $1.36$ )       11 $8.67$ ( $1.56$ ) $1.0$ % $0.24$ [ $-0.60$ , $1.0$ Wilcock 2008       15 $-6.4$ ( $5.1$ )       15 $-6.7$ ( $5.9$ ) $1.4$ % $0.05$ [ $-0.20$ , $-0.02$ ]         Fotal (95% CI)       1978       2067 $100.0$ % $-0.10$ [ $-0.20$ , $-0.02$ ]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 ( $P = 0.002$ ); $l2 = 43\%$ $-4$ $-2$ $0$ $2$ $4$	Tashijan 2006       19 $3.4$ (2.2) $24$ $3.3$ (1.75) $1.8$ % $0.05$ [- $0.55$ , $0.64$ Thomas 2002a       78 $-0.87$ ( $3.03$ )       78 $-0.06$ ( $2.88$ ) $3.8$ % $-0.27$ [- $0.59$ , $0.04$ Thomas 2002b       114 $-1.21$ ( $3.52$ )       119 $-1.61$ ( $3.31$ ) $4.4$ % $0.12$ [- $0.14$ , $0.33$ Tuomilehto 1980       11 $9.04$ ( $1.36$ )       11 $8.67$ ( $1.56$ ) $1.0$ % $0.24$ [- $0.60$ , $1.08$ Wilcock 2008       15 $-6.4$ ( $5.1$ )       15 $-6.7$ ( $5.9$ ) $1.4$ % $0.05$ [- $0.26$ , $-0.01$ Kotal (95% CI)       1978       2067 $100.0$ % $-0.10$ [- $0.20$ , $-0.01$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = $0.002$ ); $l2 = 43\%$ $-4$ $-2$ $0$ $2$ $4$	Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)	+	2.6 %	0.21 [ -0.24, 0.67
Thomas 2002a       78 $-0.87$ (3.03)       78 $-0.06$ (2.88) $3.8 \%$ $-0.27$ [ $-0.59$ , 0.02         Thomas 2002b       114 $-1.21$ (3.52)       119 $-1.61$ (3.31) $4.4 \%$ $0.12$ [ $-0.14$ , 0.32         Tuomilehto 1980       11       9.04 (1.36)       11 $8.67$ (1.56) $1.0 \%$ $0.24$ [ $-0.60$ , 1.02         Wilcock 2008       15 $-6.4$ (5.1)       15 $-6.7$ (5.9) $1.4 \%$ $0.05$ [ $-0.66$ , 0.72         Total (95% CI)       1978       2067       100.0 % $-0.10$ [ $-0.20$ , $-0.002$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43% $-0.10$ [ $-0.20$ , $-0.012$ $-0.10$ [ $-0.20$ , $-0.012$	Thomas 2002a       78 $-0.87$ (3.03)       78 $-0.06$ (2.88)       3.8 % $-0.27$ [ $-0.59$ ,         Thomas 2002b       114 $-1.21$ (3.52)       119 $-1.61$ (3.31)       4.4 % $0.12$ [ $-0.14$ ,         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 % $0.24$ [ $-0.60$ ,         Wilcock 2008       15 $-6.4$ (5.1)       15 $-6.7$ (5.9)       1.4 % $0.05$ [ $-0.20$ , $-0.40$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       2067       100.0 % $-0.10$ [ $-0.20$ , $-0.40$ -4 $-2$ $0$ $2$ $4$	Thomas 2002a       78 $-0.87$ (3.03)       78 $-0.06$ (2.88) $3.8\%$ $-0.27$ [ $-0.59$ , 0.02         Thomas 2002b       114 $-1.21$ (3.52)       119 $-1.61$ (3.31) $4.4\%$ $0.12$ [ $-0.14$ , 0.32         Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56) $1.0\%$ $0.24$ [ $-0.60$ , 1.02         Wilcock 2008       15 $-6.4$ (5.1)       15 $-6.7$ (5.9) $1.4\%$ $0.05$ [ $-0.66$ , 0.72         Flotal (95% CI)       1978       2067 $1.4\%$ $0.05$ [ $-0.20$ , $-0.002$ ] $1.4\%$ $0.05$ [ $-0.20$ , $-0.002$ ]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43\% $-4$ $-2$ $0$ $2$ $4$	Thomas 2002a       78 $-0.87$ (3.03)       78 $-0.06$ (2.88) $-0.27$ [ $-0.59$ , $0.06$ Thomas 2002b       114 $-1.21$ (3.52)       119 $-1.61$ (3.31) $-4.4\%$ $0.12$ [ $-0.14$ , $0.33$ Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56) $1.0\%$ $0.24$ [ $-0.60$ , $1.0\%$ Wilcock 2008       15 $-6.4$ (5.1)       15 $-6.7$ (5.9) $1.4\%$ $0.05$ [ $-0.66$ , $0.75$ Fotal (95% CI)       1978       2067       100.0 % $-0.10$ [ $-0.20$ , $-0.01$ Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43% $-4 -2$ $2 -4$ $4 -2$	Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	+	3.9 %	-0.16 [ -0.46, 0.14
Thomas 2002b       I 14       -1.21 (3.52)       I 19       -1.61 (3.31) $4.4\%$ $0.12$ [ -0.14, 0.3         Tuomilehto 1980       I 1       9.04 (1.36)       I 1       8.67 (1.56)       I.0% $0.24$ [ -0.60, 1.0         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       I.4% $0.05$ [ -0.66, 0.7         Fotal (95% CI)       1978       2067       100.0%       -0.10 [ -0.20, -0.03         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       Image: Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       Image: Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%	Thomas 2002b $114$ $-1.21$ $(3.52)$ $119$ $-1.61$ $(3.31)$ $4.4$ % $0.12$ $[-0.14]$ Tuomilehto 1980       11       9.04 $(1.36)$ 11 $8.67$ $1.0$ % $0.24$ $[-0.60]$ Wilcock 2008       15 $-6.4$ $(5.1)$ 15 $-6.7$ $(5.9)$ $1.4$ % $0.05$ $[-0.66]$ Fotal (95% CI)       1978       2067       100.0 % $-0.10$ $[-0.20]$ , $-0.4$ Heterogeneity:       Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = $0.002$ ); l ² = 43% $-4$ $-2$ $0$ $2$ $4$	Thomas 2002b       I 14       -I.21 (3.52)       I 19       -I.61 (3.31) $4.4\%$ $0.12$ [ -0.14, 0.3         Tuomilehto 1980       II       9.04 (1.36)       II       8.67 (1.56)       I.0%       0.24 [ -0.60, I.0         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       I.4%       0.05 [ -0.66, 0.7         Total (95% CI)       1978       2067       I.0%       -0.10 [ -0.20, -0.0)         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       -4       -2       0       2       4	Thomas 2002b       I 14       -I.21 (3.52)       I 19       -I.61 (3.31)       4.4 %       0.12 [-0.14, 0.32]         Tuomilehto 1980       I 1       9.04 (1.36)       I 1       8.67 (1.56)       I.0 %       0.24 [-0.60, 1.08]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       I.4 %       0.05 [-0.66, 0.77]         Total (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.01]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       -4       -2       0       2       4	Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)	+	1.8 %	0.05 [ -0.55, 0.65
Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [ -0.60, 1.0         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [ -0.66, 0.7         Iterrogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       100.0 %       -0.10 [ -0.20, -0.03]         Test for overall effect: Z = 2.16 (P = 0.031)       100.0 %       -0.10 [ -0.20, -0.03]	Tuomilehto 1980       11       9.04 (1.36)       11       8.67 (1.56)       1.0 %       0.24 [-0.60,         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [-0.66,         Total (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.40]         Heterogeneity:       Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -4       -2       0       2       4	Tuomilehto 1980       II       9.04 (1.36)       II       8.67 (1.56)       I.0 % $0.24$ [-0.60, I.0         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       I.4 % $0.05$ [-0.66, 0.7         Total (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.02]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       -4       -2       0       2       4	Tuomilehto 1980       II       9.04 (1.36)       II       8.67 (1.56)       I.0 % $0.24$ [-0.60, 1.00]         Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       I.4 %       0.05 [-0.66, 0.7]         Fotal (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.01]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       -4       -2       0       2       4	Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		3.8 %	-0.27 [ -0.59, 0.04
Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9) $1.4\%$ $0.05$ [ -0.66, 0.7         Total (95% CI)       1978       2067       100.0 %       -0.10 [ -0.20, -0.02]         Heterogeneity:       Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43% $100.0\%$ $-0.10$ [ $-0.20, -0.02$ ]         Test for overall effect:       Z = 2.16 (P = 0.031) $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $100.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$ $1000.0\%$	Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9) $1.4\%$ $0.05$ [-0.66,         Total (95% CI)       1978       2067       100.0 %       -0.10 [-0.20, -0.10]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -4       -2       0       2       4	Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9) $1.4\%$ $0.05$ [ $-0.66$ , $0.7$ Total (95% CI)       1978       2067       100.0 % $-0.10$ [ $-0.20$ , $-0.00$ ]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43% $-4$ $-2$ $0$ $2$ $4$	Wilcock 2008       15       -6.4 (5.1)       15       -6.7 (5.9)       1.4 %       0.05 [ -0.66, 0.7]         Fotal (95% CI)       1978       2067       100.0 %       -0.10 [ -0.20, -0.01]         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       -4       -2       0       2       4	Thomas 2002b	114	-1.21 (3.52)	119	-1.61 (3.31)	+	4.4 %	0.12 [ -0.14, 0.37
Fotal (95% CI)       1978       2067         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       100.0 % -0.10 [ -0.20, -0.02]         Test for overall effect: Z = 2.16 (P = 0.031) $P = 0.031$	Fotal (95% CI)       1978       2067         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       100.0 % -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.10 [ -0.20, -0.20, -0.10 [ -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -0.20, -	Fotal (95% CI)       1978       2067         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); I ² = 43%       100.0 % -0.10 [ -0.20, -0.02]         Test for overall effect: Z = 2.16 (P = 0.031)       -4 -2 0 2 4	Cotal (95% CI)       1978       2067         Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43%       100.0 % -0.10 [ -0.20, -0.01         est for overall effect: Z = 2.16 (P = 0.031)       -4 -2 0 2 4	Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)	_ <del></del>	1.0 %	0.24 [ -0.60, 1.08
Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43% Test for overall effect: $Z = 2.16$ (P = 0.031)	Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43% Fest for overall effect: Z = 2.16 (P = 0.031) -4 -2 0 2 4	Heterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² = 43% Fest for overall effect: $Z = 2.16$ (P = 0.031) -4 -2 0 2 4	leterogeneity: Tau ² = 0.03; Chi ² = 75.30, df = 43 (P = 0.002); l ² =43% est for overall effect: Z = 2.16 (P = 0.031) -4 -2 0 2 4	Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		1.4 %	0.05 [ -0.66, 0.77
Test for overall effect: $Z = 2.16$ (P = 0.031)	Fest for overall effect: Z = 2.16 (P = 0.031)         -4       -2       0       2       4	Fest for overall effect: Z = 2.16 (P = 0.031)       -4       -2       0       2       4	est for overall effect: Z = 2.16 (P = 0.031) -4 -2 0 2 4	<b>Total (95% CI)</b>	1978		2067		•	100.0 %	-0.10 [ -0.20, -0.01
	Favours Placebo Favours no-treatment	Favours Placebo Favours no-treatment	Favours Placebo Favours no-treatment	8 ,			P = 0.002); 1 ² =43				

### Analysis 8.1. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 1 Binary outcomes: patients not informed that the trial involved placebo.

Review: Placebo interventions for all clinical conditions

Comparison: 8 Effect modification subgroup analysis: patient information

Outcome: I Binary outcomes: patients not informed that the trial involved placebo

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Carter 2003	3/28	20/29	-	8.5 %	0.67 [ 0.42, 1.07 ]
Guglielmi 1982	12/12	11/12	+	21.8 %	1.09 [ 0.87, 1.36 ]
Malcolm 1980	40/63	44/58	-	20.7 %	0.84 [ 0.66, 1.06 ]
Rabkin 1990	14/27	12/23	+	6.9 %	0.99 [ 0.58, 1.70 ]
Thomas 1987	47/100	50/100	+	16.9 %	0.94 [ 0.71, 1.25 ]
Tyler 1946	89/260	106/303	+	21.5 %	0.98 [ 0.78, 1.23 ]
Watzl 1986	15/34	7/36		3.7 %	2.27 [ 1.06, 4.88 ]
Total (95% CI)	524	561	•	100.0 %	0.96 [ 0.83, 1.12 ]
Total events: 230 (Placebo	o), 250 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	01; Chi ² = 9.60, df =	= 6 (P = 0.14); I ² =38%			
Test for overall effect: Z =	= 0.49 (P = 0.63)				

0.01 0.1 1 10 100

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

#### Analysis 8.2. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 2 Binary outcomes: patients informed that the trial involved placebo (or not stated).

Review: Placebo interventions for all clinical conditions

Comparison: 8 Effect modification subgroup analysis: patient information

Outcome: 2 Binary outcomes: patients informed that the trial involved placebo (or not stated)

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		2.0 %	1.31 [ 0.88, 1.94 ]
Alkaissi 1999	9/20	/20		0.9 %	0.82 [ 0.44, 1.53 ]
Alkaissi 2002	77/139	82/136	+	4.5 %	0.92 [ 0.75, 1.12 ]
Aune 1998	11/26	9/14		1.0 %	0.66 [ 0.36, 1.19 ]
Berg 1983	9/11	9/15		1.4 %	1.36 [ 0.83, 2.24 ]
Blackman 1964	6/12	6/12	-	0.6 %	1.00 [ 0.45, 2.23 ]
Corver 2006	227/279	360/416	-	7.5 %	0.94 [ 0.88, 1.01 ]
De Sanctis 2001	9/10	8/9	+	2.8 %	1.01 [ 0.74, 1.38 ]
Double 1993	3/22	3/22		0.2 %	1.00 [ 0.23, 4.42 ]
Dundee 1986	17/25	17/25	+	2.1 %	1.00 [ 0.68, 1.46 ]
Elliott 1978	6/18	6/6		0.8 %	0.37 [ 0.19, 0.71 ]
Faas 1993	107/162	108/155	+	5.6 %	0.95 [ 0.81, 1.10 ]
Fanti 2003	8/10	9/10		2.2 %	0.89 [ 0.61, 1.29 ]
Frank 1990	14/26	14/26	+	1.3 %	1.00 [ 0.60, 1.65 ]
Harrison 1975	24/28	25/30	+	4.2 %	1.03 [ 0.83, 1.28 ]
Heinzl 1981	70/130	92/132	+	4.6 %	0.77 [ 0.64, 0.94 ]
Hutton 1991	5/24	16/30		0.5 %	0.39 [ 0.17, 0.91 ]
Hyman 1986	9/15	15/15		1.8 %	0.61 [ 0.40, 0.93 ]
Jacobs 1971	9/15	12/39		0.9 %	1.95 [ 1.04, 3.65 ]
Kerr 2003	28/33	32/36	+	4.9 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	•	6.9 %	1.03 [ 0.94, 1.14 ]
Klerman 1974	17/25	16/25	+	2.0 %	1.06 [ 0.71, 1.58 ]
McMillan 1994	14/26	24/46	+	1.6 %	1.03 [ 0.66, 1.62 ]
Molsberger 2002	38/58	30/53	-	2.9 %	1.16 [ 0.86, 1.56 ]
Najnigier 1997	21/30	24/30	+	3.0 %	0.88 [ 0.65, 1.17 ]

0.01 0.1 10 100 Favours placebo Favours no-treatment

(Continued ...)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	( Continued Risk Ratio
Roughan 1981	n/N 9/12	n/N 9/14	M-H,Random,95% CI	1.3 %	M-H,Random,95% Cl
Schallreuter 2002	3/10	4/10		0.3 %	0.75 [ 0.22, 2.52 ]
Scharf 2006	179/365	224/316		6.2 %	0.69 [ 0.61, 0.78 ]
Scharff 2002	11/12	12/12	+	4.1 %	0.92 [ 0.74, 1.15 ]
Stransky 1989	1/5	1/4		0.1 %	0.80 [ 0.07, 9.18 ]
, Tan 1986	8/10	8/9	_	2.0 %	0.90 [ 0.61, 1.32 ]
Tarcin 2004	58/158	27/77	+	2.2 %	1.05 [ 0.73, 1.51 ]
Tarrier 1998	22/26	25/28	+	4.4 %	0.95 [ 0.77, 1.17 ]
Walton 1993	19/24	21/30	+	2.8 %	1.13 [ 0.83, 1.54 ]
Whittaker 1963	3/13	7/13		0.3 %	0.43 [ 0.14, 1.30 ]
Williams 1988	19/20	19/20	+	5.8 %	1.00 [ 0.87, 1.15 ]
Wilson 1980	31/40	10/10	+	4.3 %	0.80 [ 0.65, 0.99 ⁻
Total (95% CI)	2476	2480		100.0 %	0.93 [ 0.87, 0.99 ]
			0.01 0.1 1 10 100 Favours placebo Favours no-treatm	nent	
				rent	
				rent	
				rent	
				nent	
				rent	
				rent	
				nent	
				rent	
				nent	

#### Analysis 8.3. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 3 Continuous outcomes: patients not informed that the trial involved placebo.

Review: Placebo interventions for all clinical conditions

-

-

Comparison: 8 Effect modification subgroup analysis: patient information

Outcome: 3 Continuous outcomes: patients not informed that the trial involved placebo

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% CI
Allen 2006	45	12 (9.6)	44	19 (9.6)	-#-	5.3 %	-0.72 [ -1.15, -0.29 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)	<u> </u>	2.0 %	0.34 [ -0.52,  .2  ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)	_	4.7 %	-0.12 [ -0.60, 0.35 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)	-	6.6 %	-0.62 [ -0.96, -0.29 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		2.3 %	-0.33 [ -1.12, 0.46 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	7.7 %	-0.06 [ -0.33, 0.21 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)	-#-	5.2 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)	-	5.0 %	-0.28 [ -0.73, 0.16 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)	_+	3.6 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)	_+_	2.1 %	-0.19 [ -1.05, 0.67 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		2.3 %	-0.18 [ -0.98, 0.62 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)	<b>-</b> _	2.2 %	-1.07 [ -1.89, -0.25 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		3.9 %	-0.79 [ -1.34, -0.23 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		2.9 %	-0.49 [ -1.17, 0.20 ]
Lick 1977	10	66 (25)	10	63 (32)		2.0 %	0.10 [ -0.78, 0.98 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)	-	6.5 %	-0.56 [ -0.90, -0.22 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)	-#-	6.1 %	-0.70 [ -1.07, -0.33 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		5.0 %	-0.12 [ -0.57, 0.33 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		4.5 %	-0.30 [ -0.80, 0.19 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)	_+	3.8 %	-0.16 [ -0.73, 0.40 ]
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		4.6 %	-0.25 [ -0.73, 0.23 ]
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	5.1 %	0.0 [ -0.44, 0.44 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)	-#-	6.4 %	-0.84 [ -1.19, -0.50 ]
<b>Total (95% CI)</b> Heterogeneity: $Tau^2 = 0$ Test for overall effect: Z			<b>831</b> P = 0.01); I ² =435	%	•	100.0 %	-0.39 [ -0.53, -0.26 ]
				Fa	-4 -2 0 2 4 avours placebo Favours no-tr		

Placebo interventions for all clinical conditions (Review)

#### Analysis 8.4. Comparison 8 Effect modification subgroup analysis: patient information, Outcome 4 Continuous outcomes: patients informed that the trial involved placebo (or not stated).

Review: Placebo interventions for all clinical conditions

-

Comparison: 8 Effect modification subgroup analysis: patient information

Outcome: 4 Continuous outcomes: patients informed that the trial involved placebo (or not stated)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.0 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		0.6 %	-0.14 [ -0.80, 0.52 ]
Allen 1998		-2.9 (7.9)		-6.1 (10.9)		0.4 %	0.32 [ -0.52, 1.17 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.6 %	0.38 [ -0.30, 1.06 ]
Anderson 1999	30	. ,	27	. ,			
		-2.67 (0.84)		-2.74 (0.81)		0.9 %	0.08 [ -0.44, 0.60 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.2 %	0.56 [ -0.60, 1.72 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.3 %	-0.32 [ -1.28, 0.64 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		0.4 %	-1.07 [ -1.94, -0.20 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	+	1.7 %	-0.17 [ -0.43, 0.10 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		0.9 %	0.13 [ -0.39, 0.64 ]
Blades 2001	40	-16 (6)	40	-16 (6)	+	1.1 %	0.0 [ -0.44, 0.44 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)	<b>-</b> _	0.4 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		0.7 %	-0.28 [ -0.90, 0.33 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.4 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		0.5 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)	-	1.0 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)	<b>_</b>	0.5 %	-0.41 [ -1.22, 0.40 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)	<u> </u>	0.6 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)	<b>-</b>	0.2 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	_ <del></del>	0.8 %	0.10 [ -0.45, 0.66 ]
Chenard 1991	12	29 (19)	16	30 (19)		0.5 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	.3 (8.3)	15	4.4 (6. )	_+_	0.5 %	-0.41 [ -1.14, 0.31 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.2 %	0.29 [ -0.95, 1.53 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.5 %	-0.92 [ -1.72, -0.12 ]
Costello 2006	48	33 (25)	42	31 (25)	-	1.2 %	0.08 [ -0.33, 0.49 ]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo		No-treatment		Std. Mear	n Difference We	ight	( Continued) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random	,95% CI		IV,Random,95% Cl
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		0.	7 %	0.13 [ -0.47, 0.74 ]
Crosby 1994	26	3.6 ( .25)	33	13.5 (1.25)		0.	9 %	0.08 [ -0.44, 0.59 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		- 0.	4 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.	4 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.	3 %	-0.39 [ -1.35, 0.58 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	-	١.	2 %	-0.12 [ -0.51, 0.27 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	+	2.	0 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	Ι.	9 %	-0.06 [ -0.28, 0.17 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		١.	۱ %	-0.36 [ -0.80, 0.08 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		0.	5 %	-0.65 [ -1.43, 0.13 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	2.	2 %	-0.41 [ -0.57, -0.26 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.	5 %	-0.13 [ -0.89, 0.63 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.	5 %	-0.54 [ -1.27, 0.19 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.	3 %	-0.98 [ -2.02, 0.06 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.	3 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		0.	7 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.	4 %	-0.97 [ -1.91, -0.03 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.	5 %	-0.54 [ -1.30, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	١.	9 %	-0.03 [ -0.25, 0.20 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		0.	8 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		0.	9 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)		0.	8 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	<u> </u>	0.	3 %	-1.58 [ -2.61, -0.55 ]
Helms 1987	11	103 (91)	11	79 (99)		- 0.	4 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.	6 %	-0.53 [ -1.19, 0.13 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	١.	6 %	-0.06 [ -0.34, 0.22 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)	+	١.	2 %	0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)	-+-	0.	4 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	П	3.7 (1.4)		0.	4 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.	2 %	-1.17 [ -2.39, 0.04 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		١.	6%	-0.41 [ -0.71, -0.11 ]

4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	( Continued) Std. Mean Difference IV.Random,95% Cl
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.3 %	0.31 [ -0.05, 0.68 ]
Kendall 1979	П	7.54 (2.29)	11	8.18 (3.03)		0.4 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		0.9 %	-0.28 [ -0.81, 0.24 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.2 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)	_+	0.7 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		0.5 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		0.7 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	-	1.9 %	-0.12 [ -0.33, 0.09 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.0 %	-0.59 [ -1.04, -0.14 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		0.6 %	-0.31 [ -1.01, 0.38 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.3 %	-1.08 [ -2.09, -0.07 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	-	0.9 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		0.8 %	-0.51 [ -1.07, 0.05 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		1.1 %	-0.23 [ -0.67, 0.21 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	2.1 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		0.7 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.4 %	0.0 [ -0.90, 0.90 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	+	1.1 %	0.08 [ -0.36, 0.52 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		0.9 %	-0.41 [ -0.93, 0.10 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.3 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)	_ <del></del>	0.7 %	0.12 [ -0.47, 0.71 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)	-	0.8 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.4 %	0.04 [ -0.86, 0.93 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		0.7 %	-0.31 [ -0.93, 0.32 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		0.8 %	-0.49 [ -1.06, 0.08 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	1.4 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)	-	1.1 %	-0.19 [ -0.63, 0.25 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)	_	0.5 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)		0.2 %	-1.99 [ -3.24, -0.74 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.4 %	-0.33 [ -1.27, 0.61 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		1.0 %	-1.37 [ -1.85, -0.89 ]

4

Favours no-treatment

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV.Random,95% Cl
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)		0.3 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.4 %	-0.02 [ -0.90, 0.85 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		1.3 %	-0.15 [ -0.53, 0.23 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)	<del></del>	1.2 %	0.10 [ -0.31, 0.50 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.5 %	0.26 [ -0.50, 1.02 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		0.8 %	-0.24 [ -0.78, 0.30 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	1.6 %	-0.06 [ -0.35, 0.23 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		0.6 %	-0.40 [ -1.05, 0.24 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	+	1.3 %	0.20 [ -0.16, 0.55 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.4 %	-0.11 [ -0.93, 0.72 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)	<u> </u>	0.6 %	-0.11 [ -0.75, 0.54 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		0.8 %	-0.15 [ -0.69, 0.38 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.3 %	-0.67 [ -1.80, 0.46 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.3 %	-0.05 [ -1.18, 1.08 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		1.0 %	-0.72 [ -1.20, -0.23 ]
Rschke 2000	24	23 (16.2)	24	26 (16)		0.8 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.5 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.3 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.4 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)	<u> </u>	0.4 %	-0.04 [ -0.90, 0.81 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		1.0 %	0.21 [ -0.24, 0.67 ]
Sipich 1974	10	8 (14)	10	32.5 (14)	<u> </u>	0.3 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		0.5 %	0.22 [ -0.56, 1.01 ]
Sprott 1993	10	7.9 (3)	10	7.4 (3)	<del></del>	0.4 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		0.4 %	-0.69 [ -1.60, 0.22 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)		1.6 %	-0.16 [ -0.46, 0.14 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		0.8 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.2 %	0.27 [ -0.98, 1.52 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		0.4 %	0.21 [ -0.67, 1.09 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.4 %	-0.55 [ -1.36, 0.27 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		0.7 %	0.05 [ -0.55, 0.65 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo	Ν	lo-treatment		Std. Mean Difference	Weight	( Continu Std. Mean Difference	
study of subgroup	N	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl	, reight	IV,Random,95% CI	
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		0.6 %	0.48 [ -0.22, 1.19	
Thomas 1999	4	13.4 (10.28)	26	16.5 (9.73)	-+-	0.6 %	-0.31 [ -0.96, 0.35	
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		1.5 %	-0.27 [ -0.59, 0.04	
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	+	1.7 %	0.12 [ -0.14, 0.3	
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		0.9 %	0.14 [ -0.36, 0.65	
Tritrakarn 2000	41	49 (16)	41	61 (17)		1.1 %	-0.72 [ -1.17, -0.2]	
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		0.9 %	-0.08 [ -0.57, 0.4	
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.0 %	-0.60 [ -1.07, -0.1	
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)	_ <del></del>	0.4 %	0.24 [ -0.60, 1.0	
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)	+	0.4 %	-0.45 [ -1.34, 0.4	
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		0.8 %	-0.40 [ -0.96, 0.1	
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		0.5 %	-0.10 [ -0.81, 0.62	
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		0.7 %	-0.26 [ -0.88, 0.3	
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		0.5 %	0.05 [ -0.66, 0.7	
Wojciechowski 1984	9	264 (122)	12	238 (190)	_ <del></del>	0.4 %	0.15 [ -0.71, 1.0	
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)	_+_	0.7 %	-0.20 [ -0.83, 0.4	
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	<del></del>	0.3 %	-0.97 [ -2.10, 0.10	
<b>tal (95% CI)</b> terogeneity: Tau ² = 0. t for overall effect: Z	<b>4327</b> .04; Chi ² = 2	210.53, df = 134 (P =	<b>4494</b> = 0.00003); I ² =	36%	•	100.0 %	-0.19 [ -0.25, -0.13	

-2 0 -4

Favours placebo

2 Favours no-treatment

4

#### Analysis 9.1. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome I Add-on treatment: yes.

Review: Placebo interventions for all clinical conditions

Comparison: 9 Effect modification subgroup analysis: placebo as add-on treatment

Outcome: I Add-on treatment: yes

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Berg 1983	9/11	9/15		3.6 %	1.36 [ 0.83, 2.24 ]
De Sanctis 2001	9/10	8/9		6.5 %	1.01 [ 0.74, 1.38 ]
Double 1993	3/22	3/22		0.5 %	1.00 [ 0.23, 4.42 ]
Dundee 1986	17/25	17/25	-	5.2 %	1.00 [ 0.68, 1.46 ]
Faas 1993	107/162	108/155	+	10.4 %	0.95 [ 0.81, 1.10 ]
Fanti 2003	8/10	9/10		5.3 %	0.89 [ 0.61, 1.29 ]
Heinzl 1981	70/130	92/132	+	9.3 %	0.77 [ 0.64, 0.94 ]
Jacobs 1971	9/15	12/39		2.6 %	1.95 [ 1.04, 3.65 ]
Kerr 2003	28/33	32/36	+	9.5 %	0.95 [ 0.79, 1.15 ]
McMillan 1994	14/26	24/46		4.2 %	1.03 [ 0.66, 1.62 ]
Molsberger 2002	38/58	30/53		6.7 %	1.16 [ 0.86, 1.56 ]
Schallreuter 2002	3/10	4/10		0.8 %	0.75 [ 0.22, 2.52 ]
Scharf 2006	179/365	224/316	•	11.0 %	0.69 [ 0.61, 0.78 ]
Scharff 2002	/ 2	2/ 2	+	8.5 %	0.92 [ 0.74, 1.15 ]
Tan 1986	8/10	8/9		5.1 %	0.90 [ 0.61, 1.32 ]
Tarrier 1998	22/26	25/28	+	8.9 %	0.95 [ 0.77, 1.17 ]
Watzl 1986	15/34	7/36		1.8 %	2.27 [ 1.06, 4.88 ]
Total (95% CI)	959	953	•	100.0 %	0.96 [ 0.85, 1.07 ]
Total events: 550 (Placebo	o), 624 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	03; Chi ² = 38.43, df =	$= 16 (P = 0.001); I^2 = 58\%$			
Test for overall effect: Z =	0.78 (P = 0.43)				

# 0.1 0.2 0.5 1 2 5 10 Favours treatment Favours control

Placebo interventions for all clinical conditions (Review)

#### Analysis 9.2. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 2 Add-on treatment: no or not stated.

Review: Placebo interventions for all clinical conditions

Comparison: 9 Effect modification subgroup analysis: placebo as add-on treatment

Outcome: 2 Add-on treatment: no or not stated


Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		2.2 %	.3  [ 0.88,  .94 ]
Alkaissi 1999	9/20	11/20		1.0 %	0.82 [ 0.44, 1.53 ]
Alkaissi 2002	77/139	82/136	+	6.3 %	0.92 [ 0.75, 1.12 ]
Aune 1998	11/26	9/14		1.0 %	0.66 [ 0.36, 1.19 ]
Blackman 1964	6/12	6/12		0.6 %	1.00 [ 0.45, 2.23 ]
Carter 2003	13/28	20/29		1.6 %	0.67 [ 0.42, 1.07 ]
Corver 2006	227/279	360/416	•	14.8 %	0.94 [ 0.88, 1.01 ]
Elliott 1978	6/18	6/6		0.9 %	0.37 [ 0.19, 0.71 ]
Frank 1990	14/26	14/26		1.4 %	1.00 [ 0.60, 1.65 ]
Guglielmi 1982	12/12	11/12	+	5.4 %	1.09 [ 0.87, 1.36 ]
Harrison 1975	24/28	25/30	+	5.6 %	1.03 [ 0.83, 1.28 ]
Hutton 1991	5/24	16/30		0.5 %	0.39 [ 0.17, 0.91 ]
Hyman 1986	9/15	15/15		2.0 %	0.61 [ 0.40, 0.93 ]
Killen 1990	226/309	219/309	+	12.5 %	1.03 [ 0.94, 1.14 ]
Klerman 1974	17/25	16/25	_ <del></del>	2.2 %	1.06 [ 0.71, 1.58 ]
Malcolm 1980	40/63	44/58	-	5.0 %	0.84 [ 0.66, 1.06 ]
Najnigier 1997	21/30	24/30	<u> </u>	3.6 %	0.88 [ 0.65, 1.17 ]
Rabkin 1990	14/27	12/23		1.3 %	0.99 [ 0.58, 1.70 ]
Roughan 1981	9/12	9/14	_ <del></del>	1.4 %	1.17 [ 0.70, 1.94 ]
Stransky 1989	1/5	1/4	•	0.1 %	0.80 [ 0.07, 9.18 ]
Tarcin 2004	58/158	27/77		2.5 %	1.05 [ 0.73, 1.51 ]
Thomas 1987	47/100	50/100	-	3.8 %	0.94 [ 0.71, 1.25 ]
Tyler 1946	89/260	106/303	+	5.3 %	0.98 [ 0.78, 1.23 ]
Walton 1993	19/24	21/30	+-	3.3 %	1.13 [ 0.83, 1.54 ]
Whittaker 1963	3/13	7/13		0.3 %	0.43 [ 0.14, 1.30 ]

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

(Continued ...)

Placebo interventions for all clinical conditions (Review)



#### Analysis 9.3. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 3 Add-on treatment: yes.

Review: Placebo interventions for all clinical conditions

Comparison: 9 Effect modification subgroup analysis: placebo as add-on treatment

Outcome: 3 Add-on treatment: yes

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.7 %	-0.09 [ -0.56, 0.38 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		1.5 %	0.08 [ -0.44, 0.60 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.4 %	0.56 [ -0.60, 1.72 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.5 %	0.13 [ -0.39, 0.64 ]
Blanchard 1990a	3	8.3 (13.6)	11	22.5 (25.1)		0.8 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		1.2 %	-0.28 [ -0.90, 0.33 ]
Bosley 1989	13	86 (10)	4	89 (10)		0.9 %	-0.29 [ -1.05, 0.47 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		2.3 %	-0.62 [ -0.96, -0.29 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		1.0 %	-0.18 [ -0.88, 0.51 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.4 %	0.29 [ -0.95, 1.53 ]
Conn 1986	13	28.2 (18.4)	4	44.4 (15.7)		0.8 %	-0.92 [ -1.72, -0.12 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.7 %	0.0 [ -0.88, 0.88 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.6 %	-0.39 [ -1.35, 0.58 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)		2.0 %	-0.12 [ -0.51, 0.27 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		1.8 %	-0.36 [ -0.80, 0.08 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		0.9 %	-0.65 [ -1.43, 0.13 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	3.3 %	-0.41 [ -0.57, -0.26 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.9 %	-0.54 [ -1.27, 0.19 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	_ <b></b>	0.5 %	-0.98 [ -2.02, 0.06 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	2.7 %	-0.06 [ -0.33, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	2.9 %	-0.03 [ -0.25, 0.20 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		1.3 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	П	-0.88 (3.83)	10	-0.26 (2.2)	<u> </u>	0.7 %	-0.19 [ -1.05, 0.67 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		1.4 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	6 (  .7)	50	30 (18.9)		1.6 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)		1.3 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		0.5 %	-1.58 [ -2.61, -0.55 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	2.6 %	-0.06 [ -0.34, 0.22 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)	+-	2.0 %	0.21 [ -0.19, 0.60 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		2.1 %	0.31 [ -0.05, 0.68 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)	-+-	1.5 %	-0.28 [ -0.81, 0.24 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)	_ <del></del>	0.8 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.3 %	-0.55 [ -1.14, 0.03 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		1.0 %	-0.49 [ -1.17, 0.20 ]
Lick 1977	10	66 (25)	10	63 (32)	<u> </u>	0.7 %	0.10 [ -0.78, 0.98 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		1.4 %	-0.51 [ -1.07, 0.05 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)	+	2.3 %	-0.56 [ -0.90, -0.22 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	3.2 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.2 %	-0.49 [ -1.12, 0.14 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)		1.8 %	0.08 [ -0.36, 0.52 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)	<u> </u>	1.3 %	0.12 [ -0.47, 0.71 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)	-+	1.2 %	-0.31 [ -0.93, 0.32 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		2.1 %	-0.70 [ -1.07, -0.33 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	<u> </u>	2.3 %	0.06 [ -0.28, 0.40 ]

-4 -2 0 2

Favours placebo Favours no-treatment

4

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	( Continu Std. Mean Differend
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl		IV,Random,95%
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		2.1 %	-0.15 [ -0.53, 0.23
Parker 1995	49	4 (1.9)	45	3.8 (2.2)	+	2.0 %	0.10 [ -0.31, 0.50
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.9 %	0.26 [ -0.50, 1.02
Pelham 1992	38	-8.72 (1.73)	38	-8.5  ( .6 )		1.8 %	-0.12 [ -0.57, 0.33
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	2.6 %	-0.06 [ -0.35, 0.23
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		1.1 %	-0.40 [ -1.05, 0.24
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.8 %	-0.11 [ -0.93, 0.72
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)	<u> </u>	1.1 %	-0.11 [ -0.75, 0.54
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		1.4 %	-0.15 [ -0.69, 0.3
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.6 %	-0.30 [ -0.80, 0.1
Rowbotham 1996	n 1996 35 -4.4 (8.7) 35 1.9 (8.7)		1.6 %	-0.72 [ -1.20, -0.2			
Rschke 2000	24	23 (16.2)	24	26 (16)		1.3 %	-0.18 [ -0.75, 0.3
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)	<u> </u>	0.9 %	-0.02 [ -0.78, 0.7
Shen 2000	33	40.7 (12.35)	34	43.7 (  .3 )	-+-	1.6 %	-0.25 [ -0.73, 0.2
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.7 %	0.16 [ -0.72, 1.0
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		0.7 %	-0.69 [ -1.60, 0.2
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		1.2 %	0.05 [ -0.55, 0.6
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)	<u> </u>	1.6 %	-0.08 [ -0.57, 0.4
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.7 %	-0.60 [ -1.07, -0.1]
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)	_ <del></del>	0.8 %	0.24 [ -0.60, 1.0
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.7 %	-0.45 [ -1.34, 0.4
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		1.4 %	-0.40 [ -0.96, 0.1
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)	<u> </u>	1.0 %	-0.10 [ -0.81, 0.6
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)	<u> </u>	1.0 %	0.05 [ -0.66, 0.7
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		2.3 %	-0.84 [ -1.19, -0.5
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		1.1 %	-0.20 [ -0.83, 0.4
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	<b>_</b> _	0.5 %	-0.97 [ -2.10, 0.1
otal (95% CI)	2618		2805		•	100.0 %	-0.23 [ -0.31, -0.15
eterogeneity: Tau ² = ( st for overall effect: Z			$(P = 0.00002); I^2 =$	46%			

#### Favours placebo

Favours no-treatment

#### Analysis 9.4. Comparison 9 Effect modification subgroup analysis: placebo as add-on treatment, Outcome 4 Add-on treatment: no or not stated.

Review: Placebo interventions for all clinical conditions

Comparison: 9 Effect modification subgroup analysis: placebo as add-on treatment

Outcome: 4 Add-on treatment: no or not stated

Study or subgroup	Placebo N	Mean(SD)	no-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		1.0 %	-0.14 [ -0.80, 0.52 ]
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		0.7 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		1.8 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)	<u> </u>	1.0 %	0.38 [ -0.30, 1.06 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		0.7 %	0.34 [ -0.52, 1.21 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.6 %	-0.32 [ -1.28, 0.64 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)	-	1.6 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1995	13	-2 (1.15)	П	-0.8 (1)		0.7 %	-1.07 [ -1.94, -0.20 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	+	2.6 %	-0.17 [ -0.43, 0.10 ]
Blades 2001	40	-16 (6)	40	-16 (6)	+	1.7 %	0.0 [ -0.44, 0.44 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.7 %	-0.30 [ -1.15, 0.56 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.6 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.8 %	-0.41 [ -1.22, 0.40 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.4 %	0.48 [ -0.72,  .67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	- <u>+-</u>	1.3 %	0.10 [ -0.45, 0.66 ]
Chenard 1991	12	29 (19)	16	30 (19)		0.9 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	11.3 (8.3)	15	14.4 (6.1)		0.9 %	-0.41 [ -1.14, 0.31 ]
Costello 2006	48	33 (25)	42	31 (25)	<u> </u>	1.8 %	0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	<u> </u>	1.2 %	0.13 [ -0.47, 0.74 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)		1.4 %	0.08 [ -0.44, 0.59 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)	<b>-</b> _	0.6 %	-0.94 [ -1.88, -0.01 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	+	3.0 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	2.8 %	-0.06 [ -0.28, 0.17 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		0.8 %	-0.33 [ -1.12, 0.46 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.8 %	-0.13 [ -0.89, 0.63 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	no-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued Std. Mean Difference IV,Random,95% CI
Frankel 1978	7	93 (5)	8	95 (3)		0.5 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)	_+_	1.2 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.6 %	-0.97 [ -1.91, -0.03 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		1.8 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.7 %	-0.28 [ -0.73, 0.16 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.9 %	-0.54 [ -1.30, 0.21 ]
Helms 1987	11	103 (91)	11	79 (99)	<b>.</b>	0.7 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.0 %	-0.53 [ -1.19, 0.13 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		0.8 %	-0.18 [ -0.98, 0.62 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.7 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)	<b>_</b> _	0.7 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.4 %	-1.17 [ -2.39, 0.04 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)	+	2.4 %	-0.41 [ -0.71, -0.11 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.7 %	-1.07 [ -1.89, -0.25 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.7 %	-0.23 [ -1.07, 0.61 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.3 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		1.2 %	0.19 [ -0.42, 0.80 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	2.9 %	-0.12 [ -0.33, 0.09 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		1.3 %	-0.79 [ -1.34, -0.23 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.7 %	-0.59 [ -1.04, -0.14 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		1.0 %	-0.31 [ -1.01, 0.38 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.5 %	-1.08 [ -2.09, -0.07 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	-	1.5 %	0.04 [ -0.47, 0.55 ]
Lincoln 2003	42	4.4 ( 0)	38	16.7 (10)		1.7 %	-0.23 [ -0.67, 0.21 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.6 %	0.0 [ -0.90, 0.90 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		1.5 %	-0.41 [ -0.93, 0.10 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.5 %	0.03 [ -1.01, 1.08 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)	+	1.3 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.7 %	0.04 [ -0.86, 0.93 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		1.3 %	-0.49 [ -1.06, 0.08 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		1.7 %	-0.19 [ -0.63, 0.25 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	no-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Morton 1993	13	22.11 (16.38)	3	24.53 (16.38)		0.8 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)		0.4 %	-1.99 [ -3.24, -0.74 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.6 %	-0.33 [ -1.27, 0.61 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		1.6 %	-1.37 [ -1.85, -0.89 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)	<del></del>	0.5 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)	<u> </u>	0.7 %	-0.02 [ -0.90, 0.85 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)	-+-	1.4 %	-0.24 [ -0.78, 0.30 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		2.1 %	0.20 [ -0.16, 0.55 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)	<del></del>	0.4 %	-0.67 [ -1.80, 0.46 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.4 %	-0.05 [ -1.18, 1.08 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		1.3 %	-0.16 [ -0.73, 0.40 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.4 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)	<b>_</b> _	0.7 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.7 %	-0.04 [ -0.90, 0.81 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		1.7 %	0.21 [ -0.24, 0.67 ]
Sipich 1974	10	8 (14)	10	32.5 (14)		0.5 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	_ <del></del>	0.8 %	0.22 [ -0.56, 1.01 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	+	2.4 %	-0.16 [ -0.46, 0.14 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)	-+	1.3 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)	<u>_</u>	0.4 %	0.27 [ -0.98, 1.52 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	_ <b>-</b>	0.7 %	0.21 [ -0.67, 1.09 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.8 %	-0.55 [ -1.36, 0.27 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	<u> </u>	0.9 %	0.48 [ -0.22, 1.19 ]
Thomas 1999	14	3.4 ( 0.28)	26	16.5 (9.73)		1.1 %	-0.3  [ -0.96, 0.35 ]
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)	-	2.3 %	-0.27 [ -0.59, 0.04 ]
Thomas 2002b	114	-1.21 (3.52)	119	-1.61 (3.31)	+	2.6 %	0.12 [ -0.14, 0.37 ]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		1.5 %	0.14 [ -0.36, 0.65 ]
Tritrakarn 2000	41	49 (16)	41	61 (17)		1.7 %	-0.72 [ -1.17, -0.27 ]
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	1.7 %	0.0 [ -0.44, 0.44 ]
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)	-+-	1.1 %	-0.26 [ -0.88, 0.37 ]
Wojciechowski 1984	9	264 (122)	12	238 (190)	<u> </u>	0.7 %	0.15 [ -0.71, 1.02 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	no-1 Mean(SD)	treatment N	Mean(SD)				n Differei 1,95% Cl		Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Total (95% CI)	2570		2520				٠			100.0 %	-0.22 [ -0.30, -0.14 ]
Heterogeneity: $Tau^2 = 0$	0.05; Chi ² = 14	10.54, df = 86 (P = 0.0	$000 9);  ^2 = 3$	19%							
Test for overall effect: Z	= 5.46 (P < 0	.00001)									
					-4	-2	0	2	4		
				Fav	vours	placebo		Favours	no-tre	atment	

#### Analysis 10.1. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome I Placebo intervention provider blinded: yes.

Review: Placebo interventions for all clinical conditions

Comparison: 10 Risk of bias subgroup analysis: blinding of placebo treatment providers

Outcome: I Placebo intervention provider blinded: yes

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% CI		M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		2.9 %	1.31 [ 0.88, 1.94 ]
Berg 1983	9/11	9/15		1.9 %	1.36 [ 0.83, 2.24 ]
Blackman 1964	6/12	6/12		0.8 %	1.00 [ 0.45, 2.23 ]
Corver 2006	227/279	360/416	•	21.7 %	0.94 [ 0.88, 1.01 ]
De Sanctis 2001	9/10	8/9	+	4.4 %	1.01 [ 0.74, 1.38 ]
Double 1993	3/22	3/22		0.2 %	1.00 [ 0.23, 4.42 ]
Frank 1990	14/26	4/26		1.8 %	1.00 [ 0.60, 1.65 ]
Guglielmi 1982	12/12	/ 2	+	7.2 %	1.09 [ 0.87, 1.36 ]
Harrison 1975	24/28	25/30	+	7.4 %	1.03 [ 0.83, 1.28 ]
Hutton 1991	5/24	6/30		0.7 %	0.39 [ 0.17, 0.91 ]
Jacobs 1971	9/15	2/39		1.2 %	1.95 [ 1.04, 3.65 ]
Kerr 2003	28/33	32/36	+	9.5 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	+	17.8 %	1.03 [ 0.94, 1.14 ]
Klerman 1974	17/25	16/25		2.8 %	1.06 [ 0.71, 1.58 ]
Malcolm 1980	40/63	44/58		6.7 %	0.84 [ 0.66, 1.06 ]
Najnigier 1997	21/30	24/30		4.7 %	0.88 [ 0.65, 1.17 ]
			<u> </u>		

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

						( Continued)
Study or subgroup	Placebo	No-treatment	F	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Ran	dom,95% Cl		M-H,Random,95% Cl
Stransky 1989	1/5	1/4	• • •		0.1 %	0.80 [ 0.07, 9.18 ]
Whittaker 1963	3/13	7/13	+		0.4 %	0.43 [ 0.14, 1.30 ]
Wilson 1980	31/40	10/10	-		7.9 %	0.80 [ 0.65, 0.99 ]
Total (95% CI)	1285	1422			100.0 %	0.97 [ 0.91, 1.05 ]
Total events: 735 (Placebo	o), 855 (No-treatme	nt)				
Heterogeneity: $Tau^2 = 0.0$	00; Chi ² = 24.50, df	= 18 (P = 0.14); 1 ² =27%				
Test for overall effect: Z =	= 0.70 (P = 0.48)					
			0.1 0.2 0.5	1 2 5 10		
			Favours placebo	Favours no-treatme	nt	

#### Analysis 10.2. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 2 Placebo intervention provider blinded: no or not stated.

Review: Placebo interventions for all clinical conditions

Comparison: 10 Risk of bias subgroup analysis: blinding of placebo treatment providers

Outcome: 2 Placebo intervention provider blinded: no or not stated

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Alkaissi 1999	9/20	11/20		1.6 %	0.82 [ 0.44, 1.53 ]
Alkaissi 2002	77/139	82/136	+	6.4 %	0.92 [ 0.75, 1.12 ]
Aune 1998	11/26	9/14	<b>.</b>	1.7 %	0.66 [ 0.36, 1.19 ]
Carter 2003	3/28	20/29	<u> </u>	2.5 %	0.67 [ 0.42, 1.07 ]
Dundee 1986	17/25	17/25		3.3 %	1.00 [ 0.68, 1.46 ]
Elliott 1978	6/18	6/6	<u> </u>	1.4 %	0.37 [ 0.19, 0.71 ]
Faas 1993	107/162	108/155	+	7.5 %	0.95 [ 0.81, 1.10 ]
Fanti 2003	8/10	9/10	<u> </u>	3.4 %	0.89 [ 0.61, 1.29 ]
Heinzl 1981	70/130	92/132	+	6.5 %	0.77 [ 0.64, 0.94 ]
Hyman 1986	9/15	15/15		3.0 %	0.61 [ 0.40, 0.93 ]
McMillan 1994	14/26	24/46	<u> </u>	2.6 %	1.03 [ 0.66, 1.62 ]
Molsberger 2002	38/58	30/53		4.5 %	1.16 [ 0.86, 1.56 ]

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

(Continued ...)

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	( Continued) Risk Ratio M-H,Random,95% Cl
Rabkin 1990	14/27	12/23	<u> </u>	2.0 %	0.99 [ 0.58, 1.70 ]
Roughan 1981	9/12	9/14		2.2 %	1.17 [ 0.70, 1.94 ]
Schallreuter 2002	3/10	4/10		0.5 %	0.75 [ 0.22, 2.52 ]
Scharf 2006	179/365	224/316	•	8.1 %	0.69 [ 0.61, 0.78 ]
Scharff 2002	11/12	12/12	+	5.9 %	0.92 [ 0.74, 1.15 ]
Tan 1986	8/10	8/9		3.3 %	0.90 [ 0.61, 1.32 ]
Tarcin 2004	58/158	27/77		3.5 %	1.05 [ 0.73, 1.51 ]
Tarrier 1998	22/26	25/28	+	6.2 %	0.95 [ 0.77, 1.17 ]
Thomas 1987	47/100	50/100		4.7 %	0.94 [ 0.71, 1.25 ]
Tyler 1946	89/260	106/303	+	5.8 %	0.98 [ 0.78, 1.23 ]
Walton 1993	19/24	21/30	<u>+-</u>	4.3 %	1.13 [ 0.83, 1.54 ]
Watzl 1986	15/34	7/36		1.1 %	2.27 [ 1.06, 4.88 ]
Williams 1988	19/20	19/20	+	7.8 %	1.00 [ 0.87, 1.15 ]
Fotal (95% CI)	1715	1619	•	100.0 %	0.90 [ 0.83, 0.99 ]
otal events: 872 (Placebo) Heterogeneity: Tau ² = 0.02 Test for overall effect: Z = $\frac{1}{2}$	; Chi ² = 48.53, df	nt) = 24 (P = 0.002); I ² =5 I %			
			0.1 0.2 0.5   2 5 10 Favours placebo Favours no-treatme	ent	

#### Analysis 10.3. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 3 Placebo intervention provider blinded: yes.

Review: Placebo interventions for all clinical conditions

Comparison: 10 Risk of bias subgroup analysis: blinding of placebo treatment providers

Outcome: 3 Placebo intervention provider blinded: yes

-

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		1.5 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		3.0 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)	<u></u>	1.9 %	0.38 [ -0.30, 1.06 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.9 %	0.56 [ -0.60, 1.72 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		1.4 %	-1.07 [ -1.94, -0.20 ]
Blades 2001	40	-16 (6)	40	-16 (6)	+	3.0 %	0.0 [ -0.44, 0.44 ]
Classen 1983	15	11.3 (8.3)	15	4.4 (6. )		1.8 %	-0.41 [ -1.14, 0.31 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.8 %	0.29 [ -0.95, 1.53 ]
Costello 2006	48	33 (25)	42	31 (25)		3.1 %	0.08 [ -0.33, 0.49 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)		2.6 %	0.08 [ -0.44, 0.59 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)		3.2 %	-0.12 [ -0.51, 0.27 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)	<del></del>	1.7 %	-0.13 [ -0.89, 0.63 ]
Frega 1994	21	20 (16)	21	23 (16)	<u> </u>	2.2 %	-0.18 [ -0.79, 0.42 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		1.7 %	-0.54 [ -1.30, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	4.1 %	-0.03 [ -0.25, 0.20 ]
Hashish 1986	25	6 (  .7)	50	30 (18.9)		2.7 %	-0.82 [ -1.32, -0.32 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)	+	3.4 %	0.31 [ -0.05, 0.68 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		2.2 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)	<del></del>	1.6 %	0.23 [ -0.56, 1.02 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		1.9 %	-0.31 [ -1.01, 0.38 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	4.3 %	0.15 [ -0.04, 0.33 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	-	3.0 %	0.08 [ -0.36, 0.52 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		2.6 %	-0.41 [ -0.93, 0.10 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)	+	2.4 %	-0.02 [ -0.59, 0.54 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		2.4 %	-0.49 [ -1.06, 0.08 ]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		2.8 %	-1.37 [ -1.85, -0.89 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		2.9 %	-0.12 [ -0.57, 0.33 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	3.8 %	-0.06 [ -0.35, 0.23 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	+-	3.4 %	0.20 [ -0.16, 0.55 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		2.1 %	-0.11 [ -0.75, 0.54 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.9 %	-0.67 [ -1.80, 0.46 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		2.8 %	-0.72 [ -1.20, -0.23 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		2.9 %	0.21 [ -0.24, 0.67 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)	<u> </u>	1.3 %	-0.69 [ -1.60, 0.22 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)		3.7 %	-0.16 [ -0.46, 0.14 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)	-	2.2 %	0.05 [ -0.55, 0.65 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	<u></u>	1.9 %	0.48 [ -0.22, 1.19 ]
Tritrakarn 2000	41	49 (16)	41	61 (17)		2.9 %	-0.72 [ -1.17, -0.27 ]
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)		1.5 %	0.24 [ -0.60,  .08 ]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		1.8 %	0.05 [ -0.66, 0.77 ]
Wojciechowski 1984	9	264 (122)	12	238 (190)	<del></del>	1.4 %	0.15 [ -0.71, 1.02 ]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		2.1 %	-0.20 [ -0.83, 0.44 ]
<b>otal (95% CI)</b> eterogeneity: Tau ² = 0.0 st for overall effect: Z =			<b>1522</b> <0.00001); I ² =58	%	•	1 <b>00.0</b> %	-0.15 [ -0.27, -0.02 ]

-2 0 -4

2 Favours placebo Favours no-treatment

4

#### Analysis 10.4. Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 4 Placebo intervention provider blinded: no or not stated.

Review: Placebo interventions for all clinical conditions

-

Comparison: 10 Risk of bias subgroup analysis: blinding of placebo treatment providers

Outcome: 4 Placebo intervention provider blinded: no or not stated

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% CI
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.1 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)	_	0.7 %	-0.14 [ -0.80, 0.52 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		1.0 %	0.08 [ -0.44, 0.60 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		0.4 %	0.34 [ -0.52,  .2  ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.4 %	-0.32 [ -1.28, 0.64 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		1.1 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	+	2.2 %	-0.17 [ -0.43, 0.10 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.0 %	0.13 [ -0.39, 0.64 ]
Blanchard 1990a	13	8.3 (13.6)	П	22.5 (25.1)		0.5 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		0.8 %	-0.28 [ -0.90, 0.33 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.4 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		0.5 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.2 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.5 %	-0.41 [ -1.22, 0.40 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		1.7 %	-0.62 [ -0.96, -0.29 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.6 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.2 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		0.9 %	0.10 [ -0.45, 0.66 ]
Chenard 1991	12	29 (19)	16	30 (19)	_	0.6 %	-0.05 [ -0.80, 0.70 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.5 %	-0.92 [ -1.72, -0.12 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		0.8 %	0.13 [ -0.47, 0.74 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)	—	0.4 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.4 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.4 %	-0.39 [ -1.35, 0.58 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	_	2.7 %	-0.02 [ -0.22, 0.17 ]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	( Continued) Std. Mean Difference
Ditto 2006	N 140	Mean(SD)	N 155	Mean(SD)	IV,Random,95% Cl ↓	2.4 %	IV,Random,95% CI
Erdogmus 2007		0.43 (0.35)		0.45 (0.37)			-0.06 [ -0.28, 0.17 ]
5	40	-27.4 (19.7)	40	-20.3 (19.7)		1.3 %	-0.36 [ -0.80, 0.08 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		0.5 %	-0.65 [ -1.43, 0.13 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		0.5 %	-0.33 [ -1.12, 0.46 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	3.0 %	-0.41 [ -0.57, -0.26 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.6 %	-0.54 [ -1.27, 0.19 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.3 %	-0.98 [ -2.02, 0.06 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	2.2 %	-0.06 [ -0.33, 0.21 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.3 %	-0.47 [ -1.50, 0.57 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)	<b>_</b>	0.4 %	-0.97 [ -1.91, -0.03 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		1.3 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.2 %	-0.28 [ -0.73, 0.16 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		0.8 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)	<u> </u>	0.4 %	-0.19 [ -1.05, 0.67 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		0.9 %	-0.16 [ -0.72, 0.39 ]
Hashish 1988	25	42 (25)	25	60 (23)		0.9 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	<u> </u>	0.3 %	-1.58 [ -2.61, -0.55 ]
Helms 1987	П	103 (91)	11	79 (99)	_ <del></del>	0.5 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.7 %	-0.53 [ -1.19, 0.13 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		0.5 %	-0.18 [ -0.98, 0.62 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	2.1 %	-0.06 [ -0.34, 0.22 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.5 %	0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.4 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.5 %	-0.35 [ -1.19, 0.50 ]
acobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.2 %	-1.17 [ -2.39, 0.04 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		2.0 %	-0.4  [ -0.7 , -0.   ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.5 %	-1.07 [ -1.89, -0.25 ]
Kendall 1979		7.54 (2.29)		8.18 (3.03)		0.5 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		1.0 %	-0.28 [ -0.81, 0.24 ]
Kilmann 1987			4			0.2 %	
	4	-33 (47)		-35 (47)			0.04 [ -1.35, 1.42 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		0.8 %	-0.55 [ -1.14, 0.03 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	2.6 %	-0.12 [ -0.33, 0.09 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		0.9 %	-0.79 [ -1.34, -0.23 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.2 %	-0.59 [ -1.04, -0.14 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.6 %	-0.49 [ -1.17, 0.20 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.3 %	-1.08 [ -2.09, -0.07 ]
Lick 1977	10	66 (25)	10	63 (32)	_ <u>_</u>	0.4 %	0.10 [ -0.78, 0.98 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	+	1.0 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		0.9 %	-0.5  [ -1.07, 0.05 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		1.3 %	-0.23 [ -0.67, 0.21 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)	+	1.7 %	-0.56 [ -0.90, -0.22 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		0.7 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)	<u> </u>	0.4 %	0.0 [ -0.90, 0.90 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)	<u> </u>	0.3 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)		0.8 %	0.12 [ -0.47, 0.71 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)	<u> </u>	0.4 %	0.04 [ -0.86, 0.93 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)	-+-	0.8 %	-0.3  [ -0.93, 0.32 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		1.6 %	-0.70 [ -1.07, -0.33 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	1.7 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		1.3 %	-0.19 [ -0.63, 0.25 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)	<u> </u>	0.5 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)		0.2 %	-1.99 [ -3.24, -0.74 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)	<del></del>	0.4 %	-0.33 [ -1.27, 0.61 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)	_ <del></del>	0.3 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.4 %	-0.02 [ -0.90, 0.85 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)	-	1.5 %	-0.15 [ -0.53, 0.23 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		1.4 %	0.10 [ -0.31, 0.50 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.5 %	0.26 [ -0.50, 1.02 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		0.9 %	-0.24 [ -0.78, 0.30 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		0.7 %	-0.40 [ -1.05, 0.24 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.5 %	-0.11 [ -0.93, 0.72 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)	_ <u>+</u>	1.0 %	-0.15 [ -0.69, 0.38 ]

-4 -2 0 2 Favours placebo

Favours no-treatment

4

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continue) Std. Mean Difference IV,Random,95% C
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.1 %	-0.30 [ -0.80, 0.19
Rossi 1982	6	107 (17)	6	108 (20)		0.3 %	-0.05 [ -1.18, 1.08
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		0.9 %	-0.16 [ -0.73, 0.40
Rschke 2000	24	23 (16.2)	24	26 (16)	_+_	0.9 %	-0.18 [ -0.75, 0.38
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.5 %	-0.02 [ -0.78, 0.73
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)	<u> </u>	0.3 %	-0.13 [ -1.26, 1.00
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.5 %	-1.12 [ -1.94, -0.30
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.4 %	-0.04 [ -0.90, 0.8
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		1.1 %	-0.25 [ -0.73, 0.23
Sipich 1974	10	8 (14)	10	32.5 (14)		0.3 %	-1.68 [ -2.73, -0.63
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	<u></u>	0.5 %	0.22 [ -0.56, 1.01
Sprott 1993	10	7.9 (3)	10	7.4 (3)	<del></del>	0.4 %	0.16 [ -0.72, 1.04
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		0.9 %	-0.28 [ -0.83, 0.28
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.2 %	0.27 [ -0.98, 1.52
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	<del></del>	0.4 %	0.21 [ -0.67, 1.09
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.5 %	-0.55 [ -1.36, 0.27
Thomas 1999	14	3.4 ( 0.28)	26	16.5 (9.73)		0.7 %	-0.3  [ -0.96, 0.35
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		1.9 %	-0.27 [ -0.59, 0.04
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	-+-	2.2 %	0.12 [ -0.14, 0.37
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		1.0 %	0.14 [ -0.36, 0.65
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		1.1 %	-0.08 [ -0.57, 0.41
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.1 %	-0.60 [ -1.07, -0.12
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)	<b>+</b>	0.4 %	-0.45 [ -1.34, 0.44
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	1.3 %	0.0 [ -0.44, 0.44
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		0.9 %	-0.40 [ -0.96, 0.15
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		0.6 %	-0.10 [ -0.81, 0.62
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)	-+	0.8 %	-0.26 [ -0.88, 0.37
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		1.7 %	-0.84 [ -1.19, -0.50
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	<b>-</b> _	0.3 %	-0.97 [ -2.10, 0.16
otal (95% CI)	3641		3803		•	100.0 %	-0.26 [ -0.32, -0.19

-4	-2	0	2	4	
Favours	olacebo		Favours	no-treatmer	nt
		-			

### Analysis 11.1. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 1 Blinding of observer: yes.

Review: Placebo interventions for all clinical conditions

Comparison: II Risk of bias subgroup analysis: blinding of observer

Outcome: I Blinding of observer: yes

-

-

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% CI		M-H,Random,95% Cl
Heinzl 1981	70/130	92/132	-	51.4 %	0.77 [ 0.64, 0.94 ]
Tarrier 1998	22/26	25/28	+	48.6 %	0.95 [ 0.77, 1.17 ]
Total (95% CI)	156	160	•	100.0 %	0.85 [ 0.68, 1.07 ]
Total events: 92 (Placebo	, 117 (No-treatment	)			
Heterogeneity: $Tau^2 = 0.0$	02; Chi ² = 2.43, df =	I (P = 0.12); I ² =59%			
Test for overall effect: Z =	= 1.40 (P = 0.16)				
			0.1 0.2 0.5 1 2 5 10		
			Favours placebo Favours no-treatm	nent	

### Analysis 11.2. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 2 Blinding of observer: not stated.

Review: Placebo interventions for all clinical conditions

Comparison: II Risk of bias subgroup analysis: blinding of observer

Outcome: 2 Blinding of observer: not stated

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		5.3 %	1.31 [ 0.88, 1.94 ]
De Sanctis 2001	9/10	8/9	+	8.0 %	1.01 [ 0.74, 1.38 ]
Double 1993	3/22	3/22		0.4 %	1.00 [ 0.23, 4.42 ]
Fanti 2003	8/10	9/10		5.8 %	0.89 [ 0.61, 1.29 ]
Harrison 1975	24/28	25/30	+	13.5 %	1.03 [ 0.83, 1.28 ]
Hyman 1986	9/15	15/15		4.8 %	0.61 [ 0.40, 0.93 ]
Kerr 2003	28/33	32/36	-	17.2 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	•	31.5 %	1.03 [ 0.94, 1.14 ]
			0.1 0.2 0.5 2 5 10 Favours placebo Favours no-treatment		

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

									( Continued)
Study or subgroup	Placebo	No-treatment		F	Risk Rati	0		Weight	Risk Ratio
	n/N	n/N	٢	I-H,Ran	dom,959	% CI			M-H,Random,95% Cl
Malcolm 1980	40/63	44/58		-	-			12.2 %	0.84 [ 0.66, 1.06 ]
Schallreuter 2002	3/10	4/10	_					0.6 %	0.75 [ 0.22, 2.52 ]
Whittaker 1963	3/13	7/13			_			0.7 %	0.43 [ 0.14, 1.30 ]
Total (95% CI)	841	838		•	•			100.0 %	0.96 [ 0.87, 1.06 ]
Total events: 403 (Placebo	o), 404 (No-treatme	nt)							
Heterogeneity: $Tau^2 = 0.0$	1; Chi ² = 12.77, df	= 10 (P = 0.24); I ² =22%							
Test for overall effect: Z =	= 0.80 (P = 0.42)								
			0.1 0.2	0.5	1 2	5	10		
			Favours p	acebo	Favour	rs no-tr	eatment		

# Analysis 11.3. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 3 Blinding of observer: yes.

Review: Placebo interventions for all clinical conditions

Comparison: II Risk of bias subgroup analysis: blinding of observer

Outcome: 3 Blinding of observer: yes

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% Cl
Allen 1998		-2.9 (7.9)		-6.1 (10.9)		3.9 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)	-	9.7 %	-0.72 [ -1.15, -0.29 ]
Bosley 1989	13	86 (10)	4	89 (10)		4.5 %	-0.29 [ -1.05, 0.47 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		4.1 %	-0.41 [ -1.22, 0.40 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		4.3 %	-0.33 [ -1.12, 0.46 ]
Frankel 1978	7	93 (5)	8	95 (3)		2.7 %	-0.47 [ -1.50, 0.57 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		4.2 %	0.23 [ -0.56, 1.02 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)	-#-	7.2 %	-0.79 [ -1.34, -0.23 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)	-	7.0 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		3.5 %	0.04 [ -0.86, 0.93 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		3.6 %	-0.02 [ -0.90, 0.85 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		7.4 %	-0.24 [ -0.78, 0.30 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	( Continued) Std. Mean Difference
, , ,	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	0	IV,Random,95% CI
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		4.0 %	-0.   [ -0.93, 0.72 ]
Rossi 1982	6	107 (17)	6	108 (20)		2.3 %	-0.05 [ -1.18, 1.08 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)	<u> </u>	4.0 %	-1.12 [ -1.94, -0.30 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		3.4 %	-0.69 [ -1.60, 0.22 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		5.1 %	0.48 [ -0.22, 1.19 ]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)	+	8.1 %	0.14 [ -0.36, 0.65 ]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)	<u> </u>	5.0 %	-0.10 [ -0.81, 0.62 ]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		5.9 %	-0.20 [ -0.83, 0.44 ]
Fotal (95% CI)	347		322		•	100.0 %	-0.23 [ -0.42, -0.05 ]
Heterogeneity: Tau ² = 0	.04; Chi ² = 1	25.22, df = 19 (P	= 0.15); 12 = 25%				
Test for overall effect: Z	= 2.5 I (P =	0.012)					
				_			

-4 -2 0 2 4 Favours placebo Favours no-treatment

# Analysis 11.4. Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 4 Blinding of observer: not stated.

Review: Placebo interventions for all clinical conditions

Comparison: II Risk of bias subgroup analysis: blinding of observer

Outcome: 4 Blinding of observer: not stated

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		1.9 %	0.34 [ -0.52,  .2  ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)	<b>.</b>	1.1 %	0.56 [ -0.60, 1.72 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)	-	4.8 %	-0.12 [ -0.60, 0.35 ]
Blades 2001	40	-16 (6)	40	-16 (6)	-	5.3 %	0.0 [ -0.44, 0.44 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		1.9 %	-0.30 [ -1.15, 0.56 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)	<b>·</b>	1.1 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		3.9 %	0.10 [ -0.45, 0.66 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)	<del>.</del>	1.0 %	0.29 [ -0.95, 1.53 ]
					-4 -2 0 2 4		

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

84)   1.2) 5 1.4) 2 54) 22 54) 22 38)   .2) 24)   138)   1	<ul> <li>4 46.88 (16.16)</li> <li>95.4 (33)</li> <li>0.92 (7.83)</li> <li>00.26 (2.2)</li> <li>95.05 (4.84)</li> <li>7 5.9 (0.6)</li> <li>38.1 (16)</li> <li>6.75 (0.53)</li> </ul>		4.3 % 5.4 % 9.6 % 3.6 % 2.2 % - 2.2 % - 6.5 % 3.8 % 10.7 % - 2.3 % 1.0 %	0.08 [-0.44, 0.59 ] -0.72 [-1.15, -0.29 ] -0.03 [-0.25, 0.20 ] -0.17 [-0.76, 0.41 ] -0.19 [-1.05, 0.67 ] -0.18 [-0.98, 0.62 ] 0.31 [-0.05, 0.68 ] -0.51 [-1.07, 0.05 ] 0.15 [-0.04, 0.33 ] -0.14 [-0.91, 0.63 ]
0.7)       15         83)       2         83)       1         84)       1         1.2)       5         1.4)       2         54)       22         38)       1         1.2)       5         1.2)       5         1.2)       1         2.3)       1         1.2)       1         38)       1	0         95.4 (33)           2         0.92 (7.83)           0         -0.26 (2.2)           2         95.05 (4.84)           7         5.9 (0.6)           5         38.1 (16)           6         6.75 (0.53)           3         24.53 (16.38)           1         -0.8 (6.4)           3         57.5 (13.8)		9.6 % 3.6 % 1.9 % 2.2 % 6.5 % 3.8 % 10.7 % 2.3 %	-0.03 [ -0.25, 0.20 ] -0.17 [ -0.76, 0.41 ] -0.19 [ -1.05, 0.67 ] -0.18 [ -0.98, 0.62 ] 0.31 [ -0.05, 0.68 ] -0.51 [ -1.07, 0.05 ] 0.15 [ -0.04, 0.33 ]
83) 2 83) 1 84) 1 1.2) 5 1.4) 2 54) 22 38) 1 9.3) 1 1.2) 1 24) 1 38) 1	2 0.92 (7.83) 0 -0.26 (2.2) 2 95.05 (4.84) 7 5.9 (0.6) 5 38.1 (16) 6 6.75 (0.53) 3 24.53 (16.38) 1 -0.8 (6.4) 3 57.5 (13.8)		3.6 % 1.9 % 2.2 % 6.5 % 3.8 % 10.7 % 2.3 %	-0.17 [ -0.76, 0.41 ] -0.19 [ -1.05, 0.67 ] -0.18 [ -0.98, 0.62 ] 0.31 [ -0.05, 0.68 ] -0.51 [ -1.07, 0.05 ] 0.15 [ -0.04, 0.33 ]
83)     84)     1.2) 55 1.4) 22 54) 22 54) 22 54) 22 54) 1 38)     1.2)   24)     38)	0         -0.26 (2.2)           2         95.05 (4.84)           7         5.9 (0.6)           5         38.1 (16)           6         6.75 (0.53)           3         24.53 (16.38)           1         -0.8 (6.4)           3         57.5 (13.8)		<ul> <li>1.9 %</li> <li>2.2 %</li> <li>6.5 %</li> <li>3.8 %</li> <li>10.7 %</li> <li>2.3 %</li> </ul>	-0.19 [ -1.05, 0.67 ] -0.18 [ -0.98, 0.62 ] 0.31 [ -0.05, 0.68 ] -0.51 [ -1.07, 0.05 ] 0.15 [ -0.04, 0.33 ]
84)   1.2) 5 1.4) 2 54) 22 54) 22 38)   .2) 24)   138)   1	2 95.05 (4.84) 7 5.9 (0.6) 5 38.1 (16) 6 6.75 (0.53) 3 24.53 (16.38) 1 -0.8 (6.4) 3 57.5 (13.8)		2.2 % 6.5 % 3.8 % 10.7 % 2.3 %	-0.18 [ -0.98, 0.62 ] 0.31 [ -0.05, 0.68 ] -0.51 [ -1.07, 0.05 ] 0.15 [ -0.04, 0.33 ]
1.2) 5 1.4) 2 54) 22 38) 1 9.3) 1 1.2) 1 24) 1 38) 1	7         5.9 (0.6)           5         38.1 (16)           6         6.75 (0.53)           3         24.53 (16.38)           1         -0.8 (6.4)           3         57.5 (13.8)		6.5 % 3.8 % 10.7 % 2.3 %	0.31 [ -0.05, 0.68 ] -0.51 [ -1.07, 0.05 ] 0.15 [ -0.04, 0.33 ]
4.4) 2 54) 22 38) 1 2.3) 1 1.2) 24) 1 38) 1	5         38.1 (16)           6         6.75 (0.53)           3         24.53 (16.38)           1         -0.8 (6.4)           3         57.5 (13.8)		3.8 % 10.7 % 2.3 %	-0.51 [ -1.07, 0.05 ] 0.15 [ -0.04, 0.33 ]
54) 22 38) I 2.3) I 1.2) 24) I 38) I	6 6.75 (0.53) 3 24.53 (16.38) 1 -0.8 (6.4) 3 57.5 (13.8)		10.7 %	0.15 [ -0.04, 0.33 ]
38)   9.3)   1.2) 24)   18)	3 24.53 (16.38) I -0.8 (6.4) B 57.5 (13.8)		2.3 %	
2.3)   1.2) 24)   38)	I -0.8 (6.4) 3 57.5 (13.8)			-0.14 [ -0.91, 0.63 ]
1.2) 24) I 38) I	8 57.5 (13.8)		1.0 %	
24) I 38) I	,			-1.99 [ -3.24, -0.74 ]
38) I	9 -2.9 (3.05)		1.7 %	-0.33 [ -1.27, 0.61 ]
,			3.1 %	-0.   [ -0.75, 0.54 ]
	0 47.87 (7.53)		- 1.9 %	-0.04 [ -0.90, 0.81 ]
35) 3	4 43.7 (11.31)		4.7 %	-0.25 [ -0.73, 0.23 ]
9.7) 2	7 64.1 (13.9)	-	5.0 %	0.21 [ -0.24, 0.67 ]
72) I	) 14.9 (1.8)		- 1.9 %	0.2  [ -0.67,  .09 ]
36) I	I 8.67 (I.56)		2.0 %	0.24 [ -0.60, 1.08 ]
7.3) 2	6   3.4 (5.8)		3.9 %	-0.40 [ -0.96, 0.15 ]
5.I) I	5 -6.7 (5.9)		2.6 %	0.05 [ -0.66, 0.77 ]
53)	7 0.71 (1.44)		1.2 %	-0.97 [ -2.10, 0.16 ]
		ł	100.0 %	-0.07 [ -0.20, 0.06 ]
		-4 -2 0	2 4 Favours po-treatment	
5:	3) <b>900</b>	, , , ,	3) 7 0.71 (1.44) <b>906</b> 8 (P = 0.06); I ² = 31%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

#### Analysis 12.1. Comparison 12 Risk of bias subgroup analysis: variance inequality and skewness, Outcome I No signs of unequal variance or skewness.

Review: Placebo interventions for all clinical conditions

Comparison: 12 Risk of bias subgroup analysis: variance inequality and skewness

Outcome: I No signs of unequal variance or skewness

-

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		2.0 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		1.3 %	-0.14 [ -0.80, 0.52 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.5 %	0.56 [ -0.60, 1.72 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	+	3.2 %	-0.17 [ -0.43, 0.10 ]
Bosley 1989	13	86 (10)	14	89 (10)		1.0 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		2.0 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.9 %	-0.41 [ -1.22, 0.40 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)	<b>+</b>	1.2 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.5 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		1.6 %	0.10 [ -0.45, 0.66 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)	<b>·</b>	0.5 %	0.29 [ -0.95, 1.53 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)	<b>_</b> _	1.0 %	-0.92 [ -1.72, -0.12 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)		1.8 %	0.08 [ -0.44, 0.59 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.8 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.7 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.7 %	-0.39 [ -1.35, 0.58 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		1.0 %	-0.33 [ -1.12, 0.46 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	4.0 %	-0.41 [ -0.57, -0.26 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		1.0 %	-0.13 [ -0.89, 0.63 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.6 %	-0.98 [ -2.02, 0.06 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.6 %	-0.47 [ -1.50, 0.57 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.7 %	-0.97 [ -1.91, -0.03 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		2.1 %	-0.28 [ -0.73, 0.16 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)	_+_	1.6 %	-0.16 [ -0.72, 0.39 ]
Hashish 1988	25	42 (25)	25	60 (23)		1.5 %	-0.74 [ -1.31, -0.16 ]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo	Mara (CD)	No-treatment	Mara (CD)	Std. Mean Difference	Weight	( Continued) Std. Mean Difference
Hawkins 1995	N 10	Mean(SD) 37.4 (8.5)	N 10	Mean(SD) 52.1 (9.3)	IV,Random,95% Cl	0.6 %	IV,Random,95% Cl -1.58 [ -2.61, -0.55 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		0.9 %	-0.18 [ -0.98, 0.62 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	3.1 %	-0.06 [ -0.34, 0.22 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.8 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	10	3.3 (0.7)	10	3.7 (1.4)		0.9 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.7)	6	3.47 (0.5)		0.5 %	-0.35 [ -1.17, 0.50 ]
Kaptchuk 2008	88	-4.3 (1.4)	87			3.0 %	-0.41 [ -0.71, -0.11 ]
Karst 2007	19	45.21 (10.82)	10	-3.8 (1) 56.5 (9.1)		0.9 %	-1.07 [ -1.89, -0.25 ]
						1.4 %	
Kober 2002	20	66.7 (10)	21	64.4 (13.3)			0.19 [ -0.42, 0.80 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.5 %	-0.55 [ -1.14, 0.03 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		2.1 %	-0.59 [ -1.04, -0.14 ]
Lick 1977	10	66 (25)	10	63 (32)		0.8 %	0.10 [ -0.78, 0.98 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)		1.8 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		1.6 %	-0.51 [ -1.07, 0.05 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	3.8 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.4 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.8 %	0.0 [ -0.90, 0.90 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	+	2.1 %	0.08 [ -0.36, 0.52 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)	_ <del></del>	1.5 %	0.12 [ -0.47, 0.71 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		2.1 %	-0.19 [ -0.63, 0.25 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.7 %	-0.33 [ -1.27, 0.61 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		1.0 %	0.26 [ -0.50, 1.02 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)	-	2.1 %	-0.12 [ -0.57, 0.33 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		1.7 %	-0.24 [ -0.78, 0.30 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		2.6 %	0.20 [ -0.16, 0.55 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		1.7 %	-0.15 [ -0.69, 0.38 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.9 %	-0.30 [ -0.80, 0.19 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)	<b>.</b>	0.5 %	-0.67 [ -1.80, 0.46 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.5 %	-0.05 [ -1.18, 1.08 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		1.0 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.5 %	-0.13 [ -1.26, 1.00 ]

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	( Continued) Std. Mean Difference
Study of subgroup	N	Mean(SD)	N N	Mean(SD)	IV,Random,95% CI	VVelgill	IV,Random,95% Cl
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.9 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.9 %	-0.04 [ -0.90, 0.81 ]
Shen 2000	33	40.7 (12.35)	34	43.7 (  .3 )		1.9 %	-0.25 [ -0.73, 0.23 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		2.0 %	0.21 [ -0.24, 0.67 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		1.0 %	0.22 [ -0.56, 1.01 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)	<b>-</b> _	0.8 %	-0.69 [ -1.60, 0.22 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		1.6 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.4 %	0.27 [ -0.98, 1.52 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	<b>.</b>	0.8 %	0.21 [ -0.67, 1.09 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.9 %	-0.55 [ -1.36, 0.27 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	+	1.2 %	0.48 [ -0.22, 1.19 ]
Tritrakarn 2000	41	49 (16)	41	61 (17)		2.1 %	-0.72 [ -1.17, -0.27 ]
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.9 %	-0.60 [ -1.07, -0.12 ]
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)		0.9 %	0.24 [ -0.60, 1.08 ]
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		1.4 %	-0.26 [ -0.88, 0.37 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		2.7 %	-0.84 [ -1.19, -0.50 ]
<b>Total (95% CI)</b> Heterogeneity: Tau ² = Test for overall effect: 2			<b>2227</b> = 0.00065); l ² =	-39%	•	100.0 %	-0.24 [ -0.33, -0.15 ]

-2 0

-4

Favours placebo

2 Favours no-treatment

4

### Analysis 12.2. Comparison 12 Risk of bias subgroup analysis: variance inequality and skewness, Outcome 2 Signs of either unequal variance or skewness.

Review: Placebo interventions for all clinical conditions

Comparison: 12 Risk of bias subgroup analysis: variance inequality and skewness

Outcome: 2 Signs of either unequal variance or skewness

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Allen 2006	45	12 (9.6)	44	19 (9.6)		2.5 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)	<u>+</u>	1.4 %	0.38 [ -0.30, 1.06 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.8 %	-0.32 [ -1.28, 0.64 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		2.0 %	0.13 [ -0.39, 0.64 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		1.0 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		1.6 %	-0.28 [ -0.90, 0.33 ]
Chenard 1991	12	29 (19)	16	30 (19)	-	1.2 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	11.3 (8.3)	15	4.4 (6.1)		1.3 %	-0.4  [ -1.14, 0.3  ]
Costello 2006	48	33 (25)	42	31 (25)	+	2.6 %	0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	<u> </u>	1.6 %	0.13 [ -0.47, 0.74 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	+	2.7 %	-0.12 [ -0.51, 0.27 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	-	4.2 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	3.9 %	-0.06 [ -0.28, 0.17 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		1.1 %	-0.65 [ -1.43, 0.13 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)	<u> </u>	1.3 %	-0.54 [ -1.27, 0.19 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	3.6 %	-0.06 [ -0.33, 0.21 ]
Frega 1994	21	20 (16)	21	23 (16)		1.6 %	-0.18 [ -0.79, 0.42 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		2.4 %	-0.28 [ -0.73, 0.16 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	3.9 %	-0.03 [ -0.25, 0.20 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		2.1 %	-0.82 [ -1.32, -0.32 ]
Helms 1987	11	103 (91)	11	79 (99)		1.0 %	0.24 [ -0.60, 1.08 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)	+-	2.7 %	0.21 [ -0.19, 0.60 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		1.0 %	-0.35 [ -1.19, 0.50 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)	+	2.9 %	0.31 [ -0.05, 0.68 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		2.0 %	-0.28 [ -0.81, 0.24 ]

-4 -2 0 Favours placebo Favours no-treatment

2 4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continu Std. Mean Differend IV,Random,95% (
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.4 %	0.04 [ -1.35, 1.42
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		1.1 %	0.23 [ -0.56, 1.02
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	4.1 %	-0.12 [ -0.33, 0.09
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		1.8 %	-0.79 [ -1.34, -0.2]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		1.4 %	-0.49 [ -1.17, 0.20
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		2.4 %	-0.23 [ -0.67, 0.2
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)	<u> </u>	0.9 %	0.04 [ -0.86, 0.93
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		2.9 %	-0.70 [ -1.07, -0.3]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		1.8 %	-0.49 [ -1.06, 0.0
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		2.2 %	-1.37 [ -1.85, -0.89
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)		0.8 %	0.19 [ -0.80, 1.1
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.9 %	-0.02 [ -0.90, 0.8
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		2.8 %	-0.15 [ -0.53, 0.2
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		2.6 %	0.10 [ -0.31, 0.5
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	3.5 %	-0.06 [ -0.35, 0.2
Reading 1982	18	1.6 (1.3)	20	2.3 (2)	_+_	1.5 %	-0.40 [ -1.05, 0.2
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)	<u> </u>	1.0 %	-0.11 [ -0.93, 0.7
Rschke 2000	24	23 (16.2)	24	26 (16)	_ <del></del>	1.8 %	-0.18 [ -0.75, 0.3
Sipich 1974	10	8 (14)	10	32.5 (14)	<b>-</b>	0.7 %	-1.68 [ -2.73, -0.6
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)		3.4 %	-0.16 [ -0.46, 0.1
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		1.7 %	0.05 [ -0.55, 0.6
Thomas 1999	14	3.4 ( 0.28)	26	16.5 (9.73)		1.5 %	-0.31 [ -0.96, 0.3
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)	<b>·</b> _	0.9 %	-0.45 [ -1.34, 0.4
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)	_+_	1.8 %	-0.40 [ -0.96, 0.1
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		1.3 %	0.05 [ -0.66, 0.7
Wojciechowski 1984	9	264 (122)	12	238 (190)		1.0 %	0.15 [ -0.71, 1.0
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		1.5 %	-0.20 [ -0.83, 0.44
otal (95% CI) eterogeneity: Tau ² = 0.0 st for overall effect: Z =			<b>2070</b> = 0.00022); l ² =4	6%	•	100.0 %	-0.20 [ -0.30, -0.11

## Analysis 13.1. Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome I Selection of outcome: primary trial outcome clearly indicated.

Review: Placebo interventions for all clinical conditions

Comparison: 13 Risk of bias subgroup analysis: selection of outcome

Outcome: I Selection of outcome: primary trial outcome clearly indicated

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326		2.6 %	1.31 [ 0.88, 1.94 ]
Alkaissi 2002	77/139	82/136	-	5.1 %	0.92 [ 0.75, 1.12 ]
Aune 1998	11/26	9/14		1.4 %	0.66 [ 0.36, 1.19 ]
Blackman 1964	6/12	6/12		0.8 %	1.00 [ 0.45, 2.23 ]
Carter 2003	3/28	20/29		2.0 %	0.67 [ 0.42, 1.07 ]
Double 1993	3/22	3/22		0.3 %	1.00 [ 0.23, 4.42 ]
Dundee 1986	17/25	17/25		2.7 %	1.00 [ 0.68, 1.46 ]
Elliott 1978	6/18	6/6		1.2 %	0.37 [ 0.19, 0.71 ]
Faas 1993	107/162	108/155	+	6.0 %	0.95 [ 0.81, 1.10 ]
Frank 1990	14/26	14/26		1.8 %	1.00 [ 0.60, 1.65 ]
Harrison 1975	24/28	25/30	+	4.8 %	1.03 [ 0.83, 1.28 ]
Heinzl 1981	70/130	92/132	-	5.2 %	0.77 [ 0.64, 0.94 ]
Hyman 1986	9/15	15/15		2.4 %	0.61 [ 0.40, 0.93 ]
Jacobs 1971	9/15	12/39		1.3 %	1.95 [ 1.04, 3.65 ]
Kerr 2003	28/33	32/36	+	5.4 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	+	6.9 %	1.03 [ 0.94, 1.14 ]
Klerman 1974	17/25	16/25		2.5 %	1.06 [ 0.71, 1.58 ]
Malcolm 1980	40/63	44/58		4.5 %	0.84 [ 0.66, 1.06 ]
McMillan 1994	14/26	24/46		2.1 %	1.03 [ 0.66, 1.62 ]
Molsberger 2002	38/58	30/53		3.6 %	1.16 [ 0.86, 1.56 ]
Najnigier 1997	21/30	24/30		3.6 %	0.88 [ 0.65, 1.17 ]
Rabkin 1990	14/27	12/23		1.6 %	0.99 [ 0.58, 1.70 ]
Roughan 1981	9/12	9/14	<u> </u>	1.8 %	1.17 [ 0.70, 1.94 ]
Scharf 2006	179/365	224/316	•	6.5 %	0.69 [ 0.61, 0.78 ]
Scharff 2002	9/11	11/12		3.2 %	0.89 [ 0.64, 1.24 ]

0.1 0.2 0.5 1 2 5 10 Favours placebo Favours no-treatment

(Continued ...)

Placebo interventions for all clinical conditions (Review)

					( Continued)
Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Tarrier 1998	22/26	25/28		5.0 %	0.95 [ 0.77, 1.17 ]
Thomas 1987	47/100	50/100	_+_	3.8 %	0.94 [ 0.71, 1.25 ]
Tyler 1946	89/260	106/303	+	4.6 %	0.98 [ 0.78, 1.23 ]
Watzl 1986	15/34	7/36		0.9 %	2.27 [ 1.06, 4.88 ]
Whittaker 1963	3/13	7/13		0.4 %	0.43 [ 0.14, 1.30 ]
Williams 1988	19/20	19/20	+	6.2 %	1.00 [ 0.87, 1.15 ]
Total (95% CI)	2386	2389	•	100.0 %	0.93 [ 0.86, 1.00 ]
Total events: 1206 (Placeb	oo), 1306 (No-treatr	ment)			
Heterogeneity: $Tau^2 = 0.0$	02; Chi ² = 65.90, df	$= 30 (P = 0.000   7);  ^2 = 54$	4%		
Test for overall effect: Z =	= 1.90 (P = 0.057)				

0.1 0.2 0.5 2 5 10 Favours placebo Favours no-treatment

## Analysis 13.2. Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 2 Selection of outcome: primary trial outcome not clearly indicated (or not selected).

Review: Placebo interventions for all clinical conditions

Comparison: 13 Risk of bias subgroup analysis: selection of outcome

Outcome: 2 Selection of outcome: primary trial outcome not clearly indicated (or not selected)

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Alkaissi 1999	9/20	11/20		1.0 %	0.82 [ 0.44, 1.53 ]
Berg 1983	9/11	9/15		1.6 %	1.36 [ 0.83, 2.24 ]
Corver 2006	227/279	360/416	•	62.6 %	0.94 [ 0.88, 1.01 ]
De Sanctis 2001	9/10	8/9	+	4.2 %	1.01 [ 0.74, 1.38 ]
Fanti 2003	8/10	9/10		2.9 %	0.89 [ 0.61, 1.29 ]
Guglielmi 1982	12/12	11/12	+	7.9 %	1.09 [ 0.87, 1.36 ]
Hutton 1991	5/24	16/30		0.6 %	0.39 [ 0.17, 0.91 ]
Schallreuter 2002	3/10	4/10		0.3 %	0.75 [ 0.22, 2.52 ]
Stransky 1989	1/5	1/4	·	0.1 %	0.80 [ 0.07, 9.18 ]

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

(Continued ...)

Placebo interventions for all clinical conditions (Review)

					( Continued)
Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Tan 1986	8/10	8/9		2.7 %	0.90 [ 0.61, 1.32 ]
Tarcin 2004	58/158	27/77	<u> </u>	3.0 %	1.05 [ 0.73, 1.51 ]
Walton 1993	19/24	21/30	- <del></del>	4.2 %	1.13 [ 0.83, 1.54 ]
Wilson 1980	31/40	10/10	-	8.8 %	0.80 [ 0.65, 0.99 ]
Total (95% CI)	613	652	•	100.0 %	0.95 [ 0.89, 1.01 ]
Total events: 399 (Placeb	o), 495 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	00; Chi ² = 12.31, df	= 12 (P = 0.42); 1 ² = 3%			
Test for overall effect: Z =	= 1.64 (P = 0.10)				
			0.1 0.2 0.5 1 2 5 10		

Favours placebo Favours no-treatment

## Analysis 13.3. Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 3 Selection of outcome: primary trial outcome clearly indicated.

Review: Placebo interventions for all clinical conditions

Comparison: 13 Risk of bias subgroup analysis: selection of outcome

Outcome: 3 Selection of outcome: primary trial outcome clearly indicated

Study or subgroup	Placebo	N	o-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Allen 2006	45	12 (9.6)	44	19 (9.6)		1.6 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.9 %	0.38 [ -0.30, 1.06 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		0.6 %	0.34 [ -0.52, 1.21 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.4 %	0.56 [ -0.60, 1.72 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		0.6 %	-1.07 [ -1.94, -0.20 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	-	2.2 %	-0.17 [ -0.43, 0.10 ]
Blades 2001	40	-16 (6)	40	-16 (6)	+	1.5 %	0.0 [ -0.44, 0.44 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.7 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		0.8 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)	-+-	1.4 %	-0.14 [ -0.61, 0.33 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)	+	1.9 %	-0.62 [ -0.96, -0.29 ]

-4 -2 0 2 4 Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV.Random,95% Cl
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.4 %	0.48 [ -0.72, 1.67 ]
Chenard 1991	12	29 (19)	16	30 (19)		0.8 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	.3 (8.3)	15	4.4 (6.1)		0.8 %	-0.41 [ -1.14, 0.31 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.7 %	-0.92 [ -1.72, -0.12 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)		1.3 %	0.08 [ -0.44, 0.59 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	-	2.5 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	2.4 %	-0.06 [ -0.28, 0.17 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		1.5 %	-0.36 [ -0.80, 0.08 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		0.7 %	-0.33 [ -1.12, 0.46 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.8 %	-0.13 [ -0.89, 0.63 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.8 %	-0.54 [ -1.27, 0.19 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	2.2 %	-0.06 [ -0.33, 0.21 ]
Frankel 1978	7	93 (5)	8	95 (3)	<b>.</b>	0.5 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		1.1 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.6 %	-0.97 [ -1.91, -0.03 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		1.6 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	.  ( .6)	39	1.6 (1.9)		1.5 %	-0.28 [ -0.73, 0.16 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.8 %	-0.54 [ -1.30, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	2.4 %	-0.03 [ -0.25, 0.20 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)		0.7 %	-0.19 [ -1.05, 0.67 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)	_+_	1.2 %	-0.16 [ -0.72, 0.39 ]
Hashish 1988	25	42 (25)	25	60 (23)		1.1 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		0.5 %	-1.58 [ -2.61, -0.55 ]
Helms 1987	11	103 (91)	П	79 (99)	_ <del></del>	0.7 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.0 %	-0.53 [ -1.19, 0.13 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	2.1 %	-0.06 [ -0.34, 0.22 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		2.1 %	-0.41 [ -0.71, -0.11 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.8 %	0.31 [ -0.05, 0.68 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.7 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)	-+	1.3 %	-0.28 [ -0.81, 0.24 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.5 %	-0.59 [ -1.04, -0.14 ]

-4 -2 0 2 4

Favours no-treatment

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo		No-treatment	M (CD)	Std. Mean Difference	Weight	( Continued) Std. Mean Difference
Levine 1984	N 12	Mean(SD) -0.3 (0.69)	N 24	Mean(SD) 0.37 (2.5)	IV,Random,95% Cl	0.9 %	IV,Random,95% Cl -0.31 [ -1.01, 0.38 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)	_	1.5 %	-0.23 [ -0.67, 0.21 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)	-	1.9 %	-0.56 [ -0.90, -0.22 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		1.3 %	-0.41 [ -0.93, 0.10 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.5 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)		1.1 %	0.12 [ -0.47, 0.71 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		1.2 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.6 %	0.04 [ -0.86, 0.93 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		1.0 %	-0.31 [ -0.93, 0.32 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		1.8 %	-0.70 [ -1.07, -0.33 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)	+	1.9 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		1.5 %	-0.19 [ -0.63, 0.25 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		0.8 %	-0.14 [ -0.91, 0.63 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.6 %	-0.33 [ -1.27, 0.61 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		1.4 %	-1.37 [ -1.85, -0.89 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.6 %	-0.02 [ -0.90, 0.85 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		1.8 %	-0.15 [ -0.53, 0.23 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)	_ <del></del>	0.8 %	0.26 [ -0.50, 1.02 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	2.1 %	-0.06 [ -0.35, 0.23 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		1.0 %	-0.40 [ -1.05, 0.24 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		1.0 %	-0.11 [ -0.75, 0.54 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)	_+_	1.3 %	-0.15 [ -0.69, 0.38 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.4 %	-0.30 [ -0.80, 0.19 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.4 %	-0.05 [ -1.18, 1.08 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		1.4 %	-0.72 [ -1.20, -0.23 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)	_	1.2 %	-0.16 [ -0.73, 0.40 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.8 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.4 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.7 %	-1.12 [ -1.94, -0.30 ]
Sipich 1974	10	8 (14)	10	32.5 (14)		0.5 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	<u> </u>	0.7 %	0.22 [ -0.56, 1.01 ]

Favours no-treatment

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo No-treatment				Std. Mean Difference	Weight	( Continued) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% Cl
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)	-+	1.2 %	-0.28 [ -0.83, 0.28 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	<u> </u>	0.6 %	0.21 [ -0.67, 1.09 ]
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)	-+-	2.0 %	-0.27 [ -0.59, 0.04 ]
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	+	2.2 %	0.12 [ -0.14, 0.37 ]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)	<u>+-</u>	1.3 %	0.14 [ -0.36, 0.65 ]
Tritrakarn 2000	41	49 (16)	41	61 (17)		1.5 %	-0.72 [ -1.17, -0.27 ]
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)	-	1.4 %	-0.08 [ -0.57, 0.41 ]
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)	_+_	1.0 %	-0.26 [ -0.88, 0.37 ]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		0.9 %	0.05 [ -0.66, 0.77 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)	-	1.9 %	-0.84 [ -1.19, -0.50 ]
Wojciechowski 1984	9	264 (122)	12	238 (190)	_ <del></del>	0.6 %	0.15 [ -0.71, 1.02 ]
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)		0.4 %	-0.97 [ -2.10, 0.16 ]
<b>botal (95% CI)</b> eterogeneity: $Tau^2 = 0$ .	<b>2976</b> 05: Chi ² = 1	62 39 df = 84 (P<(	3052	1%	•	100.0 %	-0.26 [ -0.34, -0.19 ]
est for overall effect: 7							

Test for overall effect: Z = 6.58 (P < 0.00001)

-2 -4 Favours placebo

2 Favours no-treatment

4

0

### Analysis 13.4. Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 4 Selection of outcome: primary trial outcome not clearly indicated (or not selected).

Review: Placebo interventions for all clinical conditions

-

Comparison: 13 Risk of bias subgroup analysis: selection of outcome

Outcome: 4 Selection of outcome: primary trial outcome not clearly indicated (or not selected)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.9 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		1.2 %	-0.14 [ -0.80, 0.52 ]
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)	_ <del></del>	0.8 %	0.32 [ -0.52, 1.17 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)	<u> </u>	1.7 %	0.08 [ -0.44, 0.60 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.6 %	-0.32 [ -1.28, 0.64 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)	-	1.9 %	-0.12 [ -0.60, 0.35 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)	_ <del></del>	1.7 %	0.13 [ -0.39, 0.64 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)	<b>_</b> _	0.8 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		1.3 %	-0.28 [ -0.90, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.8 %	-0.41 [ -1.22, 0.40 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		1.1 %	-0.18 [ -0.88, 0.51 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	_ <u></u>	1.5 %	0.10 [ -0.45, 0.66 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.4 %	0.29 [ -0.95, 1.53 ]
Costello 2006	48	33 (25)	42	31 (25)		2.3 %	0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	_ <u></u>	1.4 %	0.13 [ -0.47, 0.74 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.7 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.7 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.6 %	-0.39 [ -1.35, 0.58 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	-	2.4 %	-0.12 [ -0.51, 0.27 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		0.9 %	-0.65 [ -1.43, 0.13 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	4.6 %	-0.41 [ -0.57, -0.26 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.5 %	-0.98 [ -2.02, 0.06 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)	<u> </u>	1.4 %	-0.17 [ -0.76, 0.41 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		1.8 %	-0.82 [ -1.32, -0.32 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)	· · · · · ·	0.9 %	-0.18 [ -0.98, 0.62 ]

-4 -2 0 2 Favours placebo Favours no-treatment

4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo	Maan (CD)	No-treatment	Maga (SD)	Std. Mean Difference	Weight	( Continued Std. Mean Difference
Hruby 2006	N 49	Mean(SD)	N 51	Mean(SD) 0.86 (1.5)	IV,Random,95% Cl	2.4 %	IV,Random,95% CI 0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.7 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	10	3.7 (1.4)		0.8 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.4 %	-1.17 [ -2.39, 0.04 ]
Karst 2007	, 19	45.21 (10.82)	10	56.5 (9.1)		0.8 %	-1.07 [ -1.89, -0.25 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.3 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20		21			1.3 %	
		66.7 (10)		64.4 (13.3)			0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		0.9 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.4 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)		4.0 %	-0.12 [ -0.33, 0.09 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		1.5 %	-0.79 [ -1.34, -0.23 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		1.1 %	-0.49 [ -1.17, 0.20 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.6 %	-1.08 [ -2.09, -0.07
Lick 1977	10	66 (25)	10	63 (32)		0.7 %	0.10 [ -0.78, 0.98
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	-	1.8 %	0.04 [ -0.47, 0.55
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		1.5 %	-0.5   [ -1.07, 0.05
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	4.3 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.3 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.7 %	0.0 [ -0.90, 0.90
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)		2.1 %	0.08 [ -0.36, 0.52 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		1.5 %	-0.49 [ -1.06, 0.08
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)		0.4 %	-1.99 [ -3.24, -0.74 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)		0.6 %	0.19 [ -0.80, 1.18
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		2.3 %	0.10 [ -0.31, 0.50
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		2.0 %	-0.12 [ -0.57, 0.33
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		1.6 %	-0.24 [ -0.78, 0.30
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		2.7 %	0.20 [ -0.16, 0.55
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.8 %	-0.11 [ -0.93, 0.72
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.5 %	-0.67 [ -1.80, 0.46
Rschke 2000	24	23 (16.2)	24	26 (16)	_+	1.5 %	-0.18 [ -0.75, 0.38
Senediak 1985	П	47.52 (8.38)	10	47.87 (7.53)		0.8 %	-0.04 [ -0.90, 0.81

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Shen 2000	33	40.7 (12.35)	34	43.7 (  .3 )		1.9 %	-0.25 [ -0.73, 0.23 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		2.0 %	0.21 [ -0.24, 0.67 ]
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.7 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)	<del></del>	0.7 %	-0.69 [ -1.60, 0.22 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	+	3.1 %	-0.16 [ -0.46, 0.14 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)	<b>,</b>	0.4 %	0.27 [ -0.98, 1.52 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)	<del></del>	0.8 %	-0.55 [ -1.36, 0.27 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		1.4 %	0.05 [ -0.55, 0.65 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		1.1 %	0.48 [ -0.22, 1.19 ]
Thomas 1999	14	3.4 ( 0.28)	26	16.5 (9.73)		1.2 %	-0.31 [ -0.96, 0.35 ]
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.9 %	-0.60 [ -1.07, -0.12 ]
Tuomilehto 1980	П	9.04 (1.36)	11	8.67 (1.56)	<b>-</b>	0.8 %	0.24 [ -0.60, 1.08 ]
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.7 %	-0.45 [ -1.34, 0.44 ]
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	2.1 %	0.0 [ -0.44, 0.44 ]
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)	-+-	1.5 %	-0.40 [ -0.96, 0.15 ]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		1.0 %	-0.10 [ -0.81, 0.62 ]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)	_+_	1.3 %	-0.20 [ -0.83, 0.44 ]
<b>Total (95% CI)</b> Heterogeneity: Tau ² = 0 Test for overall effect: Z			<b>2273</b> (P = 0.01); I ² = 319	%	•	100.0 %	-0.17 [ -0.25, -0.09 ]

-2 0 2

-4

Favours placebo Favours no-treatment

4

## Analysis 14.1. Comparison 14 Risk of bias subgroup analysis: format of outcome, Outcome I Outcome was final values.

Review: Placebo interventions for all clinical conditions

Comparison: 14 Risk of bias subgroup analysis: format of outcome

Outcome: I Outcome was final values

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		0.7 %	-0.14 [ -0.80, 0.52 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		1.2 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.7 %	0.38 [ -0.30, 1.06 ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (  .2)		0.3 %	0.56 [ -0.60, 1.72 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.4 %	-0.32 [ -1.28, 0.64 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)		1.8 %	-0.17 [ -0.43, 0.10 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)	<del></del>	1.0 %	0.13 [ -0.39, 0.64 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		0.5 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		0.8 %	-0.28 [ -0.90, 0.33 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.5 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		0.6 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.1 %	-0.14 [ -0.61, 0.33 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.7 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.3 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		0.9 %	0.10 [ -0.45, 0.66 ]
Chenard 1991	12	29 (19)	16	30 (19)		0.6 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	.3 (8.3)	15	4.4 (6. )		0.6 %	-0.41 [ -1.14, 0.31 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.3 %	0.29 [ -0.95, 1.53 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.6 %	-0.92 [ -1.72, -0.12 ]
Costello 2006	48	33 (25)	42	31 (25)	_ <del></del>	1.3 %	0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		0.8 %	0.13 [ -0.47, 0.74 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)	<del></del>	1.0 %	0.08 [ -0.44, 0.59 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.5 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.4 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.4 %	-0.39 [ -1.35, 0.58 ]

-2 -1 0 I 2 Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)		1.4 %	-0.12 [ -0.51, 0.27 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	+	2.0 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)		1.9 %	-0.06 [ -0.28, 0.17 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		0.6 %	-0.65 [ -1.43, 0.13 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)		2.2 %	-0.41 [ -0.57, -0.26 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.6 %	-0.13 [ -0.89, 0.63 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.6 %	-0.54 [ -1.27, 0.19 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)		1.8 %	-0.06 [ -0.33, 0.21 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.4 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		0.8 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.4 %	-0.97 [ -1.91, -0.03 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)	<u> </u>	1.2 %	-0.28 [ -0.73, 0.16 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	1.9 %	-0.03 [ -0.25, 0.20 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)	<u> </u>	0.9 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		1.1 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)		0.9 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	<b>←</b> → → →	0.4 %	-1.58 [ -2.61, -0.55 ]
Helms 1987	11	103 (91)	11	79 (99)		0.5 %	0.24 [ -0.60, 1.08 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		0.6 %	-0.18 [ -0.98, 0.62 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.3 %	0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.5 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.5 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)	<del> </del>	0.3 %	-1.17 [ -2.39, 0.04 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.5 %	-1.07 [ -1.89, -0.25 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.4 %	0.31 [ -0.05, 0.68 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.5 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		1.0 %	-0.28 [ -0.81, 0.24 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)	<u> </u>	0.8 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		0.6 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		0.9 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	-+	2.0 %	-0.12 [ -0.33, 0.09 ]

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.2 %	-0.59 [ -1.04, -0.14 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.7 %	-0.49 [ -1.17, 0.20 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)	·	0.4 %	-1.08 [ -2.09, -0.07 ]
Lick 1977	10	66 (25)	10	63 (32)		0.5 %	0.10 [ -0.78, 0.98 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	<u> </u>	1.0 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		0.9 %	-0.5  [ -1.07, 0.05 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)	<u> </u>	1.2 %	-0.23 [ -0.67, 0.21 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)		2.1 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		0.8 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.5 %	0.0 [ -0.90, 0.90 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	<u> </u>	1.2 %	0.08 [ -0.36, 0.52 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.4 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)		0.9 %	0.12 [ -0.47, 0.71 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.5 %	0.04 [ -0.86, 0.93 ]
Melchart 2005	57	10.8 (8.3)	63	6.3 (7.4)		1.4 %	-0.70 [ -1.07, -0.33 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)	<u> </u>	0.9 %	-0.49 [ -1.06, 0.08 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		0.6 %	-0.14 [ -0.91, 0.63 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.4 %	-0.33 [ -1.27, 0.61 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		1.1 %	-1.37 [ -1.85, -0.89 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)		0.4 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.5 %	-0.02 [ -0.90, 0.85 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		1.4 %	-0.15 [ -0.53, 0.23 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)	<del></del>	1.3 %	0.10 [ -0.31, 0.50 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.6 %	0.26 [ -0.50, 1.02 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	<u> </u>	1.7 %	-0.06 [ -0.35, 0.23 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)	<u> </u>	0.8 %	-0.40 [ -1.05, 0.24 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	<u> </u>	1.5 %	0.20 [ -0.16, 0.55 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.5 %	-0.11 [ -0.93, 0.72 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		1.0 %	-0.15 [ -0.69, 0.38 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.1 %	-0.30 [ -0.80, 0.19 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.3 %	-0.67 [ -1.80, 0.46 ]

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Rossi 1982	6	107 (17)	6	108 (20)		0.3 %	-0.05 [ -1.18, 1.08 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		0.9 %	-0.16 [ -0.73, 0.40 ]
Rschke 2000	24	23 (16.2)	24	26 (16)		0.9 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.6 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.3 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.5 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.5 %	-0.04 [ -0.90, 0.81 ]
Shen 2000	33	40.7 (12.35)	34	43.7 (  .3 )		1.1 %	-0.25 [ -0.73, 0.23 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		1.2 %	0.21 [ -0.24, 0.67 ]
Sipich 1974	10	8 (14)	10	32.5 (14)	<b>←</b> −−−−	0.4 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	<b>·</b>	0.6 %	0.22 [ -0.56, 1.01 ]
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.5 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		0.5 %	-0.69 [ -1.60, 0.22 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)		1.7 %	-0.16 [ -0.46, 0.14 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		0.5 %	0.21 [ -0.67, 1.09 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.5 %	-0.55 [ -1.36, 0.27 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		0.8 %	0.05 [ -0.55, 0.65 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)	- <u>+-</u>	0.7 %	0.48 [ -0.22, 1.19 ]
Thomas 1999	14	13.4 (10.28)	26	16.5 (9.73)	<b>.</b>	0.7 %	-0.31 [ -0.96, 0.35 ]
Tritrakarn 2000	41	49 (16)	41	61 (17)		1.2 %	-0.72 [ -1.17, -0.27 ]
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		1.1 %	-0.08 [ -0.57, 0.41 ]
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.1 %	-0.60 [ -1.07, -0.12 ]
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)		0.5 %	0.24 [ -0.60, 1.08 ]
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.5 %	-0.45 [ -1.34, 0.44 ]
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)		1.2 %	0.0 [ -0.44, 0.44 ]
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)	<del></del>	0.9 %	-0.40 [ -0.96, 0.15 ]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		0.7 %	-0.10 [ -0.81, 0.62 ]
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		0.8 %	-0.26 [ -0.88, 0.37 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)	<u> </u>	1.5 %	-0.84 [ -1.19, -0.50 ]
Wojciechowski 1984	9	264 (122)	12	238 (190)		0.5 %	0.15 [ -0.71, 1.02 ]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		0.8 %	-0.20 [ -0.83, 0.44 ]

Favours no-treatment

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N		-treatment	Mean(SD)		1ean Difference	Weight	( Continued) Std. Mean Difference
Total (95% CI)	3884	Mean(SD)	N 3982	Mean(SD)	IV,NdHC	lom,95% Cl	100.0 %	IV,Random,95% Cl -0.21 [ -0.28, -0.14 ]
Heterogeneity: Tau ² = ( Test for overall effect: Z	0.05; Chi ² = 2			%			10000 /0	0.21 [ 0.20, 0.11 ]
					2 - I ours placebo	0 I 2 Favours no-tre	eatment	

# Analysis 14.2. Comparison 14 Risk of bias subgroup analysis: format of outcome, Outcome 2 Outcome was change from baseline.

Review: Placebo interventions for all clinical conditions

Comparison: 14 Risk of bias subgroup analysis: format of outcome

Outcome: 2 Outcome was change from baseline

Study or subgroup	Experimental N	Mean(SD)	Control N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		3.0 %	-0.09 [ -0.56, 0.38 ]
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		1.3 %	0.32 [ -0.52, 1.17 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)	,	2.7 %	0.08 [ -0.44, 0.60 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		1.2 %	0.34 [ -0.52,  .2  ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		3.0 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)	·	1.2 %	-1.07 [ -1.94, -0.20 ]
Blades 2001	40	-16 (6)	40	-16 (6)		3.3 %	0.0 [ -0.44, 0.44 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)	·	1.4 %	-0.41 [ -1.22, 0.40 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)	•	4.3 %	-0.62 [ -0.96, -0.29 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)	·	3.2 %	-0.36 [ -0.80, 0.08 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)	·	1.4 %	-0.33 [ -1.12, 0.46 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	•	0.9 %	-0.98 [ -2.02, 0.06 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)	·	3.3 %	-0.72 [ -1.15, -0.29 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)	•	1.6 %	-0.54 [ -1.30, 0.21 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		2.3 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)		1.3 %	-0.19 [ -1.05, 0.67 ]

-100 -50 0 50 100

Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Experimental		Control		Std. Mean Difference	Weight	( Continued) Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.9 %	-0.53 [ -1.19, 0.13 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)		4.9 %	-0.06 [ -0.34, 0.22 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		4.7 %	-0.41 [ -0.71, -0.11 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.5 %	0.04 [ -1.35, 1.42 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)	•	2.4 %	-0.79 [ -1.34, -0.23 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		1.8 %	-0.3  [ -1.0 , 0.38 ]
Linde 2005	76	-2.2 (2.7)	76	-0.8 (2.2)		4.4 %	-0.57 [ -0.89, -0.24 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		2.7 %	-0.41 [ -0.93, 0.10 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		2.4 %	-0.02 [ -0.59, 0.54 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		2.1 %	-0.31 [ -0.93, 0.32 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)		4.2 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		3.3 %	-0.19 [ -0.63, 0.25 ]
Murphy 1982	6	-16.5 (9.3)	П	-0.8 (6.4)		0.6 %	-1.99 [ -3.24, -0.74 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		3.2 %	-0.12 [ -0.57, 0.33 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		2.5 %	-0.24 [ -0.78, 0.30 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		2.0 %	-0.   [ -0.75, 0.54 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		2.9 %	-0.72 [ -1.20, -0.23 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		2.4 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.7 %	0.27 [ -0.98, 1.52 ]
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		4.5 %	-0.27 [ -0.59, 0.04 ]
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	•	5.2 %	0.12 [ -0.14, 0.37 ]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		2.8 %	0.14 [ -0.36, 0.65 ]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		1.7 %	0.05 [ -0.66, 0.77 ]
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)		0.8 %	-0.97 [ -2.10, 0.16 ]
otal (95% CI)	1304		1355			100.0 %	-0.27 [ -0.37, -0.16 ]

0 50 100 -100 -50

Favours experimental

Favours control

## Analysis 15.1. Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 1 Concealed allocation adequate.

Review: Placebo interventions for all clinical conditions

Comparison: 15 Risk of bias subgroup analysis: concealed allocation

Outcome: I Concealed allocation adequate

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Alkaissi 2002	77/139	82/136	+	15.3 %	0.92 [ 0.75, 1.12 ]
Aune 1998	11/26	9/14	<u> </u>	4.7 %	0.66 [ 0.36, 1.19 ]
Carter 2003	13/28	20/29		6.8 %	0.67 [ 0.42, 1.07 ]
De Sanctis 2001	9/10	8/9		11.0 %	1.01 [ 0.74, 1.38 ]
Faas 1993	107/162	108/155	+	17.5 %	0.95 [ 0.81, 1.10 ]
Molsberger 2002	38/58	30/53		11.3 %	1.16 [ 0.86, 1.56 ]
Scharf 2006	179/365	224/316	-	18.5 %	0.69 [ 0.61, 0.78 ]
Tarrier 1998	22/26	25/28	+	15.0 %	0.95 [ 0.77, 1.17 ]
Total (95% CI)	814	740	•	100.0 %	0.88 [ 0.76, 1.02 ]
Total events: 456 (Placebo	o), 506 (No-treatme	nt)			
Heterogeneity: $Tau^2 = 0.0$	)3; Chi ² = 21.38, df	= 7 (P = 0.003); I ² =67%			
Test for overall effect: Z =	= 1.70 (P = 0.089)				

0.1 0.	2 0.5	I.	2	5	10
Favours	s placebo		Favour	s no-	treatment

Placebo interventions for all clinical conditions (Review)

# Analysis 15.2. Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 2 Concealed allocation unclear.

Review: Placebo interventions for all clinical conditions

Comparison: 15 Risk of bias subgroup analysis: concealed allocation

Outcome: 2 Concealed allocation unclear

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Adriaanse 1995	50/328	38/326	<u>+</u>	1.9 %	.3  [ 0.88,  .94 ]
Alkaissi 1999	9/20	/20		0.8 %	0.82 [ 0.44, 1.53 ]
Berg 1983	9/11	9/15	<u> </u>	1.3 %	1.36 [ 0.83, 2.24 ]
Blackman 1964	6/12	6/12		0.5 %	1.00 [ 0.45, 2.23 ]
Corver 2006	227/279	360/416	-	11.2 %	0.94 [ 0.88,  .0  ]
Double 1993	3/22	3/22		0.2 %	1.00 [ 0.23, 4.42 ]
Dundee 1986	17/25	17/25		2.0 %	1.00 [ 0.68, 1.46 ]
Elliott 1978	6/18	6/6		0.8 %	0.37 [ 0.19, 0.71 ]
Fanti 2003	8/10	9/10		2.1 %	0.89 [ 0.61, 1.29 ]
Frank 1990	14/26	14/26		1.2 %	1.00 [ 0.60, 1.65 ]
Guglielmi 1982	12/12	11/12	+-	4.5 %	1.09 [ 0.87, 1.36 ]
Harrison 1975	24/28	25/30	+	4.6 %	1.03 [ 0.83, 1.28 ]
Heinzl 1981	70/130	92/132	-	5.4 %	0.77 [ 0.64, 0.94 ]
Hutton 1991	5/24	16/30		0.5 %	0.39 [ 0.17, 0.91 ]
Hyman 1986	9/15	15/15		1.7 %	0.61 [ 0.40, 0.93 ]
Jacobs 1971	9/15	12/39		0.8 %	1.95 [ 1.04, 3.65 ]
Kerr 2003	28/33	32/36	+	5.7 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	+	9.6 %	1.03 [ 0.94, 1.14 ]
Klerman 1974	17/25	16/25	_ <u></u>	1.9 %	1.06 [ 0.71, 1.58 ]
Malcolm 1980	40/63	44/58		4.2 %	0.84 [ 0.66, 1.06 ]
McMillan 1994	14/26	24/46		1.5 %	1.03 [ 0.66, 1.62 ]
Najnigier 1997	21/30	24/30		3.0 %	0.88 [ 0.65, 1.17 ]
Rabkin 1990	14/27	12/23		1.1 %	0.99 [ 0.58, 1.70 ]
Roughan 1981	9/12	9/14	_ <del></del>	1.2 %	1.17 [ 0.70, 1.94 ]
Schallreuter 2002	3/10	4/10		0.2 %	0.75 [ 0.22, 2.52 ]

0.1 0.2 0.5 1 2 5 10

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	( Continued) Risk Ratio M-H,Random,95% Cl
Scharff 2002	/ 2	12/12	-	4.5 %	0.92 [ 0.74, 1.15 ]
Stransky 1989	1/5	1/4	<b>٠</b>	0.1 %	0.80 [ 0.07, 9.18 ]
Tan 1986	8/10	8/9	_+_	2.0 %	0.90 [ 0.61, 1.32 ]
Tarcin 2004	58/158	27/77	<u> </u>	2.1 %	1.05 [ 0.73, 1.51 ]
Thomas 1987	47/100	50/100		3.2 %	0.94 [ 0.71, 1.25 ]
Tyler 1946	89/260	106/303	+	4.4 %	0.98 [ 0.78, 1.23 ]
Walton 1993	19/24	21/30	<u> </u>	2.8 %	1.13 [ 0.83, 1.54 ]
Watzl 1986	15/34	7/36		0.6 %	2.27 [ 1.06, 4.88 ]
Whittaker 1963	3/13	7/13		0.3 %	0.43 [ 0.14, 1.30 ]
Williams 1988	19/20	19/20	+	7.4 %	1.00 [ 0.87, 1.15 ]
Wilson 1980	31/40	10/10		4.8 %	0.80 [ 0.65, 0.99 ]
<b>Total (95% CI)</b> Total events: 1151 (Placeb Heterogeneity: Tau ² = 0.0	, (	,	•	100.0 %	0.95 [ 0.90, 1.01 ]

Test for overall effect: Z = 1.56 (P = 0.12)

0.1 0.2 0.5 1 2 5 10

Favours placebo

Favours no-treatment

### Analysis 15.3. Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 3 Concealed allocation adequate.

Review: Placebo interventions for all clinical conditions

Comparison: 15 Risk of bias subgroup analysis: concealed allocation

Outcome: 3 Concealed allocation adequate

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		6.3 %	-0.62 [ -0.96, -0.29 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	<del></del> +	3.5 %	0.10 [ -0.45, 0.66 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		2.0 %	-0.92 [ -1.72, -0.12 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)	<b>_</b> _	4.7 %	-0.36 [ -0.80, 0.08 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	-	7.6 %	-0.06 [ -0.33, 0.21 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		6.9 %	-0.4  [ -0.7 , -0.   ]
Kotani 2001	23	15 (4.5)	24	18 (6)	<u> </u>	3.2 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	-	8.7 %	-0.12 [ -0.33, 0.09 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		2.5 %	-0.49 [ -1.17, 0.20 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		4.7 %	-0.23 [ -0.67, 0.21 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		6.2 %	-0.56 [ -0.90, -0.22 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		5.7 %	-0.70 [ -1.07, -0.33 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		3.3 %	-0.49 [ -1.06, 0.08 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		5.6 %	-0.15 [ -0.53, 0.23 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	-	7.1 %	-0.06 [ -0.35, 0.23 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		1.9 %	-0.11 [ -0.93, 0.72 ]
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)	+ <del>_</del>	4.2 %	-0.25 [ -0.73, 0.23 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)		6.9 %	-0.16 [ -0.46, 0.14 ]
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)	<u> </u>	2.9 %	-0.26 [ -0.88, 0.37 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		6.1 %	-0.84 [ -1.19, -0.50 ]
<b>Total (95% CI)</b> Heterogeneity: Tau ² = Test for overall effect:			<b>1099</b> (P = 0.01); I ² =48	%	•	100.0 %	-0.34 [ -0.46, -0.22 ]

- | 0

-2

L Favours experimental Favours control

2

Placebo interventions for all clinical conditions (Review)

# Analysis 15.4. Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 4 Concealed allocation unclear.

Review: Placebo interventions for all clinical conditions

Comparison: 15 Risk of bias subgroup analysis: concealed allocation

Outcome: 4 Concealed allocation unclear

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.0 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		0.7 %	-0.14 [ -0.80, 0.52 ]
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		0.4 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)	<b>_</b> _	1.1 %	-0.72 [ -1.15, -0.29 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.6 %	0.38 [ -0.30, 1.06 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		0.9 %	0.08 [ -0.44, 0.60 ]
Antivalle 1990	11	-1.6 (5.6)	10	-3.9 (7.3)		0.4 %	0.34 [ -0.52,  .2  ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.3 %	0.56 [ -0.60, 1.72 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.4 %	-0.32 [ -1.28, 0.64 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		1.0 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		0.4 %	-1.07 [ -1.94, -0.20 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)		1.6 %	-0.17 [ -0.43, 0.10 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)	— <u> </u>	0.9 %	0.13 [ -0.39, 0.64 ]
Blades 2001	40	-16 (6)	40	-16 (6)		1.1 %	0.0 [ -0.44, 0.44 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		0.5 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		0.7 %	-0.28 [ -0.90, 0.33 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.4 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		0.5 %	-0.29 [ -1.05, 0.47 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.0 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		0.5 %	-0.41 [ -1.22, 0.40 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.6 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.2 %	0.48 [ -0.72, 1.67 ]
Chenard 1991	12	29 (19)	16	30 (19)		0.5 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	11.3 (8.3)	15	4.4 (6. )		0.6 %	-0.41 [ -1.14, 0.31 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)		0.2 %	0.29 [ -0.95,  .53 ]

-2 -1 0 1 2 Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	( Continued) Std. Mean Difference
Costello 2006	N 48	Mean(SD) 33 (25)	N 42	Mean(SD) 31 (25)	IV,Random,95% CI	1.2 %	IV,Random,95% CI 0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)		0.7 %	0.13 [ -0.47, 0.74 ]
Crosby 1994	21	. ,	33	. ,		0.9 %	
,		13.6 (1.25)		13.5 (1.25)			0.08 [ -0.44, 0.59 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.4 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.4 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.4 %	-0.39 [ -1.35, 0.58 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)		1.2 %	-0.12 [ -0.51, 0.27 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	Ť	1.9 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	-	1.8 %	-0.06 [ -0.28, 0.17 ]
Espie 1989	4	63.5 (30.6)	13	96.5 (63.5)		0.5 %	-0.65 [ -1.43, 0.13 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		0.5 %	-0.33 [ -1.12, 0.46 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)		2.0 %	-0.41 [ -0.57, -0.26 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.5 %	-0.13 [ -0.89, 0.63 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.6 %	-0.54 [ -1.27, 0.19 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	•	0.3 %	-0.98 [ -2.02, 0.06 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.3 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		0.7 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.4 %	-0.97 [ -1.91, -0.03 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		1.1 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.1 %	-0.28 [ -0.73, 0.16 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)	<b>-</b> _	0.5 %	-0.54 [ -1.30, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	1.8 %	-0.03 [ -0.25, 0.20 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		0.8 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	П	-0.88 (3.83)	10	-0.26 (2.2)		0.4 %	-0.19 [ -1.05, 0.67 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		0.8 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		0.9 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)		0.8 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	•••••	0.3 %	-1.58 [ -2.61, -0.55 ]
Helms 1987		103 (91)	11	79 (99)		0.5 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.6 %	-0.53 [ -1.19, 0.13 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		0.5 %	-0.18 [ -0.98, 0.62 ]

Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)		1.6 %	-0.06 [ -0.34, 0.22 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.2 %	0.21 [ -0.19, 0.60 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.4 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.4 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)	•	0.2 %	-1.17 [ -2.39, 0.04 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.5 %	-1.07 [ -1.89, -0.25 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.3 %	0.31 [ -0.05, 0.68 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.5 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		0.9 %	-0.28 [ -0.81, 0.24 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.2 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		0.7 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		0.5 %	0.23 [ -0.56, 1.02 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)	<u> </u>	0.8 %	-0.79 [ -1.34, -0.23 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		1.1 %	-0.59 [ -1.04, -0.14 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		0.6 %	-0.31 [ -1.01, 0.38 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)	•	0.3 %	-1.08 [ -2.09, -0.07 ]
Lick 1977	10	66 (25)	10	63 (32)		0.4 %	0.10 [ -0.78, 0.98 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	<u> </u>	0.9 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)	<u> </u>	0.8 %	-0.5  [ -1.07, 0.05 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)		1.9 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		0.7 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.4 %	0.0 [ -0.90, 0.90 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	<del></del>	1.1 %	0.08 [ -0.36, 0.52 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		0.9 %	-0.41 [ -0.93, 0.10 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (  .9 )		0.3 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)		0.8 %	0.12 [ -0.47, 0.71 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		0.8 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.4 %	0.04 [ -0.86, 0.93 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		0.7 %	-0.3  [ -0.93, 0.32 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)		1.4 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)	<del></del>	1.1 %	-0.19 [ -0.63, 0.25 ]

Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		0.5 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)	*	0.2 %	-1.99 [ -3.24, -0.74 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.4 %	-0.33 [ -1.27, 0.61 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)	<b>;</b>	1.0 %	-1.37 [ -1.85, -0.89 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)	,	0.3 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.4 %	-0.02 [ -0.90, 0.85 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)	<del></del>	1.2 %	0.10 [ -0.31, 0.50 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.5 %	0.26 [ -0.50, 1.02 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		1.1 %	-0.12 [ -0.57, 0.33 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		0.9 %	-0.24 [ -0.78, 0.30 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		0.7 %	-0.40 [ -1.05, 0.24 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)	_ <u></u>	1.3 %	0.20 [ -0.16, 0.55 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)	<u> </u>	0.7 %	-0.11 [ -0.75, 0.54 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		0.9 %	-0.15 [ -0.69, 0.38 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)	<u> </u>	1.0 %	-0.30 [ -0.80, 0.19 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.3 %	-0.67 [ -1.80, 0.46 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.3 %	-0.05 [ -1.18, 1.08 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)	<b>_</b> _	1.0 %	-0.72 [ -1.20, -0.23 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)	<del></del>	0.8 %	-0.16 [ -0.73, 0.40 ]
Rschke 2000	24	23 (16.2)	24	26 (16)		0.8 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		0.5 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.3 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.5 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.4 %	-0.04 [ -0.90, 0.81 ]
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		1.0 %	0.21 [ -0.24, 0.67 ]
Sipich 1974	10	8 (14)	10	32.5 (14)	<	0.3 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		0.5 %	0.22 [ -0.56,  .0  ]
Sprott 1993	10	7.9 (3)	10	7.4 (3)	<u> </u>	0.4 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		0.4 %	-0.69 [ -1.60, 0.22 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		0.8 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.2 %	0.27 [ -0.98, 1.52 ]

Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Differenc IV,Random,95% Cl	e Weight	( Continu Std. Mean Differenc IV,Random,95% (
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		0.4 %	0.21 [ -0.67, 1.09
, Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.5 %	-0.55 [ -1.36, 0.27
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		0.7 %	0.05 [ -0.55, 0.65
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		0.6 %	0.48 [ -0.22, 1.19
Thomas 1999	14	3.4 ( 0.28)	26	16.5 (9.73)		0.7 %	-0.3  [ -0.96, 0.35
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)	_+_	1.5 %	-0.27 [ -0.59, 0.04
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	<u> </u>	1.7 %	0.12 [ -0.14, 0.3]
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		0.9 %	0.14 [ -0.36, 0.65
Tritrakarn 2000	41	49 (16)	41	61 (17)	<u> </u>	1.1 %	-0.72 [ -1.17, -0.2]
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		1.0 %	-0.08 [ -0.57, 0.4
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.0 %	-0.60 [ -1.07, -0.12
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)		0.5 %	0.24 [ -0.60, 1.0
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.4 %	-0.45 [ -1.34, 0.4
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)		1.1 %	0.0 [ -0.44, 0.4
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)	<u> </u>	0.8 %	-0.40 [ -0.96, 0.1
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		0.6 %	-0.10 [ -0.81, 0.62
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)	<u> </u>	0.6 %	0.05 [ -0.66, 0.7
Wojciechowski 1984	9	264 (122)	12	238 (190)	<u> </u>	0.4 %	0.15 [ -0.71, 1.02
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		0.7 %	-0.20 [ -0.83, 0.44
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	·	0.3 %	-0.97 [ -2.10, 0.16
<b>btal (95% CI)</b> eterogeneity: Tau ² = 0. est for overall effect: Z =			<b>4226</b> (P<0.00001); I ² =	39%	•	1 <b>00.0</b> %	-0.20 [ -0.26, -0.14
est for overall effect: Z =	= 6.24 (P <	0.00001)			-2 -1 0 1 experimental Favours co	2 ntrol	

### Analysis 16.1. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 1 Trial size >49.

Review: Placebo interventions for all clinical conditions

Comparison: 16 Risk of bias subgroup analysis: trial size


Outcome: I Trial size >49

Risk Ratio M-H,Random,95% C	Weight	Risk Ratio M-H,Random,95% Cl	No-treatment n/N	Placebo n/N	itudy or subgroup
1.31 [ 0.88, 1.94	2.3 %		38/326	50/328	Adriaanse 1995
0.92 [ 0.75, 1.12	5.1 %	-	82/136	77/139	Alkaissi 2002
0.67 [ 0.42, 1.07	1.7 %		20/29	3/28	Carter 2003
0.94 [ 0.88, 1.01	8.4 %	-	360/416	227/279	Corver 2006
1.00 [ 0.68, 1.46	2.4 %		17/25	17/25	Dundee 1986
0.95 [ 0.81, 1.10	6.3 %	+	108/155	107/162	Faas 1993
1.00 [ 0.60, 1.65	1.5 %		14/26	14/26	Frank 1990
1.03 [ 0.83, 1.28	4.7 %	<u> </u>	25/30	24/28	Harrison 1975
0.77 [ 0.64, 0.94	5.2 %		92/132	70/130	Heinzl 1981
0.39 [ 0.17, 0.91	0.6 %	•	16/30	5/24	Hutton 1991
1.95 [ 1.04, 3.65	1.1 %		12/39	9/15	Jacobs 1971
0.95 [ 0.79, 1.15	5.5 %	-	32/36	28/33	Kerr 2003
1.03 [ 0.94, 1.14	7.7 %	-	219/309	226/309	Killen 1990
1.06 [ 0.71, 1.58	2.2 %	<del></del>	16/25	17/25	Klerman 1974
0.84 [ 0.66, 1.06	4.3 %		44/58	40/63	Malcolm 1980
1.03 [ 0.66, 1.62	1.8 %		24/46	14/26	McMillan 1994
1.16 [ 0.86, 1.56	3.3 %		30/53	38/58	Molsberger 2002
0.88 [ 0.65, 1.17	3.4 %		24/30	21/30	Najnigier 1997
0.99 [ 0.58, 1.70	1.4 %		12/23	14/27	Rabkin 1990
0.69 [ 0.61, 0.78	7.0 %	-	224/316	179/365	Scharf 2006
1.05 [ 0.73, 1.51	2.5 %		27/77	58/158	Tarcin 2004
0.95 [ 0.77, 1.17	4.9 %		25/28	22/26	Tarrier 1998
0.94 [ 0.71, 1.25	3.5 %		50/100	47/100	Thomas 1987
0.98 [ 0.78, 1.23	4.5 %	_	106/303	89/260	Tyler 1946
1.13 [ 0.83, 1.54	3.1 %		21/30	19/24	Walton 1993
2.27 [ 1.06, 4.88	0.7 %		7/36	15/34	Watzl 1986

0.2 0.5 2 5 Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)



### Analysis 16.2. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 2 Trial size 49 or less.

Review: Placebo interventions for all clinical conditions

Comparison: 16 Risk of bias subgroup analysis: trial size

Outcome: 2 Trial size 49 or less

Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl	No-treatment n/N	Placebo n/N	Study or subgroup
0.82 [ 0.44, 1.53 ]	3.6 %		11/20	9/20	Alkaissi 1999
0.66 [ 0.36, 1.19 ]	3.9 %		9/14	11/26	Aune 1998
1.36 [ 0.83, 2.24 ]	5.2 %	-	9/15	9/11	Berg 1983
1.00 [ 0.45, 2.23 ]	2.4 %	+	6/12	6/12	Blackman 1964
1.01 [ 0.74, 1.38 ]	9.5 %	+	8/9	9/10	De Sanctis 2001
1.00 [ 0.23, 4.42 ]	0.8 %		3/22	3/22	Double 1993
0.37 [ 0.19, 0.71 ]	3.3 %	- <b>-</b> -	6/6	6/18	Elliott 1978
0.89 [ 0.61, 1.29 ]	7.7 %	+	9/10	8/10	Fanti 2003
1.09 [ 0.87, 1.36 ]	12.7 %	+	11/12	12/12	Guglielmi 1982
0.61 [ 0.40, 0.93 ]	6.7 %	+	15/15	9/15	Hyman 1986
1.17 [ 0.70, 1.94 ]	5.0 %	+	9/14	9/12	Roughan 1981
0.75 [ 0.22, 2.52 ]	1.1 %		4/10	3/10	Schallreuter 2002
0.92 [ 0.74, 1.15 ]	12.7 %	+	12/12	11/12	Scharff 2002
0.80 [ 0.07, 9.18 ]	0.3 %		1/4	1/5	Stransky 1989
0.90 [ 0.61, 1.32 ]	7.4 %	+	8/9	8/10	Tan 1986

Favours experimental

Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo	No-treatment			Risk Ratio		Weight	( Continued) Risk Ratio
	n/N	n/N		M-H,Kar	ndom,95% C			M-H,Random,95% Cl
Whittaker 1963	3/13	7/13			Ť		1.3 %	0.43 [ 0.14, 1.30 ]
Williams 1988	19/20	19/20			+		16.4 %	1.00 [ 0.87, 1.15 ]
Total (95% CI)	238	217			•		100.0 %	0.91 [ 0.80, 1.04 ]
Total events: 136 (Placebo	o), 147 (No-treatme	nt)						
Heterogeneity: $Tau^2 = 0.0$	02; Chi ² = 25.64, df	= 16 (P = 0.06); 1 ² = 38%						
Test for overall effect: Z =	= 1.44 (P = 0.15)							
				I				
			0.01	0.1	1 10	100		
		Fa	vours exp	erimental	Favours c	ontrol		

### Analysis 16.3. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 3 Trial size >49.

Review: Placebo interventions for all clinical conditions

Comparison: 16 Risk of bias subgroup analysis: trial size

Outcome: 3 Trial size >49

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)		1.3 %	-0.09 [ -0.56, 0.38 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		1.5 %	-0.72 [ -1.15, -0.29 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		1.2 %	0.08 [ -0.44, 0.60 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		1.3 %	-0.12 [ -0.60, 0.35 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	<del></del>	2.1 %	-0.17 [ -0.43, 0.10 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.2 %	0.13 [ -0.39, 0.64 ]
Blades 2001	40	-16 (6)	40	-16 (6)		1.4 %	0.0 [ -0.44, 0.44 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)		1.3 %	-0.14 [ -0.61, 0.33 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		1.8 %	-0.62 [ -0.96, -0.29 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)		1.1 %	0.10 [ -0.45, 0.66 ]
Costello 2006	48	33 (25)	42	31 (25)		1.5 %	0.08 [ -0.33, 0.49 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)		1.2 %	0.08 [ -0.44, 0.59 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)		1.6 %	-0.12[-0.51, 0.27]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)		2.3 %	-0.02 [ -0.22, 0.17 ]

-I -0.5 0 0.5 I

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)		2.2 %	-0.06 [ -0.28, 0.17 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		1.4 %	-0.36 [ -0.80, 0.08 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)		2.4 %	-0.41 [ -0.57, -0.26 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)		2.0 %	-0.06 [ -0.33, 0.21 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)	•	1.5 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.4 %	-0.28 [ -0.73, 0.16 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	<u> </u>	2.2 %	-0.03 [ -0.25, 0.20 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		1.1 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)	•	1.3 %	-0.82 [ -1.32, -0.32 ]
Hashish 1988	25	42 (25)	25	60 (23)	•	1.1 %	-0.74 [ -1.31, -0.16 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)		2.0 %	-0.06 [ -0.34, 0.22 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)		1.6 %	0.21 [ -0.19, 0.60 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		1.9 %	-0.41 [ -0.71, -0.11 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.7 %	0.31 [ -0.05, 0.68 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		1.2 %	-0.28 [ -0.81, 0.24 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)		2.2 %	-0.12 [ -0.33, 0.09 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)	<b>←</b> →	1.1 %	-0.79 [ -1.34, -0.23 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)	•	1.4 %	-0.59 [ -1.04, -0.14 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)		1.2 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)	•	1.1 %	-0.51 [ -1.07, 0.05 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		1.4 %	-0.23 [ -0.67, 0.21 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		1.8 %	-0.56 [ -0.90, -0.22 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)		2.3 %	0.15 [ -0.04, 0.33 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)		1.4 %	0.08 [ -0.36, 0.52 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		1.2 %	-0.41 [ -0.93, 0.10 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)	<b>←</b> →	1.7 %	-0.70 [ -1.07, -0.33 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)		1.8 %	0.06 [ -0.28, 0.40 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)		1.4 %	-0.19 [ -0.63, 0.25 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)	<b>←</b>	1.3 %	-1.37 [ -1.85, -0.89 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		1.6 %	-0.15 [ -0.53, 0.23 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		1.5 %	0.10 [ -0.31, 0.50 ]

Favours placebo Favours no-treatment

1

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

							( Continue
Study or subgroup	Placebo N	f Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% C
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		1.4 %	-0.12 [ -0.57, 0.33
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		1.2 %	-0.24 [ -0.78, 0.30
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)		2.0 %	-0.06 [ -0.35, 0.23
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		1.7 %	0.20 [ -0.16, 0.55
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		1.2 %	-0.15 [ -0.69, 0.38
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.3 %	-0.30 [ -0.80, 0.19
Rowbotham 1996	35	-4.4 (8.7)	35	I.9 (8.7) <b>+</b>	_ <b></b>	1.3 %	-0.72 [ -1.20, -0.23
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		1.3 %	-0.25 [ -0.73, 0.23
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		1.4 %	0.21 [ -0.24, 0.67
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	<b>.</b>	1.9 %	-0.16 [ -0.46, 0.14
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		1.1 %	-0.28 [ -0.83, 0.28
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)	<del></del>	1.9 %	-0.27 [ -0.59, 0.04
Thomas 2002b	114	-1.21 (3.52)	9	-1.61 (3.31)		2.1 %	0.12 [ -0.14, 0.37
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		1.3 %	0.14 [ -0.36, 0.65
Tritrakarn 2000	41	49 (16)	41	61 (17) 🕇		1.4 %	-0.72 [ -1.17, -0.27
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)		1.3 %	-0.08 [ -0.57, 0.41
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82) +	<b>.</b>	1.3 %	-0.60 [ -1.07, -0.12
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)		1.4 %	0.0 [ -0.44, 0.44
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		1.1 %	-0.40 [ -0.96, 0.15
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3) +	·	1.7 %	-0.84 [ -1.19, -0.50
<b>Total (95% CI)</b>	3960		4090		•	100.0 %	-0.22 [ -0.29, -0.14
leterogeneity: Tau ² =			$< 0.00001$ ); $ ^2 = 6$	63%			

-I -0.5 0 0.5 I

Favours placebo Favours no-treatment

### Analysis 16.4. Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 4 Trial size 49 or less.

Review: Placebo interventions for all clinical conditions

Comparison: I 6 Risk of bias subgroup analysis: trial size

Outcome: 4 Trial size 49 or less

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Fixed,95% Cl	Weight	Std. Mean Difference IV,Fixed,95% Cl
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)		1.5 %	-0.14 [ -0.80, 0.52 ]
Allen 1998	П	-2.9 (7.9)	11	-6.1 (10.9)	<b>·</b>	0.9 %	0.32 [ -0.52, 1.17 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		1.4 %	0.38 [ -0.30, 1.06 ]
Antivalle 1990	П	-1.6 (5.6)	10	-3.9 (7.3)	<b>·</b>	0.9 %	0.34 [ -0.52,  .2  ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)		0.5 %	0.56 [ -0.60, 1.72 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.7 %	-0.32 [ -1.28, 0.64 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		0.9 %	-1.07 [ -1.94, -0.20 ]
Blanchard 1990a	13	8.3 (13.6)	11	22.5 (25.1)		0.9 %	-0.70 [ -1.53, 0.13 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)	<b>·</b>	1.7 %	-0.28 [ -0.90, 0.33 ]
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.9 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		1.1 %	-0.29 [ -1.05, 0.47 ]
Bramston 1985	12	-78 (14.21)	12	-72 (13.82)		1.0 %	-0.41 [ -1.22, 0.40 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		1.4 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)		0.5 %	0.48 [ -0.72, 1.67 ]
Chenard 1991	12	29 (19)	16	30 (19)		1.2 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	11.3 (8.3)	15	14.4 (6.1)		1.2 %	-0.4  [ -1.14, 0.3  ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)	<b>·</b>	0.4 %	0.29 [ -0.95, 1.53 ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		1.0 %	-0.92 [ -1.72, -0.12 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	<b>·</b>	1.8 %	0.13 [ -0.47, 0.74 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.9 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.7 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)		0.7 %	-0.39 [ -1.35, 0.58 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		1.1 %	-0.65 [ -1.43, 0.13 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		1.0 %	-0.33 [ -1.12, 0.46 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		1.1 %	-0.13 [ -0.89, 0.63 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		1.2 %	-0.54 [ -1.27, 0.19 ]

Favours experimental

0

I 2

Favours control

-2 -1

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Std. Mean Difference IV,Fixed,95% Cl
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)	<b>←</b> →	0.6 %	-0.98 [ -2.02, 0.06 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.6 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		1.8 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	4.3 (7)	10	21.4 (7)		0.7 %	-0.97 [ -1.91, -0.03 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		1.1 %	-0.54 [ -1.30, 0.21 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		1.9 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)		0.9 %	-0.19 [ -1.05, 0.67 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)	← ↓	0.6 %	-1.58 [ -2.61, -0.55 ]
Helms 1987	11	103 (91)	11	79 (99)		0.9 %	0.24 [ -0.60, 1.08 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		1.5 %	-0.53 [ -1.19, 0.13 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)		1.0 %	-0.18 [ -0.98, 0.62 ]
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)		0.8 %	-0.21 [ -1.09, 0.67 ]
Irvin 1996	11	3.3 (0.7)	П	3.7 (1.4)		0.9 %	-0.35 [ -1.19, 0.50 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)	•	0.4 %	-1.17 [ -2.39, 0.04 ]
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		1.0 %	-1.07 [ -1.89, -0.25 ]
Kendall 1979	11	7.54 (2.29)	П	8.18 (3.03)		0.9 %	-0.23 [ -1.07, 0.61 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.3 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		1.7 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)		1.0 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.9 %	-0.55 [ -1.14, 0.03 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		1.3 %	-0.31 [ -1.01, 0.38 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		1.4 %	-0.49 [ -1.17, 0.20 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)	·	0.6 %	-1.08 [ -2.09, -0.07 ]
Lick 1977	10	66 (25)	10	63 (32)		0.8 %	0.10 [ -0.78, 0.98 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.6 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.8 %	0.0 [ -0.90, 0.90 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.6 %	0.03 [ -1.01, 1.08 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)	<u> </u>	1.9 %	0.12 [ -0.47, 0.71 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		2.0 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.8 %	0.04 [ -0.86, 0.93 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		1.7 %	-0.31 [ -0.93, 0.32 ]

-2 - | 0 L

2

Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Std. Mean Difference IV,Fixed,95% Cl
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		2.0 %	-0.49 [ -1.06, 0.08 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		1.1 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)	П	-0.8 (6.4)	*	0.4 %	-1.99 [ -3.24, -0.74 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)		0.7 %	-0.33 [ -1.27, 0.61 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)		0.7 %	0.19 [ -0.80, 1.18 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.9 %	-0.02 [ -0.90, 0.85 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		1.1 %	0.26 [ -0.50, 1.02 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)		1.6 %	-0.40 [ -1.05, 0.24 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		1.0 %	-0.11 [ -0.93, 0.72 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)		1.6 %	-0.11 [ -0.75, 0.54 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.5 %	-0.67 [ -1.80, 0.46 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.5 %	-0.05 [ -1.18, 1.08 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		2.1 %	-0.16 [ -0.73, 0.40 ]
Rschke 2000	24	23 (16.2)	24	26 (16)		2.0 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)		1.1 %	-0.02 [ -0.78, 0.73 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.5 %	-0.13 [ -1.26, 1.00 ]
Seer 1980	4	92.5 (9.8)	13	104.5 (11)		1.0 %	-1.12 [ -1.94, -0.30 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)		0.9 %	-0.04 [ -0.90, 0.81 ]
Sipich 1974	10	8 (14)	10	32.5 (14)	<b></b>	0.6 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)		1.1 %	0.22 [ -0.56, 1.01 ]
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.8 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)		0.8 %	-0.69 [ -1.60, 0.22 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.4 %	0.27 [ -0.98, 1.52 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)		0.8 %	0.21 [ -0.67, 1.09 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		1.0 %	-0.55 [ -1.36, 0.27 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		1.8 %	0.05 [ -0.55, 0.65 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		1.3 %	0.48 [ -0.22, 1.19 ]
Thomas 1999	14	13.4 (10.28)	26	16.5 (9.73)		1.5 %	-0.31 [ -0.96, 0.35 ]
Tuomilehto 1980	11	9.04 (1.36)	П	8.67 (1.56)		0.9 %	0.24 [ -0.60, 1.08 ]
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.8 %	-0.45 [ -1.34, 0.44 ]
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)		1.3 %	-0.10 [ -0.81, 0.62 ]

-2 - | 0 L 2

Favours experimental Favours control

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

							( Continued)
Study or subgroup	Placebo	N	o-treatment		Std. Mean Differ	rence Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		1.7 %	-0.26 [ -0.88, 0.37 ]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)		1.3 %	0.05 [ -0.66, 0.77 ]
Wojciechowski 1984	9	264 (122)	12	238 (190)		0.9 %	0.15 [ -0.71, 1.02 ]
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		1.6 %	-0.20 [ -0.83, 0.44 ]
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	•	0.5 %	-0.97 [ -2.10, 0.16 ]
Total (95% CI)	1228		1235		•	100.0 %	-0.24 [ -0.32, -0.16 ]
Heterogeneity: Chi ² = 95	5.63, df = 92	(P = 0.38); I ² =4%					
Test for overall effect: Z =	= 5.80 (P < 0	0.00001)					
					-2 -1 0 1	2	
				Favour	s experimental Favour	s control	

# Analysis 17.1. Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 1 Dropout rates no more than 15%.

Review: Placebo interventions for all clinical conditions

Comparison: 17 Risk of bias subgroup analysis: dropouts

Outcome: I Dropout rates no more than 15%

Risk Rat	Weight	Risk Ratio	No-treatment	Placebo	Study or subgroup
M-H,Random,95%		M-H,Random,95% CI	n/N	n/N	
0.92 [ 0.75, 1.12	5.7 %	-	82/136	77/139	Alkaissi 2002
0.66 [ 0.36, 1.19	1.3 %		9/14	11/26	Aune 1998
1.36 [ 0.83, 2.24	1.8 %		9/15	9/11	Berg 1983
1.00 [ 0.45, 2.23	0.8 %		6/12	6/12	Blackman 1964
0.94 [ 0.88, 1.01	9.4 %	-	360/416	227/279	Corver 2006
0.95 [ 0.81, 1.10	7.1 %	+	108/155	107/162	Faas 1993
0.89 [ 0.61, 1.29	2.8 %		9/10	8/10	Fanti 2003
1.00 [ 0.60, 1.65	1.7 %		14/26	14/26	Frank 1990
1.09 [ 0.87, 1.36	5.2 %	-	/ 2	12/12	Guglielmi 1982
0.77 [ 0.64, 0.94	5.9 %	-	92/132	70/130	Heinzl 1981
0.39 [ 0.17, 0.91	0.7 %		16/30	5/24	Hutton 1991

0.1 0.2 0.5 2 5 10

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	( Continued Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% CI
Hyman 1986	9/15	15/15		2.4 %	0.61 [ 0.40, 0.93 ]
Kerr 2003	28/33	32/36	-	6.2 %	0.95 [ 0.79, 1.15 ]
Killen 1990	226/309	219/309	+	8.6 %	1.03 [ 0.94, 1.14 ]
McMillan 1994	14/26	24/46		2.1 %	1.03 [ 0.66, 1.62 ]
Molsberger 2002	38/58	30/53		3.7 %	1.16 [ 0.86, 1.56 ]
Najnigier 1997	21/30	24/30	-+-	3.8 %	0.88 [ 0.65, 1.17 ]
Rabkin 1990	14/27	12/23		1.6 %	0.99 [ 0.58, 1.70 ]
Scharf 2006	179/365	224/316	•	7.8 %	0.69 [ 0.61, 0.78 ]
Scharff 2002	/ 2	12/12	-	5.2 %	0.92 [ 0.74, 1.15 ]
Tan 1986	8/10	8/9	_+_	2.6 %	0.90 [ 0.61, 1.32 ]
Tarrier 1998	22/26	25/28	+	5.6 %	0.95 [ 0.77, 1.17 ]
Watzl 1986	15/34	7/36	·	0.8 %	2.27 [ 1.06, 4.88 ]
Williams 1988	19/20	19/20	+	7.3 %	1.00 [ 0.87, 1.15 ]
<b>Fotal (95% CI)</b>	1796	1891	•	100.0 %	0.93 [ 0.86, 0.99 ]
otal events: 1150 (Placeb	o), 1367 (No-treatr	ment)			
Heterogeneity: $Tau^2 = 0.0$	l; Chi ² = 53.34, df	= 23 (P = 0.00033); I ² =579	6		
est for overall effect: Z =	2.10 (P = 0.036)				

0.1 0.2 0.5	2 5 10
Favours placebo	Favours no-treatment

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Analysis 17.2. Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 2 Dropout rates >15%, or not stated.

Review: Placebo interventions for all clinical conditions

Comparison: 17 Risk of bias subgroup analysis: dropouts

Outcome: 2 Dropout rates >15%, or not stated

Study or subgroup	Placebo n/N	No-treatment n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratic M-H,Random,95% C
Adriaanse 1995	50/328	38/326		5.1 %	1.31 [ 0.88, 1.94 ]
Alkaissi 1999	9/20	11/20		2.4 %	0.82 [ 0.44, 1.53 ]
Carter 2003	13/28	20/29		3.9 %	0.67 [ 0.42, 1.07 ]
De Sanctis 2001	9/10	8/9	+	7.1 %	1.01 [ 0.74, 1.38]
Double 1993	3/22	3/22		0.5 %	1.00 [ 0.23, 4.42
Dundee 1986	17/25	17/25	+	5.4 %	1.00 [ 0.68, 1.46
Elliott 1978	6/18	6/6	<u> </u>	2.2 %	0.37 [ 0.19, 0.71
Harrison 1975	24/28	25/30	+	10.3 %	1.03 [ 0.83, 1.28
Jacobs 1971	9/15	12/39		2.4 %	1.95 [ 1.04, 3.65
Klerman 1974	17/25	16/25	-	5.0 %	1.06 [ 0.71, 1.58
Malcolm 1980	40/63	44/58		9.6 %	0.84 [ 0.66, 1.06
Roughan 1981	9/12	9/14	_ <del></del>	3.4 %	1.17 [ 0.70, 1.94
Schallreuter 2002	3/10	4/10		0.7 %	0.75 [ 0.22, 2.52
Stransky 1989	1/5	1/4	·	0.2 %	0.80 [ 0.07, 9.18
Tarcin 2004	58/158	27/77		5.7 %	1.05 [ 0.73, 1.51
Thomas 1987	47/100	50/100	+	7.8 %	0.94 [ 0.71, 1.25
Tyler 1946	89/260	106/303	+	9.9 %	0.98 [ 0.78, 1.23
Walton 1993	19/24	21/30		7.0 %	1.13 [ 0.83, 1.54
Whittaker 1963	3/13	7/13		0.8 %	0.43 [ 0.14, 1.30
Wilson 1980	31/40	10/10	-	10.6 %	0.80 [ 0.65, 0.99
Total (95% CI)	1204	1150	•	100.0 %	0.96 [ 0.86, 1.06
Total events: 457 (Placebo Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	l; Chi ² = 27.16, df	ent) = 19 (P = 0.10); l ² =30%			

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review)

# Analysis 17.3. Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 3 Dropout rates no more than 15%.

Review: Placebo interventions for all clinical conditions

Comparison: 17 Risk of bias subgroup analysis: dropouts

Outcome: 3 Dropout rates no more than 15%

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI		IV,Random,95% Cl
Allen 1998	11	-2.9 (7.9)	11	-6.1 (10.9)		0.9 %	0.32 [ -0.52, 1.17 ]
Allen 2006	45	12 (9.6)	44	19 (9.6)		2.1 %	-0.72 [ -1.15, -0.29 ]
Anderson 1999	30	-2.67 (0.84)	27	-2.74 (0.81)		1.7 %	0.08 [ -0.44, 0.60 ]
Antivalle 1990	П	-1.6 (5.6)	10	-3.9 (7.3)		0.9 %	0.34 [ -0.52,  .2  ]
Antonio 1999	6	79.7 (12.2)	6	72.6 (11.2)	_ <del></del>	0.5 %	0.56 [ -0.60, 1.72 ]
Asmar 1996	34	-0.2 (7.7)	34	0.7 (6.5)		1.9 %	-0.12 [ -0.60, 0.35 ]
Biro 1997	29	3.6 (2.5)	29	3.3 (2.1)		1.7 %	0.13 [ -0.39, 0.64 ]
Blanchard 1990a	13	8.3 (13.6)	П	22.5 (25.1)		0.9 %	-0.70 [ -1.53, 0.13 ]
Bova 1999	34	3.82 (2.15)	36	4.14 (2.29)	-	1.9 %	-0.14 [ -0.61, 0.33 ]
Bramston 1985	12	-78 ( 4.2 )	12	-72 (13.82)		0.9 %	-0.41 [ -1.22, 0.40 ]
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)	-	2.6 %	-0.62 [ -0.96, -0.29 ]
Colker 1999	7	82.7 (18)	4	77.7 (10.5)	<del></del>	0.5 %	0.29 [ -0.95, 1.53 ]
Costello 2006	48	33 (25)	42	31 (25)	+	2.2 %	0.08 [ -0.33, 0.49 ]
Coyne 1995	21	0.73 (0.67)	21	0.64 (0.67)	_ <del></del>	1.4 %	0.13 [ -0.47, 0.74 ]
Crosby 1994	26	13.6 (1.25)	33	13.5 (1.25)	- <u>-</u> -	1.7 %	0.08 [ -0.44, 0.59 ]
Dibble 2007	49	3.13 (2.9)	51	3.5 (3.1)	-	2.3 %	-0.12 [ -0.51, 0.27 ]
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		2.0 %	-0.36 [ -0.80, 0.08 ]
Etringer 1982	13	-11.39 (3.95)	12	-10.08 (3.68)		1.0 %	-0.33 [ -1.12, 0.46 ]
Etter 2002	269	20.6 (10)	389	25.4 (12.6)	+	3.6 %	-0.41 [ -0.57, -0.26 ]
Foster 2004	6	-3.6 (0.6)	12	-2.6 (1.1)		0.6 %	-0.98 [ -2.02, 0.06 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)	+	3.0 %	-0.06 [ -0.33, 0.21 ]
Hashish 1988	25	42 (25)	25	60 (23)		1.5 %	-0.74 [ -1.31, -0.16 ]
Hawkins 1995	10	37.4 (8.5)	10	52.1 (9.3)		0.6 %	-1.58 [ -2.61, -0.55 ]
Helms 1987	П	103 (91)	П	79 (99)	_ <del></del>	0.9 %	0.24 [ -0.60, 1.08 ]
Hovell 2003	98	-155.37 (69.91)	96	-150.98 (73.75)	+	2.9 %	-0.06 [ -0.34, 0.22 ]

-4 -2 0 2

Favours placebo Favours no-treatment

4

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued Std. Mean Difference IV,Random,95% CI
Hyland 2006	10	6 (0.9)	10	6.2 (0.9)	<u> </u>	0.8 %	-0.21 [ -1.09, 0.67 ]
Jacobson 1978	7	2.53 (0.9)	6	3.47 (0.5)		0.5 %	-1.17 [ -2.39, 0.04 ]
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		2.8 %	-0.41 [ -0.71, -0.11 ]
Kilmann 1987	4	-33 (47)	4	-35 (47)		0.4 %	0.04 [ -1.35, 1.42 ]
Kober 2002	20	66.7 (10)	21	64.4 (13.3)		1.4 %	0.19 [ -0.42, 0.80 ]
Kokol 2005	16	9.5 (10.5)	10	7.3 (6.6)	<del></del>	1.0 %	0.23 [ -0.56, 1.02 ]
Kotani 2001	23	15 (4.5)	24	18 (6)		1.5 %	-0.55 [ -1.14, 0.03 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)	+	3.3 %	-0.12 [ -0.33, 0.09 ]
Lee 2005	27	-21.4 (25.9)	27	-5.9 (9.2)		1.6 %	-0.79 [ -1.34, -0.23 ]
Leibing 2002	40	3.2 (1.8)	39	4.3 (1.9)		2.0 %	-0.59 [ -1.04, -0.14 ]
Lick 1975	9	60.56 (32.73)	9	92.22 (22.09)		0.7 %	-1.08 [ -2.09, -0.07 ]
Limoges 2004	30	2.27 (1.02)	30	2.23 (1.01)	-	1.8 %	0.04 [ -0.47, 0.55 ]
Lin 2002	25	30.2 (14.4)	25	38.1 (16)		1.6 %	-0.51 [ -1.07, 0.05 ]
Lincoln 2003	42	14.4 (10)	38	16.7 (10)		2.0 %	-0.23 [ -0.67, 0.21 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		2.6 %	-0.56 [ -0.90, -0.22 ]
Lindholm 1996	227	6.83 (0.54)	226	6.75 (0.53)	+	3.4 %	0.15 [ -0.04, 0.33 ]
Liossi 2003	20	4.3 (0.6)	20	4.6 (0.6)		1.3 %	-0.49 [ -1.12, 0.14 ]
Longo 1988	10	3.6 (0.6)	9	3.6 (0.39)		0.8 %	0.0 [ -0.90, 0.90 ]
Markland 1993	7	37.29 (11.77)	7	36.86 (11.91)		0.6 %	0.03 [ -1.01, 1.08 ]
Medici 2002	23	-0.2 (0.33)	18	-0.1 (0.31)		1.4 %	-0.3  [ -0.93, 0.32 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		2.4 %	-0.70 [ -1.07, -0.33 ]
Morey 2006	38	-16.5 (9.3)	42	-14.7 (9.5)	-+-	2.0 %	-0.19 [ -0.63, 0.25 ]
Nandi 1976	10	53.2 (11.2)	8	57.5 (13.8)	<b>·</b>	0.7 %	-0.33 [ -1.27, 0.61 ]
Nicassio 1974	7	7.29 ( 33.7)	9	99.25 (35.3)		0.7 %	0.19 [ -0.80, 1.18 ]
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)	-	2.3 %	-0.15 [ -0.53, 0.23 ]
Parker 1995	49	4 (1.9)	45	3.8 (2.2)		2.2 %	0.10 [ -0.31, 0.50 ]
Reading 1982	18	1.6 (1.3)	20	2.3 (2)	<del></del>	1.3 %	-0.40 [ -1.05, 0.24 ]
Roscoe 2005	31	2.4 (1.28)	33	2.8 (1.32)		1.8 %	-0.30 [ -0.80, 0.19 ]
Rossi 1982	6	107 (17)	6	108 (20)		0.5 %	-0.05 [ -1.18, 1.08 ]
Rowbotham 1996	35	-4.4 (8.7)	35	1.9 (8.7)		1.9 %	-0.72 [ -1.20, -0.23 ]
Sanders 1990	6	2.03 (0.42)	6	2.08 (0.28)		0.5 %	-0.13 [ -1.26, 1.00 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	N Mean(SD)	o-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Seer 1980	14	92.5 (9.8)	13	104.5 (11)		0.9 %	-1.12 [ -1.94, -0.30 ]
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)	-+-	1.9 %	-0.25 [ -0.73, 0.23 ]
Sumaya 2001	10	15.4 (2.72)	10	14.9 (1.8)	_ <del></del>	0.8 %	0.21 [ -0.67, 1.09 ]
Tsay 2003	32	9.23 (4.36)	32	9.56 (4)	-	1.8 %	-0.08 [ -0.57, 0.41 ]
Tuomilehto 1980	11	9.04 (1.36)	11	8.67 (1.56)	_ <del>.</del>	0.9 %	0.24 [ -0.60, 1.08 ]
Vlaeyen 1996	39	0.4 (1.8)	40	0.4 (1.8)	+	2.0 %	0.0 [ -0.44, 0.44 ]
Wilcock 2008	15	-6.4 (5.1)	15	-6.7 (5.9)	<u> </u>	1.1 %	0.05 [ -0.66, 0.77 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)	-	2.5 %	-0.84 [ -1.19, -0.50 ]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:			<b>2530</b> (0.00001);   ² = 4	9%	•	100.0 %	-0.25 [ -0.34, -0.16 ]

-4 -2 0 2 4 Favours placebo Favours no-treatment

# Analysis 17.4. Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 4 Dropout rates > 15%, or not stated.

Review: Placebo interventions for all clinical conditions

Comparison: 17 Risk of bias subgroup analysis: dropouts

Outcome: 4 Dropout rates > 15%, or not stated

Study or subgroup	Placebo		No-treatment		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Abikoff 2004	35	-91.4 (18.9)	34	-89.5 (22.8)	-	1.4 %	-0.09 [ -0.56, 0.38 ]
Alfano 2001	24	6.2 (2.8)	14	6.6 (2.7)	-+-	0.9 %	-0.14 [ -0.80, 0.52 ]
Andersen 1990	18	35 (27.15)	16	25 (23.6)		0.9 %	0.38 [ -0.30, 1.06 ]
Ascher 1979	8	50.63 (44.13)	9	62.44 (25.25)		0.5 %	-0.32 [ -1.28, 0.64 ]
Benedetti 1995	13	-2 (1.15)	11	-0.8 (1)		0.6 %	-1.07 [ -1.94, -0.20 ]
Benedetti 1997	106	0.26 (0.06)	115	0.27 (0.06)	-+	2.5 %	-0.17 [ -0.43, 0.10 ]
Blades 2001	40	-16 (6)	40	-16 (6)	+	1.6 %	0.0 [ -0.44, 0.44 ]
Blanchard 1990b	18	11.9 (23.9)	24	20.7 (34.8)		1.0 %	-0.28 [ -0.90, 0.33 ]
					<u> </u>		
					-4 -2 0 2 4		
				F	avours placebo Favours no-trea	atment	

(Continued . . . )

Placebo interventions for all clinical conditions (Review)

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Block 1980	16	22.4 (6.6)	8	24.7 (9.2)		0.6 %	-0.30 [ -1.15, 0.56 ]
Bosley 1989	13	86 (10)	14	89 (10)		0.7 %	-0.29 [ -1.05, 0.47 ]
Cabrini 2006	16	61.7 (24)	16	66.6 (28)		0.8 %	-0.18 [ -0.88, 0.51 ]
Canino 1994	4	99 (2.7)	9	95.6 (7.6)	<del></del>	0.3 %	0.48 [ -0.72, 1.67 ]
Carbajal 1999	25	7.2 (2.77)	25	6.92 (2.57)	<u> </u>	1.2 %	0.10 [ -0.45, 0.66 ]
Chenard 1991	12	29 (19)	16	30 (19)	-	0.8 %	-0.05 [ -0.80, 0.70 ]
Classen 1983	15	.3 (8.3)	15	4.4 (6. )		0.8 %	-0.4  [ -1.14, 0.3  ]
Conn 1986	13	28.2 (18.4)	14	44.4 (15.7)		0.7 %	-0.92 [ -1.72, -0.12 ]
Cupal 2001	10	2.7 (0.95)	10	2.7 (1.34)		0.6 %	0.0 [ -0.88, 0.88 ]
Davidson 1980	10	1.8 (0.9)	10	2.9 (1.3)		0.5 %	-0.94 [ -1.88, -0.01 ]
Defrin 2005	9	7.3 (0.8)	8	7.6 (0.65)	<u> </u>	0.5 %	-0.39 [ -1.35, 0.58 ]
Ditto 2003	200	0.46 (0.42)	189	0.47 (0.41)	-	2.9 %	-0.02 [ -0.22, 0.17 ]
Ditto 2006	140	0.43 (0.35)	155	0.45 (0.37)	+	2.7 %	-0.06 [ -0.28, 0.17 ]
Espie 1989	14	63.5 (30.6)	13	96.5 (63.5)		0.7 %	-0.65 [ -1.43, 0.13 ]
Fisher 2006	12	3.83 (1.9)	15	4.14 (2.51)		0.7 %	-0.13 [ -0.89, 0.63 ]
Forster 1994	15	3.2 (2.8)	15	4.6 (2.2)		0.8 %	-0.54 [ -1.27, 0.19 ]
Frankel 1978	7	93 (5)	8	95 (3)		0.4 %	-0.47 [ -1.50, 0.57 ]
Frega 1994	21	20 (16)	21	23 (16)		1.0 %	-0.18 [ -0.79, 0.42 ]
Fuchs 1977	10	14.3 (7)	10	21.4 (7)		0.5 %	-0.97 [ -1.91, -0.03 ]
Godfrey 1973	44	34.93 (16.7)	44	46.88 (16.16)		1.6 %	-0.72 [ -1.15, -0.29 ]
Goodenough 1997	39	1.1 (1.6)	39	1.6 (1.9)		1.5 %	-0.28 [ -0.73, 0.16 ]
Gracely 1983	17	-2.9 (5.4)	12	0.15 (5.5)		0.7 %	-0.54 [ -1.30, 0.21 ]
GRECHO 1989	150	94.4 (40.7)	150	95.4 (33)	+	2.7 %	-0.03 [ -0.25, 0.20 ]
Hall 1974	23	-0.47 (7.83)	22	0.92 (7.83)		1.1 %	-0.17 [ -0.76, 0.41 ]
Hanson 1976	11	-0.88 (3.83)	10	-0.26 (2.2)	<u> </u>	0.6 %	-0.19 [ -1.05, 0.67 ]
Hargreaves 1989	25	4.5 (2.5)	25	4.9 (2.4)		1.2 %	-0.16 [ -0.72, 0.39 ]
Hashish 1986	25	16 (11.7)	50	30 (18.9)		1.3 %	-0.82 [ -1.32, -0.32 ]
Hong 1993	16	-1.09 (0.18)	21	-1.02 (0.07)		0.9 %	-0.53 [ -1.19, 0.13 ]
Hossmann 1981	12	94.15 (4.84)	12	95.05 (4.84)	<u> </u>	0.7 %	-0.18 [ -0.98, 0.62 ]
Hruby 2006	49	1.23 (2.05)	51	0.86 (1.5)	+-	1.8 %	0.21 [ -0.19, 0.60 ]
Irvin 1996	11	3.3 (0.7)	11	3.7 (1.4)		0.6 %	-0.35 [ -1.19, 0.50 ]

#### -4 -2 0 2 Favours no-treatment

4

Favours placebo

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Karst 2007	19	45.21 (10.82)	10	56.5 (9.1)		0.6 %	-1.07 [ -1.89, -0.25 ]
Karunakaran 1997	58	6.2 (1.2)	57	5.9 (0.6)		1.9 %	0.31 [ -0.05, 0.68 ]
Kendall 1979	11	7.54 (2.29)	11	8.18 (3.03)		0.6 %	-0.23 [ -1.07, 0.61 ]
Killeen 2004	24	I (2.5)	35	1.9 (3.5)		1.3 %	-0.28 [ -0.81, 0.24 ]
Levine 1984	12	-0.3 (0.69)	24	0.37 (2.5)		0.8 %	-0.31 [ -1.01, 0.38 ]
Licciardone 2003	19	2.46 (1.68)	15	3.54 (2.67)		0.9 %	-0.49 [ -1.17, 0.20 ]
Lick 1977	10	66 (25)	10	63 (32)	<del></del>	0.6 %	0.10 [ -0.78, 0.98 ]
Lorr 1961	42	58.3 (9.91)	38	57.5 (9.91)	-	1.6 %	0.08 [ -0.36, 0.52 ]
Macaluso 1995	30	-3.3 (3.83)	30	-1.8 (3.29)		1.3 %	-0.41 [ -0.93, 0.10 ]
Matros 2006	23	76 (36.3)	21	72 (28.3)		1.1 %	0.12 [ -0.47, 0.71 ]
May 1988	24	-1.23 (0.46)	24	-1.22 (0.46)		1.1 %	-0.02 [ -0.59, 0.54 ]
McLachlan 1991	8	6.25 (12.25)	12	5.67 (17.35)		0.6 %	0.04 [ -0.86, 0.93 ]
Moffet 1996	22	24.04 (18.56)	27	34.56 (23.2)		1.1 %	-0.49 [ -1.06, 0.08 ]
Moreland 2006	50	-2 (1.3)	99	-2.1 (1.7)		2.0 %	0.06 [ -0.28, 0.40 ]
Morton 1993	13	22.11 (16.38)	13	24.53 (16.38)		0.7 %	-0.14 [ -0.91, 0.63 ]
Murphy 1982	6	-16.5 (9.3)	11	-0.8 (6.4)		0.3 %	-1.99 [ -3.24, -0.74 ]
Nawrocki 1997	40	9.5 (6)	42	17 (4.8)		1.4 %	-1.37 [ -1.85, -0.89 ]
Nocella 1982	10	0.81 (0.88)	10	0.83 (0.65)		0.6 %	-0.02 [ -0.90, 0.85 ]
Parker 2003	13	16.2 (7.5)	14	14.2 (7.5)		0.7 %	0.26 [ -0.50, 1.02 ]
Pelham 1992	38	-8.72 (1.73)	38	-8.51 (1.61)		1.5 %	-0.12 [ -0.57, 0.33 ]
Quahagen 1995	28	-108.3 (14.8)	25	-104.8 (13.9)		1.2 %	-0.24 [ -0.78, 0.30 ]
Rawling 2001	89	5.3 (4.72)	96	5.6 (4.9)	+	2.3 %	-0.06 [ -0.35, 0.23 ]
Ristikankare 1999	61	40.25 (21.5)	61	36 (21.5)		2.0 %	0.20 [ -0.16, 0.55 ]
Robinson 2001	13	3.85 (3.48)	10	4.25 (3.74)		0.6 %	-0.11 [ -0.93, 0.72 ]
Roongpisuthip 1999	18	-3.3 (4.24)	19	-2.9 (3.05)	<u> </u>	0.9 %	-0.11 [ -0.75, 0.54 ]
Roscoe 2002	27	5.9 (5.2)	27	6.6 (3.64)		1.2 %	-0.15 [ -0.69, 0.38 ]
Rosen 1976	9	6.86 (2.02)	5	8.28 (1.91)		0.4 %	-0.67 [ -1.80, 0.46 ]
Rybarczyk 1990	25	7.12 (2.2)	24	7.54 (2.8)		1.2 %	-0.16 [ -0.73, 0.40 ]
Rschke 2000	24	23 (16.2)	24	26 (16)		1.1 %	-0.18 [ -0.75, 0.38 ]
Rsler 2003	13	5.92 (3.41)	14	6 (2.98)	<u> </u>	0.7 %	-0.02 [ -0.78, 0.73 ]
Senediak 1985	11	47.52 (8.38)	10	47.87 (7.53)	_	0.6 %	-0.04 [ -0.90, 0.81 ]

-4 -2 0 2 Favours placebo

Favours no-treatment

4

(Continued . . . )

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continued Std. Mean Difference IV,Random,95% CI
Sinaiko 1991	60	66.5 (9.7)	27	64.1 (13.9)		1.5 %	0.21 [ -0.24, 0.67 ]
Sipich 1974	10	8 (14)	10	32.5 (14)	<b>_</b> _	0.4 %	-1.68 [ -2.73, -0.63 ]
Spanos 1995	13	21.39 (9.7)	12	19.08 (10.33)	_ <del></del>	0.7 %	0.22 [ -0.56, 1.01 ]
Sprott 1993	10	7.9 (3)	10	7.4 (3)		0.6 %	0.16 [ -0.72, 1.04 ]
Stabholz 1991	10	1.4 (0.5)	10	1.8 (0.6)	<del></del>	0.5 %	-0.69 [ -1.60, 0.22 ]
Steinsbekk 2004	102	44.48 (58.88)	74	52.99 (45.2)	-	2.3 %	-0.16 [ -0.46, 0.14 ]
Stewart 1991	25	-14.3 (5.5)	25	-12.8 (5.2)		1.2 %	-0.28 [ -0.83, 0.28 ]
Straub 2001	5	-5.85 (0.31)	5	-6.01 (0.69)		0.3 %	0.27 [ -0.98, 1.52 ]
Tan 1982	12	1.3 (0.6)	12	1.7 (0.8)		0.7 %	-0.55 [ -1.36, 0.27 ]
Tashjian 2006	19	3.4 (2.2)	24	3.3 (1.75)		1.0 %	0.05 [ -0.55, 0.65 ]
Theroux 1993	17	3.2 (0.67)	15	2.88 (0.62)		0.8 %	0.48 [ -0.22, 1.19 ]
Thomas 1999	4	3.4 ( 0.28)	26	16.5 (9.73)		0.9 %	-0.31 [ -0.96, 0.35
Thomas 2002a	78	-0.87 (3.03)	78	-0.06 (2.88)		2.2 %	-0.27 [ -0.59, 0.04
Thomas 2002b	4	-1.21 (3.52)	119	-1.61 (3.31)	+	2.5 %	0.12 [ -0.14, 0.37
Tremeau 1992	39	-0.89 (1.27)	25	-1.08 (1.38)		1.3 %	0.14 [ -0.36, 0.65
Tritrakarn 2000	41	49 (16)	41	61 (17)		1.5 %	-0.72 [ -1.17, -0.27
Tsay 2004	35	4.7 (1.51)	36	5.71 (1.82)		1.4 %	-0.60 [ -1.07, -0.12 ]
Turner 1979	10	44.2 (41.26)	10	59.8 (22.9)		0.6 %	-0.45 [ -1.34, 0.44 ]
Wang 1997	25	10.7 (7.3)	26	13.4 (5.8)		1.2 %	-0.40 [ -0.96, 0.15
Weingaertner 1971	15	1.06 (1.29)	15	1.2 (1.56)	<del></del>	0.8 %	-0.10 [ -0.81, 0.62
Werntoft 2001	20	5.9 (2.4)	20	6.5 (2.2)		1.0 %	-0.26 [ -0.88, 0.37 ]
Wojciechowski 1984	9	264 (122)	12	238 (190)		0.6 %	0.15 [ -0.71, 1.02
Woods 2005	19	1.24 (1.26)	19	1.48 (1.12)		1.0 %	-0.20 [ -0.83, 0.44
Yates 1988	7	-1.43 (2.53)	7	0.71 (1.44)	<b>_</b>	0.4 %	-0.97 [ -2.10, 0.16 ]
<b>otal (95% CI)</b> eterogeneity: Tau ² = 0.0	<b>2745</b> 14; Chi ² =	141.60, df = 93 (	<b>2795</b> (P = 0.00088); I ² :	=34%	•	100.0 %	-0.20 [ -0.27, -0.13 ]

-4 -2 0 2 4

Favours placebo Favours no-treatment

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Analysis 18.1. Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%, Outcome I Binary outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%

Outcome: I Binary outcomes

Study or subgroup	Placebo	No-treatment	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
l Pain (incidence)					
Faas 1993	107/162	108/155	-	22.3 %	0.95 [ 0.81, 1.10 ]
Molsberger 2002	38/58	30/53		15.0 %	1.16 [ 0.86, 1.56 ]
Scharf 2006	179/365	224/316	+	23.5 %	0.69 [ 0.61, 0.78 ]
Subtotal (95% CI)	585	524	•	<b>60.8</b> %	0.89 [ 0.67, 1.19 ]
Total events: 324 (Placebo), 3	62 (No-treatment)				
Heterogeneity: $Tau^2 = 0.05$ ; (	$Chi^2 = 15.62, df = 2$	$P = 0.00041$ ; $I^2 = 87\%$			
Test for overall effect: $Z = 0.7$	'9 (P = 0.43)				
2 Schizophrenia (lack of 50%	improvement)				
Tarrier 1998	22/26	25/28	-	19.4 %	0.95 [ 0.77, 1.17 ]
Subtotal (95% CI)	26	28	+	19.4 %	0.95 [ 0.77, 1.17 ]
Total events: 22 (Placebo), 25	(No-treatment)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.5$	el (P = 0.61)				
3 Nausea					
Alkaissi 2002	77/139	82/136	-	19.8 %	0.92 [ 0.75, 1.12 ]
Subtotal (95% CI)	139	136	•	19.8 %	0.92 [ 0.75, 1.12 ]
Total events: 77 (Placebo), 82	(No-treatment)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.8$	82 (P = 0.41)				
Total (95% CI)	750	688	•	100.0 %	0.90 [ 0.76, 1.08 ]
Total events: 423 (Placebo), 4	69 (No-treatment)				
Heterogeneity: $Tau^2 = 0.03$ ; (	Chi ² = 18.16, df = 4	H (P = 0.00 I); I ² =78%			
Test for overall effect: $Z = 1.1$	5 (P = 0.25)				

0.5 Favours placebo Favours no-treatment

2

5

0.2

Placebo interventions for all clinical conditions (Review)

# Analysis 18.2. Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%, Outcome 2 Continuous outcomes.

Review: Placebo interventions for all clinical conditions

Comparison: 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%

Outcome: 2 Continuous outcomes

Study or subgroup	Placebo N	Mean(SD)	No-treatment N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% C
I Pain (various scales, see	table of incl	uded studies for	details)				
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)	-•-	9.4 %	-0.62 [ -0.96, -0.29
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		7.3 %	-0.36 [ -0.80, 0.08
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)		11.0 %	-0.06 [ -0.33, 0.21
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)		12.3 %	-0.12 [ -0.33, 0.09
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)		9.3 %	-0.56 [ -0.90, -0.22
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)		8.7 %	-0.70 [ -1.07, -0.33
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)		9.2 %	-0.84 [ -1.19, -0.50
Subtotal (95% CI)	600		581		•	67.3 %	-0.45 [ -0.69, -0.21
Heterogeneity: $Tau^2 = 0.0$	08; Chi ² = 24	4.07, df = 6 (P =	= 0.0005 l ); l ² =75	5%			
Test for overall effect: Z =	= 3.67 (P = 0	0.00024)					
2 Nausea (Rhodes invente	ory of nause	a and vomiting,	escape medicatior	n)			
O'Brien 1996	53	6.7 (5.6)	54	7.5 (5.14)		8.5 %	-0.15 [ -0.53, 0.23
Shen 2000	33	40.7 (12.35)	34	43.7 (11.31)		6.7 %	-0.25 [ -0.73, 0.23
Subtotal (95% CI)	86		88		•	15.2 %	-0.19 [ -0.49, 0.11
Heterogeneity: $Tau^2 = 0.0$	); $Chi^2 = 0.1$	I, df = I (P = 0)	.74); l ² =0.0%				
Test for overall effect: Z =	= 1.23 (P = 0	).22)					
3 Irritable bowel syndrom	ne (Global in	nprovement scal	e)				
Kaptchuk 2008	88	-4.3 (1.4)	87	-3.8 (1)		10.2 %	-0.41 [ -0.71, -0.11
Subtotal (95% CI)	88		<b>8</b> 7		•	10.2 %	-0.41 [ -0.71, -0.11
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 2.68 (P = 0	).0075)					
4 Depression (Beck depre	ession invent	ory)					
Lincoln 2003	42	4.4 ( 0)	38	16.7 (10)		7.3 %	-0.23 [ -0.67, 0.21
Subtotal (95% CI)	42		38		-	7.3 %	-0.23 [ -0.67, 0.21
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.01 (P = 0	).31)					
Total (95% CI)	816		794		•	100.0 %	-0.38 [ -0.55, -0.22
Heterogeneity: $Tau^2 = 0.0$	05; Chi ² = 2	5.94, df = 10 (P	= 0.004);   ² =6 9	6			
Test for overall effect: Z =	= 4.57 (P < 0	0.00001)					

Placebo interventions for all clinical conditions (Review)

# Analysis 18.3. Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%, Outcome 3 Pain heterogeneity.

Review: Placebo interventions for all clinical conditions

Comparison: 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%

Outcome: 3 Pain heterogeneity

Study or subgroup	Placebo	I	No-treatment		Std. Mean Difference	e Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I GAT							
Brinkhaus 2006	70	-23.6 (31)	74	-6.9 (22)		14.2 %	-0.62 [ -0.96, -0.29 ]
Linde 2005	76	-2.2 (2.7)	64	-0.8 (2.2)	_ <b>-</b>	14.1 %	-0.56 [ -0.90, -0.22 ]
Melchart 2005	57	10.8 (8.3)	63	16.3 (7.4)	<b>←</b> ∎──	13.4 %	-0.70 [ -1.07, -0.33 ]
Witt 2005	73	35.8 (16.2)	67	49.6 (16.3)	<b>←</b> ∎	13.9 %	-0.84 [ -1.19, -0.50 ]
Subtotal (95% CI)	276		268		•	55.5 %	-0.68 [ -0.85, -0.50 ]
Heterogeneity: $Tau^2 = 0.0$		7, df = 3 (P = 0.69	9); I ² =0.0%				
Test for overall effect: Z =	= 7.67 (P < 0	0.00001)					
2 Not GAT							
Erdogmus 2007	40	-27.4 (19.7)	40	-20.3 (19.7)		11.8 %	-0.36 [ -0.80, 0.08 ]
Foster 2007	112	6.5 (4.8)	105	6.78 (4.5)		15.8 %	-0.06 [ -0.33, 0.21 ]
Lander 1993	172	28.5 (29.3)	168	32.3 (33.4)		17.0 %	-0.12 [ -0.33, 0.09 ]
Subtotal (95% CI)	324		313		•	44.5 %	-0.13 [ -0.28, 0.03 ]
Heterogeneity: $Tau^2 = 0.0$	); Chi ² = $1.2^{\circ}$	9, df = 2 (P = 0.53	3); I ² =0.0%				
Test for overall effect: Z =	= 1.63 (P = 0	0.10)					
Total (95% CI)	600		581		•	100.0 %	-0.45 [ -0.69, -0.21 ]
Heterogeneity: $Tau^2 = 0.0$	08; Chi ² = 24	4.07, df = 6 (P = 0	0.0005 l ); l ² =75	%			
Test for overall effect: Z =	= 3.67 (P = 0	0.00024)					
					-1 -0.5 0 0.5	I	

Favours experimental Favours control

### APPENDICES

#### Appendix I. Electronic search strategies

# Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL, *The Cochrane Library*, Issue 4, 2007)

(PLACEBO* or MOCK* or SHAM* or FAKE* or VEHICLE* or DUMM* or ATTENTION* CONTROL* or PSEUDO* TREAT* or UNSPECIFIC* or NON SPECIFIC*) and

(NO TREAT* or NON TREAT* or NOTREAT* or NONTREAT* or UNTREAT* or MINIMALTREAT* or MINIM* TREAT* or USUAL TREAT* or NO INTERV* or NON INTERV* or NOINTERV* or NONINTERV* or NO CONTACT* or NON CONTACT or USUAL CONTACT* or NONCONTACT or USUAL CONTACT* or USUAL CARE* or NO PILL* or NOPILL* or NOPILL* or NONTABLET* or NO MEDIC* or NON MEDIC* or NOMEDIC* or NONMEDIC* or NONMEDIC* or NONMEDIC* or NONSURGER* or NOSURGER* or NOSURGER* or NOSURGER* or NOOPERAT* or NOOPERAT* or NOOPERAT* or NOOPERAT* or WAITING LIST* or WAITINGLIST*

or NO THERAP* or NON THERAP* or NOTHERAP* or NONTHERAP* or MINIM* THERAP* or MINIMALTHERAP* or USUAL* THERAP* or USUALTHERAP* or NATURAL COURSE or NATURAL DEVELOPMENT or NATURAL HISTORY or SPONTANEOUS COURSE or SPONTANEOUS DEVELOPMENT or SPONTANEOUS HISTORY or (TWO GROUPS) near CONTROL* or (THREE GROUPS) near CONTROL* or (FOUR GROUPS) near CONTROL* or (FIVE GROUPS) near CONTROL* or (SIX GROUPS) near CONTROL* or (SEVEN GROUPS) near CONTROL* or (THREE TREATMENT GROUPS) near CONTROL* or (FOUR TREATMENT GROUPS) near CONTROL* or (FIVE TREATMENT GROUPS) near CONTROL* or (SIX TREATMENT GROUPS) near CONTROL* or (SEVEN TREATMENT GROUPS) near CONTROL* ) and

(RANDOM* or DOUBLE* BLIND* or SINGLE* BLIND*)

### Search strategy for MEDLINE 1966 to March 2008

(PLACEBO* or MOCK* or SHAM* or FAKE* or VEHICLE* or DUMM* or ATTENTION* CONTROL* or PSEUDO* TREAT* or UN?SPECIFIC* or NON?SPECIFIC*) and

(NO??TREAT* or NO TREAT* or NON TREAT* or UN?TREAT* or UN TREAT* or MINIM* TREAT* or USUAL?TREAT* or USUAL TREAT* or NO INTERV* or NON INTERV* or NO??INTERV* or NO CONTACT* or NON CONTACT* or NO? ?CONTACT?* or USUAL CONTACT* or USUAL CARE* or NO PILL* or NON PILL* or NO??PILL* or NO TABLET* or NO TABLET* or NO MEDIC* or NON MEDIC* or NO??TABLET* or NO MEDIC* or NON MEDIC* or NO??OPERAT* or NO SURGER* or NO OPERAT* or NON OPERAT* or NO??OPERAT* or NO SURGER* or NON SURGER* or NO??SURGER* or NO??THERAP* or NO??THERAP* or NON THERAP* or MINIM* THERAP* or USUAL* THERAP*) in AB or (NO THERAP* or NO??THERAP* or NON THERAP* or MINIM* THERAP* or USUAL* THERAP*) in TI or WAITING LIST* or WAITING?LIST* or ((NATURAL or SPONTANEOUS) NEAR1 (COURSE or DEVELOPMENT or HISTORY)) or ((TWO or "2" or THREE or "3" or FOUR or "4" or FIVE or "5" or SIX or "6" or SEVEN or "7") NEAR1 (GROUPS or TREATMENT GROUPS)) NEAR (CONTROL or CONTROLS)) and

(DOUBLE-BLIND-METHOD or SINGLE-BLIND-METHOD or RANDOM-ALLOCATION or RANDOMIZED-CON-TROLLED-TRIALS/ALL SUBHEADINGS or CLINICAL-TRIALS/ALL SUBHEADINGS or (CLINICAL-TRIAL or RANDOM-IZED-CONTROLLED-TRIAL or CONTROLLED-CLINICAL-TRIAL) in PT or RANDOM* or (CLINICAL near TRIAL*) or DOUBLE* BLIND* or SINGLE* BLIND*) and HUMAN in TG

#### Search strategy for EMBASE 1980 to March 2008

(PLACEBO* or MOCK* or SHAM* or FAKE* or VEHICLE* or DUMM* or ATTENTION* CONTROL* or PSEUDO* TREAT* or UN?SPECIFIC* or NON?SPECIFIC*) and

(NO??TREAT* or NO TREAT* or NON TREAT* or UN?TREAT* or UN TREAT* or MINIM* TREAT* or USUAL?TREAT* or USUAL TREAT* or WITHOUT TREAT* or WITHOUT?TREAT* or NO INTERV* or NON INTERV* or NO??INTERV* or NO CONTACT* or NON CONTACT* or NO??CONTACT* or USUAL CONTACT* or USUAL CARE* or (NO THERAP* or NO??THERAP* or NON THERAP* or MINIM* THERAP* or USUAL* THERAP*) in AB or (NO THERAP* or NO??THERAP* or NON THERAP* or USUAL* THERAP*) in TI or NO PILL* or NO? PILL* or NO??PILL* or NO??THERAP* or NON TABLET* or WAITING LIST* or WAITING?LIST* or ((NATURAL or SPONTANEOUS)) NEAR1 (COURSE or DEVELOPMENT or HISTORY)) or NO MEDIC* or NON MEDIC* or NO??MEDIC* or UN MEDIC* or NON SURGER* or NO??SURGER* or ((TWO or "2" or THREE or "3" or FOUR or "4" or FIVE or "5" or SIX or "6" or SEVEN or "7") NEAR1 (GROUPS or TREATMENT GROUPS)) NEAR (CONTROL or CONTROLS)) and

(CLINICAL-TRIAL or RANDOMIZED-CONTROLLED-TRIAL or RANDOMIZATION or DOUBLE-BLIND-PROCEDURE or SINGLE-BLIND-PROCEDURE or CONTROLLED-STUDY or MAJOR-CLINICAL-STUDY or CLINICAL-ARTICLE or RANDOM* or (CLINICAL near TRIAL*) or DOUBLE* BLIND* or SINGLE* BLIND*) and HUMAN- in DE.

#### Search Strategy for PsycINFO 1887 to March 2008

Neither the indexation of clinical trials nor the reporting in abstracts in PsycINFO was helpful with respect to a reliable identification of randomised trials. With the purpose of minimising the number of missed randomised trials, any search terms aimed at identifying clinical trials were omitted. In a later manual filtering process abstracts were read in full.

(PLACEBO* or MOCK* or SHAM* or FAKE* or VEHICLE* or DUMM* or PSEUDO* TREAT* or ATTENTION* CONTROL* or UNSPECIFIC* or NON?SPECIFIC*) and

(NO??TREAT* or NO TREAT* or NON TREAT* or UN?TREAT* or UN TREAT* or MINIM* TREAT* or WITHOUT TREAT* or NO??INTERV* or NO INTERV* or NON INTERV* or UN?INTERV* or UN INTERV* or MINIM* INTERV* or WITHOUT INTERV* or NO??MEDIC* or NO MEDIC* or NON MEDIC* or UN?MEDIC* or UN MEDIC* or MINIM* MEDIC* or

Placebo interventions for all clinical conditions (Review)

WITHOUT MEDIC* or NO??PILL* or NO PILL* or NON PILL* or NO??OPERAT* or NO OPERAT* or NON OPERAT* or UN OPERAT* or MINIM* OPERAT* or WITHOUT OPERAT* or NO??SURGER* or NO SURGER* or NON SURGER* or MINIM* SURGER* or WITHOUT SURGER* or WAITING?LIST* or WAITING LIST or VISITATION* or ((NATURAL or SPONTANEOUS) NEAR1 (COURSE* or DEVELOPMENT* or HISTORY*)) or ((TWO or "2" OR THREE OR "3" OR "4" OR FOUR OR FIVE OR "5" OR SIX "6" OR SEVEN OR "7") NEAR1 (GROUPS OR TREATMENT GROUOPS)) NEAR (CONTROL OR CONTROLS))

and not ANIMAL in (PO or DE).

#### Search strategy for Biological Abstracts 1986 to March 2008

(PLACEBO* or MOCK* or SHAM* or FAKE* or VEHICLE* or DUMM* or ATTENTION* CONTROL* or PSEUDO* CONTROL* or UN?SPECIFIC* or NON?SPECIFIC*) and

(NO??TREAT* or NO TREAT* or NON TREAT* or UN?TREAT* or UN TREAT* or MINIM* TREAT* or USUAL?TREAT* or USUAL TREAT* or WITHOUT TREAT* or WITHOUT?TREAT* or NO INTERV* or NON INTERV* or NO??INTERV* or NO CONTACT* or NON CONTACT* or NO??CONTACT? or NO CONTACT* or NON CONTACT* or NO??CONTACT* or USUAL CONTACT* or USUAL CARE* or NO PILL* or NO PILL* or NO??PILL* or NO TABLET* or NON TABLET* or NO??TABLET* or (NO THERAP* OR NO??THERAP* OR NON THERAP* OR MINIM* THERAP* OR USUAL* THERAP*) in TI or (NO THERAP* OR NO??THERAP* OR NON THERAP* OR MINIM* THERAP* OR USUAL* THERAP*) in TI or (NO THERAP* OR NO??THERAP* OR NON THERAP* OR MINIM* THERAP* OR USUAL* THERAP*) in AB or NO MEDIC* or NON MEDIC* or NO??MEDIC* or UN MEDIC* or UN?MEDIC* or MINIM* MEDIC* or NO OPERAT* OR NON OPERAT* OR NON SURGER* OR NON SURGER* OR NO??SURGER* or WAITING LIST* OR WAITING?LIST* OR ((NATURAL OR SPONTANEOUS) NEAR1 (COURSE OR DEVELOPMENT OR HISTORY)) or ((TWO or "2" OR THREE OR "3" OR FOUR OR "4" OR FIVE OR "5" OR SIX OR "6" OR SEVEN OR "7") NEAR1 (GROUPS OR TREATMENT GROUPS)) NEAR (CONTROL OR CONTROLS)) and

(RANDOM* or (CLINICAL near TRIAL*) or DOUBLE* BLIND* or SINGLE* BLIND*) and (HUMAN- in OR or HUMAN in DE or HUMANS in ST).

### WHAT'S NEW

Last assessed as up-to-date: 10 November 2009.

11 November 2009	New search has been performed	The update (published on issue 1 2010) includes 234 trials (52 trials added) and over 16,000 patients. The updated review includes more precise subgroup analysis, especially among trials with low risk of bias, and involves meta-regression analyses to explain heterogeneity.
11 November 2009	New citation required and conclusions have changed	We have applied new methods and use Summary of Findings tables to assist in conveying the main find- ings. In contrast to the previous versions of the re- view (Hróbjartsson 2004a) we now find both a no- table pooled effect of placebo in trials with low risk of bias, especially on pain, and a large variation in ef- fects among trials with low risk of bias. Also new is the identification of five factors explaining roughly half of the variation. However, when all trials are pooled, dis- regarding the risk of bias, results are fairly similar to the previous versions.

Placebo interventions for all clinical conditions (Review)

## HISTORY

Protocol first published: Issue 3, 1999

Review first published: Issue 1, 2003

12 June 2008	Amended	Converted to new review format.
18 April 2004	New search has been performed	We identified 52 new trials and increased the number of in- cluded patients from 8525 to 11,737 (38%). Confidence in- tervals became narrower, more clinical conditions had been investigated by three trials or more.
18 April 2004	New citation required and conclusions have changed	We updated the review on issue 3 2004 of <i>The Cochrane Library</i> . The degree of heterogeneity between trials with continuous outcomes was more pronounced in this update, but the main findings were(identical to the previous version of the review (Hróbjartsson 2003a).

### CONTRIBUTIONS OF AUTHORS

Asbjørn Hróbjartsson (AH) and Peter C. Gøtzsche (PCG) conceived the idea of the review. AH had the main responsibility for developing the search strategy, retrieving the trials, accessing additional data, and writing the first draft of the review. AH and PCG read all included trial reports. AH analysed the data.

# DECLARATIONS OF INTEREST

None known.

# SOURCES OF SUPPORT

### Internal sources

• No sources of support supplied

Placebo interventions for all clinical conditions (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### **External sources**

• Faculty of Health Sciences, University of Copenhagen, Denmark.

### DIFFERENCES BETWEEN PROTOCOL AND REVIEW

In the protocol we planned the following procedure for extraction of data: 'The primary outcome is that which is considered clinically most relevant to patients'. In the review we extracted data according to the following procedure: 'We primarily chose the outcome indicated as the main outcome in a trial report (e.g. through a power calculation). If a main outcome was not clearly indicated we chose the outcome measure we considered most relevant to patients'. The primary idea in the protocol was to minimise the risk of bias due to selective reporting of positive results in trials. We modified the procedure in an attempt to balance this risk against the risk of review author bias.

In the protocol for the first version of our review we specified a limited number of subgroup analyses (see Methods subgroup analyses 1-8). Before we conducted this update we expanded the number of planned subgroup analyses (see Methods subgroup analyses 9-12), and planned a number of meta-regression analyses (see Methods). One subgroup-analyses was conducted post-hoc (see Methods subgroup analysis 13). Furthermore, in the protocol we planned to analyse trials that reported corresponding patient-reported and observerreported outcomes. However, it became clear that the distinction between corresponding and not corresponding patient-reported and observer-reported outcomes was very subjective, and we decided to abort this comparison.

# ΝΟΤΕS

This review was originally published with the title 'Placebo treatment versus no treatment' (Hróbjartsson 2003a). For the 2003-4 update (Hróbjartsson 2004a), the title was changed to 'Placebo interventions for all clinical conditions'.

### INDEX TERMS

#### Medical Subject Headings (MeSH)

*Placebo Effect; Randomized Controlled Trials as Topic; Refusal to Treat; Treatment Outcome

#### MeSH check words

Humans